



## Joint Session of the European Association of Urology (EAU) and the World Chinese Urologists

Urology beyond Europe

Friday 10 March  
10:45 - 12:45

**Location** Pink Area, Coral 2  
**Chairs** S. Chueh, Taipei (TW)  
T-X. Lin, Guangzhou (CN)  
H. Van Poppel, Leuven (BE)

### Learning objectives

In this joint EAU - Chinese Urological Association (CUA) and Taiwanese Urological Association (TUA) session, the World Chinese urologists and the EAU faculty will highlight what is new in BPH, overactive bladder and paediatric urology. Around prostate cancer, early detection, the value of PSMA PET-CT and the treatment of castrate refractory prostate cancer will be dealt with. Finally, the treatment of kidney cancer with vena cava thrombus and metastasis will be presented.

10:45 - 10:50

**Introduction and welcome**  
C.R. Chapple, Sheffield (GB)

10:50 - 11:26

**Functional urology**

10:50 - 10:57

**What's new/best in surgical management of BPH?**  
C-H. Liao, ()

10:57 - 11:04

**Update on overactive bladder**  
P. Wu, Guangzhou (CN)

11:04 - 11:11

**What has changed in the Guidelines on Paediatric Urology**  
M.S. Silay, Istanbul (TR)

11:11 - 11:16

**Discussion**

11:16 - 11:26

**Panel discussion**

11:26 - 12:02

**Prostate cancer**

11:26 - 11:33

**Is there an optimal algorithm for CRPC?**  
To be confirmed

11:33 - 11:40

**PSMA PET CT for relapse but also for diagnosis?**  
S.T. Pang, Taipei (TW)

11:40 - 11:47

**Early detection strategy in the European Union**  
H. Van Poppel, Leuven (BE)

11:47 - 11:52

**Discussion**

11:52 - 12:02

**Panel discussion**

12:02 - 12:38

**Level III/IV Cava thrombus and M+ RCC**

12:02 - 12:09

**Role of imaging and neo-adjuvant treatment strategies**  
C-C. Yu, Kaohsiung (TW)

12:09 - 12:16

**Surgery**  
U. Capitanio, Milan (IT)

12:16 - 12:23

**Modern medical treatment of M+ Renal cell Ca.**  
To be confirmed

12:23 - 12:28

**Discussion**

12:28 - 12:38

**Panel discussion**

---

12:38 - 12:41

**Conclusion**

S. Chueh, Taipei (TW)

T-X. Lin, Guangzhou (CN)

## Challenges in supportive care in GU cancers

Plenary Session

Friday 10 March  
08:00 - 10:00

**Location** Yellow Area, eURO Auditorium 1  
**Chairs** S. Gillessen Sommer, Bellinzona (CH)  
M.C. Mir Maresma, Valencia (ES)

08:00 - 08:10	<b>State-of-the-art lecture</b> Optimising supportive care for metastatic GU cancers To be confirmed
08:10 - 08:20	<b>State-of-the-art lecture</b> Optimal pain management for bone metastases To be confirmed
08:20 - 08:37	<b>Case discussion</b> Locally advanced node positive penile cancer, what to do?
08:20 - 08:22	<b>Case presentation</b> M.W. Vetterlein, Hamburg (DE)
08:22 - 08:27	<b>Neoadjuvant systemic treatment</b> A. Necchi, Milan (IT)
08:27 - 08:32	<b>Surgical options</b> A. Muneer, London (GB)
08:32 - 08:37	<b>Definitive chemoradiation therapy</b> S.R. Ottenhof, Amsterdam (NL)
08:37 - 08:47	<b>Society of Urologic Oncology (SUO) lecture</b> Palliative treatment for wound healing problems in penile cancer surgery P. Spiess, Tampa (US)
08:47 - 08:57	<b>State-of-the-art lecture</b> QoL endpoint in clinical trials: Translation in clinical daily practice B. Escudier, Villejuif (FR)
08:57 - 09:07	<b>State-of-the-art lecture</b> Sexuality in metastatic prostate cancer: What can we do during ADT? A. Salonia, Milan (IT)
09:07 - 09:30	<b>Case discussion</b> Which interventions makes sense in best supportive care?
09:07 - 09:09	<b>Case presentation</b> R. Campi, Florence (IT)
09:09 - 09:14	<b>Endourology management: What is the best option?</b> S. Proietti, Milan (IT)
09:14 - 09:24	<b>Ethical considerations in the treatment of end stage patients</b> U. Wiesing, Tübingen (DE)
09:24 - 09:30	<b>Discussion</b> <i>Panel</i> R. Campi, Florence (IT) S. Proietti, Milan (IT) U. Wiesing, Tübingen (DE)
09:30 - 10:00	<b>Panel discussion</b> How to optimally organise interdisciplinary palliative treatment?
09:30 - 09:35	<b>The EAU Guideline's perspective</b> M.J. Ribal Caparros, Barcelona (ES)

09:35 - 09:40

**The palliative care's perspective**

C. Schulz-Quach, Toronto (CA)

09:40 - 09:45

**The nurse's perspective**

J. Wood, London (GB)

09:45 - 09:50

**The patient's perspective**

R. Cornes, London (GB)

09:50 - 10:00

**Discussion**

*Panel*

R. Cornes, London (GB)

M.J. Ribal Caparros, Barcelona (ES)

C. Schulz-Quach, Toronto (CA)

J. Wood, London (GB)

## Functional aspects of kidney transplantation

Plenary Session

Friday 10 March  
08:00 - 10:00

**Location** Yellow Area, eURO Auditorium 2

**Chairs** A. Breda, Barcelona (ES)  
J.P.F.A. Heesakkers, Maastricht (NL)

### Learning objectives

For those of us who perform renal transplantation questions about functioning of the concomitant lower urinary tract stays often enigmatic. Optimisation of the renal function is fairly well known and under control, however we would also like to know and predict how voiding and storage will develop after the transplantation. Questions that still have to be elucidated are amongst others: is pre-transplantation screening useful and how should it be done; what happens to bladder behaviour when there is no urinary production and suddenly patients have to void again. How good is functioning of LUT in the elderly after transplantation. We will try to find some answers to these questions in this session.

08:00 - 08:03

**Welcome and introduction**

08:03 - 08:18

**State-of-the-art lecture** Transplantation in a bladder cripple: What are the options?  
F.C. Burkhard, Bern (CH)

08:18 - 08:33

**Confederación Americana de Urología (CAU) lecture** Bladder function and LUTS after renal transplant  
J. Sanchez Macias, Barcelona (ES)

08:33 - 08:48

**State-of-the-art lecture** Pelvic surgery in patients with a renal transplant: Do's and don'ts  
To be confirmed

08:48 - 09:13

**Debate** Urological evaluation of the recipient before kidney transplant is obligatory

08:48 - 08:58

**Pro**  
O. Rodriguez Faba, Barcelona (ES)

08:58 - 09:08

**Con**  
R. Boissier, Marseille (FR)

09:08 - 09:13

**Discussion**

09:13 - 09:23

**State-of-the-art lecture** Living donor nephrectomy: How to avoid nightmares  
M. Musquera Felip, Barcelona (ES)

09:23 - 09:33

**State-of-the-art lecture** Kidney transplantation in the octogenarians  
A.J. Figueiredo, Coimbra (PT)

09:33 - 09:43

**State-of-the-art lecture** Technique and results of paediatric kidney transplantation  
B. Kocak, Istanbul (TR)

09:43 - 09:58

**State-of-the-art lecture** LT effects on LUT behavior of renal transplantation in children  
M.A. Koyle, Toronto (CA)

09:58 - 10:00

**Closing remarks**

## Theranostics in prostate cancer

ESU Course 01

Friday 10 March  
08:00 - 11:00

**Location** Pink Area, ESU 3

**Chair** B.A. Hadaschik, Essen (DE)

### Learning objectives

Recently theranostics, the combination of diagnosis and treatment based on the same concept, was introduced in the management of prostate cancer based on nuclear medicine technologies. This is an emerging field with promising clinical data being published very recently. The concept of theranostics has the potential to change the management of prostate cancer and to become an essential part of our armamentarium. The aim of the course is to provide an in-depth overview on these new concepts and to critically assess their performance, efficacy and limitations.

### Diagnosis and initial staging of prostate cancer

#### Diagnosis of the primary

B.A. Hadaschik, Essen (DE)

#### Initial staging of prostate cancer

W.J.G. Oyen, Arnhem (NL)

#### The EAU guideline perspective on early PET imaging

P. Cornford, Liverpool (GB)

### Biochemical recurrence

#### Staging of biochemical recurrence with PET imaging

W.J.G. Oyen, Arnhem (NL)

#### Treatment options and risk stratification for salvage treatment

B.A. Hadaschik, Essen (DE)

#### What to do with the information?

P. Cornford, Liverpool (GB)

### Metastatic disease

#### Use of PET in the management of metastatic prostate cancer

B.A. Hadaschik, Essen (DE)

#### Radioligand treatment for metastatic prostate cancer

W.J.G. Oyen, Arnhem (NL)

#### The place of radioligand treatment in the M1 prostate cancer arena

P. Cornford, Liverpool (GB)

## Chronic pelvic pain in men and women

ESU Course 02

**Friday 10 March**  
**08:00 - 11:00**

### **Location**

Pink Area, ESU 4

### **Learning objectives**

The urologist is often dealing with patients having Chronic Pelvic Pain. This course will offer the urologist practical guidance in treating these patients. In the case discussion the participants will have the opportunity to help outlining the problem. In the lectures, theoretical knowledge will be translated into daily guidelines for diagnostics and treatment of patients with pelvic pain.

At the end of this course the participant will:

- Know the basic principles of treating patients with chronic pelvic pain.
- Know how to rule out well-known causes.
- Have knowledge of the myofascial and psychological aspects.
- Be able to refer patients at the right time to the right team.



## Advanced vaginal reconstruction

ESU Course 03

Friday 10 March  
08:00 - 11:00

**Location** Pink Area, ESU 5

**Chair** T.J. Greenwell, London (GB)

### Learning objectives

Clinicians involved in the care of female patients should know vaginal surgery. A specific goal of the faculty is to employ scientific principles, published information and clinical experience to describe and position newly developed techniques in current management of urinary incontinence. Special attention will be given to new techniques that use synthetics tapes in SUI surgery. This course will also cover the management of complications of surgery for stress incontinence and mesh complications. Treatment of recurrent urinary incontinence and incontinence with mixed symptoms also will be under discussion.

Management of vesicovaginal fistulae, urethral diverticula and some rare conditions will be shown both during podium and video presentations. An interactive course means active participation by the audience and participants are encouraged to prepare and present interesting and challenging clinical cases for consultation by the faculty. After this course, participants should know how to apply the newest technique in patients with stress incontinence, urethral loss and iatrogenic injuries of lower urinary tract. This course will facilitate the decision making process for those who are just starting their careers and for advanced surgeons.

### Introduction

T.J. Greenwell, London (GB)

### Mostly vaginal surgery for stress urinary incontinence (SUI)

T. Tarcan, Istanbul (TR)

### Mostly vaginal repair of pelvic organ prolapse (POP)

K-D. Sievert, Detmold (DE)

### Management of mesh complications

K-D. Sievert, Detmold (DE)

### Surgery for female urethral stricture and loss

T. Tarcan, Istanbul (TR)

### Surgery for urethral diverticulum

T.J. Greenwell, London (GB)

### Vesico-vaginal fistulae

T.J. Greenwell, London (GB)

### Discussion and conclusions

T.J. Greenwell, London (GB)

## Lower urinary tract dysfunction and urodynamics

ESU Course 04

**Friday 10 March**  
**08:00 - 11:00**

**Location** Pink Area, ESU 6

**Chair** H. Hashim, Bristol (GB)

### **Learning objectives**

Having attended the course, the attendee should:

- Understand the basic physical principles referable to urodynamics.
- Be able to assess the quality of a urodynamic trace.
- Recognise common artefacts and know how to correct them.
- Know the indications for urodynamic studies in men, women and neurological patients.

### **Urodynamics: Philosophy, scientific basis and technique**

H. Hashim, Bristol (GB)

---

### **Urodynamics in men**

S. Musco, Florence (IT)

---

### **Urodynamics in female urology**

H. Hashim, Bristol (GB)

---

### **Urodynamics in neurourology**

S. Musco, Florence (IT)

---

## Adrenals for urologists

ESU Course 05

Friday 10 March  
08:00 - 11:00

**Location** Pink Area, ESU 7

**Chair** A.S. Gözen, Heilbronn (DE)

### Learning objectives

To teach all about the adrenal gland minimal invasive approach; starting with the correct indications for surgery and preoperative medical preparation. The different approaches and new equipment will be shown including special instructions. The operations will be given step by step in high quality videos in detail with tips and tricks. The complication videos and intraoperative management will be discussed interactively with the experts.

### Introduction

A.S. Gözen, Heilbronn (DE)

### Indications and patient preparation (medical and surgical)

J.F. Langenhuijsen, Nijmegen (NL)

### Surgical anatomy of adrenals

C. Fiori, Orbassano (IT)

### How I do it; step by step operative procedure, technical tips and tricks

#### - Transperitoneal

J.F. Langenhuijsen, Nijmegen (NL)

#### - Retroperitoneal and prone

A.S. Gözen, Heilbronn (DE)

#### - Mini-laparoscopic

C. Fiori, Orbassano (IT)

### Partial adrenalectomy and challenging cases in adrenalectomy

J.F. Langenhuijsen, Nijmegen (NL)

### Complications and management

A.S. Gözen, Heilbronn (DE)

### Discussion and interaction

A.S. Gözen, Heilbronn (DE)

J.F. Langenhuijsen, Nijmegen (NL)

C. Fiori, Orbassano (IT)

## Paradigm shifts in urology: 50 years of major developments

7th International Congress on the history of urology in conjunction with EAU23 and the EAU's 50th anniversary

Friday 10 March  
08:30 - 16:30

**Location** Yellow Area, Amber 7

**Chairs** F.M.J. Debruyne, Nijmegen (NL)  
D. Schultheiss, Giessen (DE)  
Ph. E. V. Van Kerrebroeck, Berchem- Antwerp (BE)

### Learning objectives

The 7th International Congress on the History of Urology will focus on developments within the different urological subspecialties during the last 50 years, with a specific look at the historic origins. Controversial aspects of the history of Urology in Europe will be discussed, including medical as well as political and sociological drivers of development, with attention for the international and even intercontinental interaction. The programme will allow the audience to pick up tips and tricks for their current and future practice and research.

08:30 - 08:35	<b>Opening of the congress and presentation of the annual gift book 2023 'Cache-sexe. Covered, uncovered, discovered'</b> C.R. Chapple, Sheffield (GB)
08:35 - 09:20	<b>50 years EAU: Developments and shifts</b>
08:35 - 08:50	<b>The historical perspective</b> L.W. Keizer, Arnhem (NL)
08:50 - 09:05	<b>The clinical and experimental perspective</b> C.R. Chapple, Sheffield (GB)
09:05 - 09:20	<b>The societal and feministic perspective</b> K. Hemmerechts, Berchem (BE)
09:20 - 09:55	<b>Session on female urology</b> <i>Moderator</i> C.R. Chapple, Sheffield (GB)
09:20 - 09:35	<b>History of the past 50 years</b> E. Chartier-Kastler, Paris (FR)
09:35 - 09:50	<b>Controversial topic Surgery for VVF in Europe: The result of the abuse of enslaved women in America?</b> D.M. Castro Díaz, Santa Cruz de Tenerife (ES)
09:50 - 09:55	<b>Discussion</b>
09:55 - 10:30	<b>Session on paediatric urology</b> <i>Moderator</i> A. Verit, Istanbul (TR)
09:55 - 10:10	<b>History of the past 50 years</b> P. Dik, Utrecht (NL)
10:10 - 10:25	<b>Controversial topic Modern hypospadias surgery: A South-American development?</b> J. Corrales Riveros, Lima (PE)
10:25 - 10:30	<b>Discussion</b>
10:30 - 10:45	<b>Break</b>
10:45 - 13:00	<b>Session on oncological urology</b> <i>Moderator</i> P-A. Abrahamsson, Malmö (SE)

## Scientific Programme - EAU23 Milan

---

10:45 - 11:00	<b>Prostate cancer History of the past 50 years</b> P-A. Abrahamsson, Malmö (SE)
11:00 - 11:15	<b>Prostate cancer Nerve-sparing radical prostatectomy: A European discovery?</b> P. Walsh, Baltimore (US)
11:15 - 11:30	<b>Bladder cancer History of the past 50 years</b> M.J. Ribal Caparros, Barcelona (ES)
11:30 - 11:45	<b>Bladder cancer Bladder replacement after cystectomy: A nightmare for Europeans?</b> A. Stenzl, Tübingen (DE)
11:45 - 12:00	<b>Kidney cancer History of the past 50 years</b> R. Sosnowski, Warsaw (PL)
12:00 - 12:15	<b>Kidney cancer Non-invasive surgery for renal cancer: A pan-European disaster?</b> J.J.M.C.H. de la Rosette, Istanbul (TR)
12:15 - 12:30	<b>Testis History of the past 50 years</b> L. Lund, Odense (DK)
12:30 - 12:45	<b>Testis Chemotherapy for testis tumours: Urological history in Europe?</b> J. Gómez Rivas, Madrid (ES)
12:45 - 13:00	<b>Discussion</b>
<hr/>	
13:00 - 13:30	<b>Break</b>
<hr/>	
13:30 - 14:05	<b>Session on andrologic urology</b> <i>Moderator</i> F. Moll, Stolberg (DE)
13:30 - 13:45	<b>History of the past 50 years</b> D. Schultheiss, Giessen (DE)
13:45 - 14:00	<b>Controversial topic “Me too”</b> P. Hoebeke, Ghent (BE)
14:00 - 14:05	<b>Discussion</b>
<hr/>	
14:05 - 14:40	<b>Session on male urology</b> <i>Moderator</i> M.S. Rahnama'i, Aachen (DE)
14:05 - 14:20	<b>History of the past 50 years</b> J.P.F.A. Heesakkers, Maastricht (NL)
14:20 - 14:35	<b>Controversial topic Treatment for urethral stricture in Europe: I am the history!</b> A. Mundy, London (GB)
14:35 - 14:40	<b>Discussion</b>
<hr/>	
14:40 - 14:55	<b>Break</b>
<hr/>	
14:55 - 15:30	<b>Session on stones</b> <i>Moderator</i> J.C. Goddard, Leicester (GB)
14:55 - 15:10	<b>History of the past 50 years</b> P.J.S. Osther, Vejle (DK)
15:10 - 15:25	<b>Controversial topic Endo-urologists are no better than lithotomists!</b> J. Mattelaer, Kortrijk (BE)
15:25 - 15:30	<b>Discussion</b>
<hr/>	
15:30 - 16:00	<b>Session on technological urology</b> <i>Moderator</i> J.O.R. Sønksen, Herlev (DK)

---

## Scientific Programme - EAU23 Milan

---

15:30 - 15:45

**History of the past 50 years**

J. Angulo Cuesta, Getafe (ES)

15:45 - 16:00

**Controversial topic Technology in urology: Intelligence waived?**

K.A.O. Tikkinen, Helsinki (FI)

16:00 - 16:05

**Discussion**

16:05 - 16:20

**Finale lecture History is the past of the future!**

Ph. E. V. Van Kerrebroeck, Berchem- Antwerp (BE)

16:20 - 16:30

**Summary and closing remarks of the 7th International Congress on the History of Urology**

F.M.J. Debruyne, Nijmegen (NL)

## Urological Patient Presentations

Patient information poster session

**Friday 10 March**  
**09:00 - 10:00**


**Location** Yellow Area, Amber 5

**Chairs** To be confirmed  
To be confirmed

### Learning objectives

The session seeks to highlight the needs of patients with urological disease; identify innovations in patient centred care, and to listen to patients' voices as they report the outcomes and experiences of their treatment.

<b>PA01</b>	<b>A comprehensive summary of patient and caregiver experiences with bladder cancer: Results of a survey from 49 countries</b>
<b>09:05 - 09:09</b>	<b>Discussion</b>
<b>PA02</b>	<b>2022 Global Patient Survey: Reported experience of diagnosis, management, and burden of renal cell carcinomas in &gt;2,200 patients from 39 countries</b> R. Giles, Duivendrecht (NL)
<b>09:14 - 09:18</b>	<b>Discussion</b>
<b>PA03</b>	<b>Importance of shared decision making in prostate cancer to ensure that patients and clinicians recognize and address patients' treatment goals</b>
<b>09:23 - 09:27</b>	<b>Discussion</b>
<b>PA04</b>	<b>How can we improve patient-clinician communication in men diagnosed with prostate cancer?</b>
<b>09:32 - 09:36</b>	<b>Discussion</b>
<b>PA05</b>	<b>A commitment to collaboration in continence care</b>
<b>09:41 - 09:45</b>	<b>Discussion</b>
<b>PA06</b>	<b>Collection of patient reported outcomes in daily clinical practice – experiences from a prostate cancer network</b> L.D.F. Venderbos, Rotterdam (NL)
<b>09:50 - 09:54</b>	<b>Discussion</b>
<b>09:54 - 10:00</b>	<b>Closing remarks</b> To be confirmed


 Game changing session

**Friday 10 March**  
**10:00 - 10:30**

**Location**

Yellow Area, eURO Auditorium 1



 Game changing session

**Friday 10 March**  
**10:00 - 10:30**

**Location**

Yellow Area, eURO Auditorium 2

## Roundtable: Patient-Physician Communication

Patient information session

**Friday 10 March  
10:15 - 11:15**

**Location** Yellow Area, Amber 5  
**Chair** To be confirmed

---

**10:15 - 10:17**

**Welcome & introduction**  
To be confirmed

---

**10:17 - 10:29**

**Patient engagement interventions not only improve health but survival in patients with cancer**  
R. Giles, Duivendrecht (NL)

---

**10:29 - 10:41**

**Physician-patient communication: Examples of best practice to improve patient experience**  
To be confirmed

---

**10:41 - 10:53**

**Recommendation and Guidelines including a framework with W. Yared**  
To be confirmed

---


**10:53 - 11:05**

**Addressing sexual taboos with patients and spouses**  
J. Daly, Galway (IE)

---

**11:05 - 11:15**

**Q&A and closing**  
To be confirmed

 Thematic Session: VB health care

**Friday 10 March**  
**10:45 - 12:15**

**Location**

Yellow Area, Brown 3

## European Urology Surgery-in-Motion: Solving difficult situations in endourology

Thematic Session

Friday 10 March  
10:45 - 12:15

**Location** Yellow Area, eURO Auditorium 2

**Chairs** G. Giusti, Milan (IT)  
A. Mottrie, Aalst (BE)

### Learning objectives

The Surgery-in-Motion session is dedicated to endourology. Experts in the field will provide explanations and video demonstrations of various surgical techniques in the most challenging clinical scenarios and discuss why they do it “their way”.

10:45 - 10:55

### Difficult RIRS: The right laser for the right job

K. Ghani, Ann Arbor (US)

10:55 - 11:00

### Discussion

11:00 - 11:10

### How to become a dust buster: The role of suctions in RIRS

B. H. Eisner, Boston (US)

11:10 - 11:15

### Discussion

11:15 - 11:25

### Endourological approach to stones in caliceal diverticulum

S. Proietti, Milan (IT)

11:25 - 11:30

### Discussion

11:30 - 11:40

### How to perform conservative treatment of UTUC in best conditions

O. Traxer, Paris (FR)

11:40 - 11:45

### Discussion

11:45 - 11:55

### PCNL in morbidly obese patients

L. Ajayi, London (GB)

11:55 - 12:00

### Discussion

12:00 - 12:10

### When endourology calls robotics... Management of iatrogenic ureteral strictures

A. Volpe, Novara (IT)

12:10 - 12:15

### Discussion

## Joint session of the EAU, EANM, ESMO and ESTRO: Multidisciplinary management of urothelial cancer 2.0

Thematic Session

Friday 10 March  
10:45 - 12:15

**Location** Yellow Area, eURO Auditorium 1

**Chairs** B.A. Jerezek-Fossa, Milan (IT)  
To be confirmed  
K. Herrmann, Essen (DE)  
J. Walz, Marseille (FR)

### Learning objectives

This will be a 360° approach of urothelial cancer. The following will be discussed:

- Different points of view on the best management of urothelial cancer: Urologists, medical oncologists, radiation oncologists, nuclear medicine specialists will discuss the best management
- How to deal with any phase of the disease: From the non-invasive to metastatic urothelial cancer
- Challenges in the management and how to solve them
- Innovative strategies for urothelial cancer on the horizon

10:45 - 11:35

### Localised disease

10:45 - 10:55

#### Current and future options after BCG failure

G. Pignot, Marseille (FR)

10:55 - 11:05

#### Neoadjuvant treatment of MIBC

M. De Santis, Berlin (DE)

11:05 - 11:15

#### Trimodal treatment: Selection and outcome

V. Fonteyne, Ghent (BE)

11:15 - 11:25

#### Surgical approaches for MIBC: Has the evidence become of age for robotics?

To be confirmed

11:25 - 11:35

#### Current adjuvant treatment options

A. Necchi, Milan (IT)

11:35 - 12:05

### Metastatic disease

11:35 - 11:45

#### PET imaging for urothelial cancer: FDG and beyond

D.E. Oprea-Lager, Amsterdam (NL)

11:45 - 11:55

#### Current treatment options for metastatic urothelial cancer

To be confirmed

11:55 - 12:05

#### Future perspectives

R.J.A. Van Moorselaar, Amsterdam (NL)

12:05 - 12:15

### Discussion

## Joint Session of the European Association of Urology (EAU) and the Urological Society of Australia and New Zealand (USANZ)

Urology beyond Europe

**Friday 10 March**  
10:45 - 12:45

**Location** Yellow Area, Amber 3  
**Chairs** P. Albers, Düsseldorf (DE)  
H. O'Connell, East Melbourne (AU)

### Learning objectives

This collaborative session will update the audience in specific and very controversial topics of uro-oncology. Tough clinical cases will be discussed by world-wide known leaders in the field followed by a panel discussion.

10:45 - 10:50

**Introduction**

10:50 - 11:19

**Locally advanced kidney cancer**

10:50 - 10:55

**Case presentation** Locally advanced tumour with level III/IV cava thrombus  
To be confirmed

10:55 - 11:02

**Pre-op work up and surgery**  
To be confirmed

11:02 - 11:09

**Role of neoadjuvant treatment?**  
To be confirmed

11:09 - 11:19

**Panel discussion** Surgical approaches  
*Panel* A. Bex, London (GB)  
To be confirmed  
To be confirmed  
To be confirmed

11:19 - 12:02

**High risk locally advanced prostate cancer**

11:29 - 11:34

**Case presentation** cT3 cN0 ISUP GG 4  
J.P. Radtke, Düsseldorf (DE)

11:34 - 11:41

**Role of imaging and theranostics**  
R. Eapen, Melbourne (AU)

11:41 - 11:48

**Role of neoadjuvant treatment?**  
S. Joniau, Leuven (BE)

11:48 - 11:55

**Debate** Radiotherapy first  
To be confirmed

11:55 - 12:02

**Debate** Surgery first  
A. De La Taille, Créteil (FR)

11:19 - 11:29

**Panel discussion**  
*Panel* A. De La Taille, Créteil (FR)  
R. Eapen, Melbourne (AU)  
S. Joniau, Leuven (BE)  
D. Murphy, Melbourne (AU)  
J.P. Radtke, Düsseldorf (DE)

12:02 - 12:45

**Locally advanced bladder cancer in frail patient**

12:02 - 12:07

**Case presentation** 75 yrs, male, GFR 50, ECOG1, cT3 TCC, hydronephrosis  
A.R. Zlotta, Toronto (CA)

12:07 - 12:14

**Neoadjuvant treatment options**

G. Niegisch, Düsseldorf (DE)

12:14 - 12:21

**Trimodality treatment**

D. Hayne, East Fremantle (AU)

12:21 - 12:28

**(Robot-assisted) Cystectomy with ileal conduit or ureterocutaneostomy**

J. Palou, Barcelona (ES)

12:28 - 12:35

**Adjuvant treatment options**

To be confirmed

12:35 - 12:45

**Panel discussion and concluding remarks**

*Panel*

P. Anderson, Melbourne (AU)

D. Hayne, East Fremantle (AU)

G. Niegisch, Düsseldorf (DE)

J. Palou, Barcelona (ES)

A.R. Zlotta, Toronto (CA)

## Joint Session of the European Association of Urology (EAU) and the Federation of ASEAN Urological Associations (FAUA)

Urology beyond Europe EAU

**Friday 10 March**  
**10:45 - 12:45**

**Location** Pink Area, Coral 4  
**Chairs** K.A. Mohd Ghani, Kuala Lumpur (MY)  
J. Palou, Barcelona (ES)

<b>10:45 - 10:50</b>	<b>Welcome and introduction</b>
<b>10:50 - 11:20</b>	<b>Urolithiasis</b>
<b>10:50 - 11:00</b>	<b>X-ray-free Ultrasound-guided percutaneous nephrolithotomy: Asian experience</b> To be confirmed
<b>11:00 - 11:10</b>	<b>Which laser for which stone?</b> O. Angerri Feu, Barcelona (ES)
<b>11:10 - 11:20</b>	<b>Discussion</b>
<b>11:20 - 11:50</b>	<b>Bladder cancer</b>
<b>11:20 - 11:30</b>	<b>The emerging role of MRI in bladder cancer staging: Do we still need 2nd look TURBT?</b> V. Panebianco, Rome (IT)
<b>11:30 - 11:40</b>	<b>Neoadjuvant treatment before radical cystectomy: Is it the standard in Asia?</b> To be confirmed
<b>11:40 - 11:50</b>	<b>Discussion</b>
<b>11:50 - 12:20</b>	<b>Reconstructive</b>
<b>11:50 - 12:00</b>	<b>Recent advances in minimally invasive surgery of female stress incontinence</b> B. Peyronnet, Rennes (FR)
<b>12:00 - 12:10</b>	<b>Penile reconstruction for management of penile paraffinoma: South Asian experience</b> To be confirmed
<b>12:10 - 12:20</b>	<b>Discussion</b>
<b>12:20 - 12:40</b>	<b>Prostate cancer and BPH</b>
<b>12:20 - 12:30</b>	<b>Postagram: Changing paradigms in MRI</b> To be confirmed
<b>12:30 - 12:40</b>	<b>REZUM therapy for BPH; Limitations during patient selection</b> To be confirmed
<b>12:40 - 12:45</b>	<b>Conclusion and closing remarks</b>



## Joint Session of the European Association of Urology (EAU) and the Société Internationale d'Urologie (SIU)

Urology beyond Europe

**Friday 10 March**  
**10:45 - 12:45**

**Location** Pink Area, Coral 7

**Chairs** A. Stenzl, Tübingen (DE)  
L-P. Xie, Hangzhou (CN)

### Learning objectives

Aspects of male LUTS related to BPO still remain underscored at international meetings. However worldwide the clinical problems in this field remain an important aspect of any urological practice. In this joint Session of the European Association of Urology (EAU) and the Société Internationale d'Urologie (SIU) worldwide recognised specialists will deal with aspects of recent advances and trends in the surgical treatment of BPO globally. This session will present you a unique overview of evidence and experience-based state of the art strategies in the field of male LUTS because of BPO.

**10:45 - 10:55**

**Welcome and introduction**

**10:55 - 11:05**

**EAU guidelines trends and strategies for surgical management of BPO**  
S. Gravas, Larissa (GR)

**11:05 - 11:55**

**Trends in surgical management of male LUTS due to BPO**

**11:05 - 11:15**

**TURP – an ancient relic or still the gold standard?**  
D. Elterman, Toronto (CA)

**11:15 - 11:25**

**Enucleation – the best option for everybody**  
To be confirmed

**11:25 - 11:35**

**Robotic TURP – do we really need it?**  
To be confirmed

**11:35 - 11:45**

**Robotic adenomectomy – pros and cons**  
To be confirmed

**11:45 - 11:55**

**Discussion**

**11:55 - 12:35**

**Quality of life issues in BPO management**

**11:55 - 12:05**

**Telehealth and BPO management**  
M. Gacci, Florence (IT)

**12:05 - 12:15**

**Big data and AI for BPO management – how to implement?**  
C. Gratzke, Freiburg (DE)

**12:15 - 12:25**

**Patients preferences and values in decision-making process for BPO management**  
J-N.L. Cornu, Rouen (FR)

**12:25 - 12:35**

**Ejaculation preservation for BPO management**  
To be confirmed

**12:35 - 12:45**

**Conclusions**


## Joint Session of the European Association of Urology (EAU) and the Iranian Urological Association (IUA)

Urology beyond Europe

**Friday 10 March**  
**13:00 - 15:00**

**Location** Yellow Area, Amber 3  
**Chairs** S.J. Hosseini, Tehran (IR)  
B. Malavaud, Toulouse (FR)

<b>13:00 - 13:05</b>	<b>Introduction</b>
<b>13:05 - 13:40</b>	<b>2022 Surgical decision-making in female Stress Urinary Incontinence (SUI)</b>
<b>13:05 - 13:20</b>	<b>Indications &amp; challenges of surgical reconstruction procedures in uncomplicated and complicated SUI</b> To be confirmed
<b>13:20 - 13:25</b>	<b>Case presentation Laparoscopy colposuspension for uncomplicated SUI</b> To be confirmed
<b>13:25 - 13:30</b>	<b>Discussion</b>
<b>13:30 - 13:35</b>	<b>Case presentation Expert management of a mid-urethral sling complication</b> To be confirmed
<b>13:35 - 13:40</b>	<b>Discussion</b>
<b>13:40 - 14:30</b>	<b>The revolution of immune therapy (IT) in genitourinary oncology</b>
<b>13:40 - 13:55</b>	<b>How basic science revolutionized cancer specific survival in genitourinary oncology</b> S. Shariat, Vienna (AT)
<b>13:55 - 14:00</b>	<b>Case presentation From chemo to IT, reporting a case of metastatic bladder cancer fit for cisplatin</b> To be confirmed
<b>14:00 - 14:08</b>	<b>Discussion</b>
<b>14:08 - 14:13</b>	<b>Case presentation Making use of IT in Mr. N., a de novo metastatic renal cell cancer patient</b> M. Soleimani, Tehran (IR)
<b>14:13 - 14:18</b>	<b>Discussion</b>
<b>14:18 - 14:23</b>	<b>Case presentation The complexity of managing IT adverse effects, a case report</b> To be confirmed
<b>14:23 - 14:30</b>	<b>Discussion</b>
<b>14:30 - 14:55</b>	<b>A new vision on sexual dysfunction in the context of localised prostate cancer treatment</b>
<b>14:30 - 14:45</b>	<b>Tips &amp; tricks in urethroplasty, controlling the risk of sexual dysfunction</b> To be confirmed
<b>14:45 - 14:50</b>	<b>Case presentation My management of ED after radical prostatectomy</b> G. Gandaglia, Milan (IT)
<b>14:50 - 14:55</b>	<b>Discussion</b>
<b>14:55 - 15:00</b>	<b>Take home message &amp; farewell</b>

 Abstract Session

**Friday 10 March**  
**10:45 - 12:15**

**Location**

Pink Area, Coral 2

## Joint Session of the European Association of Urology (EAU) and the Urological Society of India (USI)

Urology beyond Europe

Friday 10 March  
10:45 - 12:45

**Location** Yellow Area, Brown 2  
**Chairs** S. Kulkarni, Pune (IN)  
E. Liatsikos, Patras (GR)

### Learning objectives

Attendees will be able to learn about the latest guidelines in management of locally advanced prostate cancer.  
Attendees will be able to learn the tips and trick of robotic surgery for LAPC  
Attendees will be able to understand the developments in single use RIRS and how to use laser effectively in stones.  
Attendees will be able to listen from the experts on paediatric RIRS , PCNL and troubleshooting in PCNL  
Attendees will be able to learn the management of complex urethral strictures with surgical videos.

10:45 - 10:50

### Introduction

10:50 - 11:17

### Locally Advanced Prostate Cancer (LAPC)

*Moderator* S. Rawal, Delhi (IN)

10:50 - 10:57

### Predicting factors for outcome in LAPC

A.S. Merseburger, Lübeck (DE)

10:57 - 11:04

### Optimising outcome in LAPC - role of neoadjuvant therapy

To be confirmed

11:04 - 11:11

### Robotic surgery for LAPC - extra precautions to be taken

R. Nayyar, new delhi (IN)

11:11 - 11:17

### Concluding remarks

S. Rawal, Delhi (IN)

11:17 - 12:13

### Urolithiasis

*Moderators* A.K. Chawla, Manipal (IN)  
E. Liatsikos, Patras (GR)

11:17 - 11:24

### Single use RIRS - Does size matter?

B. Somani, Southampton (GB)

11:24 - 11:31

### Single use RIRS - has its time come?

To be confirmed

11:31 - 11:38

### Mini PCNL for Staghorn stone

R Kukreja, Indore (IN)

11:38 - 11:45

### Thulium vs Holmium

O. Angerri Feu, Barcelona (ES)

11:45 - 11:52

### ECIRS for Staghorn stone

To be confirmed

11:52 - 11:59

### Paediatric RIRS

V. Chandra Mohan, Hyderabad (IN)

11:59 - 12:06

### Paediatric PCNL

A. Bujons Tur, Barcelona (ES)

## Scientific Programme - EAU23 Milan

---

12:06 - 12:13

### **PCNL Track loss**

To be confirmed

---

12:13 - 12:32

### **Complex urethral stricture**

*Moderators*

S. Kulkarni, Pune (IN)

To be confirmed

---

12:13 - 12:20

### **Complex urethroplasty**

C.R. Chapple, Sheffield (GB)

---

12:20 - 12:27

### **Graft plus flap for complex urethroplasty**

P. Joshi, Pune (IN)

---

12:27 - 12:32

### **Discussion**

---

12:32 - 12:39

### **New robotic platforms**

E. Liatsikos, Patras (GR)

---

12:39 - 12:43

### **Closing remarks**

---

## Meeting of the Young Academic Urologists (YAU)

Special Session

Friday 10 March  
10:45 - 15:00

**Location** Pink Area, Coral 6

**Chair** J. Gómez Rivas, Madrid (ES)

### Learning objectives

The Young Academic Urologists (YAU) is a group of talented and already renowned European young urologists. We aim to promote high-quality studies in order to provide strong evidence for the best urological practice. In this session both scientific and educational context will be discussed among the members of YAU and the leaders of European Urology.

10:45 - 11:05

### Overview of the Young Academics

*Moderators* J. Gómez Rivas, Madrid (ES)  
J.L. Vásquez, Roskilde (DK)

10:55 - 11:05

### EAU Young Academics Development of your academic skills

J. Gómez Rivas, Madrid (ES)

10:45 - 10:55

### Non-oncology groups Update on the latest news

M.W. Vetterlein, Hamburg (DE)

10:55 - 11:05

### Oncology groups Update on the latest news

G. Cacciamani, Los Angeles (US)

11:05 - 11:15

### YAU Awards

*Moderators* J. Gómez Rivas, Madrid (ES)  
J.L. Vásquez, Roskilde (DK)

### Best paper published in 2022 by a YAU group

To be confirmed

### Best poster presented at EAU23 by a YAU group

To be confirmed

### YAU reviewer of the year

To be confirmed

11:15 - 11:55

### YAU-EAU Patient Office session

*Moderators* G. Gandaglia, Milan (IT)  
To be confirmed

11:15 - 11:25

### State-of-the-art lecture Patient engagement is a potential blockbuster treatment that urologists should prescribe for their cancer patients

To be confirmed

11:25 - 11:35

### Disease specific: PCa – Results PROMS Studies

To be confirmed

11:35 - 11:45

### Presentation about the PO

To be confirmed

11:45 - 11:55

### Discussion

### Creating controversies

*Moderators* F. Castiglione, London (GB)  
N.I. Osman, Sheffield (GB)

11:55 - 12:15

### Varicocele repair before ART

11:55 - 12:05	<b>Yes</b> G.I. Russo, Catania (IT)
11:55 - 12:05	<b>No</b> To be confirmed
12:05 - 12:15	<b>Discussion</b>
12:15 - 12:45	<b>Mesh removal surgery</b>
12:15 - 12:25	<b>Robotic</b> V. Phé, Paris (FR)
12:25 - 12:35	<b>Open</b> H. Hashim, Bristol (GB)
12:35 - 12:45	<b>Discussion</b>
12:45 - 13:15	<b>Retroperitoneal lymph node dissection for testicular cancer</b>
12:45 - 12:55	<b>Robotic</b> A. Larcher, Milan (IT)
12:55 - 13:05	<b>Open</b> W. Cazzaniga, London (GB)
13:05 - 13:15	<b>Discussion</b>
13:15 - 13:45	<b>Highlights from the YAU</b> <i>Moderators</i> A. Pietropaolo, Southampton (GB) A. Territo, Barcelona (ES)
13:15 - 13:25	<b>Getting to the guidelines: The YAU endourology perspective</b> T. Taily, Ghent (BE)
13:25 - 13:35	<b>Preoperative evaluation of children for renal transplantation. Surgical factors predicting early graft dysfunction</b> B. Bañuelos Marco, Berlin (DE)
13:35 - 13:45	<b>Novel concepts to optimise care for patients with localised renal masses</b> R. Campi, Florence (IT)
13:45 - 14:25	<b>YAU-ESUP session: Promising tissue biomarkers and predictive molecular tests from clinical research</b> <i>Moderators</i> A. Cimadamore, Ancona (IT) M. Colecchia, Milan (IT)
13:45 - 13:55	<b>Kidney tumours and prediction of response to immunotherapy</b> R.G. Bertolo, Rome (IT)
13:55 - 14:05	<b>Nectin and Trop-2 in bladder tumours</b> M. Moschini, Milan (IT)
14:05 - 14:15	<b>BRCA and other molecular tests in metastatic PCa</b> A. Cimadamore, Ancona (IT)
14:15 - 14:25	<b>Discussion</b> <i>Panel</i> R.G. Bertolo, Rome (IT) A. Cimadamore, Ancona (IT) T. Gevaert, Leuven (BE) R. Lucianò, Milan (IT) M. Moschini, Milan (IT) To be confirmed

---

---

<b>14:25 - 14:55</b>	<b>What's new in active surveillance: From indolent prostate cancer to stage I testis tumours</b>
<b>14:25 - 14:35</b>	<b>Cribriform PCa and prediction of progression in active surveillance</b> G. Van Leenders, Rotterdam (NL)
<b>14:35 - 14:45</b>	<b>MicroRNA and recurrence of germ cell tumours</b> C.D. Fankhauser, Lucerne (CH)
<b>14:45 - 14:55</b>	<b>Discussion</b> <i>Panel</i> A. Cimadamore, Ancona (IT) C.D. Fankhauser, Lucerne (CH) I. Heidegger, Innsbruck (AT) To be confirmed G. Van Leenders, Rotterdam (NL)
<b>14:55 - 15:00</b>	<b>Closing remarks</b> M. Colecchia, Milan (IT) J. Gómez Rivas, Madrid (ES)

---



## Challenging cases in robotic renal transplantation

Video Session 01

**Friday 10 March**  
**10:45 - 12:15**

**Location** Blue Area, Room 1  
**Chairs** To be confirmed  
To be confirmed  
To be confirmed

**10:45 - 10:48**

**Introduction**

V001

**The RAKT Box: a novel, entirely 3D-printed hyper-accuracy simulator for vascular anastomoses during robot-assisted kidney transplantation**

R. Campi, Florence (IT)

V002

**Robot-assisted living donor nephrectomy: Toward a new standard?**

D. Stracci, Florence (IT)

V003

**Native ureter reimplantation on kidney graft: Robotic technique using the Davinci Firefly system**

O. Blezian, Nice (FR)

V004

**Robotic pyelo-ureterostomy to native ureter to solve urinary tract stricture after kidney transplantation: Step by step**

P. Sanz-Serra, Barcelona (ES)

V005

**Robotic assisted kidney transplant with ileal conduit surgery**

D. Kaddu, Miraj (IN)

V006

**Innovative technique of reducing rewarm ischemia time in robotic assisted kidney transplant with multiple vessels**

A. Kumar, Noida (IN)

V007

**Robotic surgery in patients with horseshoe kidney: surgical strategies and description of the technique**

**12:06 - 12:11**

**Closing remarks**

## Preventing complications of male LUTS/BPO surgical management: The male health challenge

Abstract Session 01

Friday 10 March  
10:45 - 12:15

**Location** Pink Area, Coral 3  
**Chairs** C. Fiori, Turin (IT)  
To be confirmed  
S.O. Kim, Gwangju (KR)

10:45 - 10:48

**Introduction**

- A0001 **Functional outcomes after Ejaculation-sparing anatomic Photoselective Vaporization (ESa-PVP), standard vaporization or transurethral resection of the prostate: A respective comparison**  
M. Sibona, Torino (IT)
- A0002 **Erectile and ejaculatory function after Rezum water vapour thermal therapy at 12- and 24-months follow-up**  
D. Elterman, Toronto (CA)
- A0003 **Consensus meeting on ejaculation sparing surgery for benign prostatic hyperplasia. Preliminary step of the PARTURP randomized study.**  
G.Y. Robert, Bordeaux (FR)
- A0004 **Ejaculation-sparing enucleation of the prostate with Thulium:YAG laser (ES-ThuLEP) versus Thulium Fiber Laser (ES-TFLEP): Outcomes on sexual function**  
A. Pacchetti, Genova (IT)
- A0005 **Thulium laser enucleation (ThuLEP) versus transurethral prostate resection (TURP): Impact on erectile function**  
G. Chiarelli, Milan (IT)
- A0006 **Predictors of BPH6 achievement for urethral-sparing robot-assisted simple prostatectomy: Results of a multicentric series**  
U. Anceschi, Rome (IT)
- A0007 **Ejaculation preservation in patients with benign prostatic obstruction: the safety and efficacy of transperineal interstitial laser ablation**  
F. Sessa, Florence (IT)
- A0008 **Low serum 25-OH vitamin D level as a potential risk factor of erectile dysfunction in elderly men with moderate to severe lower urinary tract symptoms**
- A0009 **Orgasmic function worsening could lead to erectile function decrease after holep – results from a prospective trial (expho)**  
P. Capogrosso, Milan (IT)
- A0010 **Is the Urolift a fertility sparing technique in patients suffered from BPH?**  
N. d'Altilia, Foggia (IT)
- A0011 **A novel outcomes categorization for current minimally invasive ejaculation-sparing treatments of benign prostatic hyperplasia: Results of a multicentric series**  
U. Anceschi, Rome (IT)

## Scientific Programme - EAU23 Milan

---

11:10 - 11:34

Discussion

---

A0012 **To do or not to do? Is acetylsalicylic acid a safe drug to continue in bipolar turp?**  
S.S. Qazi, Karachi (PK)

---

A0013 **Patient characteristics and dynamic variables predictive of meaningful quality of life and sexual function improvement after prostatic urethral lift (PUL)**  
N. Barber, Camberley (GB)

---

A0014 **Predictors of urinary tract infection Post-Holmium Laser Enucleation of Prostate (HoLEP)**  
M. El Tayeb, alexandria (EG)

---

A0015 **Holmium Laser Enucleation of the Prostate is associated with complications and sequelae even in the hands of an experienced surgeon. Results from a prospective series.**  
P. Capogrosso, Varese (IT)

---

A0016 **Impact of age and frailty on surgical outcomes of Holmium Laser Enucleation of Prostate (HoLEP) in nonagenarians and octogenarians patients**

---

A0017 **Greenlight laser (XPSTM) 180w prostatectomy for treatment of benign prostate hyperplasia in patients with uncorrectable bleeding tendency**

---

A0018 **Does prostate artery embolization prior to Aquablation® reduce peri-operative morbidity and increase the likelihood of same day discharge?**  
S. Marhamati, Alexandria (US)

---

A0019 **Lower Urinary Tract Symptoms (LUTS) after Aquablation for the treatment of Benign Prostatic Hyperplasia (BPH): Evaluation of Symptoms Category (Filling versus voiding phase) Prevalence Rates**  
S.T. De Cillis, Turin (IT)

---

11:50 - 12:08

Discussion

---

12:08 - 12:15

Closing remarks

---

## Joint Session of the European Association of Urology (EAU) and the Pan-African Urological Surgeons Association (PAUSA)

Urology beyond Europe

**Friday 10 March**  
**10:45 - 12:45**

**Location** Pink Area, ESU 1

**Chairs** M. Jalloh, Dakar (SN)  
J. N'Dow, Aberdeen (GB)

### Learning objectives

The session comprise 4 Topics: Bladder Cancer, Urolithiasis, Reconstructive Urology and Collaboration in Urotechnology (minimally invasive Urology) with a perspective from Africa and a perspective from Europe.

The learning objectives for each topics are:

- To describe the practice in underserved areas and confront them with evidence based practice
- Underscore the innovations in Urology practice and explore the best ways to apply them in current practice
- Develop partnership to improve global urology practice by bridging the north South gap

**10:45 - 10:47**

### Introduction

**10:47 - 11:16**

### Bladder cancer

**10:47 - 10:54**

#### Bladder cancer in Libya

R. Abusamra, Misurata (LY)

**10:54 - 11:01**

#### What's new in non-muscle invasive bladder cancer diagnosis and treatment

To be confirmed

**11:01 - 11:16**

### Discussion

**11:16 - 11:45**

### Urolithiasis

**11:16 - 11:23**

#### What water and lemons can do to stones and stone fragments

S.R. Aminu, Rochdale (GB)

**11:23 - 11:30**

#### How to follow-up patients after definitive stone treatment

A. Skolarikos, Athens (GR)

**11:30 - 11:45**

### Discussion

**11:45 - 12:14**

### Uro-genital reconstruction

**11:45 - 11:52**

#### Urethral strictures, improving care in South Africa

To be confirmed

**11:52 - 11:59**

#### What's new in the EAU Urethral Stricture Guidelines

T.J. Greenwell, London (GB)

**11:59 - 12:14**

### Discussion

**12:14 - 12:43**

### Minimally invasive techniques

**12:14 - 12:21**

#### South South Collaboration in the development of mini invasive techniques in urology

H.J.G. Berthe, Bamako (ML)

**12:21 - 12:28**

#### Opportunities for increasing role of technology in urological care globally

A.S. Gözen, Heilbronn (DE)

**12:28 - 12:43**

### Discussion

12:43 - 12:45

Closing remarks

## Joint Session of the European Association of Urology (EAU) and the Pakistan Association of Urological Surgeons (PAUS)

Urology beyond Europe

Friday 10 March  
10:45 - 12:45

**Location** Pink Area, ESU 2

**Chairs** J.P.M. Sedelaar, Nijmegen (NL)  
M. Sheriff, Kent (GB)

### Learning objectives

This session will collaboratively endeavor to provide an overview of the latest developments in the training of Minimally Invasive Surgery (MIS) and management of Muscle Invasive Bladder Cancer (MIBC) with the aim of optimising patient care.

10:45 - 10:50

### Welcome and introduction

M.A. Khan, Islamabad (PK)

10:50 - 11:35

### MIS training

*Moderators* J.W. Collins, London (GB)  
To be confirmed

10:50 - 11:05

### Latest developments in MIS training

To be confirmed

11:05 - 11:20

### MIS training: Where are we in Pakistan?

To be confirmed

11:20 - 11:35

### Questions and answers

11:35 - 12:20

### Management of MIBC

*Moderators* M. Ather, Karachi (PK)  
J.A. Witjes, Nijmegen (NL)

11:35 - 11:50

### Management of MIBC: Update

To be confirmed

11:50 - 12:05

### Management of MIBC: Challenges in Pakistan

To be confirmed

12:05 - 12:20

### Questions and answers

12:20 - 12:30

### Case presentation Challenging clinical case

S. Abbasi, Islamabad (PK)

12:30 - 12:40

### Questions and answers

12:40 - 12:45

### Conclusion

F. Mumtaz, London (GB)

## Roundtable discussion: Surviving Urological Cancer and Chronic disability from Urological Disease

Patient information session

**Friday 10 March**  
**11:30 - 12:30**

**Location** Yellow Area, Amber 5

**Chair** To be confirmed

**11:30 - 11:32**

**Welcome & introduction**  
To be confirmed

**11:32 - 11:44**

**Incontinence**  
To be confirmed

**11:44 - 11:56**

**Sexual dysfunction: (Male and Female)/Infertility penile cancer patients**  
E. Briers, Hasselt (BE)

**11:56 - 12:08**

**Haematuria (Patients receiving RT suffer from haematuria and are more prone to BCa)**  
To be confirmed

**12:08 - 12:20**

**Mental health (Active surveillance: anxiety, depression)**  
C. Schulz-Quach, Toronto (CA)

**12:20 - 12:30**

**Q&A and closing**  
To be confirmed

## Prostate cancer screening and active surveillance – Where are we now?

ESU Course 06

Friday 10 March  
11:30 - 13:30

**Location** Pink Area, ESU 3

**Chair** S. Carlsson, New York (US)

### Learning objectives

- Prostate cancer is a global public health concern. While large randomised trials have shown a reduction in prostate cancer mortality with regular prostate-specific antigen (PSA) screening, there is potential for negative effects from over-diagnosis and treatment, making screening a controversial topic. This course will provide an overview of the evidence of both benefits and harm from the randomised trials as well as data from epidemiological studies illustrating the global incidence and mortality trends.
- Today's challenges include the age when to start screening, screening intervals and the optimal use of "smarter screening". This course will cover the EAU-ESTRO-SIOG Guidelines and other risk-stratified approaches to screening based on age, health and PSA-values, family history, ethnicity and genetic risk.
- Active surveillance (AS) is now widely accepted as a management strategy for low-risk prostate cancer with definitive treatment used if there is evidence that the patient is at increased risk for disease progression. Several AS studies have consistently shown a low rate of progression to metastatic disease or death from prostate cancer with AS, with the majority of patients remaining free from definitive therapy for many years.
- Clinical and pathological factors influencing the risk of disease progression in patients with low risk prostate cancer under AS, surveillance strategy, role of repeat biopsy, inclusion criteria, and the use of MRI will be discussed.
- The course will be interactive and include illustrative and practical clinical case discussions.

### Prostate cancer screening: Where are we now?

S. Carlsson, New York (US)

### Prostate cancer active surveillance: Where are we now?

R.C.N. Van Den Bergh, Utrecht (NL)



## Updates and controversies: Incontinence, bladder and male LUTS guidelines 2023: What has changed?

ESU Course 07

Friday 10 March  
11:30 - 13:30

**Location** Pink Area, ESU 4

**Chair** A.K. Nambiar, Newcastle-upon-Tyne (GB)

### Learning objectives

This course will focus on 3 non-oncology Guidelines (Non-Neurogenic Female and Male LUTS, and Urolithiasis) and there will be a brief review of the EAU guidelines methodology and process of guideline development.

The course will then involve an interactive discussion of the main new changes to these guidelines, challenges in development, areas of inconsistency and opportunities for further research.

### Welcome and introduction

A.K. Nambiar, Newcastle-upon-Tyne (GB)

### Urolithiasis guideline: New diagnostic algorithms, best clinical practice in urinary stone intervention, how and how often to follow up and time to discharge urinary stone patients after treatment

R. Geraghty, Newcastle upon Tyne (GB)

### Non-neurogenic male LUTS guideline: Updates and controversies

J-N.L. Cornu, Rouen (FR)

### Female Non-neurogenic LUTS: A re-birth, revamp and re-naming. Changes to expect in 2023

A.K. Nambiar, Newcastle-upon-Tyne (GB)

## Robot-assisted laparoscopic radical cystectomy

ESU Course 08

Friday 10 March  
11:30 - 13:30

**Location** Pink Area, ESU 5

**Moderator** To be confirmed

### Learning objectives

The course is video-based. The steps in the surgical treatment of muscle-invasive bladder cancer by conventional laparoscopy and robot-assisted technique will be described. The surgical technique to perform male and female cystectomy, lymph node dissection, urinary diversion with extracorporeal and intracorporeal technique, conduits as well as orthotopic neobladders, will be shown. Indications, contraindications, outcomes and handling of complications will be discussed.

- The surgical steps in nerve-sparing and non-nerve sparing male cystectomy.
- The surgical steps in female cystectomy with and without organ-sparing technique.
- The surgical steps in lymph node dissection during cystectomy.
- The technique in urinary diversion, conduit and neobladder, with intra- and extracorporeal technique.
- Indications, outcomes and complications after minimally-invasive cystectomy.
- The handling of the most common complications after minimally-invasive cystectomy.

### Introduction

To be confirmed

### Laparoscopic cystectomy in males (video-based teaching)

#### Robot-assisted technique with nerve-sparing technique

To be confirmed

### Laparoscopic cystectomy in females (video-based teaching)

#### Robot-assisted cystectomy with organ preservation

To be confirmed

### Laparoscopic urinary diversion (video-based teaching)

#### Intracorporeal: Bricker

To be confirmed

#### Intracorporeal: Neobladder

To be confirmed

### Challenge the expert: Controversies in laparoscopic and robotic cystectomy

#### Oncological outcomes in laparoscopic cystectomy: Challenger

To be confirmed

#### Oncological outcomes in laparoscopic cystectomy: Pro

To be confirmed

#### Complications and functional outcomes in laparoscopic cystectomy: Pro

To be confirmed

### Discussion

To be confirmed

## How we manage upper tract tumours

ESU Course 09

Friday 10 March  
11:30 - 13:30

**Location** Pink Area, ESU 6

**Chair** S. Shariat, Vienna (AT)

### Learning objectives

This course will address contemporary concepts and controversies in UTUC such as:

- Accurate staging and its role in clinical decision-making/risk stratification.
- Risks, benefits, and side effects of current and novel therapeutic approaches including endoscopic and minimal-invasive surgery.
- Optimal management of the bladder cuff as well as indication and extent of lymphadenectomy.
- Systemic therapy for high-risk and metastatic patients.

### Epidemiology, diagnosis, evaluation

M. Rouprêt, Paris (FR)

### Prognostic and predictive factors, pathology

S. Shariat, Vienna (AT)

### Treatment of low-risk cancer (high grade Ta, T1 and carcinoma in situ (CIS))

M. Rouprêt, Paris (FR)

### Treatment of localised high-risk (invasive) and metastatic cancer

S. Shariat, Vienna (AT)

## Practical tips for pelvic laparoscopic surgery: Cystectomy, radical prostatectomy adenomectomy and sacrocolpopexy

ESU Course 10

Friday 10 March  
11:30 - 13:30

**Location** Pink Area, ESU 7  
**Chair** J.M. Gaya Sopena, Barcelona (ES)

### Learning objectives

**Patient positioning and trocar placement**  
J.M. Gaya Sopena, Barcelona (ES)

**Laparoscopic adenomectomy and radical prostatectomy**  
P. Kallidonis, Patras (GR)

**Laparoscopic radical cystectomy**  
J.M. Gaya Sopena, Barcelona (ES)

**Laparoscopic reconstructive surgery of the pelvic floor and sacrocolpopexy**  
P. Kallidonis, Patras (GR)

**Identify and solve complications**  
J.M. Gaya Sopena, Barcelona (ES)

## Emergencies in urology

Thematic Session

Friday 10 March  
12:30 - 14:00

**Location** Yellow Area, eURO Auditorium 2

**Chairs** A. Pietropaolo, Southampton (GB)  
J. Rassweiler, Krems - Stein (AT)

### Learning objectives

The main topic of this session will be the exchange of ideas if one is confronted with the respective emergency. Emergencies are the most critical situations for surgeons and urologists and we have picked the most relevant urological emergencies presented by experienced speakers. If possible, the presentation will be supported by video-demonstration.

12:30 - 12:33

### Welcome and introduction

A. Pietropaolo, Southampton (GB)

12:33 - 12:43

### Video-based presentation Scrotal emergencies

T. Taily, Ghent (BE)

12:43 - 12:48

### Discussion

12:48 - 12:58

### Video-based presentation Emergencies related to sexual activities

A.S. Gözen, Heilbronn (DE)

12:58 - 13:03

### Discussion

13:03 - 13:13

### Video-based presentation Fourniers Gangrene: Primary and secondary management

J. Rassweiler, Krems - Stein (AT)

13:13 - 13:18

### Discussion

13:18 - 13:33

### Video-based presentation Renal and ureteral trauma

L. Tzelves, Athens (GR)

13:33 - 13:38

### Discussion

13:38 - 13:53

### Video-based presentation Urethral trauma

D.E. Andrich, London (GB)

13:53 - 13:58

### Discussion

13:58 - 14:00

### Closing remarks

J. Rassweiler, Krems - Stein (AT)

## 9th ESO Prostate Cancer Observatory: Innovation and care in the next 12 month

Thematic Session



**Friday 10 March**  
12:30 - 14:30

**Location** Yellow Area, Brown 3  
**Chairs** To be confirmed  
U. Vogl, Bellinzona (CH)

### Learning objectives

ESO Observatories are high-level sessions organised during major international congresses with the aim of providing the audience with updated and unbiased information on a given topic. An ESO Observatory concentrates on a forecast given by panel of experts of what it is expected to happen in their own field in the coming 12 months. The panel includes distinguished clinicians and/or scientists and a patient advocate. The forecast by each panel member is given in the form of concise take-home messages with 8 minute slide presentation for each topic + 2 minutes for discussion.

12:30 - 12:35	<b>Welcome and introduction</b>
12:35 - 12:45	<b>The urologist's perspective on surgery</b> S. Joniau, Leuven (BE)
12:45 - 12:55	<b>The urologist's perspective on active surveillance</b> P. Cornford, Liverpool (GB)
12:55 - 13:05	<b>The radiation oncologist's perspective</b> G. De Meerleer, Leuven (BE)
13:05 - 13:15	<b>The medical oncologist's perspective</b> U. Vogl, Bellinzona (CH)
13:15 - 13:25	<b>The pathologist's perspective</b> E. Comp�rat, Paris (FR)
13:25 - 13:35	<b>The geneticist's perspective</b> E. Castro, Madrid (ES)
13:35 - 13:45	<b>The imaging specialist's perspective on PSMA-PET/CT</b> S. Fanti, Bologna (IT)
13:45 - 13:55	<b>The imaging specialist's perspective on MRI</b> J. Barentsz, Nijmegen (NL)
13:55 - 14:05	<b>The urologist's perspective on focal therapy</b> R. Sanchez-Salas, Montreal (CA)
14:05 - 14:15	<b>The nurse's perspective</b> C.N. Tillier, Amsterdam (NL)
14:15 - 14:25	<b>The patient's perspective</b> To be confirmed
14:25 - 14:30	<b>Closing remarks</b>

## Joint Session of the European Association of Urology (EAU) and the Korean Urological Association (KUA)

Urology beyond Europe

Friday 10 March  
13:00 - 15:00

**Location** Pink Area, Coral 2  
**Chairs** S.K. Hong, Seongnam (KR)  
M.J. Ribal Caparros, Barcelona (ES)

### Learning objectives

This session will address a variety of hot urology topics with the help of specialists and key opinion leaders from South Korea and Europe. Delegates can expect detailed and up-to-date coverage of topics of renal cancer, urolithiasis and prostate cancer.

In this session some of the regional similarities and differences in approaches will be explored.

13:00 - 13:06

### Welcome and introduction

M.J. Ribal Caparros, Barcelona (ES)  
J.H. Hong, Seoul (KR)

13:06 - 13:44

### Kidney cancer

*Moderators* W.K. Han, Seoul (KR)  
M.C. Mir Maresma, Valencia (ES)

13:06 - 13:14

### Expanding boundaries for partial nephrectomy

J.Y. Park, Ansan (KR)

13:14 - 13:22

### Emerging biomarkers to immunotherapy in aRCC

M-O. Grimm, Jena (DE)

13:22 - 13:30

### Current role of surgery for metastatic RCC in immuno-oncology era?

To be confirmed

13:30 - 13:44

### Panel discussion

*Panel* E.C. Hwang, Gwangju (KR)  
M-O. Grimm, Jena (DE)  
M. Kang, Seoul (KR)  
To be confirmed

13:44 - 14:22

### Endourology and paediatrics

*Moderators* A. Budía Alba, Valencia (ES)  
S.H. Jeon, Seoul (KR)

13:44 - 13:52

### Ureteroscopy: What can we expect in the near future?

H.J. Kim, Daejeon (KR)

13:52 - 14:00

### Medical expulsive therapy for ureter stones: Future trends and knowledge gaps

C.M. Cracco, Turin (IT)

14:00 - 14:08

### Current evidence of bladder bowel dysfunction treatment for VUR

S.W. Kim, Seoul (KR)

14:08 - 14:22

### Panel discussion

*Panel* C.M. Cracco, Turin (IT)  
S.O. Kim, Gwangju (KR)  
K. Park, Seoul (KR)

14:22 - 15:00

### Prostate cancer

*Moderators* I.M. Van Oort, Nijmegen (NL)  
T.W. Kang, Gwangju (KR)

14:22 - 14:30

**Management of BCR after definitive treatment in PSMA PET era: Early salvage treatment vs. waiting for PSMA PET positivity**  
A. Vilaseca, Barcelona (ES)

14:30 - 14:38

**Active surveillance in the era of MR targeted biopsy**  
C.W. Jeong, Seoul (KR)

14:38 - 14:46

**Complications and recurrence after focal therapy**  
E. Barret, Paris (FR)

14:46 - 15:00

**Panel discussion**

*Panel*

E. Barret, Paris (FR)  
J.Y. Joung, Goyang (KR)  
S.H. Kang, Seoul (KR)  
A. Vilaseca, Barcelona (ES)



## Reconstruction: Pick and mix

Video Session 02

**Friday 10 March**  
**12:30 - 14:00**

**Location** Blue Area, Room 1  
**Chairs** To be confirmed  
O. Kose, Sakarya (TR)  
To be confirmed

**12:30 - 12:33**

**Introduction**

V008

**Ventral onlay buccal mucosa graft for female urethral stricture: Medium-term results in our referral center**

E. Berdondini, Turin (IT)

V009

**Transobturator vaginal wall sling (Elgamasy technique): for the treatment of female stress urinary incontinence (Video and oral presentation)**

A.K.E Elgamasy, Tanta (EG)

V010

**Genital manifestation of Chron's disease: a surgical approach.**

C.G. Costi, (IT)

V011

**Glans resurfacing for lichen sclerosus**

P. Joshi, Pune (IN)

V012

**Minimally invasive treatment of bladder leiomyoma: Endoscopic and laparoscopic approaches**

V013

**Laparoscopic extravesical ureteric reimplantation for high grade vesico-ureteric reflux in pediatric population: Our experience**

V. Chandra Mohan, Hyderabad (IN)

V014

**Robotic buccal mucosa graft ureteroplasty for post angioplasty ureteral stricture**

V015

**Full laparoscopic Mitrofanoff procedure**

D. Thillou, Saint-Georges-des-Coteaux (FR)

**13:51 - 13:56**

**Closing remarks**

## Male voiding LUTS: Clinical issues, diagnosis, and medical treatment

Abstract Session 02

**Friday 10 March  
12:30 - 14:00**

**Location** Pink Area, Coral 3  
**Chairs** M. Tutolo, Milan (IT)  
T. Antunes Lopes, Porto (PT)  
P.K-F. Chiu, Hong Kong (HK)

**12:30 - 12:33**

**Introduction**

A0020 **Computational fluid dynamics analysis of urethral pressure in benign prostatic hyperplasia**

A0021 **The impact of arterial stiffness on under active bladder**  
A. Niimi, Tokyo (JP)

A0022 **Development and validation of a clinical nomogram predicting detrusor underactivity via symptoms and noninvasive test parameters in men with benign prostatic hyperplasia**  
Y. Wu, Beijing (CN)

A0023 **Validation and clinical utility of the Nagoya diagnostic criteria for detrusor underactivity in men**

**12:41 - 12:53**

**Discussion**

A0024 **Association between urinary flow rate and cognition in the elderly: A cross-sectional study**

A0025 **Clinical predictors of bladder outlet obstruction among men consulting for routine urological screening**  
P. Capogrosso, Milan (IT)

A0026 **Predicting prostate surgery outcome in men with lower urinary tract symptoms to derive symptom score and flowmetry thresholds**  
H. Ito, Yokohama (JP)

A0027 **A Novel Clinical Prostate Score (CLIPS) for Minimally Invasive Therapy (MIST) of Prostate**  
W.C. Tsang, Singapore (SG)

A0028 **Personalized bedtime determined by a wearable device improves nocturia; A prospective interventional crossover study**

A0029 **The 5 years effects of bariatric surgery on the improvement of lower urinary tract symptoms in morbidly obese male patients**  
C.F.A. Ng, Hong Kong (HK)

A0030 **Efficacy and safety of clean intermittent catheterization in management of acute urinary retention: A multicenter prospective randomized trial**  
V. Malkhasyan, Moscow (RU)

## Scientific Programme - EAU23 Milan

---

A0031	<b>Clinical outcomes of withdrawing one medication from long-term combination therapy comprising <math>\alpha</math>-blocker and 5<math>\alpha</math>-reductase inhibitor for benign prostatic hyperplasia</b>
A0032	<b>The association of 5-alpha reductase inhibitors treatment with prostate cancer in benign prostate hyperplasia patients: A population based case control study</b> S.E. Lee, Taichung (TW)
A0033	<b>The impact of 5-alpha reductase inhibitors on perioperative and functional outcomes of Greenlight photovaporization of the prostate: An analysis of the Global Greenlight Group database</b> T. Elsherbini, Dorval (CA)
A0034	<b>Cost-effectiveness of alternative first- and second-line treatments for benign prostatic hyperplasia in Singapore</b>
A0035	<b>The Impact of BPH Care: Procedural Complications Associated with MIST and Traditional Surgery Compared to Disease Progression with Medical Therapy</b> S.A. Kaplan, New York (US)
A0036	<b>Impact of persistent bladder outlet obstruction on bladder function in male BPH patients</b> M.S. Choo, Seoul (KR)
A0037	<b>Pathophysiological analysis of detrusor overactivity following partial bladder outlet obstruction</b> H. Morinaka, Kurashiki (JP)
13:21 - 13:53	<b>Discussion</b>
13:53 - 14:00	<b>Closing remarks</b>

---

## Joint Session of the European Association of Urology (EAU) and the Maghreb Union countries

Urology beyond Europe

Friday 10 March  
10:45 - 12:45

**Location** Pink Area, Coral 1  
**Chairs** K. Ait El Hadj, Draria (DZ)  
J. Rassweiler, Krems - Stein (AT)

### Learning objectives

We expect an update on the most recent advances on the conservative management of upper urinary tract cancer, the new treatment of lithiasis, specially Thulium fiber, we are also interested in the update on the management of BCG refractory NMIBC (Immunotherapy, IL15 superagonist, Anti PD1 Hyperthermic intravesical chemotherapy,...).

10:45 - 10:46

### Introduction

10:46 - 11:14

### Upper urinary tract tumours

*Moderators* J. Bedke, Tübingen (DE)  
To be confirmed  
S. Braiek, Kairouan (TN)  
To be confirmed

10:46 - 10:53

### Survival of non-metastatic upper urinary tract urothelial carcinoma: Through a simple score

Y. Ouanes, Tunis (TN)

10:53 - 11:00

### Endoscopic treatment in upper tract urinary tumours

A. Belkacem Nacer, Algiers (DZ)

11:00 - 11:07

### Locally advanced upper tract urothelial carcinoma: Surgery

A. Touzani, Rabat (MA)

11:07 - 11:14

### Perioperative medical treatment

J. Bedke, Tübingen (DE)

11:14 - 11:42

### Bladder tumours

*Moderators* K. Chettibi, Annaba (DZ)  
M. Babjuk, Prague (CZ)  
I. Sarf, Marrakech (MA)  
W. ZAKHAMA, Mahdia (TN)

11:14 - 11:21

### Epidemiological profile and clinical aspect of bladder carcinoma in Maghreb countries

S. Kerroumi, Oran (DZ)

11:21 - 11:28

### BCG Tunisian strain which protocol

M. Raboudi, Tunis (TN)

11:28 - 11:35

### Clinical case discussion Conservative management for multifocal NMIBC

A. Mellouki, Fes (MA)

11:35 - 11:42

M. Babjuk, Prague (CZ)

11:42 - 12:17

### Urolithiasis

*Moderators* To be confirmed  
B. Somani, Southampton (GB)  
To be confirmed  
A.S. Zribi, Tunis (TN)

11:42 - 11:49	<b>The future of ESWL in Maghreb countries</b> S. Braiek, Kairouan (TN)
11:49 - 11:56	<b>Particularities of flexible ureteroscopy during endoscopic combined treatment of renal stone</b> To be confirmed
11:56 - 12:03	<b>Case-based discussion Staghorn stone</b> A. Slaoui, Rabat (MA)
12:03 - 12:10	<b>Epidemiological characteristics of Tunisian urinary stones: A retrospective study over 21 years</b> K. Bouzid Ghozzi, Tunis (TN)
12:10 - 12:17	<b>EAU Guidelines - also true for the Maghreb countries</b> B. Somani, Southampton (GB)
<hr/>	
12:17 - 12:43	<b>Discussion High risk and locally advanced prostate cancer</b> <i>Moderators</i> K. Benakila, Alger (DZ) J. Walz, Marseille (FR) To be confirmed To be confirmed
12:17 - 12:22	<b>Case presentation High risk and locally advanced prostate cancer</b> To be confirmed
12:22 - 12:29	<b>Surgery</b> M.M. Atoui, Annaba (DZ)
12:29 - 12:36	<b>Radiation therapy</b> To be confirmed
12:36 - 12:43	<b>Perioperative treatment what's in the horizon</b> J. Walz, Marseille (FR)
<hr/>	
12:43 - 12:45	<b>Conclusion</b> K. Ait El Hadj, Draria (DZ) J. Rassweiler, Krems - Stein (AT)

## Joint Session of the European Association of Urology (EAU) and the Confederación Americana de Urología (CAU)

Urology beyond Europe

Friday 10 March  
13:00 - 15:00

**Location** Pink Area, Coral 4  
**Chairs** C.R. Chapple, Sheffield (GB)  
A.R. Rodriguez, Winston Salem (US)

### Learning objectives

This session aims to show possible strategies for clinical scenarios in Europe and Latin America. The scenarios include case-based debates and state-of-the-art lectures on non-muscle invasive bladder cancer, localised prostate cancer, recurrent presumably localised and oligometastatic prostate cancer, treatment options for female stress incontinence, urinary tract reconstructive surgery, and endoscopic access variations of upper tract stone treatment.

All these topics will be presented and discussed by recognised expert representatives from both EAU and CAU.

Attendees will thus be able to obtain precise updates on diagnosis and management within these topics.

13:00 - 13:02

### Introduction

13:02 - 13:45

### Prostate cancer

#### Debate Radical prostatectomy: How to perform it?

13:02 - 13:08

#### Open

P. Albers, Düsseldorf (DE)

13:08 - 13:14

#### Robotic

R. Coelho, Sao Paulo (BR)

13:14 - 13:20

#### Discussion

13:20 - 13:30

#### Early salvage radiation therapy: In whom, how and when

To be confirmed

13:30 - 13:35

#### Case presentation Case based contemporary management of prostate cancer

R. Sanchez-Salas, Montreal (CA)

13:35 - 13:45

#### Panel discussion

*Panel*

P. Albers, Düsseldorf (DE)

To be confirmed

G. Vitagliano, Buenos Aires (AR)

13:45 - 14:09

### Bladder cancer

#### Debate Surgery in NMIBC: How to perform it?

13:45 - 13:50

#### En bloc resection

A. Breda, Barcelona (ES)

13:50 - 13:55

#### Conventional resection

M. Fernández, Santiago (CL)

13:55 - 13:59

#### Discussion

13:59 - 14:09

#### High risk NMIBC: BCG and beyond

J. Palou, Barcelona (ES)

14:09 - 14:23

### Reconstructive urology

## Scientific Programme - EAU23 Milan

---

14:09 - 14:16	<b>What role for robotic surgery</b> C.R. Chapple, Sheffield (GB)
14:16 - 14:23	<b>Effective management of anterior urethral strictures. What is new?</b> F.E. Martins, Lisbon (PT)
14:23 - 14:42	<b>Debate How to manage female incontinence?</b>
14:23 - 14:28	<b>Autologous sling</b> N.I. Osman, Wirral (GB)
14:28 - 14:33	<b>Synthetic sling</b> J.C. Truzzi, São Paulo (BR)
14:33 - 14:38	<b>Injectable therapy</b> V. Phé, Paris (FR)
14:38 - 14:42	<b>Discussion</b>
14:42 - 14:56	<b>Stones and endourology</b> <b>Debate Miniperc should be the new gold standard</b>
14:42 - 14:49	<b>Pro</b> P.N. Contreras, Buenos Aires (AR)
14:49 - 14:56	<b>Con</b> E. Liatsikos, Patras (GR)
14:56 - 15:00	<b>Conclusion</b>

---

## Joint Session of the European Association of Urology (EAU) and the Japanese Urological Association (JUA)

Urology beyond Europe

**Friday 10 March**  
**13:00 - 15:30**

**Location** Pink Area, Coral 1  
**Chairs** T. Ichikawa, Chiba (JP)  
A.S. Merseburger, Lübeck (DE)

### Learning objectives

The aim of this session is to provide the audience an insight in specific topics of current clinical practice in urology. The selected themes this year are “Advanced prostate cancer” and “Female urology.” For each topic, the discussion will follow two pathways: on one hand a synthesis of the most recent scientific evidence will be examined, on the other hand, complex scenarios will be discussed by top-class experts. The audience will learn how to face complex clinical decision-making in case of advanced prostate cancer and female urology based on the actual EAU Guidelines.

**13:00 - 13:05**

### Introduction

**13:05 - 14:00**

### Advanced prostate cancer

*Moderators* A.S. Merseburger, Lübeck (DE)  
M. Sugimoto, Kagawa (JP)

**13:05 - 13:15**

### Optimal timing of salvage therapy post local treatment for prostate cancer

To be confirmed

**13:15 - 13:25**

### Debate Maximum androgen therapy (MAB) is sufficient for mHSPC

S. Katayama, Okayama (JP)

**13:25 - 13:35**

### Debate Maximum androgen therapy (MAB) is not sufficient for mHSPC

A.S. Bjartell, Malmö (SE)

**13:35 - 14:00**

### Discussion

*Panel* A.S. Bjartell, Malmö (SE)  
N. Fujita, Hiroasaki (JP)  
K. Mori, Tokyo (JP)  
To be confirmed

**14:00 - 14:15**

### EAU-JUA exchange experiences

*Moderators* M. Eto, Fukuoka (JP)  
A.S. Merseburger, Lübeck (DE)

**14:00 - 14:05**

### Experiencing Japanese urology within the EAU-JUA exchange program – my personal summary

V. Phé, Paris (FR)

**14:05 - 14:10**

### My exciting experience in the EAU/JUA exchange program

K. Takahara, Takatsuki (JP)

**14:10 - 14:15**

### Questions and answers

**14:15 - 14:40**

### JUA poster presentations

*Moderators* M. Eto, Fukuoka (JP)  
A.S. Merseburger, Lübeck (DE)

**14:15 - 14:20**

### Abstract 1

To be confirmed



## Scientific Programme - EAU23 Milan

---

14:20 - 14:25

**Abstract 2**

To be confirmed

14:25 - 14:30

**Abstract 3**

To be confirmed

14:30 - 14:35

**Abstract 4**

To be confirmed

14:35 - 14:40

**Abstract 5**

To be confirmed

---

14:40 - 15:25

**Female urology**

*Moderators*

T. Mitsui, Chuo-City (JP)

V. Phé, Paris (FR)

14:40 - 14:50

**New era of POP management: A current situation in Japan**

A. Fujihara, Kyoto (JP)

14:50 - 15:00

**Female urology within the EAU – standards, guidelines and recent evidence**

V. Phé, Paris (FR)

15:00 - 15:25

**Panel discussion**

*Panel*

H. Ito, Yokohama (JP)

T. Iwata, Yokohama (JP)

M.J. Ribal Caparros, Barcelona (ES)

V. Phé, Paris (FR)

---

15:25 - 15:30

**Closing remarks**

N. Nonomura, Osaka (JP)

## Joint Session of the European Association of Urology (EAU) and the Arab Association of Urology (AAU)

Urology beyond Europe

**Friday 10 March**  
**13:00 - 15:00**

**Location** Yellow Area, Brown 2

**Chairs** Y. Farahat, Umm Al Quwain (AE)  
J.O.R. Sønksen, Herlev (DK)

### Learning objectives

Leading experts from the Arab Association of Urology and European Association of Urology will present updates and discuss clinical challenges and advances in PCNL in urolithiasis as well as strategies in penile prosthesis implantation followed by an expert panel discussion led by key opinion leaders. After each sub session there will be active involvement with the audience through Q&A.

**13:00 - 13:03**

**Introduction**

**13:03 - 14:00**

**Session I: Challenges and advances in PCNL**

**13:03 - 13:11**

**PCNL: Prone**  
P.J.S. Osther, Vejle (DK)

**13:11 - 13:19**

**PCNL: Supine**  
To be confirmed

**13:19 - 13:27**

**Renal access: Fluoroscopy guided**  
To be confirmed

**13:27 - 13:35**

**Renal access: US guided**  
T. Knoll, Sindelfingen (DE)

**13:35 - 13:40**

**Case discussion Difficult scenario: PCNL**  
Y. Farahat, Umm Al Quwain (AE)

**13:40 - 13:55**

**Expert discussion**  
*Panel* To be confirmed  
A.R. Hammady, Sohag (EG)  
T. Knoll, Sindelfingen (DE)  
P.J.S. Osther, Vejle (DK)

**13:55 - 14:00**

**Questions and answers**

**14:00 - 14:57**

**Session II: Strategies in penile prosthesis implantation**

**14:00 - 14:08**

**Clinical assessment and patient selection**  
To be confirmed

**14:08 - 14:16**

**Surgical approaches in inflatable penile prosthesis surgery**  
To be confirmed

**14:16 - 14:24**

**Is there a place for maleable penile prosthesis**  
N. Al-Hathal, Riyadh (SA)

**14:24 - 14:32**

**Reservoir placement: Tips & tricks**  
M. Hamdan, Amman (JO)

**14:32 - 14:37**

**Case discussion Management of perioperative complication**  
A.R. Zahran, Alexandria (EG)

**14:37 - 14:52**

**Expert discussion**

## Scientific Programme - EAU23 Milan

---

*Panel*

A.A. Al-Zarooni, Sharjah (AE)

To be confirmed

To be confirmed

To be confirmed

**14:52 - 14:57**

**Questions and answers**

---

**14:57 - 15:00**

**Closing remarks**

## Joint Session of the European Association of Urology (EAU) and the Caucasus/Central Asian countries

Urology beyond Europe

**Friday 10 March**  
**13:00 - 15:00**

**Location** Pink Area, ESU 1  
**Chairs** M. Babjuk, Prague (CZ)  
D. Nikoleishvili, Tbilisi (GE)

**13:00 - 13:04**

**Intrduction**

**13:04 - 13:41**

**Minimally invasive surgery (laparoscopy, endoscopy)**

**13:04 - 13:12**

**Ureteroscopy vs percutaneous surgery for 2 cm renal stone**

To be confirmed

**13:12 - 13:20**

**Georgie lecture**

To be confirmed

**13:20 - 13:28**

**Turkmenistan lecture**

To be confirmed

**13:28 - 13:36**

**Uzbekistan lecture**

To be confirmed

**13:36 - 13:41**

**Discussion**

**13:41 - 14:18**

**Oncology**

**13:41 - 13:49**

**Radical cystectomy for NMIBC?**

M. Babjuk, Prague (CZ)

**13:49 - 13:57**

**Kazakhstan lecture**

To be confirmed

**13:57 - 14:05**

**Kyrgyzstan lecture**

To be confirmed

**14:05 - 14:13**

**Armenia lecture**

To be confirmed

**14:13 - 14:18**

**Discussion**

**14:18 - 14:55**

**Reconstructive surgery**

**14:18 - 14:26**

**Updates in urethral stricture surgery**

P. Nyirády, Budapest (HU)

**14:26 - 14:34**

**Tajikistan lecture**

To be confirmed

**14:34 - 14:42**

**Azerbaijan lecture**

To be confirmed

**14:42 - 14:50**

**Georgia lecture**

To be confirmed

**14:50 - 14:55**

**Discussion**

**14:55 - 15:00**

**Conclusion**

## Joint Session of the European Association of Urology (EAU) and the Canadian Urological Association (CUA)

Urology beyond Europe

**Friday 10 March**  
**13:00 - 15:00**

**Location** Pink Area, ESU 2

**Chairs** R.A. Rendon, Halifax (CA)  
J.L. Vásquez, Copenhagen (DK)

### Learning objectives

For the third time the Canadian Urological Association (CUA) is joining the Urology Beyond Europe sessions at the Annual EAU Congress!

The session is organised in four parts, covering some oncology topics (UTUC, NMIBC and prostate cancer) and one miscellaneous topic (reconstructive urology). Canadian and European expert speakers will update their experience and discuss newest developments, always taking patients' perspectives into account

**13:00 - 13:05**

### Introduction

**13:05 - 13:40**

### Upper tract urothelial cell carcinoma

*Moderator* B. Pradere, Toulouse (FR)

**13:05 - 13:10**

### Case presentation

B. Pradere, Toulouse (FR)

**13:10 - 13:20**

### Should all patients undergo a lymph node dissection?

N.H. Azawi, Roskilde (DK)

**13:20 - 13:30**

### Is neoadjuvant chemotherapy the standard of care?

A. Necchi, Milan (IT)

**13:30 - 13:40**

### Panel discussion

*Panel* N.H. Azawi, Roskilde (DK)  
A. Necchi, Milan (IT)

**13:40 - 14:10**

### Staging and evaluation of NMIBC

**13:40 - 13:50**

### Role of biomarkers in NMIBC

L. Dyrskjød, Aarhus (DK)

**13:50 - 14:00**

### Are advanced endoscopic techniques ready for prime time?

To be confirmed

**14:00 - 14:10**

### Panel discussion

*Panel* L. Dyrskjød, Aarhus (DK)  
To be confirmed

**14:10 - 14:40**

### Treatment of intermediate risk prostate cancer

*Moderator* R. Sanchez-Salas, Montreal (CA)

**14:10 - 14:15**

### Case presentation

R. Sanchez-Salas, Montreal (CA)

**14:15 - 14:25**

### Active surveillance

L.H. Klotz, Toronto, ON (CA)

**14:25 - 14:35**

### Focal therapy

To be confirmed

**14:35 - 14:40**

### Panel discussion

## Scientific Programme - EAU23 Milan

---

*Panel*

To be confirmed

L.H. Klotz, Toronto, ON (CA)

---

**14:40 - 15:00**

**State-of-the-art lecture Challenges in reconstructive urology – current and future**  
S. Herschorn, Toronto (CA)

## Curiosities in pediatric urology

Thematic Session

<b>Friday 10 March 13:30 - 15:00</b>	<b>Location</b> Pink Area, Coral 7
	<b>Chairs</b> G. Bogaert, Leuven (BE) S-D. Lee, Yangsan-si (KR)
<b>13:30 - 13:35</b>	<b>Representation of women in EAU and ESPU paediatric urology sessions during the last 10 years</b> R.J.M. Lammers, Groningen (NL)
<b>13:35 - 13:40</b>	<b>Management of pediatric kidney trauma</b> L.A. 't Hoen, Rotterdam (NL)
<b>13:40 - 13:50</b>	<b>State-of-the-art lecture Urachal remnants in children: Do they deserve attention?</b> C. Radmayr, Innsbruck (AT)
<b>13:50 - 14:00</b>	<b>European Society for Paediatric Urology (ESPU) lecture Adolescent varicocele; whom to treat? Whom to follow?</b> To be confirmed
<b>14:00 - 14:05</b>	<b>Discussion</b>
<b>14:05 - 14:30</b>	<b>Debate Urolithiasis in infants: Treat or observe?</b> <i>Moderator</i> T. Tailly, Ghent (BE)
<b>14:05 - 14:08</b>	<b>Introduction</b> T. Tailly, Ghent (BE)
<b>14:08 - 14:15</b>	<b>Treat</b> To be confirmed
<b>14:15 - 14:22</b>	<b>Observe</b> B. Bañuelos Marco, Berlin (DE)
<b>14:22 - 14:25</b>	<b>Expert summary</b> U.K. Kennedy, Zurich (CH)
<b>14:25 - 14:30</b>	<b>Discussion</b>
<b>14:30 - 15:00</b>	<b>Debate Ureteral reimplantation in children in 2023: Open or robotic?</b> <i>Moderator</i> F. O'Kelly, Dublin (IE)
<b>14:30 - 14:32</b>	<b>Introduction</b> F. O'Kelly, Dublin (IE)
<b>14:32 - 14:42</b>	<b>Open</b> To be confirmed
<b>14:42 - 14:52</b>	<b>Robotic</b> M.S. Silay, Istanbul (TR)
<b>14:52 - 14:55</b>	<b>Expert summary</b> A. Van Uiter, Nijmegen (NL)
<b>14:55 - 15:00</b>	<b>Discussion</b>

## Roundtable discussion: What is Cystitis?

Patient information session

**Friday 10 March**  
**13:30 - 14:30**

**Location** Yellow Area, Amber 5

**Chairs** To be confirmed  
To be confirmed

### **Learning objectives**

At the end of the session delegates will be able to differentiate the types of cystitis and their treatment options, in addition to gaining insight in a patient's care pathway experience.

**13:30 - 13:32**

**Welcome & introduction**  
To be confirmed

**13:32 - 13:47**

**Taxonomy and nomenclature**  
J.M. Meijlink, Naarden (NL)

**13:47 - 14:02**

**Management plan**  
G. Bonkat, Basel (CH)

**14:02 - 14:17**

**A patient's care pathway experience from diagnosis to deciding on treatment**  
To be confirmed

**14:17 - 14:30**

**Q&As and closing**  
To be confirmed  
To be confirmed



## Prostate cancer challenges and controversies from guidelines to real-world

ESU Course 11

Friday 10 March  
13:45 - 16:45

**Location** Pink Area, ESU 3

**Chair** F. Gómez Veiga, Salamanca (ES)

### Learning objectives

Prostate cancer care represents an essential daily activity with a high impact on moving health resources and everyday decisions, including complex situations and weak evidence.

Guidelines are essential to take decisions, but there are gaps or not enough evidence to make a decision in some cases. We need to learn personalised choices in a continuous evolution of knowledge.

Based on multiple interactive choice questions, the course tries to analyse the risk benefits of different approaches with a practical view – real world - with a critical review from screening to mCRPC based on guidelines.

At the end of the course, the participants must be confident to:

- Optimally use PSA, new biomarkers and role of MRI to minimise unnecessary biopsy in men at risk for prostate. Cost-effectiveness.
- Stratify factors to different approaches to local and local advanced treatment and personalises elections.
- Select risk patients to diagnose and manage after local progression.
- The best election and new tools to diagnose and treat advanced tumours, mHSPC, nmCRPCM or mCRPC. A critical review of new alternatives.

### Introduction

F. Gómez Veiga, Salamanca (ES)

### Prostate cancer: First take a decision or share decision making

F. Gómez Veiga, Salamanca (ES)

### PSA is dead? New markers are profitable. Where we go

A.S. Bjartell, Malmö (SE)

### First biopsy: MRI-guided biopsy to reduce overdiagnosis or standard biopsy

F. Gómez Veiga, Salamanca (ES)

### Local disease, who to treat or not, and how

R. Sanchez-Salas, Montreal (CA)

### Radiotherapy versus surgery in locally- advanced prostate cancer; the battle continues

N. Mottet, Saint-Étienne (FR)

### Progression after local treatment, to treat or not to treat

R. Sanchez-Salas, Montreal (CA)

### How to define oligometastatic and how to treat it

N. Mottet, Saint-Étienne (FR)

### What is the best strategy to treat in the naive metastatic setting

F. Gómez Veiga, Salamanca (ES)

**nmCRPC: How to identify patients and define the best option to treat**  
N. Mottet, Saint-Étienne (FR)

---

**mCRPC: How to start and how to continue and vice-versa**  
A.S. Bjartell, Malmö (SE)

---

**Precision and personalised medicine. New roadmaps**  
A.S. Bjartell, Malmö (SE)

---

**Summary of recent advances and controversies and future directions**  
F. Gómez Veiga, Salamanca (ES)

---

## Male genital diseases

ESU Course 12

Friday 10 March  
13:45 - 16:45

**Location** Pink Area, ESU 4

**Chair** S. Minhas, London (GB)

### Learning objectives

This novel and revised course will give a state-of-the-art update on the variety of genital diseases that urologists will encounter in everyday clinical practice. The faculty consists of a group of internationally renowned experts in this field.

A spectrum of pathologies can affect the male genitals, from benign disorders to cancers. There will be particular focus and emphasis on interactive case based discussions and surgical videos of the latest surgical techniques used in this evolving field. The course will also deal with the surgical management of these diseases including the surgical indications and techniques used in genital reconstructive surgery. Particular focus will be on:

- The aetiology, diagnosis and medical management of the common genital skin diseases including inflammatory conditions.
- The medical and surgical management of HPV, BXO and pre-malignant conditions of the penis, including the techniques of circumcision, skin grafting, glans resurfacing, surgery for buried penis and the correction of genital lymphoedema.
- The surgical management of Peyronie's disease including plication procedures and grafting
- The management of penile carcinoma including the aetiopathogenesis, techniques/ outcome of organ-sparing surgery and ilioinguinal lymphadenectomy will be discussed and illustrated.

### Surgical management of Peyronie's disease

S. Minhas, London (GB)

### Penile and scrotal dermatology for the urologist

N. Watkin, London (GB)

### Circumcision, frenuloplasty and preputioplasty

C. Protzel, Schwerin (DE)

### The buried penis

S. Minhas, London (GB)

### Management of genital lymphoedema

N. Watkin, London (GB)

### Premalignant lesions of the penis and scrotum

S. Minhas, London (GB)

### Penile cancer: Penile preserving surgery

N. Watkin, London (GB)

### Penile cancer: Management of lymph nodes

C. Protzel, Schwerin (DE)

## **Percutaneous nephrolithotripsy (PCNL)**

ESU Course 13

**Friday 10 March**  
**13:45 - 16:45**

**Location**

Pink Area, ESU 5

## Robotic renal surgery

ESU Course 14

Friday 10 March  
13:45 - 16:45

**Location** Pink Area, ESU 6

**Chair** B.J. Challacombe, London (GB)

### Learning objectives

This course will cover all principal indications for robotic surgery of the upper urinary tract. The standard techniques will be explained in a video-based fashion and will be followed by discussing advanced cases as well as troubleshooting and complication management. On top of that, technical innovations and new applications will be discussed as well.

Don't miss this course, a must for all robotic surgeons!:

- Video-based step-by-step approach.
- Standard techniques.
- Complex cases.
- Troubleshooting and complication management.
- Technical innovations: What's new in robotics?

### Introduction

B.J. Challacombe, London (GB)

### Patient positioning, trocar positioning, trans- and retroperitoneal access in renal robotic surgery

B.J. Challacombe, London (GB)

### Robotic pyeloplasty: Multichannel or single technique

N.M. Buffi, Milan (IT)

### Renal surgery: Nephrectomy and nephroureterectomy: How I do it

B.J. Challacombe, London (GB)

### Partial nephrectomy I: Step 1: Isolation of renal hilum; Step 2: Mobilisation of the kidney; Step 3: Clamping of renal pedicle: Different techniques

N.M. Buffi, Milan (IT)

### Partial nephrectomy II: Step 4: Different tumour resection techniques

R. De Groote, Aalst (BE)

### Partial nephrectomy III: Step 5: Different renography techniques

B.J. Challacombe, London (GB)

### Partial nephrectomy IV: Special and difficult indications

R. De Groote, Aalst (BE)

### Partial nephrectomy V: Complication management and new tools

R. De Groote, Aalst (BE)

### Wrap up and conclusions

B.J. Challacombe, London (GB)

## Advanced endourology in the non-standard patients with urolithiasis

ESU Course 15

Friday 10 March  
13:45 - 16:45

**Location** Pink Area, ESU 7

**Chair** G.M. Kamphuis, Amsterdam (NL)

### Learning objectives

Discuss available literature and practical management options and examples treatment of urolithiasis in 'non-index' patients, covering:

- Horse shoe kidney, caliceal diverticula, duplicate urinary system.
- Pregnancy, complex metabolic patients.
- After bladder substitution/ileal conduit/reimplantation.
- In transplant kidneys and spinal malformation.

### Introduction

G.M. Kamphuis, Amsterdam (NL)

### Urolithiasis in urinary system anomalies: Horse shoe kidneys

E. Emiliani, Barcelona (ES)

### Urolithiasis in urinary system anomalies: Calyceal diverticula stones

S. Doizi, Paris (FR)

### Urolithiasis in pregnancy

G.M. Kamphuis, Amsterdam (NL)

### Urolithiasis in urinary system anomalies: After bladder substitution/ ileal conduit/ ureteral reimplantation

E. Emiliani, Barcelona (ES)

### Medullary sponge kidneys

S. Doizi, Paris (FR)

### Urolithiasis in transplant kidneys

G.M. Kamphuis, Amsterdam (NL)

### Urolithiasis in urinary system anomalies: Duplicate urinary system and ectopic kidney

S. Doizi, Paris (FR)

### Bilateral stone treatment; do's and don't's

E. Emiliani, Barcelona (ES)

### Patients with relative contraindications: Spinal malformation / bleeding diathesis

G.M. Kamphuis, Amsterdam (NL)

## Controversies in reconstruction: When to use the robot and when to use the knife

Thematic Session

**Friday 10 March**  
14:15 - 15:45

**Location** Yellow Area, eURO Auditorium 2

**Chairs** A. Breda, Barcelona (ES)  
D.J. Ralph, London (GB)

### Learning objectives

This session should be a lively contest with 3 debates about how an operation should be performed. Should we be using the robot or should we stay with the trusted knife? We will have a representative from both sections for these debates with voting at the end. Firstly the formation of an ileal conduit, ureteric reimplantation after the conduit and lastly what approach should be used to treat a recto-vesical fistula after radical prostatectomy. Hopefully there will be some useful and friendly discussion with useful information given to delegate.

Lastly we will have a state of the art lecture by our Secretary General on catheterisable continent stomas which i am sure as always will be extremely valuable

14:15 - 14:20

### Welcome and introduction

D.J. Ralph, London (GB)

14:20 - 14:44

### Debate Ileal conduit

14:20 - 14:28

### Robotic ileal conduit outcomes

V. Phé, Paris (FR)

14:28 - 14:36

### Open ileal conduit outcomes

O. Rodriguez Faba, Barcelona (ES)

14:36 - 14:44

### Questions & answers

14:44 - 15:08

### Debate Ureteric reimplantation after ileal conduit

14:44 - 14:52

### Reimplantation using the robot

A. Gallina, Lugano (CH)

14:52 - 15:00

### Reimplantation using open technique

A. Stenzl, Tübingen (DE)

15:00 - 15:08

### Questions & answers

15:08 - 15:32

### Debate Recto urethral fistula after radical prostatectomy

15:08 - 15:16

### Why I do it with a robot

J. Rassweiler, Krems - Stein (AT)

15:16 - 15:24

### Why I use the perineal approach

S. Joniau, Leuven (BE)

15:24 - 15:32

### Questions & answers

15:32 - 15:42

### State-of-the-art lecture Catheterizable continent stoma: Best techniques for best outcomes

C.R. Chapple, Sheffield (GB)

15:42 - 15:45

### Closing remarks

A. Breda, Barcelona (ES)

## How to improve robotic cystectomy

Video Session 03

**Friday 10 March**  
**14:15 - 15:45**

**Location** Blue Area, Room 1  
**Chairs** B. Pradere, Toulouse (FR)  
L.S. Mertens, Amsterdam (NL)  
To be confirmed

**14:15 - 14:18**

**Introduction**

V016

**Technique and outcomes from prostate capsule-sparing during robotic male cystectomy**

J. Olphert, London (GB)

V017

**Intrafascial robot-assisted radical cystectomy in male patients: surgical technique, perioperative, functional and oncological outcomes**

L. Misuraca, Rome (IT)

V018

**Robotic radical cystectomy in renal transplant patients: The indocyanine green (ICG) technique**

C.H. Yee, Hong Kong (HK)

V019

**Step by step urethrectomy in man, woman and combined with robot-assisted radical cystectomy**

A. Piasentin, Trieste (IT)

V020

**New simulation model for training of robotic intracorporeal urinary diversions**

I. Castillon-Vela, Boadilla del Monte (ES)

V021

**Florence robotic intracorporeal neobladder (FloRIN) stentless configuration strategy, preliminary outcomes and step-by-step technique**

V022

**Intracorporeal stentless hand-sewn Padua Ileal Bladder: Surgical technique, perioperative and early postoperative outcomes**

L. Misuraca, Rome (IT)

**15:40 - 15:45**

**Closing remarks**



## Understanding mechanisms and pathologies behind lower urinary tract symptoms

Abstract Session 03

Friday 10 March  
14:15 - 15:45

**Location** Pink Area, Coral 3  
**Chairs** To be confirmed  
B. Geavlete, Bucharest (RO)  
To be confirmed

14:15 - 14:18

**Introduction**

A0038 **NUAK1 and -2 promote contraction, proliferation and suppression of cell death in human prostate stromal cells: Evidence from isoform-specific silencing**  
M. Hennenberg, Munich (DE)

A0039 **The effect of 5- $\alpha$  reductase inhibitor on Th1, Th2, Th17 cell-related inflammatory response in BPH**  
C. Yifan, Beijing (CN)

A0040 **YAP1 is activated by RhoA/ROCK1/F-actin in inflammation-associated benign prostatic hyperplasia**  
D. Lin, Wuhan (CN)

A0041 **Arf1 gef inhibitor golgicide a inhibits adrenergic and non-adrenergic prostate smooth muscle contraction**

14:26 - 14:36

**Discussion**

A0042 **Isoform-specific silencing of WNK1-4 points to shared functions in promotion of contraction and growth of prostate stromal cells, which are inhibited by the WNK inhibitor, WNK463**  
M. Hennenberg, Munich (DE)

A0043 **Maternal diet during gestation affect prostatic tissue component in SHR/Izm offspring**  
K. Shibamori, Sapporo (JP)

A0044 **Hexane-extracted saw palmetto (Permixon®) inhibits prostate stromal cell proliferation and growth, and disrupts actin formation**

A0045 **An acute and chronic study of an investigational prostatic stent in a healthy canine model: Novel fluoroscopic technique**  
D. Elterman, Toronto (CA)

14:44 - 14:54

**Discussion**

A0046 **Bioactive Spermidine-Dextran Copolymer Enhance Wound Healing by ROS-PI3K/ Akt Pathway in Urethra Fibroblasts and Reduce Scar Formation.**  
J. Xie, Guangzhou (CN)

A0047 **Quantifying pubocervical fibromuscularis elasticity under normal and prolapse conditions by shear wave elastography and comparison with urodynamics findings**

## Scientific Programme - EAU23 Milan

---

A0048	<b>Adiponectin predicts urodynamic detrusor underactivity: A prospective study of elderly men with lower urinary tract symptoms</b>
A0049	<b>Relationship between sexual and bladder dysfunction in women consuming ketamine</b> B-E. Jong, New Taipei (TW)
A0050	<b>Central bladder proprioception: Robust findings from sensation-driven functional MRI study</b> A.D. Santoso, Leuven (BE)
<b>15:04 - 15:16</b>	<b>Discussion</b>
A0051	<b>Bariatric surgery will treat urinary incontinence</b> C. Persu, Bucharest (RO)
A0052	<b>Search for novel biomarkers that reflect the pathology of age-related bladder dysfunction</b> T. Nakatsuka, Kurashiki (JP)
A0053	<b>Therapeutic effect of platelet-rich plasma on ovariectomy-induced overactive bladder via modulating urothelium hyaluronan synthesis</b> Y-S. Juan, Kaohsiung (TW)
A0054	<b>Efficacy of intradetrusor platelet-rich plasma injection in treatment of interstitial cystitis</b> M.I. Kogan, Rostov On Don (RU)
A0055	<b>The real-life practice of intravesical botulinum toxin A injection for interstitial cystitis/bladder pain syndrome – Satisfaction rate and predictive factors</b> W-R. Yu, Hualien (TW)
<b>15:26 - 15:38</b>	<b>Discussion</b>
<b>15:38 - 15:45</b>	<b>Closing remarks</b>

## Semi-live surgery: BPH

Thematic Session

Friday 10 March  
15:15 - 16:15

**Location** Pink Area, Coral 4

**Chairs** F. Gomez Sancha, Madrid (ES)  
P. Krombach, Luxembourg (LU)

### Learning objectives

TUR-Prostate has been considered the gold standard in the treatment of obstructive male LUTS. However, after many so-called minimal-invasive techniques appeared and disappeared, enucleation is certainly here to stay and has demonstrated better outcomes with a high level of evidence. However, is enucleation = enucleation = enucleation? This session demonstrates different techniques, with the same aim: complete anatomical enucleation.

15:15 - 15:25

**Surgical video presentation Endoscopic enucleation of the prostate - Holmium: YAG laser with pulse modulation**  
P. Kallidonis, Patras (GR)

15:25 - 15:30

**Discussion**

15:30 - 15:40

**Surgical video presentation Endoscopic enucleation of the prostate - Thulium fiber laser**  
D. Enikeev, Vienna (AT)

15:40 - 15:45

**Discussion**

15:45 - 15:55

**Surgical video presentation Endoscopic enucleation of the prostate - Pulsed thulium laser**  
A. Miernik, Freiburg (DE)

15:55 - 16:00

**Discussion**

16:00 - 16:10

**Surgical video presentation Enucleation of the prostate - Aquablation**  
V. Misrai, Toulouse (FR)

16:10 - 16:15

**Discussion**

## Semi-live surgery: Surgical treatment of kidney stones in children

Thematic Session

Friday 10 March  
15:15 - 16:15

**Location** Pink Area, Coral 7

**Chairs** W.F.J. Feitz, Nijmegen (NL)  
B. Somani, Southampton (GB)

### Learning objectives

This session will update you on the latest knowledge and practical point in relation with urolithiasis management in children. Size matters in relation to the age of the children, available instruments and disposables and risk assesment of different approaches available today. The session is a must for urologists treating children for stones in the urinary tract, for residents interested in Pediatric Urology or stone management.

15:15 - 15:25

**Surgical video presentation Retrograde intrarenal surgery (RIRS)**  
R.G. Atis, Istanbul (TR)

15:25 - 15:30

**Discussion**

15:30 - 15:40

**Surgical video presentation PCNL**  
W. Gamal, Sohag (EG)

15:40 - 15:45

**Discussion**

15:45 - 15:55

**Surgical video presentation Endoscopic Combined Intrarenal surgery (ECIRS)**  
A. Bujons Tur, Barcelona (ES)

15:55 - 16:00

**Discussion**

16:00 - 16:10

**Surgical video presentation Lap & robotic-assisted stone surgery**  
S. Sforza, Florence (IT)

16:10 - 16:15

**Discussion**

## Prostate cancer biopsy indication: Added value of PET or Micro-US and markers

Abstract Session 04

**Friday 10 March**  
**15:15 - 16:45**

**Location** Yellow Area, Amber 3  
**Chairs** To be confirmed  
To be confirmed  
To be confirmed

**15:15 - 15:18**

**Introduction**

**Added value of PET, MRI or Micro-US**

**A0056** **DEPROMP Trial: The additive value of PSMA-PET/CT-guided biopsy for prostate cancer management in biopsy naïve men**  
P. Krausewitz, Bonn (DE)

**A0057** **Clinical and high-resolution micro-ultrasound risk factors for detecting clinically significant prostate cancer in men with PI-RADS 3 lesions: Update from a large single center experience.**  
P.P. Avolio, Pieve Emanuele (IT)

**A0058** **Comparing all published MRI prostate cancer risk calculators in a large 2-centre European cohort**

**A0059** **Development and multicenter validation of the PROMOD Likert scale including PIRADS score and PSA density for risk stratification of patients with a Positive MRI**  
M. Finati, Gavirate (IT)

**A0060** **PSMA-PET in high-risk prostate cancer patients suitable for radical treatments: Scenario of detection and clinical impact for staging setting**

**A0061** **Clinical validation of optimized neural network risk models to predict grade group 2 and above prostate cancer and avoid unneeded biopsies**  
A. Kinnaird, Edmonton (CA)

**A0062** **Prediction of significant prostate cancer in equivocal MRI lesions: a high-volume international multicenter study**  
S. Mahjoub, Cologne (DE)

**A0063** **Prostate cancer detection rate of repeated biopsy in patients with positive mpMRI and negative initial target and random biopsy. An EAU-YAU Prostate Cancer Working Group multi-institutional study**  
F. Zattoni, Verona (IT)

**15:34 - 15:50**

**Discussion**

**Added value of risk stratification**

**A0064** **Metabolic syndrome evaluation improves prostate cancer detection in patients undergoing a repeat biopsy**  
E. Mancini, Rome (IT)

---

A0065	Prostate biopsies can be omitted in most patients with a positive Stockholm3-test and an negative prostate magnetic resonance imaging
A0066	A novel model Integrating clinical, mp-MRI, and epigenomic features to predict lymph node invasion in prostate cancer patients undergoing radical prostatectomy and pelvic lymph node dissection
A0067	External validation of Stockholm3 in a retrospective German clinical cohort
A0068	Tiered integrated diagnostics for the early detection of aggressive prostate cancer: The TARGET study to refine investigations for suspected prostate cancer
A0069	ReIMAGINE Prostate Cancer Risk: A prospective cohort study in men with a suspicion of prostate cancer who are referred onto an MRI-based diagnostic pathway with donation of tissue, blood, urine and imaging for biomarker analyses. H.U. Ahmed, London (GB)
A0070	Integration of Polygenic risk score (PRS) with multiparametric MRI in men at risk for clinically significant prostate cancer I.C. Madueke, Boston (US)
A0071	Gene expression in multi-parametric MRI-visible and invisible prostate cancers is associated with progression T-P. Lehto, Helsinki (FI)
A0072	The Capio S:t Göran model for prostate cancer diagnosis using Stockholm3, magnetic resonance imaging and targeted biopsies
16:08 - 16:26	Discussion
	Added values of targeted biopsies
A0073	Does the percentage of Gleason 4 in patients with targeted prostate biopsies predict the percentage of Gleason 4 at final pathology results of radical prostatectomy specimen? A. Caviglia, Genova (IT)
A0074	PIRADS $\geq$ 4 lesions in MRI: Is performing randomized biopsies still essential? F Taha, Reims (FR)
A0075	How many transrectal fusion prostate biopsies needed from a lesion on MRI for accurate diagnosis of significant prostate cancer? D Dothan, Jerusalem (IL)
16:32 - 16:38	Discussion
16:38 - 16:45	Closing remarks

---

## Locally advanced BCa: Misconception of informed consent

Plenary Session

**Saturday 11 March**  
**08:00 - 10:00**

**Location** Yellow Area, eURO Auditorium 1

**Chairs** J.L. Boormans, Rotterdam (NL)  
F. Cruz, Porto (PT)

### Learning objectives

Delegates will be informed about differences in quality of life of MIBC patients treated by radical surgery versus bladder-sparing treatment.

**08:00 - 08:05**

**Welcome and introduction**

**08:05 - 08:40**

**Debate MIBC: Oncological outcomes**

**08:05 - 08:10**

**Case presentation**

T. Zuiverloon, Rotterdam (NL)

**08:10 - 08:20**

**Radical cystectomy**

J.E. Gschwend, Munich (DE)

**08:20 - 08:30**

**Trimodality treatment**

N. James, London (GB)

**08:30 - 08:40**

**Discussion Realistic oncological outcomes**

*Discussants*

L. Makaroff, Chinnor (GB)

T. Zuiverloon, Rotterdam (NL)

*Speakers*

N. James, London (GB)

J.E. Gschwend, Munich (DE)

**08:40 - 09:15**

**Debate MIBC: Functional outcomes**

**08:40 - 08:45**

**Case presentation**

T. Zuiverloon, Rotterdam (NL)

**08:45 - 08:55**

**Is there an ideal sexual preserving technique for radical cystectomy: Male and female**

G. Pignot, Marseille (FR)

**08:55 - 09:05**

**Orthotopic neobladder vs. abdominal urinary diversion: How to balance patients' preference with the risk of urethral recurrence and pelvic recurrence?**

J. Cresswell, Middlesbrough (GB)

**09:05 - 09:15**

**Discussion Real life after surgery**

*Speakers*

J. Cresswell, Middlesbrough (GB)

G. Pignot, Marseille (FR)

*Discussants*

L. Makaroff, Chinnor (GB)

T. Zuiverloon, Rotterdam (NL)

**09:15 - 09:25**

**State-of-the-art lecture Psycho-oncological counselling**

C. Schulz-Quach, Toronto (CA)

**09:25 - 09:35**

**State-of-the-art lecture Nurse and stoma therapist's (hidden) role**

B. Thoft Jensen, Aarhus (DK)

**09:35 - 09:45**

**State-of-the-art lecture Treatment of incontinence and sexual dysfunction after cystectomy**

M. Tutolo, Milan (IT)

## Scientific Programme - EAU23 Milan

---

**09:45 - 09:55**

**State-of-the-art lecture Long term follow-up of patients after cystectomy:  
Functional and vigilance**  
J.P.F.A. Heesakkers, Maastricht (NL)

---

**09:55 - 10:00**

**Closing remarks**



## Incontinence nightmares

Plenary Session

**Saturday 11 March**  
**08:00 - 10:00**

**Location** Yellow Area, eURO Auditorium 2

**Chairs** J. Gómez Rivas, Madrid (ES)  
J. Walz, Marseille (FR)

### Learning objectives

This session will provide you with detailed information about the importance of patients counseling and patient information when offering surgical treatments. Three cases with unfavorable outcome will be presented and cross examined by a lawyer, highlighting the importance of clear patient communication and realistic outcome predictions, both being the base for shared decision making and informed consent from the patient.

**08:00 - 08:40**

### Female incontinence after mesh graft

**08:00 - 08:10**

#### Case presentation and discussion

V. Phé, Paris (FR)

**08:10 - 08:30**

#### Cross-examination

B. Leigh, London (GB)

V. Phé, Paris (FR)

**08:30 - 08:40**

#### Case solution and audience questions

**08:40 - 09:20**

### Salvage prostatectomy: Not as expected!

**08:40 - 08:50**

#### Case presentation and discussion

M. Graefen, Hamburg (DE)

**08:50 - 09:10**

#### Cross-examination

B. Leigh, London (GB)

M. Graefen, Hamburg (DE)

**09:10 - 09:20**

#### Case solution and audience questions

**09:20 - 10:00**

### HoLEP for BPH: Incontinence not as rare as expected!

**09:20 - 09:30**

#### Case presentation and discussion

F. Montorsi, Milan (IT)

**09:30 - 09:50**

#### Cross-examination

B. Leigh, London (GB)

F. Montorsi, Milan (IT)

**09:50 - 10:00**

#### Case solution and audience questions

## The infertile couple: Urological aspects

ESU Course 16

**Saturday 11 March**  
**08:00 - 11:00**

**Location** Pink Area, ESU 1

**Chair** M. Dinkelman-Smit, Rotterdam (NL)

### **Learning objectives**

This course provides state-of-the-art information on urological aspects of diagnosis and therapy of modern reproductive medicine. Diagnostic procedures should be standardised and coordinated in a timely fashion for both partners, focusing on the possible urological, hormonal and genetic causes of male infertility. In terms of therapy, this course will provide updated information on evidence-based data and will discuss the importance of varicoceles in male infertility. We will show microsurgical techniques on video and explain why proper training and skills perfection is key to successful case management. A successful IVF/ICSI outcome depends upon the use of state-of-the-art techniques for sperm retrieval and sperm preparation. We will also provide information on genetic aspects and stress the responsibility of the urologist as an adviser and gatekeeper for the treatment of the infertile couple.

### **Diagnostic work-up, medical treatment**

A. Salonia, Milan (IT)

### **Pathophysiology, diagnosis and treatment of varicocele**

M. Dinkelman-Smit, Rotterdam (NL)

### **Microsurgical refertilisation**

M. Dinkelman-Smit, Rotterdam (NL)

### **Sperm retrieval techniques and genetic aspects of IVF/ICSI**

A. Salonia, Milan (IT)

## Urinary tract and genital trauma

ESU Course 17

**Saturday 11 March**  
**08:00 - 11:00**

**Location** Pink Area, ESU 2

**Chair** N. Kitrey, Ramat Gan (IL)

### **Learning objectives**

Trauma is a leading cause of morbidity and death. Most urologists are involved in the management of trauma patients, therefore need to understand and follow the basic principles.

The ESU urological trauma course details the epidemiology, mechanism of action, diagnosis, and management of urogenital trauma – renal, ureteric, bladder, urethra, and external genitalia. The course is based on the peer-reviewed annually-updated EAU Guidelines on urological trauma. Interactive case-based discussion will highlight the key points of trauma management.

### **Introduction and trauma management principles**

N. Kitrey, Ramat Gan (IL)

### **Renal trauma**

To be confirmed

### **Renal trauma case**

N. Kitrey, Ramat Gan (IL)

N. Lumen, Ghent (BE)

To be confirmed

### **Ureteral trauma**

N. Lumen, Ghent (BE)

### **Bladder trauma**

N. Kitrey, Ramat Gan (IL)

### **Urethral trauma**

N. Lumen, Ghent (BE)

### **Urethral trauma case**

N. Kitrey, Ramat Gan (IL)

N. Lumen, Ghent (BE)

To be confirmed

### **Genital trauma**

To be confirmed

## Updated renal, bladder and prostate cancer guidelines 2023: What has changed?

ESU Course 18

Saturday 11 March  
08:00 - 11:00

**Location** Pink Area, ESU 3

**Moderator** H.G. Van Der Poel, Amsterdam (NL)

### Learning objectives

During the course recent practice changing alterations in the EAU guidelines will be discussed. Based on the clinical recommendations the highlights of the guidelines on prostate, renal and bladder cancer as changed in the 2022 updates will be presented and illustrated by clinical cases. A basic knowledge of the guidelines information is assumed for participating trainees.

### Introduction

H.G. Van Der Poel, Amsterdam (NL)

### Update renal cancer: Localised

To be confirmed

### Discussion

### Update renal cancer: Metastasised

To be confirmed

### Discussion

### Update bladder cancer: Non-muscle invasive

J.L. Domínguez Escrig, Valencia (ES)

### Discussion

### Update bladder cancer: Muscle invasive

J.L. Domínguez Escrig, Valencia (ES)

### Discussion

### Update prostate cancer: Localised

N. Grivas, Ioannina (GR)

### Discussion

### Update prostate cancer: Metastasised

N. Grivas, Ioannina (GR)

### Discussion

## Male prosthetic urology

ESU Course 19

**Saturday 11 March**  
**08:00 - 11:00**

**Location** Pink Area, ESU 4

**Chair** D.J. Ralph, London (GB)

### **Learning objectives**

#### **Introduction to biofilms and prosthetic infections**

A. Muneer, London (GB)

#### **Penile prosthesis**

#### **Different types of prosthesis**

A. Muneer, London (GB)

#### **Theatre set-up and preparation of patients**

A. Muneer, London (GB)

#### **Surgical techniques and intraoperative complications**

I. Moncada Iribarren, Madrid (ES)

#### **The difficult implant: Peyronie's, priapism, fibrosis**

D.J. Ralph, London (GB)

#### **Revision surgery and post operative complications**

D.J. Ralph, London (GB)

#### **Prosthetic surgery for male urinary incontinence**

#### **AUS: Indications, types, techniques and complications**

I. Moncada Iribarren, Madrid (ES)

#### **Slings: Indications, types, techniques and complications**

S. Malde, London (GB)

#### **Neuromodulation devices**

S. Malde, London (GB)

#### **Future of prosthetic urology**

I. Moncada Iribarren, Madrid (ES)

## Robotic-assisted laparoscopic prostatectomy

ESU Course 20

**Saturday 11 March**  
**08:00 - 11:00**

**Location** Pink Area, ESU 5

**Chair** A. De La Taille, Créteil (FR)

### Learning objectives

The objectives are to explain, using videos and step-by-step explanations, robotic assisted radical prostatectomy with 3 presenters using 3 different approaches: Transperitoneal, preperitoneal and retzius-sparing techniques.

General principles regarding port placement, prostate anatomy and surgical landmarks will be also reminded considering the different possible options and the different types of robotic systems used. Finally, the course will present the possible intraoperative risks of complications and 'how to manage them' strategies. This course will be interactive including direct and/or multichoice questions to the audience.

### Introduction

A. De La Taille, Créteil (FR)

### Robotic radical prostatectomy with da Vinci systems

#### Operative protocol: Operative room organization, side docking

F. Annino, Arezzo (IT)

#### Operative protocol; Ways of access port placements: TransPeritoneal

N. Soomro, Newcastle upon Tyne (GB)

#### Operative protocol; Ways of access port placements; PrePeritoneal

A. De La Taille, Créteil (FR)

#### Operative protocol; Ways of access port placements: Retzius-sparing

F. Annino, Arezzo (IT)

### Anatomical reminders

F. Annino, Arezzo (IT)

### Technique of lymphadenectomy

N. Soomro, Newcastle upon Tyne (GB)

### Robotic prostatectomy: How I do it

N. Soomro, Newcastle upon Tyne (GB)

F. Annino, Arezzo (IT)

A. De La Taille, Créteil (FR)

### How do I manage bleeding/Lymphocele/ureter repair

F. Annino, Arezzo (IT)

### Operative complications

#### How do I manage urine leakage

N. Soomro, Newcastle upon Tyne (GB)

#### How do I manage bladder strictures

A. De La Taille, Créteil (FR)

### Robotic-assisted radical prostatectomy with other systems

A. De La Taille, Créteil (FR)

## **Conclusion**

A. De La Taille, Créteil (FR)

## Treatment of localised renal masses

ESU Course 21

**Saturday 11 March**  
**08:00 - 11:00**


**Location** Pink Area, ESU 6

**Chair** A. Minervini, Florence (IT)

### **Learning objectives**

- The course aims to address the multiplicity of treatment options for small renal masses (SRM).
- Essential concepts to guide the clinical decision making process will be interactively discussed with the help of clinical cases.
- Practical tips for a safe and effective treatment delivery will be provided on the current standard of ablative therapies and minimally invasive surgery.
- Attendees should become familiar on when and how to propose active surveillance in their daily clinical practice.



 Game changing session

**Saturday 11 March**  
**10:00 - 10:30**

**Location**

Yellow Area, eURO Auditorium 2

## Progress and controversies in oncological urology

Meeting of the EAU Section of Oncological Urology (ESOU)

**Saturday 11 March**  
**10:15 - 13:45**

**Location** Yellow Area, Brown 3

**Chairs** M. Rouprêt, Paris (FR)  
G. Giannarini, Udine (IT)

### Learning objectives

To strengthen the leading role of European urologists in providing care to patients with genitourinary malignancies. To recognize the value of multidisciplinary collaborations between urologists, medical oncologists, radiation oncologists, and other stakeholders involved in the multifaceted care of patients with genitourinary malignancies. To navigate the evolving landscape of multi modal, minimally invasive and technologically advanced therapeutic options with the aim to implement personalized pathways of care across the wide spectrum of genitourinary malignancies stage by stage.

**10:15 - 10:20**

### Welcome and introduction

G. Giannarini, Udine (IT)  
M. Rouprêt, Paris (FR)

**10:20 - 11:05**

### Session 1: Burning questions in oncological urology

*Moderators* G. Giannarini, Udine (IT)  
M. Rouprêt, Paris (FR)

**10:20 - 10:30**

### The evolving landscape in the management of high-risk non-muscle-invasive bladder cancer

A.M. Kamat, Houston (US)

**10:30 - 10:35**

### Questions & Answers

**10:35 - 10:45**

### How to integrate metastasis-directed and systemic treatment in patients with oligometastatic renal cell carcinoma

J. Brugarolas, Dallas (US)

**10:45 - 10:50**

### Questions & Answers

**10:50 - 11:00**

### The current and future role of PSMA-based theranostics in men with advanced prostate cancer

S. Gillessen Sommer, Bellinzona (CH)

**11:00 - 11:05**

### Questions & Answers

**11:05 - 11:30**

### Case discussion Will PSMA PET supplant multiparametric MRI for prostate cancer detection?

**11:05 - 11:09**

### Case presentation

To be confirmed

**11:09 - 11:17**

### Pro

To be confirmed

**11:17 - 11:25**

### Con

H.U. Ahmed, London (GB)

**11:25 - 11:30**

### Discussion

**11:30 - 11:55**

### Case-based debate What is the optimal treatment for patients with high-risk muscle-invasive bladder cancer scheduled for radical cystectomy?

**11:30 - 11:34**

### Case presentation

To be confirmed

## Scientific Programme - EAU23 Milan

---

11:34 - 11:42	<b>Neoadjuvant + adjuvant</b> To be confirmed
11:42 - 11:50	<b>One is enough</b> S. Psutka, Seattle (US)
11:50 - 11:55	<b>Discussion</b>
11:55 - 12:20	<b>Case-based debate</b> Should men with limited pN1 disease after radical prostatectomy receive adjuvant treatment?
11:55 - 11:59	<b>Case presentation</b> E. Mazzone, Milan (IT)
11:59 - 12:07	<b>No, observation</b> D. Tilki, Hamburg (DE)
12:07 - 12:15	<b>Yes, radiation therapy +/- hormone therapy</b> To be confirmed
12:15 - 12:20	<b>Discussion</b>
12:20 - 12:35	<b>European Urology Oncology Lecture</b> The future of systemic treatment in patients with locally advanced and metastatic renal cell carcinoma To be confirmed L. Albiges, Villejuif (FR)
12:35 - 13:35	<b>Session 2: ESOU-ERUS session: Common problems in oncological urology</b> <i>Moderators</i> M. Rouprêt, Paris (FR) A. Breda, Barcelona (ES)
12:35 - 12:47	<b>Minimally invasive vs open nephroureterectomy: Should we change our guidelines?</b> To be confirmed
12:47 - 12:59	<b>Clinical T1 renal cancer/pathological T3a: Still a controversy?</b> To be confirmed
12:59 - 13:11	<b>Single port vs. Standard robotic cystectomy</b> To be confirmed
13:11 - 13:23	<b>Tricks to avoid ureteral complications in uretero-ileal anastomosis</b> To be confirmed
13:23 - 13:35	<b>Robotic vs. Open inguinal LND: Quick update</b> To be confirmed
13:35 - 13:45	<b>Closing remarks</b> M. Rouprêt, Paris (FR)

---

## Technological and research matters in kidney transplantation

Joint meeting of the EAU Section of Transplantation Urology (ESTU), EAU Section of Urological Research (ESUR), US Renal Transplant Society (USTRS), and YAU

**Saturday 11 March**  
**10:15 - 13:45**

**Location** Yellow Area, Amber 3

**Chairs** E. Lledó García, Madrid (ES)  
A.S. Gözen, Heilbronn (DE)

**10:15 - 10:20**

**Welcome and introduction**  
E. Lledó García, Madrid (ES)

**10:20 - 11:00**

**Surgical complications of kidney transplant: Face to face**  
*Moderators* E. Lledó García, Madrid (ES)  
M. Musquera Felip, Barcelona (ES)

**10:40 - 11:00**

**Vascular complications: Open vs. robotic**  
K. Decaestecker, Ghent (BE)  
V. Hevia Palacios, Madrid (ES)

**10:20 - 10:40**

**Urological complications: Open vs. robotic**  
J.D.J.M. Branchereau, Nantes (FR)  
To be confirmed

**11:00 - 11:45**

**ESTU-ESU Kidney transplant and technological controversial issues**  
*Moderators* S. Micali, Baggiovara (IT)  
B. Da Costa Parada, Coimbra (PT)

**11:00 - 11:15**

**The use of Hem-o-lock in living kidney donors: Where is the problem?**  
A. Breda, Barcelona (ES)

**11:15 - 11:30**

**Artificial intelligence and kidney transplantation**  
To be confirmed

**11:30 - 11:45**

**Current perspective and limits of renal hypothermic perfusion-preservation**  
A. Sener, London (CA)

**11:45 - 12:15**

**ESTU-USRTS Xenotransplant worldwide: Planning the future**  
*Moderator* F.J. Burgos Revilla, Madrid (ES)

**11:45 - 12:05**

**Conference**  
To be confirmed

**12:05 - 12:15**

**Questions & Answers**

**12:15 - 13:00**

**The training process and CV in kidney transplant**  
*Moderators* A.J. Figueiredo, Coimbra (PT)  
O. Rodriguez Faba, Barcelona (ES)

**12:15 - 12:30**

**Europe prothocols**  
R. Boissier, Marseille (FR)

**12:30 - 12:45**

**Pre-recorded US prothocols**  
N. Osburn, Watertown (US)

**12:45 - 13:00**

**What would be the ideal situation for young European urologists?**  
A. Territo, Barcelona (ES)

**13:00 - 13:30**

**ESTU-YAU 2 Challenging clinical cases: senior and young urologists view**  
*Moderators* V. Gomez Dos Santos, Madrid (ES)  
To be confirmed

## Scientific Programme - EAU23 Milan

---

13:00 - 13:15

**Case 1**

To be confirmed

13:15 - 13:30

**Case 2**

F. McCaig, London (GB)

---

13:30 - 13:40

**Rene-Küss Prize 2023**

E. Lledó García, Madrid (ES)

---

13:40 - 13:45

**Closing and remarks**

E. Lledó García, Madrid (ES)

## From conventional to molecular diagnostics

Joint meeting of the EAU Section of Urothology (ESUP), EAU Section of Urological Research (ESUR) and the EAU Section of Urological Imaging (ESUI)

**Saturday 11 March**  
**10:15 - 13:45**

**Location** Pink Area, Coral 4

**Chairs** K. Junker, Homburg (DE)  
G. Salomon, Hamburg (DE)  
M. Colecchia, Milan (IT)

### Learning objectives

The session will be focused on what state of the art standard pathology and imaging in reporting should look like. We will discuss expectations from research which will change diagnostics, therapeutic targeting and monitoring.

**10:15 - 10:20**

### Welcome and introduction

G. Salomon, Hamburg (DE)

**10:20 - 11:17**

### Bladder cancer

*Moderators* E. Comp erat, Paris (FR)  
To be confirmed  
A. Vlahou, Athens (GR)

**10:20 - 10:34**

### What can the urologists expect from a perfect diagnosis and how does molecular subtypes improve it

E. Comp erat, Paris (FR)

**10:34 - 10:39**

### Discussion

**10:39 - 10:53**

### VIRADS: The new PIRADS for bladder cancer?

V. Panebianco, Rome (IT)

**10:53 - 10:58**

### Discussion

**10:58 - 11:12**

### In the pipeline and ready to start: molecular targets and therapy prediction

To be confirmed

**11:12 - 11:17**

### Discussion

**11:17 - 12:13**

### Kidney cancer: Discriminating the good from the bad guys

*Moderators* F. Algaba, Barcelona (ES)  
C. Jeronimo, Porto (PT)  
F. Sanguedolce, Barcelona (ES)

**11:17 - 11:31**

### Histological subtypes: Improvement for prognostic evaluation and therapy selection

A. Hartmann, Erlangen (DE)

**11:31 - 11:36**

### Discussion

**11:36 - 11:49**

### Better than conventional CT: PSMA PET scan for kidney cancer

To be confirmed

**11:49 - 11:54**

### Discussion

**11:54 - 12:08**

### Molecular subtyping: Improve individual selection for adjuvant therapy

K. Junker, Homburg (DE)

**12:08 - 12:13**

### Discussion

**12:13 - 13:10**

### Testicular germ cell cancer: Reduce overtreatment

*Moderators*  
I. Ahmad, Glasgow (GB)  
M. Colecchia, Milan (IT)  
To be confirmed

**12:13 - 12:27**      **Prognostic markers in orchiectomy specimen and in residual metastatic disease**  
F. Algaba, Barcelona (ES)

**12:27 - 12:32**      **Discussion**

**12:32 - 12:46**      **Imaging standards in the diagnosis of testicular cancer**  
P. Martino, Bari (IT)

**12:46 - 12:51**      **Discussion**

**12:51 - 13:05**      **Molecular markers for therapy decision making: How to differentiate residual disease from necrosis? miR-371: The perfect marker**  
To be confirmed

**13:05 - 13:10**      **Discussion**

---

**13:10 - 13:39**      **Intraoperative imaging in prostate cancer**  
*Moderators*  
M. Colecchia, Milan (IT)  
G. Salomon, Hamburg (DE)

**13:10 - 13:18**      **Associated video presentation Intraoperative frozen section in radical prostatectomy**  
G. Salomon, Hamburg (DE)

**13:18 - 13:26**      **Frozen sections in GU daily practice: The role of the pathologist in view of novel technologies**  
F. Algaba, Barcelona (ES)

**13:26 - 13:34**      **The new frozen section in prostate cancer: Intraoperative PSMA PET CT**  
C. Darr, Essen (DE)

**13:34 - 13:39**      **Discussion**

---

**13:39 - 13:45**      **Closing and remarks**  
K. Junker, Homburg (DE)

## Tips and tricks in genito-urethral surgery

Video Session 04

<b>Saturday 11 March 10:15 - 11:45</b>	<b>Location</b>	Pink Area, Coral 7
	<b>Chairs</b>	F. Campos Juanatey, Santander (ES) T.J. Greenwell, London (GB) M. Waterloos, Gent (BE)
<b>10:15 - 10:18</b>	<b>Introduction</b>	
V023	<b>Paclitaxel drug coated balloon for the treatment of recurrent bulbar urethral stricture</b>	
V024	<b>Circumferential stricture segment metaplastic squamous mucosa &amp; associated spongiofibrosis excision and urethroplasty by ventral approach with double face oral mucosal graft replacement</b> A.D. Dangi, Vellore, Tamil Nadu (IN)	
V025	<b>Preputial flap dorsal onlay urethroplasty for reconstruction of near-obliterative bulbar urethral strictures- Modified technique and short-term functional outcomes</b>	
V026	<b>Modified technique of harvesting Preputial free graft for reconstruction of long anterior urethral strictures</b>	
V027	<b>Nontransecting anastomotic urethroplasty via ventral approach without full mobilization of the corpus spongiosum dorsal semicircumference</b> A. Bogdanov, Moscow region (RU)	
V028	<b>Revascularization of the dorsal artery of the penis using the descending branch of the lateral circumflex femoral artery: description of a new surgical technique</b> F. Zorzi, Cividale del Friuli (IT)	
V029	<b>Distal penile prosthesis herniation: repair with polypropylene mesh reinforcement</b>	
<b>11:40 - 11:45</b>	<b>Closing remarks</b>	



## Basic research, screening, and transition in paediatric urology

Abstract Session 10

**Saturday 11 March  
15:30 - 17:00**

**Location** Pink Area, Coral 1  
**Chairs** A.K. Ebert, Ulm (DE)  
G. De Win, Antwerpen (BE)  
T. Mitsui, Chuo-City (JP)

**15:30 - 15:33**

**Introduction**

- A0190** **Development of nerves and vessels in the penis during the human fetal period**  
F. Sampaio, Rio de Janeiro (BR)
- A0191** **The cadherin-catenin complex is crucial for the initial step of nephron formation**
- A0192** **Detection of a familial androgen receptor gene germline mutation: Genotype-phenotype correlations and oncogenic risks**  
N. Bouayed Abdelmoula, Sfax (TN)
- A0193** **Is age-dependent the effect of hCG-adjuvant therapy? A molecular perspective of hCG treatment on gubernacular cells derived from cryptorchid patients**  
I. Dando, Verona (IT)
- A0194** **Dysfunction of the Blood–Testis Barrier in Undescended Testes and the Role of Androgens in the Blood–Testis Barrier Composition**  
T. Kato, Nagoya (JP)
- A0195** **Evolution of Peak Retrograde Flow in Varicocele boys during pubertal development.**  
G. De Win, Antwerpen (BE)
- 15:45 - 15:59** **Discussion**
- A0196** **Toxicity of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (hipec) in pediatric patients with rhabdomyosarcoma: Early phase 1 trial experience and results**
- A0197** **Paratesticular rhabdomyosarcoma: A systematic review and analysis of patient characteristics and treatment outcome of 191 patients**  
N. Lautenbach, Meilen (CH)
- A0198** **Tailored treatment of childhood renal tumors using artificial intelligence to predict tumor response to preoperative chemotherapy**
- A0199** **Renal transplantation in children with abnormal lower urinary tract: single center experience**  
O.M. Sarhan, Mansoura (EG)
- A0200** **The strengths and complexities of European registries regarding pediatric kidney transplant health care**  
L. Oomen, Nijmegen (NL)

**16:09 - 16:20**

**Discussion**

## Scientific Programme - EAU23 Milan

---

A0201	<b>Comparison between contrast enhanced voiding urosonography (CEVUS) with standard cystography under fluoroscopy (VCUG) for detection of vesicoureteral reflux in pediatric patients</b> O. Nativ, Haifa (IL)
A0202	<b>Voiding video is recommended additional to meatal appearance in boys who are candidates for meatotomy</b>
A0203	<b>External Validation of a Deep-learning Model for Segmentation of Kidney Outline and Hydronephrotic Area Outline in Kidney Ultrasonography</b>
<b>16:26 - 16:32</b>	<b>Discussion</b>
A0204	<b>Outcomes of a newly established transitional urology outpatient clinic: A real-world experience</b> M.I Dönmez, Istanbul (TR)
A0205	<b>Magnetic Resonance Imaging of the bladder, prostate, penile vasculature and pelvic floor muscles anatomy in adult men after childhood bladder exstrophy-epispadias complex repair</b> A. Elkashef, Mansoura (EG)
A0206	<b>Transitional care program for spina bifida patients: 10 years-experience from a multidisciplinary referral centre</b> M. Della Corte, (IT)
A0207	<b>Cross-sectional study and literature review on perceptions and attitudes of urology specialist providers toward transitional urologic care process</b> M. Chua, Quezon City (PH)
A0208	<b>Risk factors for upper urinary tract deterioration in adult patients with spina bifida</b>
<b>16:42 - 16:53</b>	<b>Discussion</b>
<b>16:53 - 17:00</b>	<b>Closing remarks</b>

---

## Andrology in the office and outpatient setting: practical considerations for everyday practice

Meeting of the EAU Section of Urologists in Office (ESUO)

**Saturday 11 March**  
10:15 - 13:45

**Location** Pink Area, Coral 2

**Chairs** H. Haas, Heppenheim (DE)  
F. Dimitriadis, Kalamaria, Thessaloniki (GR)

### Learning objectives

The investigation and management of male infertility can be a formidable diagnostic challenge to urologists. In this year ESUO meeting, noted clinical physicians and distinguished scientists have joined forces to create a comprehensive resource guide to current diagnostic and treatment options for a broad spectrum of clinical issues relevant to male infertility and sexual disorders. Topics covered range from evaluation of infertile men and male endocrinology to sexual dysfunction and treatment modalities in the office or outpatient clinic. Controversial medical and surgical treatment options are also discussed. Other topics of interest include metabolic syndrome and male infertility, fertility and cancer therapy, and scrotum MRI.

10:15 - 10:20

### Welcome and introduction

H. Haas, Heppenheim (DE)

10:20 - 11:10

### Male reproductive endocrinology – Male hormone disorders

*Moderators* F. Dimitriadis, Kalamaria, Thessaloniki (GR)  
T.H. Kuru, Köln (DE)

10:20 - 10:35

### State-of-the-art lecture Testosterone replacement therapy; evidence of the benefit-risk ratio in aging men

G. Corona, Bologna (IT)

10:35 - 10:50

### Hormonal management of male infertility: Promises and pitfalls

C. Krausz, Florence (IT)

10:50 - 11:05

### Metabolic syndrome and male infertility: Modern view of an old problem

A. Khelaia, Tbilisi (GE)

11:05 - 11:10

### Discussion

11:10 - 11:45

### Fertility dilemmas in younger patients

*Moderators* S.M. Haensel, Rotterdam (NL)  
P. Tsafarakidis, Kirkcaldy (GB)

11:10 - 11:25

### Decision-making dilemma: When and how to treat varicoceles in adolescents?

M. Dinkelman-Smit, Rotterdam (NL)

11:25 - 11:40

### Fertility and cancer therapy in outpatient setting

H. Brenneis, Pirmasens (DE)

11:40 - 11:45

### Discussion

11:45 - 12:10

### ESUO – ESAU joint session: Andrology-Surgery taken decisions in the outpatient urology institutions

*Moderators* H. Brenneis, Pirmasens (DE)  
A. Khelaia, Tbilisi (GE)

11:45 - 12:05

### Debate Management of adult non-obstructed azoospermic man with bilateral cryptorchidism

*Discussants* P. Capogrosso, Milan (IT)  
F. Dimitriadis, Kalamaria, Thessaloniki (GR)

12:05 - 12:10

**Discussion**

---

12:10 - 13:05

**Sexual dysfunction & disorders**

*Moderators* S.M. Haensel, Rotterdam (NL)  
A. Zachariou, Ioannina (GR)

12:10 - 12:25

**Subfertility and sexual dysfunction: Double trouble or one disease?**

S.M. Haensel, Rotterdam (NL)

12:25 - 12:45

**Debate Controversies in office urology: Is persistent erectile dysfunction associated with 5ARIs a reality or a myth in daily practice?**

*Discussants* M. Benyó, Debrecen (HU)  
F. Dimitriadis, Thessaloniki (GR)

12:45 - 13:00

**State-of-the-art lecture Shockwaves and PRP in office urology: Protocols for the everyday clinical practice**

D. Hatzichristou, Thessaloniki (GR)

13:00 - 13:05

**Discussion**

---

13:05 - 13:40

**Clinical assessment of male fertility**

*Moderators* M. Benyó, Debrecen (HU)  
A. Verit, Istanbul (TR)

13:05 - 13:20

**Why is it necessary to evaluate infertile men in the era of IVF?**

A. Zachariou, Volos (GR)

13:20 - 13:35

**When to refer for an MRI of the scrotum?**

L.P. Zapala, Warsaw (PL)

13:35 - 13:40

**Discussion**

---

13:40 - 13:45

**Closing remarks**

F. Dimitriadis, Kalamaria, Thessaloniki (GR)

## YUORDay23 - Part I: EAU Young Urologists Office (YUO) & European Society of Residents in Urology (ESRU)

Special session

**Saturday 11 March**  
**10:15 - 14:15**

**Location** Yellow Area, Brown 2  
**Chairs** D.M. Carrión Monsalve, Madrid (ES)  
J.L. Vásquez, Roskilde (DK)

### Learning objectives

In this session we introduce the European Society of Residents in Urology (ESRU) and the Young Urology Office (YUO). The aim of this session is to offer talks tailored to residents' and young urologists' educational needs. We present the traditional surgical tips and tricks and research and academic topics. A brand-new session called nightmare cases will take place, in which residents and young urologists will participate alongside with experts in the discussion of complicated case management. The other two sessions called urology for dummies and challenging the guidelines will summarize key current topics. We will finish with the great finale of the EAU Guidelines Cup, a competition between the three finalists of the Cup and the audience

**10:15 - 10:30**

**Welcome and introduction**  
D.M. Carrión Monsalve, Madrid (ES)  
J.L. Vásquez, Roskilde (DK)

**10:30 - 11:25**

**European Urology Scholarship Programme (EUSP)**  
*Moderators* E. Laukhtina, Vienna (AT)  
A.S. Merseburger, Lübeck (DE)

**10:30 - 10:40**

**EUSP Application: How to apply and what is important**  
E. Laukhtina, Vienna (AT)

**10:40 - 10:50**

**EUSP Host center experience**  
A. Heidenreich, Cologne (DE)

**10:50 - 11:00**

**EUSP Programmes and news in 2023**  
A.S. Merseburger, Lübeck (DE)

**11:00 - 11:05**

**Presentation of best scholars**  
A.S. Merseburger, Lübeck (DE)

**11:05 - 11:15**

**Best scholar winner clinical My experience and how it influenced my career**  
To be confirmed

**11:15 - 11:25**

**Best scholar winner basic research My experience and how it influenced my career**  
To be confirmed

**11:25 - 12:25**

**Surgery tips & tricks**  
*Moderators* L. Baekelandt, Leuven (BE)  
E.C. Bujoreanu, Cluj Napoca (RO)  
To be confirmed

**11:25 - 11:40**

**Laparoscopic retroperitoneal surgery**  
To be confirmed

**11:40 - 11:55**

**Anatomic enucleation of the prostate - HoLEP**  
F. Gomez Sancha, Madrid (ES)

**11:55 - 12:10**

**Open nephrectomy**  
To be confirmed

12:10 - 12:25

**Ureteroscopy**  
O. Traxer, Paris (FR)

---

12:25 - 13:15

**Research and academic**  
*Moderators* E. Checcucci, Candiolo (IT)  
A. Khelif, Mons (BE)  
H. Warren, London (GB)

12:25 - 12:35

**Urologists and social media: Advantages and risks**  
J Dubin, Miami (US)

12:35 - 12:45

**Young Academic Urologists (YAU): What is it? Is it for me?**  
M. Moschini, Milan (IT)

12:45 - 12:55

**Urology: How to study smarter not harder**  
E. García Rojo, Madrid (ES)

12:55 - 13:05

**The importance of collaborative prospective studies**  
To be confirmed

13:05 - 13:15

**ESU: Opportunities for residents**  
E. Liatsikos, Patras (GR)

---

13:15 - 14:15

**Nightmare cases**  
*Moderators* D.M. Carrión Monsalve, Madrid (ES)  
F. Esperto, Rome (IT)  
V. Quaresma, Louzan (PT)

13:15 - 13:35

**Case I Renal trauma, urinary leak, and robotic surgical repair**  
*Speaker* F. Piramide, Turin (IT)  
*Expert* A. Mottrie, Aalst (BE)

13:35 - 13:55

**Case II A delayed bleeding complication after PCNL surgery**  
*Speaker* A. Rautio, Tallinn (EE)  
*Expert* To be confirmed

13:55 - 14:15

**Case III Ureteral lesion, open surgical repair: Complications of open surgery**  
*Speaker* L.E. Ortega Polledo, Madrid (ES)  
*Expert* G. Giusti, Milan (IT)

## Disorders in reproductive and sexual health: From the diagnosis to the pharmaceutical and surgical treatment and from the laboratory to the clinic

Meeting of the EAU Section of Andrological Urology (ESAU)

**Saturday 11 March**  
**10:15 - 13:45**

**Location** Pink Area, Coral 6

**Chair** N. Sofikitis, Ioannina (GR)

### Learning objectives

The Scientific Meeting of The EAU Section of ESAU will focus on penile surgery for prosthesis implantation and the selection and placement of the appropriate graft for the amelioration of the erectile dysfunction caused by Peyronie's disease. In addition the pharmaceutical and surgical treatment of male infertility will be discussed extensively. Emphasis will be given to the beneficial effects and the contraceptive effects, as well, of exogenous testosterone administration. The scientific dream to haploidize a diploid male germ cell or a somatic cell in vitro will be presented

**10:15 - 10:16**

### Welcome and introduction

N. Sofikitis, Ioannina (GR)

**10:16 - 10:41**

### Metabolic syndrome, obesity, and

*Moderators* M.M. Fode, Herlev (DK)  
A. Zachariou, Ioannina (GR)

**10:16 - 10:26**

### Cancer risk

F. Montorsi, Milan (IT)

**10:26 - 10:36**

### Male sexual health and male reproductive potential

G.I. Russo, Catania (IT)

**10:36 - 10:41**

### Discussion

**10:41 - 11:06**

### Surgery-in-Motion 1: Tips and tricks in penile surgery for prosthesis implantation

*Moderators* C. Bettocchi, Foggia (IT)  
To be confirmed

**10:41 - 10:51**

### Penile implant with local anesthesia: A simple procedure

E. Ruiz-Castañé, Barcelona (ES)

**10:51 - 11:01**

### Salvage penile prosthesis implantation with tunneling technique after priapism

D. Osmonov, Kiel (DE)

**11:01 - 11:06**

### Discussion

**11:06 - 11:31**

### Surgery-in-Motion 2: Tips and tricks in penile surgery for Peyronie's disease

*Moderators* F. Fusco, Naples (IT)  
D. Hatzichristou, Thessaloniki (GR)

**11:06 - 11:16**

### New techniques in the surgical treatment of Peyronie's disease

A. Kadioglu, Istanbul (TR)

**11:16 - 11:26**

### The choice of the graft and its optimal placement for the therapeutic management of Peyronie's disease

R. Djinovic, Belgrade (RS)

**11:26 - 11:31**

### Discussion

**11:31 - 11:56**

### Surgery-in-Motion 3: Tips and tricks in penile surgery

*Moderators* P.A.S. Vendeira, Porto (PT)  
A. Papatsoris, Athens (GR)

11:31 - 11:41	<b>Management of the floppy glans following penile prosthesis surgery</b> D.J. Ralph, London (GB)
11:41 - 11:51	<b>Optimization of the cylinder size and rigidity in penile implantation</b> P. Egydio, Sao Paulo (BR)
11:51 - 11:56	<b>Discussion</b>
11:56 - 12:31	<b>Surgery-in-Motion 4: Tips and tricks in the surgery for the alleviation of male infertility</b> <i>Moderators</i> S. Kliesch, Münster (DE) To be confirmed
11:56 - 12:06	<b>Surgery for ejaculatory duct obstruction</b> A. Muneer, London (GB)
12:06 - 12:16	<b>Micro-surgical testicular sperm retrieval vs non-magnified testicular sperm retrieval</b> T. Diemer, Giessen (DE)
12:16 - 12:26	<b>Micro-surgical varicocelectomy: Does it remain the gold standard for varicocele repair?</b> Z. Kopa, Budapest (HU)
12:26 - 12:31	<b>Discussion</b>
12:31 - 13:06	<b>State-of-the-art lectures Improving the quality of the reproductive and sexual life of the male</b> <i>Moderators</i> H. Behre, Halle (DE) J. Rassweiler, Krems - Stein (AT)
12:31 - 12:41	<b>Management of the sub fertile male-for the health of the female and the offspring</b> A. Giwercman, Malmö (SE)
12:41 - 12:51	<b>Updated diagnostic work-up of the infertile male</b> A. Salonia, Milan (IT)
12:51 - 13:01	<b>Contemporary and future treatments for male infertility</b> S. Minhas, London (GB)
13:01 - 13:06	<b>Discussion</b>
13:06 - 13:36	<b>State-of-the-art lectures Hot questions in clinical and experimental andrology</b> <i>Moderators</i> G. Corona, Bologna (IT) S. Binsaleh, Riyadh (SA)
13:06 - 13:16	<b>Is testosterone treatment associated with increased risk of prostate cancer or worsening of lower urinary tract symptoms?</b> H. Behre, Halle (DE)
13:16 - 13:26	<b>Testosterone therapy: Which are the indications, contraindications, and risks?</b> M. Dinkelman-Smit, Rotterdam (NL)
13:26 - 13:36	<b>Approaching the target in vitro: from the haploidization of the diploid human male germ cell to the haploidization of the diploid somatic cell</b> N. Sofikitis, Ioannina (GR)
13:36 - 13:41	<b>Discussion</b>
13:41 - 13:45	<b>Closing remarks</b> N. Sofikitis, Ioannina (GR)

---



## The complex world of treatment of non-neurogenic and neurogenic bladder dysfunctions: from neuromodulation to bladder augmentation

Meeting of the EAU Section of Female and Functional Urology (ESFFU)

Saturday 11 March  
10:15 - 13:45

**Location** Blue Area, Room 1

**Chair** F. Cruz, Porto (PT)

10:15 - 10:20

**Welcome and introduction**  
F. Cruz, Porto (PT)

10:20 - 11:20

**Sacral neuromodulation**

*Moderators* T. Tarcan, Istanbul (TR)  
E. Chartier-Kastler, Paris (FR)

10:20 - 10:25

**Clinical case**

V. Sakalis, Thessaloniki (GR)

10:25 - 10:35

**Botox vs. SNM: How to inform the patient?**

K-D. Sievert, Detmold (DE)

10:35 - 10:45

**How I do SNM and PTNS**

S. De Wachter, Edegem (BE)

10:45 - 10:55

**Long term efficacy and safety**

G. Van Koeveringe, Maastricht (NL)

10:55 - 11:05

**SNM in neurogenic cases**

U. Mehnert, Zurich (CH)

11:05 - 11:20

**Discussion**

To be confirmed

11:20 - 11:55

**Debate Female SUI**

*Moderators* H. Hashim, Bristol (GB)  
S. Arlandis, Valencia (ES)

11:20 - 11:25

**Case presentation**

M. Manso, Porto (PT)

11:25 - 11:35

**Mini slings**

M.S. Abdel-Fattah, Aberdeen (GB)

11:35 - 11:45

**Standard slings**

V. Phé, Paris (FR)

11:45 - 11:55

**Discussion**

To be confirmed

11:55 - 12:55

**ESFFU meets other societies**

*Moderators* F. Cruz, Porto (PT)  
S. Charalampous, Limassol (CY)

11:55 - 12:00

**Case presentation**

B.Y. Padilla Fernandez, San Cristóbal De La Laguna (ES)

12:00 - 12:15

**Italian Society of Urodynamics: What is the best urodynamic test to diagnose DU?**

V. Li Marzi, Florence (IT)

12:15 - 12:30

**ICS: Is prostatectomy an acceptable treatment for patients with BPH/BOO and detrusor underactivity?**

G. Van Koeveringe, Maastricht (NL)

12:30 - 12:45	<b>SUFU: Can we predict using urodynamic tests, detrusor morphology or genomics DU patients that will void after prostatectomy?</b> To be confirmed
12:45 - 12:55	<b>Discussion</b>
12:55 - 13:40	<b>Neurogenic detrusor overactivity</b> <i>Moderators</i> M. Drake, London (GB) E. Finazzi Agrò, Rome (IT)
12:55 - 13:00	<b>Clinical case presentation: SCI vs. MS</b> O. Gülpinar, Belgat - Ankara (TR)
13:00 - 13:10	<b>When is urodynamic really necessary?</b> G. Del Popolo, Florence (IT)
13:10 - 13:20	<b>What is new for the treatment of neurogenic bladder dysfunction?</b> C. Konstantinidis, Ilion (GR)
13:20 - 13:30	<b>Vigilance of a patient after ileal bladder augmentation</b> A.K. Nambiar, Newcastle upon Tyne (GB)
13:30 - 13:40	<b>Discussion</b>
13:40 - 13:45	<b>Conclusions</b> F. Cruz, Porto (PT)

## Prostate cancer: Role of imaging and PSA density for biopsy indication, and tumour staging

Abstract Session 06

**Saturday 11 March**  
**10:15 - 11:45**

**Location** Pink Area, Coral 3  
**Chairs** To be confirmed  
To be confirmed  
A.S. Rannikko, Espoo (FI)

**10:15 - 10:18**

**Introduction**

**Imaging to identify men for first biopsy**

**A0088** **A multicentre parallel-group randomised trial assessing multiparametric MRI characterisation and image-guided biopsy of prostate in men suspected of having prostate cancer: MULTIPROS study**  
A. Bates, Dundee (GB)

**A0089** **External validation of a Multiparametric MRI volumetric model to predict the utility of systematic biopsies at the time of targeted biopsy**  
A. Ninivaggi, Altamura (IT)

**A0090** **mpMRI of the prostate in patients carrying a high clinical risk of prostate cancer diagnosis: is this imaging test necessary for diagnostic purposes in this subset of patients?**

**10:24 - 10:30**

**Discussion**

**Imaging and PSA density in selecting men for first biopsy**

**A0091** **Integrating Index lesion volume to better classify men with indolent prostate cancer among patients with intermediate risk disease. Results from a large, multi-institutional series.**

**A0092** **Discharging after reassuring mpMRI Prostate? Caution from a prospective study comparing mpMRI Prostate with transperineal biopsies and prostatectomy specimens**  
C.T. Berridge, Redditch (GB)

**A0093** **Addition of PSA density to MRI PIRADS score guides selection for transperineal biopsy: a risk adapted approach based on 608 cases of transperineal biopsy histology from a single centre**  
A. Kooplikattil Pushkaran, St Asaph (GB)

**A0094** **The clinical utility of risk-stratification based on combined use of Prostate Imaging Reporting and Data System (PIRADS) score and Prostate-Specific Antigen (PSA) density**  
G. Rosta, Vienna (AT)

**10:38 - 10:46**

**Discussion**

**Imaging for prediction of local and pelvic nodes staging**

---

A0095	<b>Impact of prebiopsy mri on prostate cancer staging in the norwegian prostate cancer registry</b>
A0096	<b>Multiparametric-MRI computer aid diagnosis for prostate cancer: A pathological validation of the WATSON ELEMENTARY ® system after robotic radical prostatectomy.</b> A. Mari, Firenze (IT)
A0097	<b>Can we predict the site of positive surgical margins based on the site of the index lesion at multiparametric mri ? a topographic, single center study</b>
A0098	<b>Prospective evaluation of the diagnostic accuracy of different PSMA PET/CT tracers for the nodal staging of radical prostatectomy candidates: A single institutional analysis</b> P. Arena, Pieve Emanuele MI (IT)
A0099	<b>Real-life performance of imaging vs. nomograms for the assessment of lymph-node involvement in prostate cancer: Should we trust radiology?</b> F. Chierigo, Schio (IT)
<b>10:56 - 11:06</b>	<b>Discussion</b>
	<b>Imaging and risk level prediction</b> To be confirmed
A0100	<b>PSMA PET for high risk prostate cancer patient: a cost effective strategy.</b> A. Al-Mitwalli, Cardiff (GB)
A0101	<b>"Artificial intelligence" to improve cancer detection in transperineal MRI/ultrasound fusion biopsies of the prostate – A prospective evaluation</b> K. Günzel, Berlin (DE)
A0102	<b>Diagnostic performance of high-resolution micro-ultrasound targeted biopsy for detection of clinically significant prostate cancer among naïve patients with a negative multiparametric MRI and a persistently high suspicion of prostate cancer</b> P.P. Avolio, Pieve Emanuele (IT)
A0103	<b>Investigating the role of the prostate multiparametric magnetic resonance imaging sequences quality on biopsies' outcomes</b>
A0104	<b>MRI interpretation and assessment criteria for imaging after focal therapy for prostate cancer: A systematic review</b> A. Light, Cambridge (GB)
A0105	<b>High risk ISUP group prediction by PET PSMA SUVmax in Latam</b> J.A. Alcacio Mendoza, (MX)
A0106	<b>Validation of 18F-DCFPyL PET radiomics-based machine learning models in intermediate- to high-risk primary prostate cancer</b> W. Luining, Amsterdam (NL)
A0107	<b>68Ga and 18F-PSMA PET/CT for primary diagnosis before radical prostatectomy: Which radiopharmaceutical for which indication?</b> A.V. Aksenov, Baden-Baden (DE)

---

**A0108**                      **How should lesions without anatomical correspondence in 18F-PSMA-1007 PET/CT be interpreted - a PROSTAGE follow-up study**  
O. Ettala, Kaarina (FI)

---

**11:24 - 11:38**                      **Discussion**

---

**11:38 - 11:45**                      **Closing remarks**

## Technology developments never end!

EAU23 Live Surgery Session

**Saturday 11 March**  
10:30 - 19:00

**Location** Yellow Area, eURO Auditorium 1  
**Chairs** A. Breda, Barcelona (ES)  
To be confirmed  
To be confirmed

10:30 - 10:35

**Welcome and introduction**  
A. Breda, Barcelona (ES)

10:35 - 11:05

**Part 1a**  
*Moderators* M.E. Alvarez-Maestro, Madrid (ES)  
E. Barret, Paris (FR)  
To be confirmed  
L.B. Dragoş, Cambridge (GB)  
C. Fiori, Orbassano (IT)  
To be confirmed  
To be confirmed  
To be confirmed  
A. Skolarikos, Athens (GR)

10:35 - 11:05

**Thulium fiber laser enucleation of the prostate**  
To be confirmed

10:35 - 11:05

**Holmium laser enucleation of the prostate**  
F. Gomez Sancha, Madrid (ES)

10:35 - 11:05

**Pre-recorded Transurethral vaporization procedures of the prostate**  
G. Bozzini, Como (IT)

11:05 - 11:35

**Part 1b**  
*Moderators* M.E. Alvarez-Maestro, Madrid (ES)  
To be confirmed  
To be confirmed  
L.B. Dragoş, Cambridge (GB)  
C. Fiori, Orbassano (IT)  
To be confirmed  
To be confirmed  
To be confirmed  
A. Skolarikos, Athens (GR)

11:05 - 11:35

**Combined (Ho+TFL)**  
E. Emiliani, Barcelona (ES)  
O. Angerri Feu, Barcelona (ES)

11:05 - 11:35

**Retrograde intrarenal surgery (Virtual basket)**  
S. Ferretti, Modena (IT)

11:05 - 11:35

**Pre-recorded Retrograde intrarenal surgery**  
To be confirmed

11:35 - 12:05

**Part 2a**

---

	<i>Moderators</i>	To be confirmed A. Celia, Modena (IT) To be confirmed To be confirmed To be confirmed To be confirmed J.B. Roche, Bordeaux (FR) To be confirmed To be confirmed
11:35 - 12:05	<b>3D laparoscopic partial nephrectomy</b>	A. Alcaraz, Barcelona (ES)
11:35 - 12:05	<b>Percutaneous nephrolithotomy</b>	To be confirmed
11:35 - 12:05	<b>Pre-recorded En-Bloc resection of NMIBC</b>	To be confirmed

---

12:05 - 12:35	<b>Part 2b</b>	
	<i>Moderators</i>	To be confirmed A. Celia, Modena (IT) To be confirmed To be confirmed To be confirmed To be confirmed J.B. Roche, Bordeaux (FR) To be confirmed To be confirmed
12:05 - 12:35	<b>Flexible ureteroscopic lithotripsy with thulium fiber laser</b>	P.M. Kronenberg, Lisbon (PT)
12:05 - 12:35	<b>Thulium fiber laser enucleation of the prostate</b>	J. Romero-Otero, Madrid (ES)
12:05 - 12:35	<b>Pre-recorded Minimally invasive BPH treatment</b>	S. Secco, Milan (IT)

---

12:35 - 13:35	<b>Part 3</b>	
	<i>Moderators</i>	G. Bozzini, Como (IT) O.R. Durutovic, Belgrade (RS) To be confirmed To be confirmed P. Kallidonis, Patras (GR) B. Petrut, Cluj Napoca (RO) To be confirmed To be confirmed To be confirmed
12:35 - 13:35	<b>Simultaneous bilateral endoscopic surgery</b>	To be confirmed S. Proietti, Milan (IT)
12:35 - 13:35	<b>Holmium laser enucleation of the prostate</b>	F. Montorsi, Milan (IT)
12:35 - 13:35	<b>30 min. Pre-recorded Inflatable penile prosthesis</b>	G. Antonini, Rome (IT)
	<b>30 min. Pre-recorded Inflatable penile prosthesis</b>	C. Bettocchi, Foggia (IT)

---

13:35 - 14:05

## Part 4

### Moderators

G. Bozzini, Como (IT)  
O.R. Durutovic, Belgrade (RS)  
B. Geavlete, Bucharest (RO)  
To be confirmed  
P. Kallidonis, Patras (GR)  
B. Petrut, Cluj Napoca (RO)  
To be confirmed  
To be confirmed  
To be confirmed

13:35 - 14:05

### Endoscopic enucleation of the prostate

T.R.W. Herrmann, Frauenfeld (CH)

13:35 - 14:05

### Blue light en-bloc transurethral resection of bladder tumour

L. Lusuardi, Salzburg (AT)

13:35 - 14:05

### Pre-recorded Retrograde intrarenal surgery incl. laser-lithotripsy

To be confirmed

---

14:05 - 15:20

## Part 5

14:05 - 15:20

### Unmoderated Robotic radical cystectomy

K. Decaestecker, Ghent (BE)

14:05 - 15:20

### Unmoderated Robotic radical prostatectomy

To be confirmed

---

15:20 - 16:20

## Part 6

### Moderators

A. Antonelli, Verona (IT)  
J.M. Gaya Sopena, Barcelona (ES)  
To be confirmed  
To be confirmed  
To be confirmed  
To be confirmed  
To be confirmed  
H.G. Van Der Poel, Amsterdam (NL)  
To be confirmed

15:20 - 16:20

### Robotic radical cystectomy

K. Decaestecker, Ghent (BE)

15:20 - 16:20

### Robotic partial nephrectomy

To be confirmed

15:20 - 16:20

### 30 min. Pre-recorded Artificial sphincter

V. Phé, Paris (FR)

### 30 min. Pre-recorded Simple prostate: Adenomectomy

F. Porpiglia, Turin (IT)

---

16:20 - 16:50

## Part 7a



---

	<i>Moderators</i>	A. Antonelli, Verona (IT) J.M. Gaya Sopena, Barcelona (ES) To be confirmed To be confirmed To be confirmed To be confirmed To be confirmed H.G. Van Der Poel, Amsterdam (NL) To be confirmed
16:20 - 16:50	<b>Robotic radical prostatectomy</b>	B.M.C. Rocco, Milan (IT)
16:20 - 16:50	<b>Prostatectomy with Retzius sparing technique</b>	To be confirmed
16:20 - 16:50	<b>15 min. Pre-recorded Partial nephrectomy</b>	A. Breda, Barcelona (ES)
	<b>15 min. Pre-recorded Combination of a prostatectomy and telling the story of implementing a new robot in the hospital</b>	To be confirmed

---

16:50 - 17:20	<b>Part 7b</b>	
	<i>Moderators</i>	O.R. Durutovic, Belgrade (RS) To be confirmed To be confirmed To be confirmed To be confirmed J.I. Martínez Salamanca, Majadahonda (ES) To be confirmed To be confirmed To be confirmed
16:50 - 17:20	<b>Endoscopic intrarenal surgery</b>	C.M. Cracco, Turin (IT) D.A. Pérez Fentes, Santiago de Compostela (ES)
16:50 - 17:20	<b>Triple channel scope with suction &amp; TFL: First step towards invisible percutaneous nephrolithotomy</b>	To be confirmed
16:50 - 17:20	<b>Pre-recorded video Robotic extraperitoneal radical prostatectomy</b>	E. Liatsikos, Patras (GR)

---

17:20 - 17:50	<b>Part 8</b>	
	<i>Moderators</i>	To be confirmed To be confirmed To be confirmed To be confirmed To be confirmed J.I. Martínez Salamanca, Majadahonda (ES) To be confirmed To be confirmed To be confirmed
17:20 - 17:50	<b>Flexible ureteroscopy and laser lithotripsy</b>	B. Somani, Southampton (GB)
17:20 - 17:50	<b>Pre-recorded video fURS using single-use video flexible ureteroscope</b>	E. Liatsikos, Patras (GR)

---

## Scientific Programme - EAU23 Milan

---

17:20 - 17:50

**Pre-recorded video Benign prostatic hyperplasia**

N. Barber, Camberley (GB)

---

17:50 - 18:00

**Closing remarks**

A. Breda, Barcelona (ES)

## Small renal masses in hereditary syndromes

Thematic Session

**Saturday 11 March**  
**10:45 - 12:15**

**Location** Yellow Area, eURO Auditorium 2

**Chairs** M.C. Mir Maresma, Valencia (ES)  
D. Nikoleishvili, Tbilisi (GE)

### Learning objectives

Up to date management on diagnosis and treatment for SRM in hereditary syndromes. How to optimise your clinics for RCC hereditary tumours.

**10:45 - 11:20**

**Case discussion Update in renal mass characterisation**

**10:45 - 10:48**

**Case presentation**

A. Pecoraro, Milan (IT)

**10:48 - 10:54**

**Novel ultrasound applications for SRM**

E. Roussel, Leuven (BE)

**10:54 - 11:00**

**Radiomics for SRM**

T. Kuusk, London (GB)

**11:00 - 11:06**

**New tracers on the block: Which tracer for which mass?**

C.H.J. Muselaers, Nijmegen (NL)

**11:06 - 11:12**

**Are biopsies still the golden standard? What's next?**

S. Dabestani, Malmö (SE)

**11:12 - 11:20**

**Discussion**

**11:20 - 11:55**

**Case discussion Small renal mass treatment**

**11:20 - 11:23**

**Case presentation**

A. Pecoraro, Milan (IT)

**11:23 - 11:29**

**Surgical approaches**

S. Hawlina, Ljubljana (SI)

**11:29 - 11:35**

**Active surveillance/Medical therapies**

P.M. Pierorazio, Baltimore (US)

**11:35 - 11:41**

**Focal therapy**

E. Barret, Paris (FR)

**11:41 - 11:47**

**SBRT**

B. Vanneste, Maastricht (NL)

**11:47 - 11:55**

**Discussion**

**11:55 - 12:05**

**State-of-the-art lecture Centralising and optimising care for RCC genetic syndromes**

A. Larcher, Milan (IT)

**12:05 - 12:15**

**State-of-the-art lecture Biomarkers and prediction models on renal function: Application to real life**

C.K. Bensalah, Rennes (FR)

## Minimising side effects and optimising outcomes in prostate cancer

Video Session 05

**Saturday 11 March  
12:00 - 13:30**

**Location** Pink Area, Coral 7  
**Chairs** To be confirmed  
F. Gómez Veiga, Salamanca (ES)  
C.V. Kesch, Essen (DE)

**12:00 - 12:01**

**Introduction**

- V032 **Outcomes of precision prostatectomy procedure for localized prostate cancer, and step-by-step technique of single port transvesical precision prostatectomy**  
S. Arora, Detroit (US)
- V033 **Optimizing fluorescence confocal microscopy margin assessment during RARP, the LaserSAFE technique**  
R. Almeida-Magana, London (GB)
- V034 **Ex vivo assessment of surgical margins with confocal laser microscopy during minimally-invasive radical prostatectomy: Our first 50 cases**  
P. Verri, Torino (IT)
- V035 **RARP nerve sparing with 3D model reconstruction and TilePro 3D augmented reality**
- V036 **Step-by-Step single setting 3D MRI-US guided frozen section and focal cryoablation of the index lesion**  
L. Misuraca, Rome (IT)
- V037 **Surgeon administered laparoscopic guided transversus abdominis plane block following robot-assisted laparoscopic radical prostatectomy**
- V038 **Detrusor apron sparing**  
F. Gaboardi, Milan (IT)
- V039 **Apical dissection with maximal anatomical preservation of the urethral sphincter complex: impact on the early postoperative functional outcomes**  
M. Borghesi, Bologna (IT)

**13:27 - 13:30**

**Closing remarks**

## Urological trauma and complications

Abstract Session 05

**Saturday 11 March**  
**10:15 - 11:45**

**Location** Pink Area, Coral 1  
**Chairs** B. Petrut, Cluj Napoca (RO)  
To be confirmed  
W. Altaweel, Riyadh (SA)

**10:15 - 10:18**

**Introduction**

- |                      |   |
|----------------------|---|
| A0076                | <b>External validation of a nomogram for the prediction of an intervention for bleeding control after renal trauma</b><br>T.S. Schmidli, Dübendorf (CH)   |
| A0077                | <b>Clinical values of DMSA SPECT in assessment of remaining cortical renal function after recovery of renal injuries</b>  |
| A0078                | <b>A ten-year experience of Sicilian emergency centers in penile trauma, from diagnosis to follow-up: A retrospective analysis</b><br>C. Di Gaetano, Catania (IT)   |
| A0079                | <b>Robot-assisted ureteral reconstruction for iatrogenic injuries of the ureter</b><br>V. Ficarra, Messina (IT)   |
| A0080                | <b>Outcomes of early endoscopic realignment for pelvic fracture urethral injury</b><br>K. Chaker, Manouba (TN)  |
| A0081                | <b>Evolution in the management of high-grade renal trauma over the last two decades: A retrospective review</b><br>A. Yebes, Madrid (ES)  |
| <b>10:30 - 10:46</b> | <b>Discussion</b>   |
|                      | <b>Miscellaneous</b>  |
| A0082                | <b>Increase of advanced tumor stages during the corona pandemic? An analysis of 13,228 patients from an uro-oncology outpatient rehabilitation clinic</b><br>M.C. Butea-Bocu, Bad Wildungen (DE)                |
| A0083                | <b>Cost burden of radiation cystitis presentations and investigations to a tertiary referral hospital in Ireland</b><br>B. Gilmartin, Dublin (IE)   |
| A0084                | <b>Is age only a number: Urological hospitalization reasons and outcomes of octogenarians and nonagenarians</b>   |
| A0085                | <b>Successive treatment with oral corticosteroids and infiltration of the pudendal nerve in patients with pudendal neuropathy – how effective it is and how to predict success</b><br>A. Ciudin, Barcelona (ES) |
| A0086                | <b>Subjective evaluation of hypercoagulability in patients scheduled for urologic surgery</b><br>K. Douroumis, (GR)   |

## Scientific Programme - EAU23 Milan

---

A0087	<b>Expandable ureteral stent for complex ureteral stenosis: Long term outcomes</b> M. Mata Alcaraz, Madrid (ES)
10:58 - 11:14	<b>Discussion</b>
11:14 - 11:36	<b>Video abstracts</b>
V030	<b>“Near miss” in robot-assisted partial nephrectomy. Prevention of adverse events by careful identification of the surgical anatomy</b> S. Parodi, Genoa (IT)
V031	<b>Retrocaval ureter: Robot assisted ureterolithotomy and ureteral transposition</b> M. Matinero Tor, Lérida (ES)
11:36 - 11:43	<b>Closing remarks</b>

---

**EAU Guideline session: Effective treatment in upper tract urothelial tumours**

Thematic Session

**Saturday 11 March  
12:30 - 14:00**

**Location** Yellow Area, eURO Auditorium 2

**Chairs** P. Gontero, Turin (IT)  
M. Rouprêt, Paris (FR)

**Learning objectives**

Participants will:

- Expand their knowledge on the pathology and the Molecular Landscape in upper tract urothelial cancer (UTUC) and its treatment consequences, including
  - risk stratification of UTUC
  - Genomic approach in UTUC
- Learn about UTUC, specifically:
  - Systemic therapy (neoadjuvant and adjuvant systemic chemotherapy and immunotherapy)
  - Intra vesical instillation
- Be instructed on systemic therapy in metastatic UTUC
- Develop an understanding on UTUC recurrence and follow-up
- Become familiarised with the biological and therapeutic rationale behind UTUC

**12:30 - 12:32**

**Welcome and introduction**  
M. Rouprêt, Paris (FR)

**12:32 - 12:42**

**State-of-the-art lecture Role of systemic chemotherapy after radical nephroureterectomy**  
A. Birtle, Preston (GB)

**12:42 - 12:47**

**Discussion**

**12:47 - 12:57**

**State-of-the-art lecture Evidence for neo-adjuvant treatment before radical nephroureterectomy**  
T. Seisen, Paris (FR)

**12:57 - 13:02**

**Discussion**

**13:02 - 13:27**

**Is it possible to consider systematic immediate intravesical instillation after radical nephroureterectomy?**

**13:02 - 13:07**

**Case presentation**  
F. Soria, Turin (IT)

**13:07 - 13:12**

**Pro**  
To be confirmed

**13:12 - 13:17**

**Con**  
A. Masson-Lecomte, Paris (FR)

**13:17 - 13:27**

**Discussion**

**13:27 - 13:37**

**State-of-the-art lecture Improvement in technologies and drugs to support kidney sparing surgery**  
J. Baard, Amsterdam (NL)

**13:37 - 13:42**

**Discussion**

## Scientific Programme - EAU23 Milan

---

13:42 - 13:52

**State-of-the-art lecture** Immunotherapy in locally advanced and metastatic UTUC:  
**A reality?**  
To be confirmed

---

13:52 - 13:57

**Discussion**

---

13:57 - 14:00

**Closing remarks**  
P. Gontero, Turin (IT)



## Personalised stone approach through innovation

Meeting of the EAU Section of Urolithiasis (EULIS)

**Sunday 12 March**  
**13:45 - 17:15**

**Location** Pink Area, Coral 6

**Chair** C.C. Seitz, Vienna (AT)

### Learning objectives

Personalized Stone Approach uses a variety of individual factors to guide decisions made in regard to disease prevention, diagnosis, treatment and metaphylaxis. In addition to the non-surgical medical management, use of new technology along with the effective application of miniaturized instruments in RIRS and PNL continuously changes treatment concepts. RIRS and PNL management of stones in the adult and pediatric population will be video-demonstrated and discussed. This EULIS session takes a close look on the recent developments particularly on microbiotic, genetic and pharmacological aspects, and new techniques in stone treatment procedures with a focus on the importance of experience from the experts sharing their tips and tricks.

**13:45 - 13:48**

### Welcome and introduction

C.C. Seitz, Vienna (AT)

**13:48 - 14:48**

### Inside stone formation

*Moderators* S. Moochhala, London (GB)  
M. Straub, Munich (DE)

**13:48 - 13:58**

### Intestinal and urinary microbiome, dysbiosis and inflammation: New kids on the block for kidney stone formation

E. Emiliani, Barcelona (ES)

**13:58 - 14:03**

### Discussion

**14:03 - 14:13**

### Vitamin D supplementation in stone formers: Risks and benefits

C.A. Wagner, Zurich (CH)

**14:13 - 14:18**

### Discussion

**14:18 - 14:28**

### Is neglecting metabolic work-up and metabolic management of stone disease ethical?

P.M. Ferraro, Rome (IT)

**14:28 - 14:33**

### Discussion

**14:33 - 14:43**

### Should genetic testing become part of the routine metabolic work-up?

J. Sayer, Newcastle upon Tyne (GB)

**14:43 - 14:48**

### Discussion

**14:48 - 15:58**

### New technical developments

*Moderators* M. Desai, Nadiad (IN)  
B. Somani, Southampton (GB)

**14:48 - 14:55**

### Pediatric endourology and its changing landscape

A. Bujons Tur, Barcelona (ES)

**14:55 - 14:58**

### Discussion

**14:58 - 15:05**

### Does quality of life fit in routine stone management?

A. Budía Alba, Valencia (ES)

**15:05 - 15:08**

### Discussion

**15:08 - 15:15**

### How do we get rid of the dust? Innovative solutions for dust removal

M. Straub, Munich (DE)

15:15 - 15:18	<b>Discussion</b>
15:18 - 15:25	<b>Navigation in percutaneous stone surgery</b> A. Skolarikos, Athens (GR)
15:25 - 15:28	<b>Discussion</b>
15:28 - 15:35	<b>Laser applications and settings in urolithiasis</b> E.X. Keller, Zürich (CH)
15:35 - 15:38	<b>Discussion</b>
15:38 - 15:45	<b>Suction devices in stone treatment: A difference</b> L. Tzelves, Athens (GR)
15:45 - 15:48	<b>Discussion</b>
15:48 - 15:55	<b>Future of kidney stone surgery</b> O. Traxer, Paris (FR)
15:55 - 15:58	<b>Discussion</b>
<hr/>	
<b>15:58 - 17:13</b>	<b>Video session</b> <i>Moderators</i> K. Sarica, Istanbul (TR) C.C. Seitz, Vienna (AT)
15:58 - 16:08	<b>Suction devices during RIRS</b> V. Gauhar, Singapore (SG)
16:08 - 16:13	<b>Discussion</b>
16:13 - 16:23	<b>Renal puncture: How to be successful in difficult cases</b> W. Gamal, Sohag (EG)
16:23 - 16:28	<b>Discussion</b>
16:28 - 16:38	<b>Suction and Super-mini PNL: Prone position</b> G.H. Zeng, Guangzhou (CN)
16:38 - 16:43	<b>Discussion</b>
16:43 - 16:53	<b>Suction and pediatric PNL: Supine position</b> E. Montanari, Milan (IT)
16:53 - 16:58	<b>Discussion</b>
16:58 - 17:08	<b>PNL to the upper calyx in the supine position</b> M. Cepeda, Valladolid (ES)
17:08 - 17:13	<b>Discussion</b>
<hr/>	
<b>17:13 - 17:15</b>	<b>Closing remarks</b> C.C. Seitz, Vienna (AT)

## Meet the experts in robotic surgery

Meeting of the EAU Robotic Urology Section (ERUS)

**Sunday 12 March**  
**13:45 - 17:15**

**Location** Blue Area, Room 1

**Chair** A. Breda, Barcelona (ES)

### Learning objectives

The aim of this meeting is to learn the latest advances in robotic surgery and have a vision of the different robotic platforms in the market.

**13:45 - 13:50**

### Welcome and introduction

A. Breda, Barcelona (ES)

**13:50 - 14:25**

### Prostate surgery

*Moderators*

K. Fransis, Antwerp (BE)

D. Tilki, Hamburg (DE)

H.G. Van Der Poel, Amsterdam (NL)

**13:50 - 14:00**

### Robotic prostatectomy: Different nerve sparing approaches

M. Graefen, Hamburg (DE)

**14:00 - 14:10**

### How many tricks to achieve a better continence?

To be confirmed

**14:10 - 14:25**

### My life experience with robotic prostatectomy

J.H. Witt, Gronau (DE)

**14:25 - 15:00**

### Kidney surgery

*Moderators*

A. Antonelli, Verona (IT)

B.J. Challacombe, London (GB)

N.N. Harke, Hannover (DE)

**14:25 - 14:35**

### Tips and tricks for the perfect enucleation

A. Minervini, Florence (IT)

**14:35 - 14:45**

### The retroperitoneal approach: All you need to know

J.M. Gaya Sopena, Barcelona (ES)

**14:45 - 15:00**

### My life-time experience with robotic partial nephrectomy

A. Mottrie, Melle (BE)

**15:00 - 15:35**

### Bladder surgery

*Moderators*

H.G. Van Der Poel, Amsterdam (NL)

F. Dal Moro, Padova (IT)

M. Rouprêt, Paris (FR)

**15:00 - 15:10**

### Intracorporeal diversions: Which and why?

P. Wiklund, Stockholm (SE)

**15:10 - 15:20**

### Nightmares in robotic cystectomy

C.J. Wijburg, Arnhem (NL)

**15:20 - 15:35**

### My life-time experience with robotic cystectomy

To be confirmed

**15:35 - 16:15**

### Various

*Moderators*

A.E. Canda, Istanbul (TR)

A.S. Gözen, Heilbronn (DE)

J. Walz, Marseille (FR)



## Rapid-fire debates: Common problems and controversies in bladder cancer

Thematic Session

**Saturday 11 March**  
**15:15 - 17:15**

**Location** Yellow Area, eURO Auditorium 2

**Chairs** A.M. Kamat, Houston (US)  
A. Stenzl, Tübingen (DE)

### Learning objectives

Controversies regarding the use of photodynamic diagnosis, the possible advantages of en bloc resection, the presence of variant histologies, and optimized imaging are discussed in a new format with the help of cases and data based discussions by at least 2 speakers. Further discussions include prostate sparing surgery and the role of surgery in oligometastatic bladder cancer. All discussions will have concluding remarks by the case presenters.

**15:15 - 15:18**

### Welcome and introduction

A.M. Kamat, Houston (US)

**15:18 - 15:37**

### What is best TUR strategy: Does PDD/NBI etc help alter natural history of NMIBC? Do we still need random biopsies in era of PDD/NBI?

#### Case presenter

J.A. Witjes, Nijmegen (NL)

#### Debater 1 PDD/NBI is useful and benefits patients

M. Babjuk, Prague (CZ)

#### Debater 2 Standard TUR is sufficient, additional gimmicks not needed

J. Palou, Barcelona (ES)

#### Discussion and Q&A

*Moderator*

J.A. Witjes, Nijmegen (NL)

*Discussants*

M. Babjuk, Prague (CZ)

J. Palou, Barcelona (ES)

**15:37 - 15:56**

### What is best TUR strategy: Should we all be switching to en bloc TURBT?

#### Case presenter

P. Gontero, Turin (IT)

#### Debater 1 Yes, since it follows oncologic principles

G. Gakis, Würzburg (DE)

#### Debater 2 No, standard TUR is sufficient, plus TUREB is not possible in many cases

S. Lerner, Houston (US)

#### Discussion and Q&A

*Moderator*

P. Gontero, Turin (IT)

*Discussants*

G. Gakis, Würzburg (DE)

S. Lerner, Houston (US)

**15:56 - 16:15**

### Healthy patient with very high risk NMIBC (EAU22 category): What is best treatment? Does variant histology change your recommendation?

#### Case presenter

R. Li, Houston (US)

#### Debater 1 Intravesical therapy is the best option

M. Rouprêt, Paris (FR)

## **Debater 2 Upfront radical cystectomy is best**

L.S. Mertens, Amsterdam (NL)

### **Discussion and Q&A**

*Moderator*

R. Li, Houston (US)

*Discussants*

L.S. Mertens, Amsterdam (NL)

M. Rouprêt, Paris (FR)

---

**16:15 - 16:34**

## **In young patient, is prostate sparing radical cystectomy a safe option for MIBC? What about reproductive organ sparing in women?**

### **Case presenter**

J. Bjerggaard Jensen, Aarhus (DK)

### **Debater 1 No, prostate sparing/reproductive organ sparing should be avoided**

P. Mariappan, Edinburgh (GB)

### **Debater 2 Prostate sparing/reproductive organ sparing should be offered**

M.C. Mir Maresma, Valencia (ES)

### **Discussion and Q&A**

*Moderator*

J. Bjerggaard Jensen, Aarhus (DK)

*Discussants*

P. Mariappan, Edinburgh (GB)

M.C. Mir Maresma, Valencia (ES)

---

**16:34 - 16:53**

## **Clinical staging for bladder cancer: Have imaging techniques reached a point where we can avoid TURBT – at initial diagnosis? After neoadjuvant therapy?**

### **Case presenter**

S. Shariat, Vienna (AT)

### **Debater 1 Yes, we don't need TURBT anymore**

To be confirmed

### **Debater 2 No, we still need TURBT**

A. Masson-Lecomte, Paris (FR)

### **Discussion and Q&A**

*Moderator*

S. Shariat, Vienna (AT)

*Discussants*

To be confirmed

A. Masson-Lecomte, Paris (FR)

---

**16:53 - 17:12**

## **Is there a role for local therapy to the bladder in patients with oligometastatic disease?**

### **Case presenter**

J.A. Efstathiou, Boston (US)

### **Debater 1 No, systemic therapy is sufficient and optimal**

A. Necchi, Milan (IT)

### **Debater 2 Yes, local therapy to bladder should be offered**

A. Bamias, Athens (GR)

### **Discussion and Q&A**

*Moderator*

J.A. Efstathiou, . (US)

*Discussants*

A. Bamias, Athens (GR)

A. Necchi, Milan (IT)

---

**17:12 - 17:15**

### **Closing remarks**

A. Stenzl, Tübingen (DE)

---

## YUORDay23 - Part II: EAU Young Urologists Office (YUO) & European Society of Residents in Urology (ESRU)

Special Session

**Saturday 11 March**  
15:15 - 18:00

**Location** Yellow Area, Brown 2  
**Chairs** D.M. Carrión Monsalve, Madrid (ES)  
J.L. Vázquez, Roskilde (DK)

### Learning objectives

The second part of the YUORDar23 Special Session will focus on a brand new concept of summarizing the most useful and updated data from key topics through the "Urology for dummies" session. The "Challenging the guidelines" session will take up some controversial topics in discussion with the help of experts in the field. Then, we will finish with the great finale of the EAU Guidelines Cup, our famous competition between the three finalists of the Cup and the audience.

15:15 - 16:15

### Urology for dummies: Making a complicated topic simple

*Moderators* M. Deelen, Eindhoven (NL)  
U.G. Falagario, Bari (IT)  
A. Goujon, Rennes (FR)

15:15 - 15:30

### Infertility workup

F. Castiglione, London (GB)

15:30 - 15:45

### Metabolic study

A. Pietropaolo, Southampton (GB)

15:45 - 16:00

### Castration resistant prostate cancer

J. Gómez Rivas, Madrid (ES)

16:00 - 16:15

### Urodynamic study

B. Peyronnet, Rennes (FR)

16:15 - 17:05

### Challenging the guidelines

*Moderators* V. Fiala, Prague (CZ)  
F.E. Sørensen, Herning (DK)  
L. Tzelves, Athens (GR)

16:15 - 16:40

### PSMA in initial staging of prostate cancer

*Pro* D. Murphy, Melbourne (AU)  
*Con* G. Gandaglia, Milan (IT)  
*Expert* C. Moore, London (GB)

16:40 - 17:05

### Non-neurologic obstructive LUTS in young men: Surgery now?

*Pro* C. Fiori, Orbassano (IT)  
*Con* To be confirmed  
*Expert* C. Gratzke, Freiburg (DE)

16:40 - 17:50

### Guidelines cup

#### Guideline masters

M.J. Ribal Caparros, Barcelona (ES)  
J.L. Vázquez, Roskilde (DK)

#### Guideline cup finalists

To be confirmed  
To be confirmed  
To be confirmed

17:50 - 18:15

### Prizes and awards

*Moderators*

D.M. Carrión Monsalve, Madrid (ES)

E. Checcucci, Orbassano (IT)

J.L. Vázquez, Roskilde (DK)



## Short- and long-term outcomes after local treatment for muscle-invasive bladder cancer

Abstract Session 09

**Saturday 11 March**  
**15:30 - 17:00**

**Location** Yellow Area, Brown 3  
**Chairs** To be confirmed  
To be confirmed  
To be confirmed

**15:30 - 15:33**

**Introduction**

**A0148** **High aortic calcification burden is a risk factor for acute kidney injury in patients who undergoing radical cystectomy: A multi-institutional retrospective cohort study**  
N. Fujita, Hirosaki (JP)

**A0149** **Modified GLIM status as a predictor of morbidity and mortality after radical cystectomy: A propensity matched analysis of the american college of surgeons - national surgical quality improvement program data**  
C.H. Ayoub, Riad El Solh - Beirut (LB)

**A0150** **Evaluating the impact of complications on survival outcomes in patients treated with radical cystectomy for bladder cancer. Results from a European multi-institutional collaboration (YAU Urothelial Cancer Group)**  
E. Di Trapani, Milan (IT)

**A0151** **The risk of arterial thromboembolic complications in bladder cancer patients after radical cystectomy – population-based nationwide matched cohort study**

**A0152** **The risk of Venous thromboembolic events in patients operated with radical cystectomy - A nationwide population-based cohort study**  
J. Björklund, Stockholm (SE)

**A0153** **Do all patients equally benefit from the Enhanced Recovery After Surgery (ERAS) protocol after radical cystectomy?**  
G. Basile, Milan (IT)

**15:45 - 15:59**

**Discussion**

**A0154** **Comprehensive evaluation of the association of comorbidity and health status indices with perioperative morbidity and long-term oncological outcomes after radical cystectomy**  
M. von Deimling, Hamburg (DE)

**A0155** **The black box of intraoperative adverse incident reporting during radical cystectomy: not only post-operative complications matter**  
G. Basile, Milan (IT)

**A0156** **Predictors of overall and major postoperative complications in a recent, multicenter series of patients who underwent radical cystectomy and urinary diversion for bladder cancer**  
V. Ficarra, Messina (IT)

**A0157** **Propensity-score matched survival analysis of octogenarians with muscle-invasive bladder cancer: Chemoradiation compared to radical cystectomy**

**A0158**                      **Comparing objective recovery of activity levels using wearable devices in open vs. intracorporeal robotic cystectomy: An analysis of the secondary outcomes of the iROC randomized trial**  
P. Khetrapal, London (GB)

---

**16:09 - 16:23**                      **Discussion**

---

**A0159**                      **Mid-term oncologic outcomes of open vs. robot-assisted radical cystectomy with totally intracorporeal urinary diversion: Single centre prospective randomized controlled trial**  
R. Mastroianni, Rome (IT)

---

**A0160**                      **Are quality of life and sexual functions remain same following nerve sparing, vas sparing, seminal vesicle sparing and partial prostate sparing radical cystectomy and orthotopic neobladder reconstruction: A prospective randomized trial**  
V. Singh, Lucknow (IN)

---

**A0161**                      **Urodynamic predictors of daytime and night-time urinary incontinence for Florin and Padua intracorporeal robotic neobladders: Results from two tertiary-care centres at a mid-term follow-up**  
U. Anceschi, Rome (IT)

---

**A0162**                      **Population-based assessment of determining predictors for discharge disposition in patients with bladder cancer undergoing radical cystectomy**

---

**A0163**                      **Oncological outcomes of patients with node positive disease following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive bladder cancer: A study of the EAU Young Academic Urologists urothelial carcinoma working group**  
G. Marcq, Marcq-en-Baroeul (FR)

---

**A0164**                      **Surgical safety and quality of radical cystectomy and pelvic lymph node dissection after neoadjuvant Durvalumab and Cisplatin/Gemcitabine for muscle invasive bladder cancer: results from the SAKK 06/17 phase II study**  
L. Afferi, Lucerne (CH)

---

**A0165**                      **ctDNA guiding with hotspot mutation in PLEKHS1 further improves early prediction of recurrence in muscle-invasive bladder cancer**  
T. Matsumoto, Fukuoka (JP)

---

**A0166**                      **Conditional survival after radical cystectomy for non-metastatic muscle-invasive adenocarcinoma of the urinary bladder: A population-based analysis**  
S. Tappero, Genova (IT)

---

**16:39 - 16:53**                      **Discussion**

---

**16:53 - 17:00**                      **Closing remarks**

---

## Urogenital infections in urology

Meeting of the EAU Section of Infections in Urology (ESIU)

**Saturday 11 March**  
**15:30 - 19:00**

**Location** Yellow Area, Amber 3

**Chairs** F.M.E. Wagenlehner, Giessen (DE)  
T.E. Bjerklund Johansen, Oslo (NO)

### Learning objectives

Urogenital infections play an important role, because these infections can be associated with many other urological diseases. Therefore, each urologist needs to be familiar with basic knowledge how to prevent and how to treat such infections. Because of increasing uropathogens resistant against commonly used antibiotics the local situation and antibiotic stewardship in general become important issues for practicing urologists. During the Meeting of the European Section of Infection in Urology (ESIU) all these topics will be presented and discussed.

**15:30 - 15:35**

### Welcome and introduction

F.M.E. Wagenlehner, Giessen (DE)

**15:35 - 17:00**

### Best management of urogenital infections

*Moderators* To be confirmed  
H.M. Çek, Edirne (TR)

**15:35 - 15:45**

### What has changed in the last decade in EAU Guidelines on urological infections

G. Bonkat, Basel (CH)

**15:45 - 15:55**

### Urosepsis: Headline results from the Serpens study

To be confirmed

**15:55 - 16:05**

### Catheter-associated UTI in adult patients

J. Kranz, Aachen (DE)

**16:05 - 16:15**

### Management of UTI in patients after kidney transplantation with neurogenic bladder

J. Medina Polo, Madrid (ES)

**16:15 - 16:25**

### Woundhealing and Patient-Reported Outcomes (PRO) in Fournier's gangrene

L. Schneidewind, Rostock (DE)

**16:25 - 16:35**

### Antibiotic resistance: Results from the GPIU study

To be confirmed

**16:35 - 16:45**

### Phytopharmaceuticals for antimicrobial treatment of UTI: Does it make sense?

To be confirmed

**16:45 - 16:55**

### Rates of infective complications and deaths after transrectal and transperineal prostate biopsy in Norway

T.E. Bjerklund Johansen, Oslo (NO)

**16:55 - 17:00**

### Summary

**17:00 - 18:55**

### Prevention and diagnostics of urogenital infections

*Moderators* J. Corrales Riveros, Lima (PE)  
K. Naber, Straubing (DE)

**17:00 - 17:10**

### Antibiotic perioperative prophylaxis in urology

To be confirmed

**17:10 - 17:20**

### Antiinfective prophylaxis before artificial sphincter and penile prosthesis

F. Campos Juanatey, Santander (ES)

17:20 - 17:30	<b>Reduce infectious complications after prostate biopsy</b> A. Pilatz, Giessen (DE)
17:30 - 17:40	<b>The use of fluoroquinolones for antibiotic prophylaxis in diabetic patients candidates to prostate biopsy</b> To be confirmed
17:40 - 17:50	<b>Novel approaches for phenotypic antibiotic testing in UTI: Test results in 1 h</b> S. Schubert, Munich (DE)
17:50 - 18:00	<b>Recurrent cystitis: Treating the risk factors</b> T. Cai, Trento (IT)
18:00 - 18:10	<b>Using shared decision to involve patients in their urinary tract infection treatment</b> S.E. Geerlings, Amsterdam (NL)
18:10 - 18:20	<b>ACSS questionnaire as Patient-Reported Outcome measure in uncomplicated UTI</b> To be confirmed
18:20 - 18:30	<b>Parasitic infections in urology</b> D. Batura, London (GB)
18:30 - 18:40	<b>A new indwelling transurethral catheter design may improve tolerability and safety</b> N.S. Urday, Formosa (AR)
18:40 - 18:50	<b>New transrectal prostate biopsy approach may improve tolerability and safety</b> M.J. Sieczkowski, Gdańsk (PL)
18:50 - 18:55	<b>Summary</b>
18:55 - 19:00	<b>Closing remarks</b> T.E. Bjerklund Johansen, Oslo (NO)

---

## Prostate cancer Biopsies: Protocols, peri-lesionnal, methods of targeting, routes and complications

Abstract Session 12

**Saturday 11 March**  
**15:30 - 17:00**

**Location** Pink Area, Coral 4  
**Chairs** A. Stabile, Milan (IT)  
G. Fiard, Grenoble (FR)  
To be confirmed

**15:30 - 15:33**

**Introduction**

**Protocols**

- |       |   |
|-------|---|
| A0167 | <b>Multi-parametric MRI-targeted biopsy compared to systematic TRUS biopsy for biopsy-naïve men at risk for prostate cancer: 2 year follow up data and economic analysis</b>  |
| A0168 | <b>Significance of MRI-ultrasound fusion targeted prostate biopsy for non-index PI-RADS <math>\geq 3</math> lesions in combination with index lesion-targeted biopsy and systematic biopsy</b><br>M. Kobayashi, Kodaira-shi (JP)                  |
| A0169 | <b>Regional saturation prostate biopsy and target biopsy scheme as an initial prostate cancer diagnostic strategy in men with pi-rads <math>\geq 3</math>: A prospective study</b><br>X. Jiang, Tianjin (CN)                                      |
| A0170 | <b>Does experience change the role of systematic biopsy during mpMRI-US fusion prostate biopsy? A single center experience</b><br>M. Jahnen, Munich (DE)  |
| A0171 | <b>Evaluation of the optimal strategy for prostate biopsy in men with a single unilateral lesion suspected of prostate cancer on multiparametric MRI undergoing transperineal fusion MRI-guided prostate biopsy.</b><br>E. Mazor, Beer Sheva (IL) |
| A0172 | <b>Interest of systematic prostatic biopsies in patients with a suspicious lesion on MRI: Analysis by sectors according to the target location</b><br>A. Zambon, Brest (FR)   |
| A0173 | <b>Can we replace systematic prostate biopsies with targeted biopsy only strategies in PiRADS score 4 or 5? A single high volume centre retrospective data analysis</b><br>A. Kooplikattil Pushkaran, Luton (GB)                                  |
| A0174 | <b>Can we predict for missed clinically significant prostate cancers on MRI-Targeted biopsy alone?</b><br>K. Wang, Singapore (SG)   |
| A0175 | <b>Open-label randomized controlled trial comparing biopsy guided by fused magnetic resonance and transrectal ultrasound images and 12-core systematic biopsy in biopsy naïve men</b><br>T.B. Pedersen, Middelfart (DK)                           |

**15:51 - 16:05**

**Discussion**

---

### Peri-lesionnal

---

- A0176 **Intensive sampling of the umbra and penumbra improves clinically-significant prostate cancer detection and reduces risk of grade group upgrading at radical prostatectomy**
- A0177 **Can we predict when non-targeted systematic prostate biopsies need to be performed? Outcomes from the multicentre RAPIDOnline 3,853 patient cohort**
- A0178 **Optimizing multiparametric MRI-targeted biopsies and detection of clinically significant prostate cancer: The role of perilesional sampling**  
J-P. Noujeim, Brussels (BE)
- A0179 **Value of perilesional biopsies in mpMRI fusion biopsy of the prostate – results of a prospective, phase-II, surgeon blinded study**  
G. Duwe, Mainz (DE)
- 16:13 - 16:21** **Discussion**
- Methods of targeting**
- A0180 **Cognitive targeted local anaesthetic transperineal biopsy alone in men with PIRADS/LIKERT 5 on Multiparametric Magnetic Resonance Imaging of the Prostate as an initial diagnostic investigation is safe in men with a PSA Density over 0.15**  
J. Aning, Bristol (GB)
- A0181 **Freehand cognitive registration transperineal prostate biopsies – A single centre experience**  
S. Fleville, Craigavon (GB)
- A0182 **Prospective comparison of the 4 biopsy methods for prostate cancer detection**
- A0183 **Risk factors for infection following transperineal prostate biopsy**  
M. Sandberg, Winston Salem (US)
- A0184 **Non-infectious adverse events of transperineal prostate biopsies performed under local anesthesia in an outpatient setting – results from the NORAPP study – a randomized clinical trial**  
M. Jacewicz, Oslo (NO)
- A0185 **Transperineal prostate biopsy with(out) prophylactic antibiotic**  
M. Shendy, Crewe (GB)
- A0186 **MRI/US fusion targeted prostate biopsies koelis®: impact of operator experience on clinically significant prostate cancer detection**  
F Taha, Reims (FR)
- A0187 **Recording the transition from transrectal to transperineal MRI-ultrasound fusion biopsies of the prostate: Assessing the learning curve and advantages of local anesthesia use**  
J.L. Hohenhorst, Essen (DE)
- A0188 **Learning curve during the transitioning from in theatre to in-office transperineal prostate biopsy under local anaesthetics**
- A0189 **Risk factors for acute urinary retention following transperineal prostate biopsy**
-

Discussion

---

16:55 - 17:00

Closing remarks

## Impacting stone management

Video Session 06

**Saturday 11 March  
15:30 - 17:00**

**Location** Pink Area, Coral 7  
**Chairs** E. Emiliani, Barcelona (ES)  
To be confirmed  
To be confirmed

**15:30 - 15:33**

**Introduction**

- V040 **Multi-center, prospective, single arm, pivotal study to evaluate the efficacy and safety of robotic-assisted surgery 'easyuretero-100' in patients in need of retrograde intrarenal surgery**
- V041 **Revisiting the ideal PCN tract: The 'Puncture zone' concept**  
R. Nayyar, new delhi (IN)
- V042 **A novel single surgeon approach to enhance stone clearance in Endoscopic Combined Intra Renal Surgery (ECIRS)**  
M. Thangarasu, (IN)
- V043 **Hybrid Thulium-YAG pulsed laser for stone lithotripsy in real clinical practice.**  
M.E. Rodríguez Socarrás, Madrid (ES)
- V044 **Simultaneous Bilateral Flexible Ureteroscopy Step by Step**  
Z. Savin, Tela Aviv (IL)
- V045 **Endourological management of knotted ureteral stent**  
S. Spagna, Comiso (IT)
- V046 **The modified technique of totally tubeless percutaneous nephrolithotomy with a safety suture thread**  
I. Sahalevych, Kiev (UA)
- V047 **Tubed versus tubeless with track coagulation: A revolutionary step for the death of tubed percutaneous nephrolithotomy**  
M.K.M. Omar, Shibin El Kom (EG)

**16:53 - 16:58**

**Closing remarks**



## Education and training in urology

Abstract Session 16

**Saturday 11 March  
17:15 - 18:45**

**Location** Pink Area, Coral 1  
**Chairs** To be confirmed  
To be confirmed  
To be confirmed

**17:15 - 17:18**

**Introduction**

A0309	<b>Gender bias in urology: How do patients really choose their urologist?</b>
A0310	<b>Do women choose urology residency as much as men? Female urology resident representation in Spain in the last decade</b> M.P. Moreno-Fontela, Madrid (ES)
A0311	<b>Equality, Diversity and Inclusion extends to more than who's on the panel: assessing the speakers and prominent roles at two Urological Conferences 2022</b> H. Jeffery, Stevenage (GB)
A0312	<b>Pregnancy outcomes in UK-based urologists in training</b> J. Whitburn, London (GB)
A0313	<b>Comparison between 24-hours and 12-hours oncall systems effects on urology residents quality of life and education</b> I. Khalil, Doha (QA)
<b>17:28 - 17:44</b>	<b>Discussion</b>
A0314	<b>The design and validation of a low-cost transperineal (TP) prostate biopsy simulator from 3d-printed mould: Improving trainees' confidence and cognitive targeting skills</b> K.O Ong, London (GB)
A0315	<b>Is there any difference between cognitive and fusion biopsies when performed by residents?</b> G. Gallo, Roma (IT)
A0316	<b>Evaluation of the simulation-based functional urological surgical training program with 3D printed and VR Models: EuroSOMT Erasmus+ Project Outcomes</b> E. Huri, Çayyolu, Ankara (TR)
A0317	<b>Feasibility of ethical surgical training using simulation and 3D printed synthetic organs</b> O. Niall, HAWTHORN (AU)
A0318	<b>SimBase: Results at three-years of the first teletraining experience in Urology</b> R. Miano, Rome (IT)
A0319	<b>Certificate of excellence completion rate of the CC-ERUS Fellowship and reasons for non-completion</b> M. Paciotti, Rozzano, Milan (IT)

A0320	<b>Robotic surgeons need more than just technical skills</b> O. Niall, HAWTHORN (AU)
A0321	<b>The introduction of novel robotic platforms and simulator tasks: results of a multivariate analysis of factors impacting basic skills acquisition at the Hugo™ RAS simulator</b>
<b>18:00 - 18:19</b>	<b>Discussion</b>
A0322	<b>Evaluation of different pneumoperitoneal pressures with respect to technical feasibility and physiological parameters in laparoscopic renal surgery: A prospective and randomized study to determine the safe pressure</b>
A0323	<b>Preliminary results of a novel uro-geriatric pathways: How good are the scores of frailty to categorize frailty among elderly patients?</b> R. Campi, Florence (IT)
A0324	<b>Prospective randomized trial for postoperative voiding outcome &amp; patient-clinician satisfaction in retrograde bladder filling prior to catheter removal in TURP</b> S.H. Song, Seongnam (KR)
A0325	<b>The INFLOW-OPERA Study. Investigations in Flow State measurements with EEG during surgical performance</b> M. Baumgartner, Fribourg (CH)
<b>18:27 - 18:38</b>	<b>Discussion</b>
<b>18:38 - 18:45</b>	<b>Closing remarks</b>

## Complex genitourethral reconstruction in benign and malignant disease

Meeting of the EAU Section of Genitourinary Reconstructive Surgeons (ESGURS)

**Saturday 11 March**  
**15:30 - 19:00**

**Location** Pink Area, Coral 2

**Chair** D.J. Ralph, London (GB)

### Learning objectives

This year we will be dealing with complex reconstruction with new topics to be covered. The first session covers male and female genital cancer with surgeries aimed at maintaining and preserving both urinary and sexual function.

We will be updated in the management of male incontinence, slings, artificial sphincters and the management of their complications.

There will be some lively debates on penile cosmetic surgery, pen urethral lichen sclerosis and what type of surgery is best for vesico vaginal fistula repair- voting will be encouraged. The final session is on flaps and grafts for penile, vaginal and female urethral reconstruction.

There is a wide range of topics which I am sure all will find interesting

**15:30 - 15:32**

### Welcome and introduction

D.J. Ralph, London (GB)

**15:32 - 16:09**

### Penile and urethral cancer

*Moderators* O.R. Brouwer, Amsterdam (NL)  
R.W. Rees, Southampton (GB)

**15:32 - 15:42**

### Penile glansectomy and glans resurfacing

M. Albersen, Leuven (BE)

**15:42 - 15:52**

### Phalloplasty for penile cancer

W.G. Lee, London (GB)

**15:52 - 16:02**

### Urethral carcinoma in women: Partial urethrectomy/urethrectomy & reconstruction

M.W. Vetterlein, Hamburg (DE)

**16:02 - 16:09**

### Q&A

**16:09 - 16:46**

### Incontinence

*Moderators* O.J. Nilsen, Oslo (NO)  
K. Van Renterghem, Hasselt (BE)

**16:09 - 16:19**

### The ideal patient: Sling vs. AUS - New techniques and devices

J.P.F.A. Heesakkers, Maastricht (NL)

**16:19 - 16:29**

### What to do after urethral erosion: IDC v urethral repair v urethroplasty

M. Waterloos, Gent (BE)

**16:29 - 16:39**

### Redo repeat AUS: Salvage techniques; Dartos flap/corporal tunica flaps/urethral closure

O. Shenfeld, Jerusalem (IL)

**16:39 - 16:46**

### Q&A

**16:46 - 17:21**

### The perfect penis

*Moderators* A. Cocci, Florence (IT)  
M.Y. Ortega González, Arafo (ES)

**16:46 - 16:56**

### Genital art: Piercings and tattoos

G. Mantica, Genoa (IT)

**16:56 - 17:14**

### Cosmetic penile surgery and complications debate

**Pro**

M. Djordjevic, Belgrade (RS)

**Con**

J. Romero-Otero, Madrid (ES)

17:14 - 17:21

**Q&A**

---

17:21 - 17:56

**The urethra: Lichen sclerosus et atrophicus**

*Moderators* S.C. Morgenstern, Frankfurt am Main (DE)  
F.E. Martins, Lisbon (PT)

17:21 - 17:31

**Meatoglanular disease**

W. Verla, Ghent (BE)

17:31 - 17:49

**Debate Pan urethral diseases: Reconstruction vs. Perineal urethrostomy**

**Reconstruction**

F. Campos Juanatey, Santander (ES)

**Perineal urethrostomy**

D. Hernández Hernández, San Cristóbal de La Laguna (ES)

17:49 - 17:56

**Q&A**

---

17:56 - 18:33

**Grafts and flaps in reconstructive urology**

*Moderators* M. Falcone, Torino (IT)  
N. Lumen, Ghent (BE)

17:56 - 18:06

**Management of genital lymphoedema**

To be confirmed

18:06 - 18:16

**Female urethral reconstruction after radiotherapy**

J. Ockrim, London (GB)

18:16 - 18:26

**Vaginal stenosis: Vaginoplasty techniques (grafts/flaps/bowel interposition)**

E. Kocjancic, Chicago (US)

18:26 - 18:33

**Q&A**

---

18:33 - 18:58

**Complex male and female urinary fistulae**

*Moderators* To be confirmed  
F. Mazzoleni, Como (IT)

18:33 - 18:51

**Vesico-urethro-rectal fistula: Robotic vs. open**

**Robotic**

I. Moncada Iribarren, Madrid (ES)

**Open**

R. Dahlem, Hamburg (DE)

18:51 - 18:58

**Q&A**

---

18:58 - 19:00

**Closing remarks**

D.J. Ralph, London (GB)

---

## Andrology: Androgens, comorbidities and fertility

Abstract Session 13

**Saturday 11 March**  
**15:30 - 17:00**

**Location** Pink Area, Coral 6  
**Chairs** To be confirmed  
M. Gül, Konya (TR)  
To be confirmed

**15:30 - 15:33**

**Introduction**

**Translation research**

**A0209** **Saturated-fat diet acceleration of castration-induced bone loss through specific gut microbial profiles in old male mice**  
N. Narita, Aktia (JP)

**A0210** **Pathological analysis of spermatic dysfunction following testicular ischemia-reperfusion injury**  
K. Hirata, Kurashiki (JP)

**A0211** **Experimental study to evaluate the effect of cellular phone waves on testis and penile functions**  
A.A. Hassan, Elazizia, Makkah (SA)

**15:39 - 15:45**

**Discussion**

**Testosterone and comorbidities**

**A0212** **Ageing and diabetes are the main risk factors for male hypogonadism in patients presenting for erectile dysfunction**  
A. Ribeiro Morgado, Maia (PT)

**A0213** **The association between testosterone and psychological well-being: Findings from a real-life cross-sectional study**  
C. Corsini, Ascoli Piceno (IT)

**A0214** **Late-onset hypogonadism is one of an important cause of anemia in male hemodialysis patients**  
T. Ando, Yufu (JP)

**A0215** **Follicle stimulating hormone-to-Inhibin B ratio in primary infertile men with hypergonadotropic hypogonadism — a clinical marker of testosterone deficiency severity?**  
E. Pozzi, Milan (IT)

**A0216** **Testosterone level in seminal vesicle fluid is a better indicator of erectile function than serum testosterone in patients with prostate cancer**  
E. Kashiwagi, Fukuoka (JP)

**A0217** **Peyronie's disease and metabolic syndrome. An understudied link?**

**A0218** **Association between advanced glycation end-products, carotenoids, and severe erectile dysfunction in community-dwelling men**  
N. Fujita, Hirosaki (JP)

## Scientific Programme - EAU23 Milan

---

A0219	<b>Gender dysphoria in Klinefelter syndrome: Physical characteristics and incidence</b> D. Clark, London (GB)
<b>16:01 - 16:17</b>	<b>Discussion</b>
	<b>Testosterone replacement therapy</b>
A0220	<b>Venous thromboembolism risk in testosterone treated men with and without Klinefelter syndrome</b> Y. Zhang, London (GB)
A0221	<b>Effects of long-term testosterone therapy on quality of life and lower urinary tract symptoms in men with functional hypogonadism</b> A. Haider, Bremerhaven (DE)
<b>16:21 - 16:25</b>	<b>Discussion</b>
	<b>Androgens, lifestyle and fertility</b>
A0222	<b>Incidence and risk factors of hypogonadism in men with normal sperm concentration</b> C.W. Lin, Taipei City (TW)
A0223	<b>The impact of varicocele on sperm DNA fragmentation and pregnancy rate in subfertile men with normal semen parameters: A pilot study</b> O. Mohamed Elsoghir Abdelrahim, Qena (EG)
A0224	<b>Effects of ritalin on sperm parameters among attention deficit hyperactivity disorder patients</b>
A0225	<b>Are Urologists underrepresented on fertility clinic websites? A web-based analysis</b> B. Bachir, Beirut (LB)
A0226	<b>Fertility related concerns In male Adolescent and Young Adult (AYA) cancer survivors from a multicenter cohort study (SURVAYA)</b>
A0227	<b>Impact of different legislative in-vitro fertilization coverage mandates on male infertility care</b>
A0228	<b>A Machine Learning-derived Nomogram to predict pregnancy in Infertile couples with male factor infertility undergoing medically assisted reproduction techniques</b> F. Belladelli, Milan (IT)
<b>16:39 - 16:53</b>	<b>Discussion</b>
<b>16:53 - 17:00</b>	<b>Closing remarks</b>

---

## Minimally Invasive Surgical Therapy (MIST) for male LUTS management

Abstract Session 14

**Saturday 11 March  
15:30 - 17:00**

**Location** Blue Area, Room 1  
**Chairs** K. Stav, Beer Yaakov (IL)  
S. Madersbacher, Vienna (AT)  
KC Zorn, Montreal (CA)

**15:30 - 15:33**

**Introduction**

A0229 **New minimally invasive techniques versus turp for middle volume (30-80 ml) prostates: A prospective randomized study**

A0230 **Water vapor thermal therapy for BPH: Is less more?**  
M. Leach, San Diego (US)

A0231 **Predictors of trial-without-catheter (TWOC) outcome in 384 patients treated with Rezum thermotherapy?**  
A.K.A.A. Uthman, Pontylun (GB)

A0232 **Less is more REZUM: A propensity score matched comparison**

A0233 **Rezum thermotherapy for large prostate volumes ( $\geq 80$  cc): 2-year clinical outcomes**  
A.K.A.A. Uthman, Pontylun (GB)

A0234 **Re-treatment for lower urinary tract symptoms (LUTS) after water vapor thermal therapy**  
V. Nguyen, San Diego (US)

A0235 **Rezūm water vapour therapy (Rezūm): Is it safe to continue antiplatelet or anticoagulation medication?**  
S. Lee, Singapore (SG)

A0236 **Water vapor thermal therapy: The UC San Diego experience**  
M. Leach, San Diego (US)

**15:49 - 16:04**

**Discussion**

A0237 **Transurethral water vapour thermal therapy (Rezūm<sup>TM</sup>) versus Transperineal Laser Ablation of the Prostate (TPLA) for the treatment of benign prostatic hyperplasia: a real-world prospective comparative analysis**  
J.I. Martínez Salamanca, Madrid (ES)

A0238 **Transperineal laser ablation versus trans-urethral resection of prostate for benign prostatic obstruction: A randomized trial**  
R.G. Bertolo, Roma (IT)

A0239 **Transperineal laser ablation in the clinic: One year results**  
F. Bianco, Miami Lakes (US)

A0240 **Three years outcomes of transperineal laser ablation of the prostate**  
S. Gerbasi, Bari (IT)

## Scientific Programme - EAU23 Milan

---

A0241	<b>12 months clinical outcomes of transurethral ultrasound ablation (TULSA) for benign prostatic hyperplasia</b>
<b>16:14 - 16:26</b>	<b>Discussion</b>
A0242	<b>The pinnacle trial: 12-month report from a randomized, double-blind, sham controlled study</b> S.A. Kaplan, New York (US)
A0243	<b>12-month outcomes from the first north american study of the zenflow spring system for the treatment of benign prostatic hyperplasia (BPH)</b> D. Elterman, Toronto (CA)
A0244	<b>Everest: The peak of MIST flow rate performance?</b> S.A. Kaplan, New York (US)
A0245	<b>Durability following treatment with the prostatic urethral lift (PUL): Predictors from over 330 controlled subjects across 5 distinct studies</b>
A0246	<b>Patient experience outcomes are consistent between men with median and lateral lobe obstruction following treatment with the prostatic urethral lift (PUL)</b> G. Eure, Virginia Beach (US)
<b>16:36 - 16:53</b>	<b>Discussion</b>
<b>16:53 - 17:00</b>	<b>Closing remarks</b>

---



## Long term cancer control of prostate cancer

Abstract Session 11

**Saturday 11 March**  
**15:30 - 17:00**

**Location** Pink Area, Coral 3  
**Chairs** To be confirmed  
I.J. De Jong, Groningen (NL)  
To be confirmed

**15:30 - 15:33**

**Introduction**

**Outcome predictions in N1 disease**

- A0247** **Impact of pre-operative PSMA PET/CT for men with cN0M0 conventional imaging and pN+ prostate cancer: Results from a multicenter study**
- A0248** **The prognostic impact of preoperative psma-pet on early oncological outcomes in prostate cancer patients treated with radical prostatectomy: Results of a multi-center analysis**
- A0249** **Impact of Gleason grading on survival outcomes in patients with low loco-regional lymphogenic metastatic burden at radical prostatectomy**
- A0250** **The impact of lymphovascular invasion on long-term cancer outcomes following radical prostatectomy**
- A0251** **Prognostic impact of lymph vessel invasion in radical prostatectomy patients**  
R.M. Pose, Hamburg (DE)
- Discussion**
- EBRT vs. surgery**
- A0252** **Survival after radical prostatectomy vs radiation therapy in clinical node positive prostate cancer patients: A multicentric study**  
F. Chierigo, Schio (IT)
- A0253** **Cancer-specific survival following radical prostatectomy versus radiation therapy in high-risk prostate cancer patients: A multi-trial cohort analysis**  
M. Righetto, Padova (IT)
- A0254** **Retrospective study of mid- and long-term urinary complications in patients with prostate cancer treated with radiotherapy and/or radical prostatectomy**  
R. Thériault, Sherbrooke (CA)
- A0255** **Patient reported outcomes after radical prostatectomy or radiotherapy for prostate cancer – register-based nationwide, population-based study**  
C. Corsini, Ascoli Piceno (IT)

**16:00 - 16:07**

**Discussion**

**Predicting survival**

---

A0256	<b>Reducing overtreatment of prostate cancer patients: revisiting the European Association of Urology (EAU) risk group classification by using 18 years of follow-up data</b> I.I. de Vos, Rotterdam (NL)
A0257	<b>Predicting the risk of biochemical recurrence at five years in patients treated with radical prostatectomy for prostate cancer: The PIPEN categories</b> F. Mistretta, Milan (IT)
A0258	<b>Baseline PSA levels in midlife &amp; future development of lethal prostate cancer: A diverse North American cohort analysis</b> F. Abdollah, Detroit (US)
<b>16:13 - 16:18</b>	<b>Discussion</b>
	<b>Complications</b>
A0259	<b>Nationwide in-hospital morbidity and mortality following radical prostatectomy in Germany</b> R.B. Incesu, Hamburg (DE)
A0260	<b>The risk of venous thromboembolic events among men operated with radical prostatectomy - a nationwide population-based cohort study</b> J. Björklund, Stockholm (SE)
A0261	<b>The risk of ischemic stroke and myocardial infarction in prostate cancer patients treated with radical prostatectomy – population-based nationwide matched cohort study</b> J. Rautiola, Stockholm (SE)
<b>16:24 - 16:29</b>	<b>Discussion</b>
	<b>Recurring disease</b>
A0262	<b>Wait-and-see protocol in patients with biochemical recurrence after robot-assisted radical prostatectomy, with no evidence of disease on restaging PSMA PET/CT</b> K.C.C. de Bie, Amsterdam (NL)
A0263	<b>PSMA-PET for recurrent prostate cancer and guidance of salvage treatments: is the sooner always the better? (“shoot blind” or “sharpshooting”?)</b>
A0264	<b>Exploring the Effect of Metastasis Directed Therapy on Progression Patterns of Patients with Positive 68Ga-PSMA PET/CT and Biochemical Recurrence from Prostate Cancer</b>
A0265	<b>68 Ga-PSMA PET/CT Positivity in EAU BCR Risk groups</b> C. Leplat, Tournai (BE)
A0266	<b>Validation of EAU Risk groups for biochemical recurrence after radiotherapy and radical prostatectomy for prediction of prostate cancer mortality</b> U.G. Falagario, Bari (IT)
A0267	<b>Salvage vesiculectomy for local prostate cancer recurrence: PSA response and oncological outcomes</b> A. Giesen, Alken (BE)
<b>16:41 - 16:53</b>	<b>Discussion</b>

---

16:53 - 17:00

Closing remarks

## Treatment of urogenital infections

Abstract Session 08

**Saturday 11 March  
12:00 - 13:15**

**Location** Pink Area, Coral 3  
**Chairs** G. Bonkat, Basel (CH)  
N. Stepanova, Kyiv (UA)  
To be confirmed

**12:00 - 12:03**

**Introduction**

**A0129** **Is adjuvant amikacin to oral levofloxacin effective for prevention of febrile complications following transrectal prostate biopsy in patients with fluoroquinolone-resistant E. coli in the rectal flora?**  
Y. Nasu, Okayama (JP)

**A0130** **Antibiotic prophylaxis for transrectal ultrasound guided prostate biopsy, a single centre experience after the ciprofloxacin era**  
M. Kwiatkowski, Aarau (CH)

**A0131** **Fosfomycin versus Ciprofloxacin as transrectal prostate biopsy antibiotic prophylaxis – an open randomized controlled multicenter drug trial**  
A. Andreasson, Göteborg (SE)

**A0132** **Prospective trial of Cefixime vs. Fosfomycin in prostate biopsy**  
D. Vieira E Brito, Guimaraes (PT)

**A0133** **Urinary tract infection after radiation therapy or radical prostatectomy on prognosis of patients with prostate cancer: A population-based study**  
S.Y. Choi, Seoul (KR)

**12:13 - 12:23**

**Discussion**

**A0134** **Bladder irrigation with tap water to reduce antibiotic treatment for catheter-associated urinary tract infections (CAUTIs): An evaluation of clinical practice**  
F.E.E. van Veen, Rotterdam (NL)

**A0135** **Intravesical hyaluronic-acid/chondroitin-sulfate in patients with recurrent urinary tract infections: A safe strategy of treatment management**  
M. Gubbiotti, Perugia (IT)

**A0136** **Immunoprophylaxis with MV-140 is effective in the prevention of urinary tract infections – results of a prospective study**  
F. Lopes, Lisbon (PT)

**A0137** **Antibiotic prophylaxis in urological practice: An evidence map of its effectiveness and necessity**  
Y. Li, Chengdu (CN)

**A0138** **Antibiotic prophylaxis before urodynamic studies: Are antibiotics required to decrease infections and for which patients would be prophylaxis the most beneficial?**  
S. Juste Alvarez, Madrid (ES)

**12:33 - 12:43**

**Discussion**

A0139	<b>Choosing the best way for urinary decompression and developing a novel predictive model for septic shock using Sequential Organ Failure Assessment (SOFA) in these patients</b> Y.X.T. Law, Singapore (SG)
A0140	<b>Elevated prothrombin fragment 1+2 predicts severe acute kidney injury in patients with urological sepsis</b> N. Fujita, Hiroasaki (JP)
A0141	<b>Role of ureteroscopy and stone treatment in management of recurrent UTIs: Prospective outcomes over a 10-year period</b> F. Ripa, Southampton (GB)
A0142	<b>Comparative study of in vitro biofilm formation between T-Control® catheter vs. a conventional Foley-type catheter</b> M. Luque González, Las Palmas de Gran Canaria (ES)
A0143	<b>Outbreak of carbapenemase-producing enterobacteriales – impact on radical cystectomy morbidity and mortality</b> A.S. Araújo, Trofa (PT)
<b>12:53 - 13:03</b>	<b>Discussion</b>
A0144	<b>The new pandemic: Monkeypox and its urological presentations</b>
A0145	<b>Frequentist and Bayesian analysis of potential adverse events of the COVID-19 immunization</b> M. Davis, Detroit (US)
A0146	<b>Tadalafil versus combined tamsulosin and ciprofloxacin for treatment of chronic pelvic pain syndrome: A randomized controlled trial</b> M. Ismail, Mansoura (EG)
A0147	<b>The more frequent the recurrence of urinary tract infection, the higher the anxiety in female patients</b>
<b>13:11 - 13:21</b>	<b>Discussion</b>
<b>13:21 - 13:28</b>	<b>Closing remarks</b>

## Oligometastatic prostate cancer

ESU Course 22

**Saturday 11 March**  
**16:00 - 18:00**

**Location** Pink Area, ESU 1

**Chair** S. Joniau, Leuven (BE)

### **Learning objectives**

- Provide an introduction to working definition(s), background, and biology of oligometastatic prostate cancer.
- Update the current molecular imaging to provide such a diagnosis.
- Review the potential roles of surgery and/or radiation as metastasis-directed therapy.
- Understand opportunities and challenges in individualising care of the oligometastatic prostate cancer patient.

### **Introduction: Oligometastatic prostate cancer as a diagnosis**

S. Joniau, Leuven (BE)

### **Surgery of primary oligometastatic prostate cancer (N1/M1)**

S. Joniau, Leuven (BE)

### **Surgery for recurrent nodal metastasis with updates on molecular/PET imaging**

A. Briganti, Milan (IT)

### **Radiation in oligometastatic prostate cancer (primary and recurrent) and clinical trial updates**

T. Zilli, Genève (CH)

### **Further cases (case illustrations throughout)**

A. Briganti, Milan (IT)

S. Joniau, Leuven (BE)

T. Zilli, Genève (CH)

### **Discussion and conclusion**

S. Joniau, Leuven (BE)

## Paediatric stone disease

ESU Course 23

**Saturday 11 March**  
**16:00 - 18:00**

**Location**

Pink Area, ESU 2

**Chair**

A. Bujons Tur, Barcelona (ES)

M.S. Silay, Istanbul (TR)

## Laparoscopy for beginners

ESU Course 24

**Saturday 11 March**  
**16:00 - 18:00**

**Location** Pink Area, ESU 3

**Chair** D. Veneziano, New Hyde Park NY (US)

### Learning objectives

With the large widespread of mini-invasive surgery, improving knowledge of practical aspects of laparoscopy is mandatory.

Knowledge of:

- Indications and contra-indications of laparoscopic approach.
- How to choose and use the instrumentation, in order to optimise the procedure and minimise adverse effects.
- Air insufflation parameters and optimal access in laparoscopic urology.
- How to prevent, recognise and manage complications.

This course aims to provide all this knowledge in an interactive and practical way (video clip, open discussion), in order to assist beginners in laparoscopy shortening their learning curve and optimizing the success of their laparoscopic procedures.

- Laparoscopic surgery: For which patients and which procedures?
- Masterise the armentarium.
- Tips and tricks to optimise the procedure.
- New potential and future evolutions.

### Peritoneal access and effects of pneumoperitoneum

T.M. Ribeiro De Oliveira, Lisbon (PT)

### Instrumentation and haemostatis

D. Veneziano, New Hyde Park NY (US)

### Indications for laparoscopy

T.M. Ribeiro De Oliveira, Lisbon (PT)

### Avoiding complications

D. Veneziano, New Hyde Park NY (US)



## Practical neuro-urology

ESU Course 27

**Saturday 11 March  
16:00 - 18:00**

### Location

Pink Area, ESU 6

### Learning objectives

The course aims to introduce the basic principles of the diagnostic work-up and management of the common micturition dysfunctions in neurological disease. The early introduction of correct management contributes to the patient's quality of life and prevents potential complications for neurological patients.

The main aims are:

- To refresh the pathophysiology and the key points of the investigation and management of patients with neurogenic bladder dysfunction.
- To apply those principles to specific diseases, namely spinal cord injury, multiple sclerosis, Parkinson's disease and stroke.
- To discuss with real-life clinical cases pharmacological and surgical options available for the management of neuro-urological patients.

## Markers for improved diagnosis and outcome of non-muscle invasive bladder cancer

Abstract Session 15

**Saturday 11 March  
17:15 - 18:45**

**Location** Yellow Area, Brown 3  
**Chairs** H. Mostafid, Guildford (GB)  
To be confirmed  
P.H. Song, Daegu (KR)

**17:15 - 17:18**

**Introduction**

**A0268** **Urinary comprehensive genomic profiling predicts urothelial cancer up to 12 years ahead of clinical diagnosis: An expanded analysis of the Golestan Cohort Study**  
F. Le Calvez-Kelm, Lyon (FR)

**A0269** **The hematuria cancer risk score: A validation study demonstrating reduction in the number needed to investigate while preserving fidelity of cancer detection**  
W.S. Tan, London (GB)

**A0270** **A Prospective study of the superior diagnostic role of urinary nanowire-based O-GlcNAc-transferase to urine cytology for bladder cancer in patients with hematuria**  
S.H. Kim, Goyang (KR)

**17:24 - 17:32**

**Discussion**

**A0271** **Prospective study to evaluate the sensitivity and specificity of ADX-Bladder and EpiCheck tests against urine cytology to detect early tumor recurrence in patients with non-muscle invasive bladder cancer**  
A. Rodríguez Serrano, Madrid (ES)

**A0272** **BTA stat®, Alere NMP22® BladderChek®, UBC® rapid test, and CancerCheck® UBC® rapid VISUAL in comparison to cytology as tumor marker for urinary bladder cancer: Final results of a german multicentre-study**  
T.H. Ecke, Bad Saarow (DE)

**A0273** **Assessment of the oncological safety of NICE guidelines on low risk bladder cancer surveillance**

**A0274** **An optimized surveillance protocol based on the European Association of Urology substratification improves surveillance costs after transurethral resection of bladder tumor in patients with high-risk non-muscle-invasive bladder cancer**  
N. Fujita, Hirosaki (JP)

**A0275** **Is it possible a surveillance deintensification in high-grade non-muscle invasive bladder carcinoma treated with bacillus Calmette-Guérin? A multiple survival approach for recurrence and progression risk dynamics**  
J.D. Subiela Henríquez, Madrid (ES)

**A0276** **The impact on survival outcomes of different Bacillus Calmette–Guérin strains of non-muscle invasive bladder cancer patients**

**A0277** **Asymptomatic bacteriuria does not increase the risk of infective complications in patients with non-muscle-invasive bladder cancer undergoing intravesical bacillus calmette-guérin immunotherapy**  
A. Nummi, Helsinki (FI)

17:46 - 18:03

Discussion

---

**A0278**                      **Machine learning-based survival model optimizes the outcome prediction in high-grade T1 bladder carcinoma: Improving selection of suitable candidates for timely radical cystectomy**  
J.D. Subiela Henriquez, Madrid (ES)

---

**A0279**                      **Progression-free survival as surrogate endpoint in high-risk non-muscle invasive bladder cancer studies: Results from a machine learning-based analysis of a large multi-institutional database**  
M. Marchioni, Chieti (IT)

---

**A0280**                      **Nation-wide progression outcomes after BCG therapy for high- and very high-risk T1 non-muscle invasive bladder cancer patients – a prospective registry study**  
O.M. Pijpers, Rotterdam (NL)

---

**A0281**                      **GATA2 methylation and FGFR3 mutation predict progression in BCG-treated high-risk non-muscle-invasive bladder cancer**

---

**A0282**                      **Impact of pT-stage at second transurethral resection on recurrence and progression risk dynamics in a contemporary series of high-grade T1 bladder carcinoma treated with adequate bacillus Calmette-Guérin: Implications for management**  
J.D. Subiela Henriquez, Madrid (ES)

---

18:13 - 18:24

Discussion

---

**A0283**                      **One year oncological outcome updated analysis of a single-center prospective, randomized, controlled, non-inferiority trial: En bloc vs. conventional transurethral resection of bladder tumor**  
P. Diana, Barcelona (ES)

---

**A0284**                      **Cancer-specific survival of patients with non-muscle invasive bladder cancer: A population-based analysis.**  
A. Ślusarczyk, Warsaw (PL)

---

**A0285**                      **Validation of the novel risk-class for non-muscle invasive bladder cancer: Comparison of oncological outcomes between “very-high risk” and “high risk” patients**

---

18:30 - 18:38

Discussion

---

18:38 - 18:45

Closing remarks

---

## Prostate cancer: Biopsy protocols, role of imaging to risk stratify biopsy indication, pathological issues

Abstract Session 18

**Saturday 11 March**  
**17:15 - 18:45**

**Location** Pink Area, Coral 4  
**Chairs** G. Marra, Turin (IT)  
P.B. Østergren, Copenhagen (DK)  
R Ahlawat, Noida (IN)

**17:15 - 17:18**

**Introduction**

**Incidental cancers**

**A0286** **Risk of concomitant prostate cancer in bladder cancer patients going for radical cystectomy**  
C.H. Yee, Hong Kong (HK)

**A0287** **Incidental prostate cancer in MRI era. Is there a need for expansion in guidelines?**

**A0288** **Natural history of Atypical Small Acinar Proliferation (ASAP): A 10-year contemporary series.**  
T. Anbarasan, Oxford (GB)

**A0289** **Is active surveillance a safe option when prostate biopsies have reported low-grade disease?**  
R. Taggart, Glasgow (GB)

**A0290** **Oncologic outcomes of patients with incidental prostate cancer: Can we rely on multiparametric mri to exclude aggressive prostate cancer?**

**17:28 - 17:37**

**Discussion**

**Biopsy protocols including systematic biopsies and targeted biopsies**

**A0291** **Ex Vivo Fluorescence Confocal Microscopy (FCM) of Perineal Prostate Biopsies (PPB) allows fast-track examination of MRI-Guided Targeted Biopsies in Routine Diagnostics**

**A0292** **Optimizing multiparametric magnetic resonance imaging-targeted biopsy and detection of clinically significant prostate cancer : the role of core number and location**  
R. Martin, Brussels (BE)

**A0293** **Detection of clinically significant prostate cancer in systematic prostate biopsies on the side contralateral to MRI detected PIRADS lesions - can we do away with systemic biopsies when there is a target?**  
P.P. Subedi, Biratnagar (NP)

**A0294** **Is there an impact of transperineal vs. transrectal MRI-targeted biopsy on the risk of upgrading and concordance with final pathology in prostate cancer patients undergoing radical prostatectomy? An EAU-YAU study**  
F. Zattoni, Verona (IT)

---

A0295	<b>Swich to transperineal prostate biopsies: A single-center experience</b> A. Brun, Bordeaux (FR)
A0296	<b>The importance of the location of the PI-RADS lesion within the prostate as a predictive variable of malignant degree</b> M.A. Rodríguez Cabello, Boadilla del Monte (ES)
A0297	<b>Is 12 systemic cores in transperineal biopsy sufficient for detecting clinically significant prostate cancer?</b>
A0298	<b>The role of systematic biopsy in the era of MRI guided prostate biopsy in a multi-centre Asian cohort</b> P.K-F. Chiu, Hong Kong (HK)
A0299	<b>Targeted biopsy of secondary lesions on prostate MRI: Value-add or unnecessary?</b> W.C. Tsang, Singapore (SG)
<b>17:55 - 18:07</b>	<b>Discussion</b>
	<b>Role of imaging to risk stratify biopsy and treatment indication</b>
A0300	<b>Overall detection and identification of clinical prognosticators that determine the presence of ISUP gleason grade group <math>\geq 2</math> prostate cancer in patients with multiparametric MRI PIRADS 3 lesions who underwent MRI-US fusion guided prostate biopsy</b> R.A.P. Uy, Manila (PH)
A0301	<b>Probability of detecting significant and aggressive prostate cancer by MRI-identified lesions in a series of biopsy naïve-men</b> V. Ficarra, Messina (IT)
A0302	<b>The need for advanced analytical methods for big data in urology: A first application from the ReIMAGINE risk study</b> M. Rowley, London (GB)
A0303	<b>Prostate tumor volume is a significant predictor to identify patients with no need for concomitant systematic biopsy in men undergoing transrectal ultrasound- MRI fusion guided biopsy of the prostate</b>
A0304	<b>Is a confirmatory prostate biopsy before entry into an active surveillance protocol still necessary in the era of prostate cancer diagnosis with MRI-guided biopsy?</b> O. Schwartz Gildor, Hod HaSharon (IL)
A0305	<b>Can a Physician Make the Decision of Focal Therapy for Prostate Cancer Based on the Unilateral Lesion on Magnetic Resonance Imaging / Transrectal Ultrasound Fusion Guided Transperineal Prostate Biopsy?</b> J.Y. Hsu, Taichung (TW)
<b>18:19 - 18:28</b>	<b>Discussion</b>
	<b>Pathological innovative techniques for biopsy cores</b>
A0306	<b>Introducing the FAST–Study (Frozen section analysis assisted MRI-targeted biopsy for prostate cancer diagnosis): A prospective, randomized study</b> M. Jähnen, Munich (DE)

---

---

## Scientific Programme - EAU23 Milan

---

A0307	<b>Ex vivo fluorescence confocal microscopy ensures representative tissue in prostate cancer biobanking: A feasibility study</b> K-D. Sievert, Detmold (DE)
A0308	<b>Transperineal prostate biopsy using 16G needle vs 18G: Does the size matter for a better cancer detection?</b> G. Randazzo, Padova (IT)
18:34 - 18:40	<b>Discussion</b>
18:40 - 18:45	<b>Closing remarks</b>

---

## Refining BPH enucleation

Video Session 07

<b>Saturday 11 March 17:15 - 18:45</b>	<b>Location</b>	Pink Area, Coral 7
	<b>Chairs</b>	To be confirmed To be confirmed L. Lusuardi, Salzburg (AT)
<b>17:15 - 17:16</b>	<b>Introduction</b>	
V048	<b>Robotic-assisted simple prostatectomy using the Da Vinci sp system</b> B.H. Kim, Daegu (KR)	
V049	<b>Transcapsular robotic simple prostatectomy and laparoscopic in-bag morcellation</b> I. Moncada Iribarren, Madrid (ES)	
V050	<b>Transvesical simple prostatectomy: Laparoscopic versus robotic approach</b>	
V051	<b>Veil sparing Holmium laser enucleation of the prostate; technical evolution and preliminary results of randomized trial</b> A. Elshal, Mansoura (EG)	
V052	<b>Video technique of hybrid enucleation: Bipolep-assisted holep</b> A. Gudeloglu, Ankara (TR)	
V053	<b>En-block endoscopic enucleation of the prostate with the a new Tm:YAG hybrid laser (HTLEP)</b> I. Kartalas Goumas, Vigevano (IT)	
V054	<b>LEST: Anatomical ablative ejaculation sparing surgery for BPH</b> R. Leonardi, Acireale (IT)	
V055	<b>Holep Vs Thulep TFL</b> J. Romero-Otero, Madrid (ES)	
<b>18:43 - 18:45</b>	<b>Closing remarks</b>	

## History of urology

Abstract Session 07

<b>Saturday 11 March 12:00 - 13:30</b>	<b>Location</b>	Pink Area, Coral 1
	<b>Chairs</b>	J.C. Goddard, Leicester (GB) To be confirmed To be confirmed
<b>12:00 - 12:03</b>	<b>Introduction</b>	
A0109	<b>Reed M. Nesbit (1898 - 1979): Master of all trades, jack of none</b>	
<b>12:05 - 12:07</b>	<b>Discussion</b>	
A0110	<b>Sir George Buckston Browne (1850-1945): From Henry Thompson to Charles Darwin</b> D. Schultheiss, Giessen (DE)	
<b>12:09 - 12:11</b>	<b>Discussion</b>	
A0111	<b>William Barr Stirling and the aortogram</b> K. Raza, Leicester (GB)	
<b>12:13 - 12:15</b>	<b>Discussion</b>	
A0112	<b>Illness, lust and abjection in the stalls misericords of the choir in San Salvador Cathedral in Zamora (Spain): The symbolic call for a need of reformation before Lutheranism</b> J. Angulo Cuesta, Madrid (ES)	
<b>12:17 - 12:19</b>	<b>Discussion</b>	
A0113	<b>Shiva Lingam: A devotional phallic image or symbol of divine creation?</b>	
<b>12:21 - 12:23</b>	<b>Discussion</b>	
A0114	<b>Louis-auguste mercier – the forgotten pioneer of endourology</b> J.K. Badawi, Luzern (CH)	
<b>12:25 - 12:27</b>	<b>Discussion</b>	
A0115	<b>100 years of history-making urology – the Portuguese urology association</b> J. Lima, Coimbra (PT)	
<b>12:29 - 12:31</b>	<b>Discussion</b>	
A0116	<b>Carlos Alférez Villalobos (1926-2007), pioneer surgeon in renal transplantation in Madrid</b> J.J. Szczesniewski, Milagros (ES)	
<b>12:33 - 12:35</b>	<b>Discussion</b>	



## Scientific Programme - EAU23 Milan

---

A0117	<b>Paul Rosenstein 1875-1964, a Jewish urologist in troubled times</b> D. Taussky, Montreal (CA)
12:37 - 12:39	Discussion
A0118	<b>International networks of Viennese Urology: A case study of Robert Ultzmann's list of attendance</b>
12:41 - 12:43	Discussion
A0119	<b>Management of retention of urine 1000 years ago</b> A. Al Dayel, Dammam (SA)
12:45 - 12:47	Discussion
A0120	<b>Botulinum neurotoxin: The story of how one spoiled sausage changed the world</b>
12:49 - 12:51	Discussion
A0121	<b>Bacillus Calmette–Guérin: The first immunotherapy and unlikely hero in the fight against bladder cancer</b>
12:53 - 12:55	Discussion
A0122	<b>Management of hydrocele 1000 years ago</b> A. Al Dayel, Dammam (SA)
12:57 - 12:59	Discussion
A0123	<b>100 years of the sentinel node. History of the sentinel node technique in urological tumors</b> J. Perez Ardavin, Valencia (ES)
13:01 - 13:03	Discussion
A0124	<b>What's in a name: The development of the humble ureteric stent</b>
13:05 - 13:07	Discussion
A0125	<b>Watt's in a name? - The people that focused laser lithotripsy</b> S.E. Majdalany, Sterling Heights (US)
13:09 - 13:11	Discussion
A0126	<b>Penile transplantation: Past, present and future</b>
13:13 - 13:15	Discussion
A0127	<b>A tale of two writers and a surgeon: The dispute between Lope de Vega and Miguel de Cervantes and their laudatory poems to the treaty of Francisco Diaz, Surgeon of his majesty Philip II of Spain, published in 1588</b> J. Angulo Cuesta, Madrid (ES)
13:17 - 13:19	Discussion

---

---

**A0128**                      **Sexual taboos and penis cracking: The practice of Taqaandan causing penile fracture**  
L. Waley, Bristol (GB)

---

**13:21 - 13:23**                      **Discussion**

---

**13:23 - 13:30**                      **Closing remarks**

## Update on mRCC - surgery and medical therapy. Miscellaneous on localised RCC

Abstract Session 19

**Saturday 11 March**  
**17:15 - 18:45**

**Location** Pink Area, Coral 6  
**Chairs** To be confirmed  
L. Albiges, Villejuif (FR)  
W.K. Han, Seoul (KR)

**17:15 - 17:18**

**Introduction**

**CN-surgical management**

- |               |   |
|---------------|---|
| A0326         | <b>Characterization of patients with metastatic renal cell carcinoma treated with or without cytoreductive nephrectomy in the era of combination immunotherapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC)</b> |
| A0327         | <b>Deferred cytoreductive nephrectomy following response to ipilimumab/nivolumab, is there potential for a treatment-free interval?</b><br>E.E. Fransen van de Putte, Amsterdam (NL)  |
| A0328         | <b>Differences in survival of clear cell metastatic renal cell carcinoma patients according to partial vs. radical nephrectomy</b><br>C. Cano Garcia, Frankfurt am Main (DE)  |
| A0329         | <b>Minimally invasive cytoreductive nephrectomy for metastatic renal cell carcinoma in the immunotherapy era: Results from the REMARC-IO database</b><br>M. Marchioni, Chieti (IT)  |
| A0330         | <b>Metastasectomy in oligometastatic RCC brings a survival benefit in immunotherapy era: Results from the REMARCC-IO Registry</b>   |
| A0331         | <b>Venous tumour thrombus in renal cell carcinoma: locally advanced or metastatic disease?</b><br>G. Musso, Milan (IT)  |
| 17:30 - 17:42 | <b>Discussion</b>   |
|               | <b>Medical therapy response assessment</b>  |
| A0332         | <b>On-treatment modified Glasgow prognostic score (mGPS) improves imaging-only prediction of response and outcomes in metastatic renal cell carcinoma</b><br>N. Klümper, Bonn (DE)  |
| A0333         | <b>Impact of gender on the efficacy of immune checkpoint inhibitors for urological cancers: A systematic review and meta-analysis</b><br>T. Yanagiswawa, Tokyo (JP)   |
| A0334         | <b>Long term anti-vascular endothelial growth factor receptor treatment impairs renal function in renal cell carcinoma</b><br>S. Naito, Yamagata (JP)   |

## Scientific Programme - EAU23 Milan

---

A0335	<b>Introduction of dual checkpoint inhibition with nivolumab plus ipilimumab in advanced renal cell carcinoma: results of a retrospective comparative analysis of real-world data in Germany.</b> M. Derigs, Marburg (DE)
A0336	<b>Prognostic value of fat loss in patients with metastatic clear cell renal cell carcinoma treated with immune checkpoint inhibition</b>
A0337	<b>Phase I/II study of multi-peptide cancer vaccine IMA901 in Japanese patients with advanced renal cell cancer with long-term follow up</b> F. Hongo, Kyoto (JP)
<b>17:54 - 18:06</b>	<b>Discussion</b>
	<b>Miscelanea on localized kidney cancer</b>
A0338	<b>The natural course and management strategies of renal angiomyolipoma: A comprehensive single-institution series with 20-year experience</b> A. Keles, Istanbul ()
A0339	<b>Deciphering the relationship between pathogenic variants and clinical phenotype in VHL patients: results from a prospective observational study</b>
A0340	<b>Detection of pulmonary lesion during follow-up after surgery for localized renal cell carcinoma: disease progression or a primary lung cancer?</b>
A0341	<b>New-onset chronic kidney disease after surgery for localized renal masses in patients with two kidneys and preserved renal function: A contemporary multicentre study</b> A. Pecoraro, Florence (IT)
A0342	<b>Functional BOLD-MRI (Blood Oxygenation Level Dependent) - Feasibility study for imaging the renoprotective effect of Remote Ischaemic PreConditioning (RIPC) on ischaemia/reperfusion injury after partial nephrectomy</b> F. Heuzeroth, Basel (CH)
A0343	<b>Redo robotic partial nephrectomy for recurrent renal tumors: Single high-volume center experience</b> A. Brassetti, Rome (IT)
A0344	<b>Identification of the feature of immune cells infiltration in inherited renal carcinoma with von Hippel-Lindau syndrome</b> W. Yang, Beijing (CN)
A0345	<b>Genotype-phenotype correlations and clinical outcomes of Von Hippel-Lindau disease patients with large deletions</b> K.N. Zhang, Beijing (CN)
<b>18:22 - 18:38</b>	<b>Discussion</b>
<b>18:38 - 18:45</b>	<b>Closing remarks</b>

---

## Stones: Diagnosis and conservative management

Abstract Session 20

**Saturday 11 March**  
**17:15 - 18:45**

**Location** Blue Area, Room 1  
**Chairs** O.R. Durutovic, Belgrade (RS)  
V.M.J. De Coninck, Brasschaat (BE)  
K. Ghani, Ann Arbor (US)

**17:15 - 17:18**

**Introduction**

- A0346** **Google trends: A potential infodemiological tool to assess seasonal trends of kidney stones**  
S. Warudkar, Ahmedabad (IN)
- A0347** **Effect of urology consult in the emergency department on outcome of patients with renal colic**  
A. Shemesh, Ashdod (IL)
- A0348** **A Novel Machine Learning–based Diagnostic Model for Nephrolithiasis Using Simple Clinical Information: A Multicenter Study**  
H-W. Chen, Kaohsiung (TW)
- A0349** **Using deep learning based model for detection of urolithiasis on plain X-ray of abdomen**  
J. Chen, Taoyuan City (TW)
- A0350** **Hydronephrosis & inflammatory stranding helps predict spontaneous stone passage in patients with CT diagnosed ureteral stones**  
L. Waley, Bristol (GB)
- A0351** **Accurately predicting pure uric acid urinary stones using computed tomographical images: a combined radiomics and machine learning approach**
- A0352** **Machine learning-based decision support system to distinguish uric acid stones in patients with kidney stones of ‘grey zone’ Hounsfield units: International multicenter development and external validation study**
- 17:32 - 17:46** **Discussion**
- A0353** **The development of the novel simulation system that calculates the trajectories of 10000 stones in a short time**  
M. Komeya, Yokohama (JP)
- A0354** **Treatment of non-obstructing kidney stones in patients for flank pain: A prospective multicenter trial: A CoRE initiative**  
N. Bhojani, Montreal (CA)
- A0355** **Asymptomatic spontaneous stone passage is frequent in recurrent kidney stone formers: results of the prospective, randomized NOSTONE trial**  
K. Stritt, Lausanne (CH)
- A0356** **Lower ureteric stone management by sexual intercourse**  
K.H. Bhatti, Alkhor (QA)

## Scientific Programme - EAU23 Milan

---

A0357	<b>Trend of inflammatory serum marker, in predicting spontaneous ureteral expulsion of lower ureteral calculi with mets</b> S.S. Qazi, Karachi (PK)
A0358	<b>Use of Monocyte Distribution Width (MDW) to diagnose and monitor patients with sepsis and urinary stones in an emergency setting</b> D. Baiamonte, Palermo (IT)
<b>17:58 - 18:10</b>	<b>Discussion</b>
A0359	<b>Predictive models for severe pain and urinary symptoms after ureteroscopy with ureteral stent placement from the usdrn stents study</b>
A0360	<b>Trends and Incidence of Reported Events Associated With Ureteral Stents: An Analysis of the Food and Drug Administration's Manufacturer and User Facility Device Experience Database</b> A. Nacchia, Prata Sannita (IT)
A0361	<b>Double J substitution with a Pigtail Suture Stent after ureteroscopy improves patients' quality of life</b> A. Bosio, Torino (IT)
A0362	<b>Effect of single dose prophylactic antibiotics versus phytotherapy in altering the microbial colonization related to indwelling double-J stent A prospective randomized controlled multicenter study</b> H. Khouni, Ariana (TN)
<b>18:18 - 18:26</b>	<b>Discussion</b>
A0363	<b>Is remote follow-up using patient reported outcome measure (prom) feasible in patients with urolithiasis?: The results of the first prospective feasibility study using urinary stones and intervention quality of life (usiqol) core measure</b> R. Jarvis, Cardiff (GB)
A0364	<b>The impact of bilateral stone disease on patients' disease progression and quality of life</b> B.L. Raizenne, Montreal (CA)
A0365	<b>Correlation between perioperative characteristics and quality of life measured by IT-WISQOL in patients with upper urinary tract stones</b> E. Serafin, Verona (IT)
<b>18:32 - 18:38</b>	<b>Discussion</b>
<b>18:38 - 18:45</b>	<b>Closing remarks</b>

---

## Novel biomarkers in prostate cancer

Abstract Session 17

**Saturday 11 March**  
**17:15 - 18:45**

**Location** Pink Area, Coral 3  
**Chairs** C. Jeronimo, Porto (PT)  
L. Lund, Odense (DK)  
To be confirmed

**17:15 - 17:18**

**Introduction**

**17:18 - 17:28**

**State-of-the-art lecture Novel biomarkers for diagnosis of prostate cancer**  
C. Jeronimo, Porto (PT)

**Liquid biomarkers**

A0366

**Early detection assay using ctDNA methylation for hard-to-detect cases including prostate and renal cancer**  
H.S. Dev, Cambridge (GB)

A0367

**Raman spectroscopy and fingerprinting of brand new urine biomarkers as potential tools for prostate cancer accurate diagnosis**

A0368

**RAMAN SERS Spectroscopy: a new tool to analyze exosomes from patients with prostate cancer**

A0369

**Circulating tumor cell based transcriptomic differences between localized and metastatic prostate cancer**

A0370

**The role of circulating tumor cell-based PSMA mRNA in localized or locally advanced prostate cancer**  
J.S. Chung, Busan (KR)

**17:38 - 17:55**

**Discussion**

**Novel biomarkers**

A0371

**Alterations of the collagen pathway is linked to clinical outcome in prostate cancer**  
I. Heidegger, Innsbruck (AT)

A0372

**Lipid metabolism in prostate cancer: Immunohistochemical by semiautomated tissue microarray analysis**  
M.G. Asmundo, Catania (IT)

A0373

**Regulatory role of fatty acid metabolism-related long non-coding RNA in prostate cancer**  
L. Yi, Tianjin (CN)

A0374

**Evaluation of copy number and allelic imbalance of BRCA2 by next-generation sequencing to predict prognosis and drug sensitivity in prostate cancer**  
M. Sumitomo, Aichi (JP)

## Scientific Programme - EAU23 Milan

---

A0375	<b>MCTP1 promotes SNAI1-driven neuroendocrine differentiation and epithelial-to-mesenchymal transition of prostate cancer enhancement by ZBTB46/FOXA2/HIF1A</b> Y. Ho, Taipei City (TW)
A0376	<b>Tumor-infiltrating CD103+ cells define poor prognosis prostate cancer with favorable therapeutic response</b> Q. Zhou, Shanghai (CN)
A0377	<b>Mitochondrial metabolic patterns reveal different prognostic outcomes and immunotherapy responses in prostate cancer</b> X. Zhou, Chengdu (CN)
A0378	<b>Suppression of androgen receptor signaling induces prostate cancer metastasis via activation of the CCL20–CCR6 axis</b> H. Kano, Kanazawa (JP)
A0379	<b>Exposure of phthalate enhances oxidative stress and GDF15 expression that is associated with prostate cancer aggressiveness</b> H-T. Tung, Tainan (TW)
18:13 - 18:38	<b>Discussion</b>
18:38 - 18:45	<b>Closing remarks</b>



## Hot debates in penile and testis cancer

Thematic Session

**Saturday 11 March**  
17:30 - 19:00

**Location** Yellow Area, eURO Auditorium 2

**Chairs** O.R. Brouwer, Amsterdam (NL)  
D. Nicol, London (GB)

### Learning objectives

Penile and testicular cancer are both rare diseases with common issues in their management. These include strategies to assess and treat nodal disease as well as limited options for those with cytotoxic chemotherapy resistance. In addition their treatment can be complex requiring multimodality treatment confounded by the infrequency that these are seen by individual urologists. Consequently both are best managed in large specialist referral centres. This session will focus on these issues through both debate and discussion by expert panellists and session chairs to provide a better understanding of therapeutic issues and challenges as well as strategies to facilitate centralisation of care.

17:30 - 17:54

**Debate Surgical approaches in staging of high risk penile cancer**

17:30 - 17:33

**Case presentation**

L. Elst, Leuven (BE)

17:33 - 17:40

**The case for DSNB**

A. Parnham, Manchester (GB)

17:40 - 17:47

**The case for VEIL**

J.M. Gaya Sopena, Barcelona (ES)

17:47 - 17:54

**Questions and discussion**

17:54 - 18:18

**Debate Therapeutic options in non-seminoma, marker-negative stage II**

17:54 - 17:57

**Case presentation**

S. Fischer, St. Gallen (CH)

17:57 - 18:04

**Close monitoring**

T. Zuiverloon, Rotterdam (NL)

18:04 - 18:11

**Robotic RPLND**

C.D. Fankhauser, Lucerne (CH)

18:11 - 18:18

**Questions and discussion**

18:18 - 18:39

**Overcoming chemoresistance in rare genital cancers: What lies ahead in the exploration of the tumour micro-environment?**

18:18 - 18:25

**State-of-the-art lecture Penile cancer**

To be confirmed

18:32 - 18:39

**State-of-the-art lecture Germ cell tumours**

To be confirmed

18:25 - 18:32

**Questions and discussion**

18:39 - 19:00

**Centralised healthcare in rare genital cancers: Barriers and benefits**

18:39 - 18:46

**State-of-the-art lecture Penile cancer**

B.E. Ayres, London (GB)

18:46 - 18:53

**State-of-the-art lecture Germ cell tumours**

T. Tandstad, Trondheim (NO)



## The right management of prostate cancer: Early detection and active surveillance

Plenary Session

**Sunday 12 March**  
08:00 - 10:30

**Location** Yellow Area, eURO Auditorium 1

**Chairs** P. Albers, Düsseldorf (DE)  
A. Villers, Lille (FR)

### Learning objectives

European Commission's decided to extend a recommendation of organised cancer screening programs to prostate cancer. In this session we will discuss how EU Member States have to swiftly implement this recommendation in their own populations: Raising awareness, promoting risk stratification before biopsy to help eliminate the concerns of overdiagnosis. Overtreatment risk necessitates to promote Active Surveillance but is it a safe treatment option for grade group 2 cancers?

08:00 - 08:05

**Welcome and introduction**  
A. Villers, Lille (FR)

08:05 - 08:13

**State-of-the-art lecture Mortality trends of prostate cancer in the EU**  
P. Basu, Lyon (FR)

08:13 - 08:33

**Update on current screening trials**

08:13 - 08:18

**ProScreen**  
A.P. Auvinen, Tampere (FI)

08:18 - 08:23

**PROBASE**  
K. Herkommer, München (DE)

08:23 - 08:28

**STHLM3**  
T. Nordström, Stockholm (SE)

08:28 - 08:33

**Discussion**

08:33 - 08:41

**What is the best way of risk stratification before biopsy?**  
R. Hogenhout, Rotterdam (NL)

08:41 - 08:56

**EU Cancer Plan and what it means for prostate cancer in general**

08:41 - 08:48

**Video message from the EU Commissioner**  
To be confirmed

08:48 - 08:56

**Implementing Europe's Beating Cancer Plan**  
To be confirmed

08:56 - 09:11

**Panel discussion Research Initiatives: PRAISE-U, EAU-Research Foundation and Genetic Testing**

*Panel* A.S. Bjartell, Malmö (SE)  
A. De La Taille, Créteil (FR)  
M.J. Roobol, Rotterdam (NL)  
H. Van Poppel, Leuven (BE)

09:11 - 09:41

**Active Surveillance: Game changing session**

09:11 - 09:21

**15-year update PROTECT trial - Part I: Oncology**  
F.C. Hamdy, Oxford (GB)

## Scientific Programme - EAU23 Milan

---

09:21 - 09:31	<b>15-year update PROTECT trial - Part II: QoL</b> J. Donovan, Bristol (GB)
09:31 - 09:41	<b>Discussion</b>
09:41 - 09:57	<b>How to manage active surveillance in 2023</b>
09:41 - 09:49	<b>Minimal requirements for histopathology of biopsies</b> G. Sauter, Hamburg (DE)
09:49 - 09:57	<b>Do we need a genetic biopsy test to promote AS in GG2 cancers?</b> To be confirmed
09:57 - 10:15	<b>Active surveillance for GG 2 cancers by MRI only?</b>
09:57 - 10:00	<b>Case presentation</b> J. Gómez Rivas, Madrid (ES)
10:00 - 10:05	<b>Yes</b> C. Moore, London (GB)
10:05 - 10:10	<b>No</b> A. Briganti, Milan (IT)
10:10 - 10:15	<b>Discussion</b>
10:15 - 10:30	<b>PSMA-PET in local evaluation of the prostate for active surveillance?</b>
10:15 - 10:20	<b>Yes</b> R. Eapen, Melbourne (AU)
10:20 - 10:25	<b>No</b> R.C.N. Van Den Bergh, Utrecht (NL)
10:25 - 10:30	<b>Discussion</b>

## Challenges in urogenital infections

Plenary Session

**Sunday 12 March**  
**08:00 - 10:00**

**Location** Yellow Area, eURO Auditorium 2

**Chairs** M.S. Silay, Istanbul (TR)  
F.M.E. Wagenlehner, Giessen (DE)

### Learning objectives

Urinary tract infections are very heterogeneous. This symposium highlights the challenges in the different entities of urological infections. Particular focus is laid on the host part, the role of the immune system in lower urinary tract infections, how the microbiome impacts disease development. In addition recurrent urinary tract infections are difficult to treat. What are the right strategies to reduce frequencies. The world wide increase of antimicrobial resistance calls for additional and novel strategies, such as microbiome treatments or bacteriophage applications. We shall also not forget the very important role of urinary tract infections in children, which will be addressed in a separate presentation.

**08:00 - 08:05**

**Welcome and introduction**

**08:05 - 08:15**

**State-of-the-art lecture** How does the immune system of the urinary tract respond to UTI?  
To be confirmed

**08:15 - 08:25**

**State-of-the-art lecture** Microbiome has a role in the development of genitourinary cancers  
A. Alimonti, Bellinzona (CH)

**08:25 - 09:00**

**Case discussion** Management of recurrent cystitis

**08:25 - 08:30**

**Case presentation**  
To be confirmed

**08:30 - 08:40**

**General approach is sufficient**  
J. Kranz, Aachen (DE)

**08:40 - 08:50**

**Personalised management is better**  
T. Cai, Trento (IT)

**08:50 - 09:00**

**Discussion**

**09:00 - 09:37**

**Case discussion** Treatment of resistant UTI

**09:00 - 09:05**

**Case presentation**  
H.M. Çek, Edirne (TR)

**09:05 - 09:13**

**Vaccination**  
J. Medina Polo, Madrid (ES)

**09:13 - 09:21**

**Are bacteriophages replacing antibiotics?**  
L. Leitner, Zürich (CH)

**09:21 - 09:29**

**Stool transplantation**  
To be confirmed

**09:29 - 09:37**

**Antimicrobial stewardship**  
S.E. Geerlings, Amsterdam (NL)

## Scientific Programme - EAU23 Milan

---

09:37 - 09:47

**Société Internationale d'Urologie (SIU) lecture A nightmare for urologists: How to manage urosepsis?**  
To be confirmed

---

09:47 - 09:57

**State-of-the-art lecture Small body, big problem! How to approach UTI's in children**  
A. Zachou, London (GB)

---

09:57 - 10:00

**Closing remarks**

## Prostate cancer update: 2022-2023

ESU Course 28

Sunday 12 March  
08:00 - 11:00

**Location** Pink Area, ESU 1

**Chair** F. Montorsi, Milan (IT)

### Learning objectives

This course is aimed at critically reviewing key manuscripts published during the previous 12 months and devoted to the management of prostate cancer patients with a particular focus on basic research, screening, diagnosis, staging, and local and systemic therapies. Practice-changing manuscripts published in peer-reviewed journals will be identified and discussed for each topic. For every paper a clear take home message applicable to the every-day clinical practice will be identified and discussed. The main objective of the course is to inform participants on the latest and most significant novelties related to the contemporary management of prostate cancer patients.

### Clinical implications of basic research

F. Montorsi, Milan (IT)

### Screening: Novel biomarkers and strategies

C.P. Evans, Sacramento (US)

### Diagnosis: Role of mpMRI and PET PSMA in detecting prostate lesions. Fusion biopsies

F. Montorsi, Milan (IT)

### Staging: Imaging and predictive models

M. Graefen, Hamburg (DE)

### Treatment of localised prostate cancer: Radical prostatectomy

M. Graefen, Hamburg (DE)

### Treatment of localised prostate cancer: Focal therapy

F. Montorsi, Milan (IT)

### Treatment of localised prostate cancer: Radiation therapy

M. Graefen, Hamburg (DE)

### Management of recurrence after curative treatment

M. Graefen, Hamburg (DE)

### Management of hormone sensitive metastatic prostate cancer

C.P. Evans, Sacramento (US)

### Management of castration-resistant prostate cancer

C.P. Evans, Sacramento (US)

## Focal therapy in prostate cancer

ESU Course 29

**Sunday 12 March**  
**08:00 - 11:00**

**Location** Pink Area, ESU 2

**Chair** E. Barret, Paris (FR)

### **Learning objectives**

Focal treatment (FT) is about eradicating the cancer lesion within the prostate while preserving genitourinary function. This interactive course offers delegates:

- understanding of the rationale for focal treatment and patient selection criteria.
- an update on principles, outcome and side effects of focal technologies.
- a thorough discussion of biopsy strategies and imaging in diagnostic work-up and follow-up
- information about existing registries.

As men with prostate cancer are getting younger, the side effects of whole-gland treatment are getting more important. With several new technologies available a significant development of focal treatment is expected in the coming years.

### **Definition, rationale and role in the changing landscape of localised prostate cancer**

C. Orczyk, London (GB)

### **Patient selection tools**

M. Valerio, Lausanne (CH)

### **How to select the energy source?**

E. Barret, Paris (FR)

### **The post-treatment monitoring**

C. Orczyk, London (GB)

### **The outcomes and the ongoing trials**

M. Valerio, Lausanne (CH)

### **Clinical cases: Real-life cases, stories of success and failure**

E. Barret, Paris (FR)



### Nerve-sparing cystectomy and orthotopic bladder substitution: Surgical tricks and management of complications

ESU Course 30

**Sunday 12 March**  
**08:00 - 11:00**

**Location** Pink Area, ESU 3

**Moderator** A. Stenzl, Tübingen (DE)

#### **Learning objectives**

This course has over many years dealt with the technique of urethra- and nerve-sparing cystectomy and subsequent orthotopic bladder substitution in male and female patients. It will deal with indications, technique, possible complications and their prevention. Urologists with a vast experience in cystectomy and urinary diversion will present technical tips using video clips, results in the literature as well as own data.

- Technique of nerve-sparing cystectomy.
- Optimisation of sphincter preservation for optimal continence results.
- Technical tips and tricks in orthotropic neobladder surgery.
- What to observe in male and female patients.

## Dealing with the challenge of infection in urology

ESU Course 31

**Sunday 12 March**  
**08:00 - 11:00**

**Location** Pink Area, ESU 4

**Chair** F.M.E. Wagenlehner, Giessen (DE)

### Learning objectives

This ESU course on infection diseases provides a broad, up-to-date coverage of the most important and recent problems of infectious diseases in urology. Antimicrobial resistance is one of the biggest worldwide challenges in medicine and gains increasing importance in urology. The management of infections in general and of urogenital tract infections especially, has been compromised by this rapid and continuous increase of antimicrobial resistance. Basic biological principles and strategies to treat urogenital tract infections from benign infections to life-threatening infections will be discussed in this course:

- Classification of UTI and surgical field contamination categories as a basis for treatment and prophylaxis.
- Diagnosis, treatment and prophylaxis strategies of urogenital tract infections.
- Uncomplicated and recurrent cystitis.
- Complicated urinary tract infections.
- Urosepsis and Fournier gangrene.
- Male genital tract infections.

### Introduction

F.M.E. Wagenlehner, Giessen (DE)

### Classification of urinary tract infection (UTI) and surgical field contamination categories as a basis for treatment and prophylaxis

Z. Tandođdu, London (GB)

### Low-grade and recurrent UTI

F.M.E. Wagenlehner, Giessen (DE)

### Male genital infections: Epididymitis and urethritis

J. Medina Polo, Madrid (ES)

### Hospital acquired UTI and antibiotic resistance

Z. Tandođdu, London (GB)

### Perioperative prophylaxis with special focus on prostate biopsies

J. Medina Polo, Madrid (ES)

### Sepsis and Fournier's gangrene

F.M.E. Wagenlehner, Giessen (DE)

## Advanced indications in robotic surgery

ESU Course 32

**Sunday 12 March**  
**08:00 - 11:00**

**Location**

Pink Area, ESU 5

**Chair**

A. Mottrie, Melle (BE)

## Metabolic workup and non-surgical management of urinary stone disease

ESU Course 33

**Sunday 12 March**  
**08:00 - 11:00**

**Location** Pink Area, ESU 6

**Chair** T. Tailly, Ghent (BE)

### Learning objectives

Urolithiasis is an increasingly prevalent worldwide disease with recurrence rates up to 50% over 5 years. Metabolic assessment to identify predisposing factors and prevention therefore play an important role in patient management. This course will address common findings on dietary and metabolic workup and highlight medical and non-medical treatment options for these metabolic abnormalities in the prevention of stone recurrence.

The goal of the course is for participants to be able to:

- Identify patients that would benefit from metabolic workup.
- Interpret standard metabolic workup, including dietary and medical history and biochemical analyses.
- Understand what the guidelines say on targeted medical treatment for prevention of urinary stone disease.
- Understand the influence of dietary changes on metabolic urinary values and provide dietary counseling.

### Who needs a metabolic evaluation and why should this be done

M. Straub, Munich (DE)

### How to do a metabolic evaluation, step-by-step

R. Siener, Bonn (DE)

### Common stone types: What abnormalities might we find on investigation?

T. Tailly, Ghent (BE)

### Stone and diet: What advice should we give?

M. Straub, Munich (DE)

### Medical treatment for stones: What works?

T. Tailly, Ghent (BE)

### Interactive case discussions

T. Tailly, Ghent (BE)

R. Siener, Bonn (DE)

M. Straub, Munich (DE)

## Practical approach to paediatric urology

ESU Course 34

**Sunday 12 March**  
**08:00 - 11:00**


### Location

Pink Area, ESU 7

### Learning objectives

Many children with congenital anomalies will present to the adult urologist with long-term sequelae. It is important to know what has been done in terms of surgical procedures so that the adult urologist knows what is expected and what should or can be done. It is also important to know how the urological follow-up of these patients should be done. The most common paediatric conditions will be explored by interactive case presentations.

- Many children born with hydronephrosis may not require surgical intervention, but need close follow-up until after puberty.
- The clinical presentation of congenital anomalies of the urinary tract has changed, because of prenatal US, but sometimes adults may present with the classical symptoms.
- Obstructive uropathy and VUR are not always surgical anomalies, but may be functional in nature. The treatment modalities and long-term outcomes depend on the pathophysiology.

 Game changing session

**Sunday 12 March**  
**10:00 - 10:30**

**Location**

Yellow Area, eURO Auditorium 2

## Clinically meaningful questions in the management of advanced, hormone sensitive prostate cancer

Thematic Session

**Sunday 12 March**  
10:45 - 12:15

**Location** Yellow Area, eURO Auditorium 1  
**Chairs** A. Briganti, Milan (IT)  
S. Gillessen Sommer, Bellinzona (CH)

10:45 - 10:47	<b>Welcome and introduction</b>
10:47 - 10:55	<b>State-of-the-art lecture</b> How has PSMA-PET revolutionised the management of hormone sensitive prostate cancer? H.G. Van Der Poel, Amsterdam (NL)
10:55 - 11:03	<b>State-of-the-art lecture</b> Germ line testing in hormone sensitive prostate cancer: When and why? D. Tilki, Hamburg (DE)
11:03 - 11:25	<b>Debate</b> High-risk BRCA mutated case with N0 M0 at conventional and multiple cN1 at PSMA: What to do?
11:03 - 11:06	<b>Clinical case presentation</b> M. Maggi, Rome (IT)
11:06 - 11:12	<b>Surgery + extended LND</b> J. Walz, Marseille (FR)
11:12 - 11:18	<b>RT plus systemic treatment</b> P. Blanchard, Villejuif (FR)
11:18 - 11:25	<b>Panel discussion</b>
11:25 - 11:47	<b>Debate</b> Low-volume at conventional, 5 bone mets at PSMA PET CT
11:25 - 11:28	<b>Case presentation</b> G. Gandaglia, Milan (IT)
11:28 - 11:34	<b>Low-volume mHSPC: RT to the primary + ADT alone</b> N. Mottet, Saint-Étienne (FR)
11:34 - 11:40	<b>Low-volume mHSPC: RT to the primary + ADT + ARPI</b> G. Attard, London (GB)
11:40 - 11:47	<b>Panel discussion</b>
11:47 - 11:55	<b>State-of-the-art lecture</b> In which patients with low volume mHSPC should we use metastases directed therapy? P. Ost, Ghent (BE)
11:55 - 12:14	<b>Debate</b> Is there any added value of docetaxel in combination with ADT and ARPI for the treatment of mHSPCa?
11:55 - 12:01	<b>Yes</b> K. Fizazi, Villejuif (FR)
12:01 - 12:07	<b>No</b> M. De Santis, Berlin (DE)
12:07 - 12:14	<b>Discussion</b>

12:14 - 12:15

Closing remarks



## Male LUTS/BPO surgery: Where do we stand?

Thematic Session

**Sunday 12 March**  
**10:45 - 12:15**

**Location** Yellow Area, eURO Auditorium 2

**Chairs** J-N.L. Cornu, Rouen (FR)  
C. Gratzke, Freiburg (DE)

<b>10:45 - 10:55</b>	<b>State-of-the-art lecture</b> The optimal timing for BPO relief surgery: Do we operate too late? K.A.O. Tikkinen, Helsinki (FI)
<b>10:55 - 11:24</b>	<b>Case discussion</b> What is the best option for large prostates?
<b>10:55 - 10:57</b>	<b>Case presentation</b> T. Antunes Lopes, Milheirós Maia (PT)
<b>10:57 - 10:59</b>	<b>Use laser enucleation</b> L. Tunc, Ankara (TR)
<b>10:59 - 11:01</b>	<b>Use bipolar energy</b> B. Pradere, Toulouse (FR)
<b>11:01 - 11:03</b>	<b>Use greenlight vaporisation</b> M. Rieken, Zürich (CH)
<b>11:03 - 11:05</b>	<b>Do lap/robotics</b> E.A. Rodrigues De Lima, Braga (PT)
<b>11:05 - 11:07</b>	<b>Prostatic urethra expansion (PURE) devices</b> D. Elterman, Toronto (CA)
<b>11:07 - 11:09</b>	<b>Aquablation</b> T. Bach, Hamburg (DE)
<b>11:09 - 11:24</b>	<b>Discussion</b>
<b>11:24 - 11:40</b>	<b>Persistent LUTS after BPH surgery: Troubleshooting</b>
<b>11:24 - 11:32</b>	<b>State-of-the-art lecture</b> Reasons/pathophysiology of persistent LUTS after BPH surgery G.I. Russo, Catania (IT)
<b>11:32 - 11:40</b>	<b>State-of-the-art lecture</b> Role, indications and interpretation of urodynamics M. Drake, Bristol (GB)
<b>11:40 - 12:05</b>	<b>Cross-fire</b> What is the optimal treatment of persistent OAB symptoms after a good de-obstruction surgery?
<b>11:40 - 11:45</b>	<b>Stay non-invasive: PTNS and medications only</b> C. Graugaard-Jensen, Aarhus (DK)
<b>11:45 - 11:50</b>	<b>Go for botulinum toxin injections</b> A. Apostolidis, Thessaloniki (GR)
<b>11:50 - 11:55</b>	<b>Go for neuromodulation</b> M.A. Perrouin Verbe, Nantes (FR)
<b>11:55 - 12:05</b>	<b>Discussion</b>
<b>12:05 - 12:15</b>	<b>State-of-the-art lecture</b> Evaluation and treatment of stress incontinence after BPO surgery M. Gacci, Florence (IT)

## Stones: Basic research and metabolics

Abstract Session 22

**Sunday 12 March**  
**10:45 - 12:15**

**Location** Yellow Area, Brown 3  
**Chairs** To be confirmed  
K. Sarica, Istanbul (TR)  
To be confirmed

**10:45 - 10:48**

**Introduction**

A0380	<b>Association between high-density lipoprotein and kidney stones in Americans aged <math>\geq 20</math> years old: a cross-sectional analysis of NHANES 2007-2018</b> J. Cui, Chengdu (CN)
A0381	<b>The association between circadian syndrome and the prevalence of kidney stones in overweight Americans aged <math>\geq 20</math> years old: A cross-sectional analysis of NHANES 2007-2018</b> J. Cui, Chengdu (CN)
A0382	<b>Do changes in metabolic health and obesity affect the incidence of urolithiasis? A nationally representative cohort study</b> S.T. Ahn, Seoul (KR)
A0383	<b>Metabolic diseases and kidney stone risk, a Mendelian randomization study</b> J. Cui, Chengdu (CN)
A0384	<b>The real-world effectiveness of preventive pharmacological therapy</b>
<b>10:58 - 11:08</b>	
<b>Discussion</b>	
A0385	<b>Genotype and phenotype analyses in patients with cystine stones</b>
A0386	<b>Mechanism of cystine stone growth revealed by ultrastructural observation using scanning electron microscopy</b> K.W. Wakai, Chiba (JP)
A0387	<b>Micro-CT imaging of renal papillae: Can we predict the severity of Anderson-Carr-Randall progression? - preliminary results</b> E. Aydog, Ankara (TR)
A0388	<b>Urinary uromodulin and kidney stone disease: A mendelian randomization study and mediation analysis</b> J. Jian, Chengdu (CN)
A0389	<b>Differences in the composition of urinary stone in metabolically healthy and unhealthy obese patients</b> S.B. Jo, seoul (KR)
<b>11:18 - 11:28</b>	
<b>Discussion</b>	
A0390	<b>Dapagliflozin decreases calcium oxalate stones via activating AMPK-mediated autophagy in mice</b> CJ Liu, Tainan (TW)

---

A0391	<b>Increased renal uptake and urine excretion of oxidized LDL is possibly associated with formation of large calcium oxalate nephrolithiasis</b> C-M. Liu, Tainan (TW)
A0392	<b>CAV1 alleviated CaOx stones formation via suppressing autophagy-dependent ferroptosis</b> Y. Yang, Wuhan (CN)
A0393	<b>CaOx stone patients derived exosome miR-146a-5p regulates CaOx stone progression and immune microenvironment</b> Y. Yang, Wuhan (CN)
A0394	<b>The development of a hollow three-dimensional kidney spheroid model for the study of calcium-containing crystal formation</b> J.A. Chmiel, ()
<b>11:38 - 11:48</b>	<b>Discussion</b>
A0395	<b>Gut microbiota-derived uremic toxins enhance calcium oxalate stone formation in vitro and in vivo</b>
A0396	<b>The role of urine microbiota in patients with urolithiasis</b> L. Hsiang-Ying, Kaohsiung City (TW)
A0397	<b>A comparison of male and female renal pelvis urobiome of unilateral stone formers using 2bRAD-M</b>
A0398	<b>Environmental melamine exposure increases renal tubular injury via oxidative stress in patients with calcium urolithiasis: The possible mechanism of melamine associated urolithiasis formation</b> C-C. Liu, Kaohsiung (TW)
A0399	<b>Assessment of radiological properties and stone fragmentation of artificial phantom stones used for preclinical studies on endourology in comparison to real urinary calculi</b> B. Ballesta Martinez, Alicante (ES)
<b>11:58 - 12:08</b>	<b>Discussion</b>
<b>12:08 - 12:15</b>	<b>Closing remarks</b>

---

## Transplantation in urology

Abstract Session 23

**Sunday 12 March**  
**10:45 - 12:15**

**Location** Yellow Area, Amber 3

**Chairs** R. Boissier, Marseille (FR)  
To be confirmed  
To be confirmed

**10:45 - 10:48**

**Introduction**

**A0400** **Cadaveric penile dissection and its impact on live donor penile transplantation: a preliminary study**

**A0401** **Efficacy and safety of HIF-PHI for posttransplant anemia in kidney transplant recipients**  
Y. Aoyama, Akita (JP)

**A0402** **The effect of nerolidol on the renal alterations following ischemia-reperfusion injury in the rat**

**A0403** **Role of European urologists in kidney transplantation: An EAU-YAU kidney transplantation working group survey**  
A. Pecoraro, Florence (IT)

**10:56 - 11:04**

**Discussion**

**A0404** **Vascular complications after live-donor pediatric renal transplantation with a focus on graft-saving procedures: A single center experience**  
A. Elbatta, Mansoura (EG)

**A0405** **Predicting new baseline glomerular filtration rate (NBGFR) after donor nephrectomy: Validation of a split renal function (SRF) based formula**  
H.P.N. Wong, Singapore (SG)

**A0406** **An update on urinary leakage and ureteral stricture after 3035 live-donor renal transplantations: A single center experience**  
B. Ali-EI-Dein, Mansoura (EG)

**A0407** **Rejected living kidney donors due to nephrolithiasis. Does it really matter?**  
E. Carbonell, Barcelona (ES)

**11:12 - 11:20**

**Discussion**

**A0408** **Clinical evaluation of normothermically perfused porcine kidneys with autologous whole blood**  
A.E. Yakaç, Dresden (DE)

**A0409** **Ex vivo normothermic circulation (PNEV) of grafts from DCDs. An experimental study of biochemical and metabolic condition**  
V. Gomez Dos Santos, Madrid (ES)

## Scientific Programme - EAU23 Milan

---

A0410	<b>Kidney transplantation from donation after brain death versus donation after circulatory death using abdominal normothermic oxygenated circulation: Is there a difference in surgical complications?</b> A. Costa Silva, Porto (PT)
A0411	<b>Delayed graft function incidence and 3 years graft survival in normothermic regional perfusion, super-rapid recovery after circulatory death, and death brain donors in kidney transplantation</b> J. Salguero Segura, Ansoain (ES)
<b>11:28 - 11:36</b>	<b>Discussion</b>
A0412	<b>Kidney transplant outcomes in elderly population: A systematic review and meta-analysis</b> A. Dominguez Gutierrez, Pozuelo de Alarcón (ES)
A0413	<b>Myosteatosis as a novel predictor of new-onset diabetes mellitus after kidney transplantation</b> T. Wakamiya, Wakayama (JP)
A0414	<b>Early renal transplant scintigraphy (48h) as a predictor of graft survival</b> J. Salguero Segura, Ansoain (ES)
A0415	<b>Vascular complications of renal transplantation: Risk factors and impact on graft survival</b> S. Zaghib, Ariana (TN)
<b>11:44 - 11:52</b>	<b>Discussion</b>
A0416	<b>Comparison of functional and perioperative surgical outcomes of robotic assisted kidney transplant and open kidney transplant</b> D. Kaddu, Miraj (IN)
A0417	<b>Robot-assisted kidney transplantation (RAKT) from deceased donors provides non-inferior perioperative and mid- term functional outcomes as compared to open kidney transplantation: A single-centre experience</b> R. Campi, Florence (IT)
A0418	<b>Robot-assisted versus open kidney transplantation for end-stage kidney disease patients: A meta-analysis</b>
A0419	<b>Does kidney side matters in robot-assisted kidney transplantation (RAKT) from living donors? Insights from the European Robotic Urology Section (ERUS) RAKT working group</b> R. Campi, Florence (IT)
<b>12:00 - 12:08</b>	<b>Discussion</b>
<b>12:08 - 12:15</b>	<b>Close remarks</b>

---

## Cell biology, novel biomarkers and trials in non-muscle invasive bladder cancer

Abstract Session 27

**Sunday 12 March**  
**10:45 - 12:15**

**Location** Pink Area, Coral 4  
**Chairs** K. Mouw, Boston (US)  
T. Zuiverloon, Den Haag (NL)  
To be confirmed

**10:45 - 10:48**

**Introduction**

**10:48 - 10:58**

**Subtypes and novel biomarkers for predicting response and outcome in high risk NMIBC**  
T. Zuiverloon, Den Haag (NL)

**BCG/IO treatment**

A0420

**CORE1: Phase 2 Single arm study of CG0070 combined with Pembrolizumab in patients with non-muscle invasive bladder cancer unresponsive to Bacillus Calmette-Guérin (BCG)**  
R. Li, Houston (US)

A0421

**Intravesical administration of durvalumab to patients with high risk non muscle invasive bladder cancer after BCG failure. A phase II trial by the Hellenic GU Cancer Group.**  
C. Fragkoulis, Athens (GR)

A0422

**Bladder EpiCheck methylation test predicts short- and long-term HG events in bladder cancer patients treated with bacillus Calmette-Guérin**

A0423

**The impact of purified protein derivative prior to intravesical bacillus Calmette-Guérin for the treatment of patients with non-muscle invasive bladder cancer: A controlled clinical trial**  
M. Zawky, Mansoura (EG)

A0424

**Immune responses against SARS-CoV-2 wildtype in unvaccinated patients with high-risk NMIBC undergoing intravesical BCG therapy**  
R. Pichler, Innsbruck (AT)

A0425

**Enhanced antitumor effect of the combination of Bacille Calmette-Guérin and an immune checkpoint inhibitor in bladder cancer-on-a-chip**  
S.Y. Choi, Seoul (KR)

**11:10 - 11:24**

**Discussion**

**Immune contexture**

A0426

**Characterization of urinary and fecal microbiome in bladder cancer patients and its relation to disease aggressiveness**  
O. Nativ, Haifa (IL)

A0427

**Progression of high-risk non-muscle invasive bladder cancer correlates with immune phenotypes and fibroblast activation protein- $\alpha$  (FAP)**  
L. Baekelandt, Leuven (BE)

A0428	<b>Single cell-based immune profiling of the tumor and its immune microenvironment revealed differences between non-muscle invasive and muscle invasive bladder cancer</b> M. Lazzeri, Florence (IT)
A0429	<b>Immune microenvironment-related microbiome signature to predict prognosis of bladder urothelial carcinoma</b> Y.Y. Xie, Beijing (CN)
A0430	<b>Human epidermal growth factor receptor2 overexpression is a significant prognostic biomarker in de novo non-muscle invasive bladder cancer</b> S.J. Kim, Kangwon-Do (KR)
A0431	<b>Immunological changes following blue light cystoscopy with hexaminolevulinate in bladder cancer</b> L. Dyrskjøt, Aarhus (DK)
A0432	<b>The genetic information of non-muscle-invasive bladder cancer associated with recurrence</b>
<b>11:38 - 11:50</b>	<b>Discussion</b>
	<b>Genomics, subtypes and markers</b>
A0433	<b>Identification of endothelial-related molecular subtypes for bladder cancer patients based on single-cell and bulk RNA sequencing data</b> S. Xu, Chengdu (CN)
A0434	<b>Correlation between androgen and estrogen receptor expression and clinicopathologic features in carcinoma urinary bladder</b> N. Shrivastava, Jodhpur (IN)
A0435	<b>Genomic profiling of urothelial carcinoma in situ of bladder</b>
A0436	<b>Preliminary results of germline whole genome sequencing of 119 extremely early age of onset bladder cancer patients in the MOTIEF study</b> S.H. Vermeulen, Nijmegen (NL)
<b>11:58 - 12:08</b>	<b>Discussion</b>
<b>12:08 - 12:15</b>	<b>Closing remarks</b>

## Complex retroperitoneal surgery

Video Session 09

**Sunday 12 March**  
**14:00 - 15:30**

**Location** Pink Area, Coral 7

**Chairs** A. Heidenreich, Cologne (DE)  
H.P. Beerlage, Rosmalen (NL)  
D. Nicol, London (GB)

**14:00 - 14:03**

**Introduction**

V064

**3D Augmented reality for neoplastic venous thrombus identification during robotic radical nephrectomy for RCC: A new tool for intraoperative guidance**

D. Amparore, Turin (IT)

V065

**Right radical nephrectomy with level IV thrombus by combined 3D laparoscopic and mini-thoracotomy approach**

I. Andras, Cluj- napoca (RO)

V066

**Nutcracker syndrome: Combined reno-splenic shunt**

V067

**Robotic left renal vein transposition for the treatment of Nutcracker syndrome**

N. Pereira Rodriguez, Mostoles, Madrid (ES)

V068

**Robot-assisted surgery for retrocaval ureter: a single center experience**

M. Lo Re, Florence (IT)

V069

**The 'Belly-Up' technique for pericaval nodal dissection in RPLND - Saving caval resections and reconstructions**

V070

**Robot-assisted retroperitoneal lymph node dissection and vena cava thrombectomy for residual masses of germ cell tumor**

A. Khaddad, Bordeaux (FR)

**15:21 - 15:26**

**Closing remarks**



## Urethral strictures: Research, diagnosis and treatment

Abstract Session 24

**Sunday 12 March**  
**10:45 - 12:15**

**Location** Pink Area, Coral 1  
**Chairs** To be confirmed  
F.E. Martins, Lisbon (PT)  
To be confirmed

**10:45 - 10:48**

**Introduction**

**A0437** **Studying the learning curve of urethral reconstruction based on the experience of one urethral surgeon**

**A0438** **Trends in Adult Hypospadias: Presentation, Treatment and Patient Experience Including Marital Status**  
C. Fogaing, Montreal (CA)

**A0439** **Uroflowmetry is viable surrogate for cystoscopy in evaluation of anatomical success following urethroplasty**  
T. Yanagi, Hyogo (JP)

**A0440** **What's the best bowel segment in enterourethroplasty for the salvage of bulbo-membranous stricture? Anatomical study of fresh corpses**  
S. Kerroumi, Oran (DZ)

**A0441** **Impact on postoperative oral morbidity and mid-term efficacy of anterior urethroplasty using an autologous tissue-engineered oral mucosa graft (MukoCell®) versus native oral mucosa graft**  
L. Karapanos, Cologne (DE)

**10:58 - 11:08**

**Discussion**

**A0442** **Characteristics of female urethral stricture**  
E. Day, Bishopton (GB)

**A0443** **Female urethral strictures: A multicentric study focusing on etiology, diagnosis and treatment**  
M. Waterloos, Gent (BE)

**A0444** **Dorsal on-lay versus ventral in-lay urethroplasty: Impact of surgical approach on the long-term sexual function and quality of life in female urethral stricture disease**  
G. Rohith, Bhubaneswar (IN)

**11:14 - 11:19**

**Discussion**

**A0445** **The management of adult male anterior urethral strictures in low and middle income countries. results from a pan-african survey on male anterior urethral stricture management among urologists (PASUSM)**  
A. Mellouki, Nice (FR)

**A0446** **The optimal management after ventral onlay buccal mucosa graft urethroplasty failure**  
M. Bandini, Milan (IT)

## Scientific Programme - EAU23 Milan

---

A0447	<b>Proximal urethrostomy (PU) versus urethroplasty (U) for complex urethral strictures (CUS)</b> N. Rahav, Jerusalem (IL)
A0448	<b>Open vs. robotic-assisted reconstruction in vesicourethral anastomotic stenosis</b>
A0449	<b>Vesico-urethral anastomosis stenosis after robotic radical prostatectomy: Descriptive analysis and risk factors</b> J. Sureda Riera, Barcelona (ES)
<b>11:29 - 11:38</b>	<b>Discussion</b>
A0450	<b>Redo panurethral stricture: A challenge in reconstructive urology</b>
A0451	<b>To drain or not after urethroplasty?</b>
A0452	<b>The role of multi-stage urethroplasty in Lichen Sclerosus penile urethral strictures</b> A. Gobbo, Padova (IT)
A0453	<b>Extended long-term follow-up of salvage direct vision internal urethrotomy after failed buccal mucosal graft urethroplasty</b> D.K. Filipas, Hamburg (DE)
A0454	<b>Long-term outcomes of ventral onlay buccal mucosa graft urethroplasty</b> M. Borisenkov, Hof (DE)
A0455	<b>Outcomes of urethroplasty (UP), 10 years after surgery</b> S.S. Cohen, Jerusalem (IL)
A0456	<b>4 Years of the Optilume® Drug Coated Balloon for recurrent anterior urethral strictures: A summary of ROBUST I, II and III</b> J. DeLong, Fairfax (US)
A0457	<b>Self-expandable, metallic, PTFA-covered urethral stents. Complication report and outcomes from the largest multicenter series</b> A. Gobbo, Padova (IT)
<b>11:54 - 12:09</b>	<b>Discussion</b>
<b>12:09 - 12:15</b>	<b>Closing remarks</b>

---

## Locally advanced kidney cancer

Abstract Session 25

**Sunday 12 March**  
**10:45 - 12:15**

**Location** Pink Area, Coral 2  
**Chairs** To be confirmed  
To be confirmed  
C. Beisland, Bergen (NO)

**10:45 - 10:48**

**Introduction**

**Lymph node relevance on high-risk RCC**

**A0458** **Lymphovascular invasion predicts lymph node involvement in patients with renal cell carcinoma**

**A0459** **Impact of number of positive lymph nodes on prognostic stratification in renal cell carcinoma: Analysis of the National Cancer Database**

**10:52 - 10:57**

**Discussion**

**Oncological outcomes prediction on high-risk RCC**

**A0460** **Cancer-specific mortality free survival rates in non-metastatic non-clear cell renal carcinoma patients at intermediate/high risk of recurrence**  
M.L. Piccinelli, Milan (IT)

**A0461** **Impact of preoperative C-reactive protein level on oncological outcomes after nephrectomy in patients with high-risk renal cell carcinoma: An analysis from the International Marker Consortium for Renal Cancer (INMARC) cohort**

**A0462** **Liquid biopsy can be the future detection method to predict recurrences in patients with renal cell carcinoma; use of suPARnostic in renal cell carcinoma**

**A0463** **Should adjuvant therapy be considered for positive surgical margins in renal cell carcinoma: A stage-based analysis of impact of positive surgical margins on survival outcomes using the inmarc registry**

**A0464** **Long-term prognosis and risk stratification for adult mit family translocation renal cell carcinoma**  
C. Cao, Beijing (CN)

**A0465** **Concordance of renal sinus or calyces invasion between preoperative imaging and final pathology after surgery for kidney cancer**

**A0466** **Partial vs. radical nephrectomy to treat pT3a renal cancers: Propensity score matched analysis of a single center series**  
A. Brasseti, Rome (IT)

**A0467** **The utility of Computed Tomography scans in predicting perinephric fat invasion of renal cell carcinoma**  
K. Wang, Singapore (SG)

## Scientific Programme - EAU23 Milan

---

A0468	<b>The effect of indeterminate pathologic margins on survival after surgery for renal cell carcinoma</b> D.K. Filipas, Hamburg (DE)
A0469	<b>Renal parenchymal infiltration or micronodular spread in non-metastatic clear cell renal cell carcinoma: prognostic impact and genomic backgrounds</b> H. Tanaka, Tokyo (JP)
<b>11:17 - 11:37</b>	<b>Discussion</b>
	<b>Truth about adjuvant therapy trials on high-risk RCC</b>
A0470	<b>Adjuvant therapy in renal-cell carcinoma: New drugs, old problems</b> F. Portugal Gaspar, Lisboa (PT)
A0471	<b>Defining the most useful intermediate endpoint for overall survival in intermediate and high-risk clear cell carcinoma</b>
A0472	<b>Artificial intelligence to predict recurrence after surgical resection of non-metastatic renal cell carcinoma: Is it any better than conventional systems?</b>
A0473	<b>Development of an individual postoperative prediction model for kidney cancer recurrence using machine learning (UroCCR study 120)</b> G. Margue, Bordeaux (FR)
A0474	<b>Is adjuvant immunotherapy worth for all patients with clear-cell renal cell carcinoma at high risk of recurrence?</b> R. Campi, Florence (IT)
A0475	<b>Utility of adjuvant immunotherapy in high-risk non-metastatic renal cell carcinoma: A real-world experience using national cancer database analysis</b> H. Garg, San Antonio (US)
A0476	<b>Refining the indication for adjuvant pembrolizumab in patients with clear cell renal cell carcinoma at high risk of recurrence using a risk-adapted approach: a contemporary multicentre study</b> R. Campi, Florence (IT)
<b>11:51 - 12:04</b>	<b>Discussion</b>
	<b>Quality of life assessment for recurrence</b>
A0477	<b>Patients experience with recurrence of renal cell carcinoma</b> S. Rodler, Munich (DE)
<b>12:06 - 12:08</b>	<b>Discussion</b>
<b>12:08 - 12:15</b>	<b>Closing remarks</b>

---

## Functional outcome after prostatectomy: Challenges and solutions

Abstract Session 21

**Sunday 12 March**  
**10:45 - 12:15**

**Location** Yellow Area, Brown 2  
**Chairs** To be confirmed  
R.J. Karnes, Rochester (US)  
R. Sosnowski, Warsaw (PL)

**10:45 - 10:48**

**Introduction**

**New technologies to improve nerve sparing**

**A0478** **The application of artificial intelligence guided 3D automatic augmented-reality biopsy allows to improve the oncological safety of the nerve sparing phase during robotic prostatectomy**  
G. Volpi, TORINO (IT)

**A0479** **AURORA a 3D model guided nerve sparing technique in robotic radical prostatectomy**  
C. Engesser, Basel (CH)

**A0480** **Three-dimensional prostate model use and augmented reality guided frozen section analysis during robot-assisted radical prostatectomy**  
S. Luzzago, Brescia (IT)

**A0481** **SEPERA – a novel artificial intelligence-based side-specific extra-prostatic extension risk assessment tool for patients undergoing radical prostatectomy**  
J. Kwong, Toronto (CA)

**A0482** **Intraoperative microPET/CT imaging for PSMA-positive cancer foci in radical prostatectomy – feasibility study**  
C. Darr, Essen (DE)

**10:58 - 11:08**

**Discussion**

**Intraoperative evaluation**

**A0483** **Intraoperative angiography of the neurovascular bundle improves anatomical dissection during robot-assisted radical prostatectomy Initial clinical experience**  
N. Amara, Dunkerque (FR)

**A0484** **Nerve-Sparing Radical Prostatectomy (NSRP) using the NeuroSAFE technique is oncologically safe: results after 20 years of experience**  
F. Ambrosini, Veduggio (IT)

**A0485** **Can intraoperative nerve monitoring improve functional outcomes after unilateral- or non-nerve-sparing robot-assisted radical prostatectomy – a randomized clinical trial**  
A.B Nolsøe, Herlev (DK)

**A0486** **Grading of nerve sparing (NS) and association with sexual function (SF) after radical prostatectomy (RP)**  
V. Berge, Oslo (NO)

11:16 - 11:24

Discussion

Surgical experience

A0487

**Robot-assisted versus open radical prostatectomy: outcomes of highly experienced surgeons for both approaches**

F. Ambrosini, Veduggio (IT)

A0488

**A novel robot-assisted radical prostatectomy proficiency score to assess surgical quality and evolution of learning curve: A multicentric European study**

U. Anceschi, Rome (IT)

11:28 - 11:34

Discussion

Management of the urethral sphincter

A0489

**Self-removal of catheter after robot assisted radical prostatectomy – saving the planet one catheter at a time**

D.D. Carbin Joseph, Woking (GB)

A0490

**Membranous urethral length on magnetic resonance tomography prior to radical prostatectomy as a proxy for functional urethral length from urethral pressure profile**

K. Koss Modig, Halmstad (SE)

A0491

**Association between age at surgery and urinary continence recovery after Retzius-sparing robot-assisted radical prostatectomy**

P. Dell'Oglio, Milan (IT)

A0492

**Retzius-sparing robot-assisted radical prostatectomy after previous trans-urethral resection of the prostate: Assessment of functional and oncological outcomes**

S. Tappero, Genova (IT)

A0493

**The effect of protected urethra length on continence and oncological results in patients who have radical prostatectomy with the urethra-sparing method**

A. Unsal, Ankara (TR)

11:44 - 11:54

Discussion

Long term outcome and perception

A0494

**Impact of a structured rehabilitation program on the functional outcomes of patients undergoing robot-assisted radical prostatectomy: A single tertiary-care center experience.**

P.P. Avolio, Pieve Emanuele (IT)

A0495

**Impacts on functional and oncological outcomes of robotic-assisted radical prostatectomy 10 years after the taskforce recommendations against PSA screening**

M. Covas Moschovas, Celebration (US)

A0496

**A comprehensive overview of patient reported outcomes: Results from the PIONEER consortium**

S. Remmers, Rotterdam (NL)

**A0497**                      **Prevalence and determinants of decision regret in long-term prostate cancer survivors following radical prostatectomy**  
L Lunger, Munich (DE)

---

**12:02 - 12:10**                      **Discussion**

---

**12:10 - 12:15**                      **Closing remarks**

## How can we improve diagnosis, staging and treatment of upper tract urothelial cancer?

Abstract Session 28

**Sunday 12 March**  
**10:45 - 12:15**

**Location** Pink Area, Coral 6  
**Chairs** M. Moschini, Milan (IT)  
To be confirmed  
To be confirmed

**10:45 - 10:48**

**Introduction**

**Diagnosis**

- A0498** **Radiomics analysis using dynamic computed tomography for preoperative risk stratification in upper urinary tract urothelial carcinoma**  
H. Kaneko, Tokyo (JP)
- A0499** **The role of imaging for detection of synchronous upper urinary tract urothelial carcinoma and non-muscle-invasive bladder cancer**  
M. Olivieri, Genève (CH)
- A0500** **Diagnostic value of xpert® bc detection, bladder epicheck®, urovysion® fish and cytology in the detection of upper urinary tract urothelial carcinoma**  
C. D'Elia, Bolzano (IT)
- A0501** **DNA methylation assay UriFind® enables non-invasive and convenient detection of upper tract urothelial carcinoma in a large multicentric cohort**  
C. Xu, Guangzhou (CN)
- A0502** **Genetic aberrations identified in focal barbotages– a complementary diagnostic tool in upper tract urothelial carcinoma (UTUC)**  
T. Axelsson, Stockholm (SE)
- A0503** **Upper tract urothelial carcinoma in patients with DNA mismatch repair genes mutations. Clinicopathologic characteristics, management, and recurrence patterns**  
E. Carbonell, Barcelona (ES)
- 11:00 - 11:12** **Discussion**
- Endoscopic treatment**
- A0504** **Second-look ureteroscopy scheduling for upper tract urothelial carcinoma: Do we need to rush?**  
G. Basile, Milan (IT)
- A0505** **The implementation of systematic biopsies in the endoscopic management of upper tract urothelial cancer**  
A. Gallioli, Barcelona (ES)
- A0506** **Preoperative upper tract invasive diagnostic modalities are associated with intravesical recurrence following surgery for upper tract urothelial carcinoma: A population-based study**  
J. Bobjer, Malmö (SE)



## Scientific Programme - EAU23 Milan

---

A0507	<b>Holmium:YAG versus Thulium:YAG laser in endoscopic ablation of upper tract urothelial carcinoma: A comparison on perioperative outcomes and short-term follow-up</b> E. Morini, Parma (IT)
A0508	<b>Preoperative nomogram integrating determinants of endoscopic management in upper urinary tract carcinoma</b>
A0509	<b>Development and validation of the Scottish MUO Score to predict short overall survival and augment decision-making in patients with malignant ureteric obstruction</b> J.P. Blackmur, Edinburgh (GB)
<b>11:24 - 11:38</b>	<b>Discussion</b>
	<b>Adjuvant treatment</b>
A0510	<b>Effect of adjuvant therapy on non-metastatic high risk upper urothelial carcinoma after radical nephroureterectomy: a single-center retrospective analysis</b> Q. Lu, Nanjing (CN)
A0511	<b>A 6-month maintenance schedule of intravesical mitomycin C after radical nephroureterectomy for upper tract urothelial carcinoma for the prevention of intravesical recurrence: A retrospective, single center study</b>
A0512	<b>Testing the external validity of the pout III trial (adjuvant platinum-based chemotherapy in upper tract urothelial carcinoma) in a North American cohort</b> N. Corsi, Detroit (US)
A0513	<b>Role of immune checkpoint inhibitors in non-extirpative treatment of high-grade upper tract urothelial carcinoma. Single referral center experience</b>
<b>11:46 - 11:53</b>	<b>Discussion</b>
	<b>Radical surgery</b>
A0514	<b>Segmental resection for ureter urothelial carcinoma is safe as radical nephroureterectomy</b>
A0515	<b>Inpatient outcomes of radical nephroureterectomy (NU) for upper tract urothelial cancer (UTUC), with trends in utilization and impact of robotic surgery – National Inpatient Sample (NIS) analysis</b> F. Abdollah, Detroit (US)
A0516	<b>Comparing oncological and perioperative outcomes of open versus laparoscopic versus robotic radical nephroureterectomy for the treatment of upper tract urothelial carcinoma: A multicenter, multinational, propensity score-matched analysis</b> N.C. Grossmann, Zürich (CH)
A0517	<b>Role of lymph node dissection during minimally-invasive nephroureterectomy for non-metastatic upper urinary tract urothelial carcinoma</b> A. Brassetti, Rome (IT)
<b>12:01 - 12:08</b>	<b>Discussion</b>
<b>12:08 - 12:15</b>	<b>Closing remarks</b>

---

## Clinical trials in progress

Abstract Session 29

**Sunday 12 March**  
**10:45 - 12:15**

**Location** Blue Area, Room 1  
**Chairs** A. Morgans, Boston (US)  
G. Niegisch, Düsseldorf (DE)  
J.L. Boormans, Rotterdam (NL)

**10:45 - 10:48**

**Introduction**

**Trial design and logistics**

- A0518** **KITTU: Artificial intelligence supported clinical decisions in uro-oncology – an interdisciplinary study**  
G. Duwe, Mainz (DE)
- A0519** **Novel trial designs in localised prostate cancer: Pilot phase results from the prostate pathway embedded comparative trial (ip3-prospect)**
- Urothelial cancer trials**
- A0520** **89zirconium-labelled girentuximab (89zr-tlx250) pet in urothelial cancer patients (zipup) – a phase i trial of a novel staging modality for urothelial carcinoma**  
D. Hayne, East Fremantle (AU)
- A0521** **Adding Mitomycin to BCG as adjuvant intravesical therapy for high-risk, non-muscle-invasive -bladder cancer: a randomised phase 3 trial: The BCG+MM Study (ANZUP1301)**  
D. Hayne, East Fremantle (AU)
- A0522** **Pembrolizumab with favezelimab or vibostolimab for patients with high-risk (HR) bacillus Calmette-Guérin (BCG)-unresponsive non-muscle-invasive bladder cancer (NMIBC): Phase 2 KEYNOTE-057 cohort C**  
A. Necchi, Milan (IT)
- A0523** **ALTER-UC-007: A prospective phase 2 study of anlotinib with gemcitabine and cisplatin or anlotinib with penpulimab as perioperative treatment for patients with muscle-invasive urothelial carcinoma (MIUC)**
- A0524** **Trial in progress (TiP) - neoadjuvant immunotherapy of visugromab (anti-GDF-15; CTL-002) in combination with nivolumab in muscle-invasive bladder cancer (MIBC)**  
A. Necchi, Milan (IT)
- A0525** **Perioperative pembrolizumab or pembrolizumab plus enfortumab vedotin (EV) for muscle-invasive bladder cancer (MIBC): Phase 3 KEYNOTE-905/EV-303**  
A. Necchi, Milan (IT)

**11:04 - 11:24**

**Discussion**

**Renal and testis tumour trials**

---

A0526	<b>Comparison of fdg pet-ct with conventional imaging in the staging of high-risk renal cancers and transitional cell carcinoma of bladder (COPPER-T): A prospective randomized controlled trial – trial protocol and initial short-term analysis of results.</b> R. Jena, Lucknow (IN)
A0527	<b>An exploratory prospective clinical study on efficacy and safety of anlotinib combined with sintilimab as first-line treatment in patients with advanced non-clear cell renal cell carcinoma</b>
A0528	<b>PRIMETEST II – trial to test new predictors of recurrence in CS II A/B seminoma patients treated with primary robot-assisted retroperitoneal lymph node dissection</b> Y. Che, Düsseldorf (DE)
<b>11:30 - 11:42</b>	<b>Discussion</b>
	<b>Prostate cancer trials incl. BPH trial</b> To be confirmed
A0529	<b>Prostate cancer prevention clinic for men with risk of familial prostate cancer (profam-risk)</b> A.H. Rabe, Düsseldorf (DE)
A0530	<b>Predicting treatment failure after radical prostatectomy by circulating tumour cells status (C-ProMeta-1). A single site prospective cohort: A study protocol</b> T. Al-Hammouri, Harrow (GB)
A0531	<b>CYCLONE 3: A Phase 3, randomized, double-blind, placebo-controlled study of abemaciclib in combination with abiraterone plus prednisone in men with high-risk metastatic hormone-sensitive prostate cancer (mHSPC)</b> J.M. Piulats, Barcelona (ES)
A0532	<b>Ongoing phase II study of EZH2 inhibitor CPI-0209 in patients with advanced solid tumors including metastatic castration-resistant prostate cancer (mCRPC) or hematologic malignancies</b>
A0533	<b>Non-inferiority, randomized, open-label clinical trial on the efficacy of transurethral microwave thermotherapy compared to prostatic artery embolisation in reducing severe lower urinary tract symptoms in men with benign prostatic hyperplasia</b> A. Kristensen-Alvarez, København N (DK)
A0534	<b>Comparison of biparametric and multiparametric magnetic resonance imaging for prostate cancer detection: an 8-month update on the PRIME Study (NCT04571840)</b> A. Ng, London (GB)
<b>11:54 - 12:08</b>	<b>Discussion</b>
<b>12:08 - 12:15</b>	<b>Closing remarks</b>

---

## Metastatic urothelial cancer: News in immunotherapy and more

Abstract Session 26

**Sunday 12 March**  
**10:45 - 12:15**

**Location** Pink Area, Coral 3  
**Chairs** To be confirmed  
S. Crabb, Southampton (GB)  
P. Patel, Edgbaston, Birmingham (GB)

**10:45 - 10:48**

**Introduction**

**News in immunotherapy**

- A0535** **The immune-related adverse events paradox in locally advanced or metastatic urothelial cancer patients receiving atezolizumab: Analysis of individual participant data from IMvigor210 and IMvigor211**  
D. Robesti, Milan (IT)
- A0536** **LAG-3/FGL1 axis predicts response to immune checkpoint inhibitors in advanced urothelial carcinoma**
- A0537** **Chronological transition in oncological outcome of second-line treatment in patients with metastatic urothelial cancer after pembrolizumab approval.**  
T. Naiki, Nagoya (JP)
- A0538** **MMP-14 implication in immunoregulation of bladder cancer**  
S. Zhu, Berlin (DE)
- A0539** **Cadherin-11 blockade activates pyroptosis-mediated anti-tumor immunity in bladder cancer**  
T. Hwang, Taipei (TW)
- A0540** **Utility of pre- and post-pembrolizumab (Pembro) Vesical Imaging–Reporting and Data System (VI-RADS) to predict the pathological response in muscle-invasive urothelial bladder cancer (MIBC): An analysis of the PURE-01 cohort**  
D. Raggi, Milan (IT)
- 11:00 - 11:12** **Discussion**
- Novel prognostic and predictive factors**
- A0541** **Loss of membranous NECTIN-4 occurs frequently during metastatic spread of urothelial carcinoma and predicts resistance to enfortumab vedotin**  
N. Klümper, Bonn (DE)
- A0542** **CDH1-mutated clinically advanced urothelial bladder cancer (UBC): A genomic landscape and real-world clinical outcome study (RWCOS)**  
P. Spiess, Tampa (US)
- A0543** **Expression of Nectin-4 in variant histologies of bladder cancer – implications for future trials?**  
S. Rodler, Munich (DE)

---

A0544	<b>Correlation between elevated tissue level of mercury, selenium, vanadium and barium and expression of luminal (GATA3) and basal (CYTOKERATIN5/6) markers in bladder cancer</b> B. Ali-El-Dein, Mansoura (EG)
A0545	<b>Neoadjuvant chemotherapy-induced acute kidney injury is associated with poor oncological outcomes in patients who underwent radical cystectomy: A multicenter retrospective study</b> N. Fujita, Hiroasaki (JP)
11:22 - 11:34	<b>Discussion</b>
	<b>Lymphnode metastases</b>
A0546	<b>UBE2C functions as a potential oncogene by promoting bladder tumor progression and lymphatic metastasis</b>
A0547	<b>Carboplatin induction chemotherapy in clinically lymph node-positive bladder cancer</b> M. von Deimling, Hamburg (DE)
11:38 - 11:44	<b>Discussion</b>
	<b>Treatment strategies in advanced disease</b>
A0548	<b>Efficacy and safety of derazantinib (DZB) in patients with metastatic urothelial carcinoma (mUC) with activating FGFR1/2/3 genetic aberrations (GA): Results from the phase 1b/2 FIDES-02 study</b> A. Necchi, Milan (IT)
A0549	<b>Gemcitabine–cisplatin versus MVAC chemotherapy in urothelial carcinoma: A nationwide cohort study</b> S.Y. Choi, Seoul (KR)
A0550	<b>Real-world outcomes versus clinical trial results for first-line systemic treatment in patients with unresectable stage-IV urothelial carcinoma of the bladder</b>
A0551	<b>End of life care - Preferences of patients with advanced urologic malignancies</b> H. Heers, Marburg (DE)
A0552	<b>The impact of a multidisciplinary team on treatment of patients with bladder cancer</b>
A0553	<b>Impact of systemic treatments on overall survival in metastatic urothelial bladder cancer: A time-trend analysis</b> H. Garg, San Antonio (US)
11:56 - 12:08	<b>Discussion</b>
12:08 - 12:15	<b>Closing remarks</b>

---

## The road to evidence-based European policy on early detection of prostate cancer

Thematic Session

**Sunday 12 March**  
**13:45 - 15:15**

**Location** Yellow Area, eURO Auditorium 1

**Chairs** E-G. Carl, Tornesch (DE)  
A. Stenzl, Tübingen (DE)

### Learning objectives

The mounting evidence for early detection of prostate cancer both from the scientific, patients' and political side is presented by those affected, those faced with the dilemma of vanishing treatment possibilities, and policy makers.

**13:45 - 13:50**

### Introduction: Why policy matters

A. Stenzl, Tübingen (DE)

**13:50 - 14:00**

### EAU journey on advocacy on prostate cancer and building alliances

H. Van Poppel, Leuven (BE)

**14:00 - 14:10**

### The scientific evidence review of the EU cancer screening recommendations

H.J. De Koning, Rotterdam (NL)

**14:10 - 14:20**

### Working with countries to identify and tackle barriers and enablers of cancer screening

P. Basu, Lyon (FR)

**14:20 - 14:30**

### Experiences from the Swedish population based organised prostate cancer testing programme

O. Bratt, Gothenburg (SE)

**14:30 - 14:40**

### EAU led data initiatives to support evidence based policy making

M.J. Roobol, Rotterdam (NL)

**14:40 - 14:50**

### Towards the delivery of comprehensive cancer centers - what it means for prostate cancer

T. Albreht, Ljubljana (SI)

**14:50 - 15:00**

### Vision from the EU Cancer Mission Board

To be confirmed

**15:00 - 15:10**

### Discussion

**15:10 - 15:15**

### Closing remarks

E-G. Carl, Tornesch (DE)

## EAU Guideline session: Non-neurogenic female LUTS

Thematic Session

**Sunday 12 March**  
**13:45 - 15:15**

**Location** Yellow Area, eURO Auditorium 2  
**Chairs** C. Harding, Newcastle upon Tyne (GB)  
M.A. Perrouin Verbe, Nantes (FR)

### Learning objectives

This session aims to explore the multiple etiologies underlying female voiding dysfunction and detail the current clinical evidence in this topic area. We will initially explore both diagnostics and therapeutics of female voiding dysfunctions with specific emphasis on bladder outlet obstruction, detrusor under activity and detrusor overactivity. In the second part of the session, we will be concentrating on stress urinary incontinence beginning with a series of talks on both the classification and management of mesh complications. This will feed into the section exploring both clinicians and patient's perspectives regarding the range of treatments available for stress urinary incontinence. We will conclude the session with the state-of-the-art lecture on the assessment and management of transgender patients with lower urinary tract symptoms. By the end of this session attendees will have a knowledge of appropriate diagnostics and treatment options for female voiding dysfunction, an appreciation of the range of complications associated with the use of vaginally-inserted mesh, an insight into the similarities and differences from both clinicians and patient's perspectives regarding surgical treatment for stress incontinence and an outline of the most appropriate approach to transgender patients presenting with lower urinary tract symptoms.

13:45 - 13:47

**Welcome and introduction**

13:47 - 14:12

**Female voiding dysfunction**

13:47 - 13:52

**Female bladder outlet obstruction**

M.C. Lapitan, Manila (PH)

13:52 - 13:57

**Detrusor under activity**

S. Arlandis, Valencia (ES)

13:57 - 14:02

**Detrusor over activity**

T. Tarcan, Istanbul (TR)

14:02 - 14:12

**Discussion**

14:12 - 14:42

**MESH Complications**

14:12 - 14:17

**Classification of MESH complications**

H. Hashim, Bristol (GB)

14:17 - 14:22

**Pain management**

R.A.P. Almeida Pinto, Vila Nova de Gaia (PT)

14:22 - 14:27

**Physical therapy**

To be confirmed

14:27 - 14:32

**Surgery**

V. Phé, Paris (FR)

14:32 - 14:42

**Discussion**

14:42 - 15:02

**Debate SUI Surgery: Patient vs. Doctor satisfaction with treatment options**

14:42 - 14:47

**The doctor's perspective**

A.K. Nambiar, Newcastle upon Tyne (GB)

## Scientific Programme - EAU23 Milan

---

14:47 - 14:52

**The patient's perspective**  
M. De Heide, Sprang-Capelle (NL)

14:52 - 15:02

**Discussion**

---

15:02 - 15:12

**State-of-the-art lecture Transgender patients with LUTS: What is needed from the guidelines?**  
To be confirmed

---

15:12 - 15:15

**Closing remarks**



## Advances in Uro-Technology and the road ahead

Meeting of the EAU Section of Uro-Technology (ESUT)

**Sunday 12 March**  
**13:45 - 17:15**

**Location** Pink Area, Coral 3  
**Chair** A.S. Gözen, Heilbronn (DE)

**13:45 - 13:47**

**Introduction**  
A.S. Gözen, Heilbronn (DE)

**13:47 - 14:47**

**More technology for endoscopic surgery**  
*Moderators* E. Liatsikos, Patras (GR)  
J. Rassweiler, Krems - Stein (AT)

**13:47 - 13:57**

**Auris Monarch platform for advanced endoscopic stone surgery**  
M.M. Desai, Los Angeles (US)

**13:57 - 14:07**

**ILY robotic URS**  
To be confirmed

**14:07 - 14:17**

**Avicenna Roboflex URS robot**  
K. Sarica, Istanbul (TR)

**14:17 - 14:27**

**Virtuoso, mini endoscopic-robotic arms for transurethral surgeries**  
D. Herrell, Nashville (US)

**14:27 - 14:37**

**Aquabeam for robot-assisted transurethral ablation of prostate**  
T. Bach, Hamburg (DE)

**14:37 - 14:47**

**Discussion**

**14:47 - 15:57**

**Imaging and navigation in urology**  
*Moderators* A.S. Gözen, Heilbronn (DE)  
D. Veneziano, New Hyde Park NY (US)

**14:47 - 14:59**

**3D Endoscopy camera systems, what can we expect more?**  
A.S. Gözen, Heilbronn (DE)

**14:59 - 15:11**

**Surgical navigation in 2023, where are we standing?**  
G. Cacciamani, Los Angeles (US)

**15:11 - 15:23**

**Imaging for bladder pathologies during endoscopic operations: What is new?**  
G.M. Kamphuis, Amsterdam (NL)

**15:23 - 15:35**

**Virtual reality and artificial intelligence: Novel pathways in surgical training**  
D. Veneziano, New Hyde Park NY (US)

**15:35 - 15:47**

**Fluorescence imaging in laparoscopic surgery**  
To be confirmed

**15:47 - 15:57**

**Discussion**

**15:57 - 17:13**

**Laparoscopy and new minimal invasive therapy options**  
*Moderators* E. Barret, Paris (FR)  
F. Porpiglia, Turin (IT)  
P.J. Zondervan, Amsterdam (NL)

**15:57 - 16:09**

**Current place of the 3D image reconstruction and 3D models in urology**  
F. Porpiglia, Turin (IT)

**16:09 - 16:20**

**Standardization of digital information in the OR**  
P. Dasgupta, London (GB)

## Scientific Programme - EAU23 Milan

---

16:20 - 16:31

**ESWT and EMTT in and beyond the urology**

J. Rassweiler, Krems - Stein (AT)

16:31 - 16:41

**Current focal therapy options and strategies for renal masses**

E. Barret, Paris (FR)

16:41 - 16:52

**Computed camera arms in laparoscopy theater**

To be confirmed

16:52 - 17:03

**On demand computer-assisted laparoscopic surgery platforms**

K.P. Jünemann, Kiel (DE)

17:03 - 17:13

**Discussion**

---

17:13 - 17:15

**Closing remarks**

A.S. Gözen, Heilbronn (DE)

## Andrology: Risk factors, comorbidities and sexological aspects of male sexual functioning

Abstract Session 31

**Sunday 12 March**  
**14:00 - 15:30**

**Location** Yellow Area, Brown 3  
**Chairs** To be confirmed  
To be confirmed  
To be confirmed

**14:00 - 14:03**

**Introduction**

**Risk factors and comorbidities**

**A0554** **Are bothersome sleep disturbances predictors of severe ED at first visit? Findings from a real-life cross-sectional study**  
A. Bertini, Milan (IT)

**A0555** **Genetically predicted insomnia causally increases the risk of erectile dysfunction**  
Y. Xiong, Chengdu (CN)

**A0556** **Sexuality in men after kidney transplantation**  
F. Zouari, Sfax (TN)

**A0557** **Cancer survivorship in male patients: The importance of involving the andrologist in the real-life world**  
S. Cilio, Naples (IT)

**A0558** **Erectile dysfunction is associated with left ventricular diastolic dysfunction: A systematic review and meta-analysis**  
E. Durukan, Valby (DK)

**A0559** **Can erectile dysfunction severity predict major adverse cardiovascular events in men undergoing dialysis: A prospective cohort study**  
M. Momota, Hiroasaki (JP)

**A0560** **Prevalence of and predictors of unrecognized orgasmic dysfunction in men with new onset erectile dysfunction – findings from a cross-sectional, real-life study**  
S. Cilio, Naples (IT)

**A0561** **Does the seminal microflora differ in patients with premature ejaculation?**  
E. Akkus, Istanbul (TR)

**14:19 - 14:35**

**Discussion**

**Novel diagnostics**

**A0562** **Establishing the role of shear wave elastography in differentiating vasculogenic versus non-vasculogenic erectile dysfunction**

**A0563** **Serum elastin derived peptides(EDPS): A novel promising marker for erectile dysfunction severity**  
R.O. Yazar, Istanbul (TR)

## Scientific Programme - EAU23 Milan

---

A0564	<b>Atherosclerosis of the iliac arteries for the prediction of erectile dysfunction in men undergoing abdominal ct scan</b> F.A. Schmid, Zurich (CH)
<b>14:41 - 14:47</b>	<b>Discussion</b>
	<b>Premature ejaculation and sexology</b>
A0565	<b>Compliance to oral treatment for premature ejaculation – data from a single academic center</b> P. Capogrosso, Milan (IT)
A0566	<b>Depressive symptom rather than somatic symptoms is predictive of premature ejaculation in young Taiwanese males</b> W-C. Liao, Taipei (TW)
A0567	<b>The clinical profile of men with premature ejaculation at presentation has changed over the last fifteen years: analysis from a longitudinal study</b> L. Boeri, Milan (IT)
A0568	<b>Long term follow-up outcomes of pelvic floor rehabilitation in subjects suffering from lifelong premature ejaculation: Retrospective multicentre study</b>
A0569	<b>Pornography habits and partnered erectile function, Results from a large scale survey</b> G. De Win, Antwerpen (BE)
A0570	<b>Vasectomy is not associated with sexual dysfunctions: Results from the BMH-Study</b> M. Jahnke, Munich (DE)
A0571	<b>Impact of OAB on sexual life and marital relationship of patients with multiple sclerosis</b> F. Gavi, Rome (IT)
A0572	<b>Ablation vaginectomy for genital gender affirmation surgery in individuals assigned female at birth</b> W.G. Lee, London (GB)
A0573	<b>A morphometric analysis of the penis before and after prostaglandin injection: Is shower and grower even a thing ?</b>
<b>15:05 - 15:23</b>	<b>Discussion</b>
<b>15:23 - 15:30</b>	<b>Closing remarks</b>

---

## Minimally invasive treatments in children

Abstract Session 32

**Sunday 12 March**  
**14:00 - 15:30**

**Location** Yellow Area, Amber 3  
**Chairs** A-F. Spinoit, Ghent (BE)  
O. Telli, Istanbul (TR)  
To be confirmed

**14:00 - 14:03**

**Introduction**

- |                      |  |
|----------------------|--|
| A0574                | <b>Comparison of open and robotic-assisted laparoscopic ureteral reimplantation in children with high grade (IV-V) vesicoureteral reflux: A multi-institutional comparative study</b>                            |
| A0575                | <b>Robot-assisted continent urinary diversion in children according to the Mitrofanoff principle: It is safe and feasible even in low-volume centers – a bi-institutional study</b><br>T. Loubersac, Nantes (FR) |
| A0576                | <b>Cumulative sum analysis for the learning curve of robot-assisted laparoscopic ureteral reimplantation surgery in children.</b>  |
| A0577                | <b>Does previous endoscopic subureteric injection (sting) effect the outcomes of robot- assisted laparoscopic ureteral reimplantation surgery (ralur) in children?</b>   |
| A0578                | <b>Treatment of Zinner syndrome with robot-assisted surgery</b><br>A. Govorov, Moscow (RU)   |
| <b>14:13 - 14:25</b> | <b>Discussion</b>  |
| A0579                | <b>Validation of a hands-on porcine bladder model for endoscopic correction of vesicoureteral reflux with bulking agents.</b><br>A-F. Spinoit, Ghent (BE)  |
| A0580                | <b>What to expect on the long-term follow-up of pediatric pyeloplasty?: Critical time intervals and risk factors</b><br>I. Selvi, Istanbul (TR)  |
| A0581                | <b>Quadratus Lumborum Block in ESWL - novel perioperative pain management strategy in pediatric population – prospective study on patients</b><br>A.H. Halinski, Nowa Sól (PL)                                   |
| A0582                | <b>Prognostic factors in the recurrence of urolithiasis in patients with exstrophy-epispadias complex</b>  |
| <b>14:33 - 14:43</b> | <b>Discussion</b>  |
| A0583                | <b>Flexible ureteroscopy versus ESWL for large renal stones (≥1 cm) in pediatrics</b>  |
| A0584                | <b>Superpulsed thulium fiber laser: Clinical results of the first multicenter study of rirs in children</b>  |

## Scientific Programme - EAU23 Milan

---

A0585	<b>Pediatric retrograde intra renal surgery with thulium fibre laser or high power holmium laser, is there a clear winner: An experience in 126 cases</b> D. Castellani, Ancona (IT)
A0586	<b>The utility and safety of ureteral access sheath during retrograde intrarenal surgery in children</b> Y. Tanidir, Istanbul (TR)
A0587	<b>Role of paediatric ureteral access sheath and outcomes related to flexible ureteroscopy and laser stone fragmentation: A systematic review of literature</b> F. Ripa, Southampton (GB)
<b>14:53 - 15:03</b>	<b>Discussion</b>
A0588	<b>Lessons learnt from a multicenter series of 400 cases on the utility of pre-stenting for pediatric retrograde intra renal surgery (RIRS)</b>
A0589	<b>Endoscopic methods of treatment of urolithiasis in children in a short-stay hospital. Experience in the treatment of 383 children</b> A.A. Abdurizaev, Tashkent (UZ)
A0590	<b>Is paediatric 'Dusting and Pop-dusting' with high power laser a new standard of care for treatment of ureteroscopy and lasertripsy (URSL): Prospective outcomes from a university teaching hospital</b>
A0591	<b>Supine mini Percutaneous nephrolithotomy in children.</b> A. Tursunkulov, Tashkent (UZ)
<b>15:11 - 15:23</b>	<b>Discussion</b>
<b>15:23 - 15:30</b>	<b>Closing remarks</b>

## Non-muscle invasive bladder cancer: From diagnosis to follow-up

Abstract Session 35

**Sunday 12 March**  
**14:00 - 15:30**

**Location** Pink Area, Coral 4  
**Chairs** To be confirmed  
To be confirmed  
Y.C.J. Teoh, Hong Kong (CN)

**14:00 - 14:03**

**Introduction**

**A0592** **Artificial intelligence to improve cytology performance in bladder urothelial carcinoma diagnosis: Results of the French, multicenter, prospective VISIOCYT1 trial**

**A0593** **Can cystoscopy artificial intelligence overcome differences between cystoscope products?**  
A. Ikeda, Tsukuba (JP)

**A0594** **Deep learning diagnostics for bladder tumor identification and grade prediction using RGB method**  
K.S. Lee, Seoul (KR)

**A0595** **The Efficacy of Red Channel Enhanced Images for AI Segmentation of Bladder Tumors in Cystoscopic**  
J. Mutaguchi, Fukuoka (JP)

**A0596** **CT-based radiomics for prediction of PD-L1 expression in urothelial carcinoma**  
J.Y. Ku, Busan (KR)

**14:13 - 14:23**

**Discussion**

**A0597** **Multiparametric MRI of the bladder as a predictive factor of histopathology at reTUR in T1GH with presence of detrusor muscle: Could it have a role?**  
A. Giordano, Torino (IT)

**A0598** **Computed tomography urography with corticomedullary phase can exclude urinary bladder cancer with high accuracy**  
S. Abuhasanein, Uddevalla (SE)

**A0599** **Can we avoid second transurethral resection according to VI-RADS score in patients with high-risk non-muscle-invasive bladder cancer?**  
Y. Nakamura, Bunkyo-ku (JP)

**14:29 - 14:35**

**Discussion**

**A0600** **Fourier-transform infrared spectroscopy on urine sample as a new diagnostic tool for urothelial cancer**  
F Taha, Reims (FR)

**A0601** **Liquid biopsy assay to triage patients with high-risk non-muscle-invasive bladder cancer for secondary transurethral resection of bladder tumors**

---

A0602	<b>The impact of variant histologies in patients with pT1 non-muscle invasive bladder cancer undergoing re-staging transurethral resection of bladder tumor</b> F. Claps, Trieste (IT)
A0603	<b>Specific miRNAs characterize invasive potential of bladder cancer and are associated with molecular subtypes</b> S. Rau, Homburg/Saar (DE)
A0604	<b>Performance of the OncoUrine test on the predictive capacity of non-muscle-invasive bladder cancer patients candidate for repeated transurethral resection</b> Q. Lu, Nanjing (CN)
<b>14:45 - 14:55</b>	<b>Discussion</b>
A0605	<b>Association of age with non-muscle-invasive bladder cancer: A biological basis for epidemiological disparities?</b>
A0606	<b>5-alpha reductase inhibitors (5-ARi) with or without alpha-blockers for Benign Prostatic Hyperplasia do not lower the risk of incident Bladder Cancer: an analysis of US insurance claims data</b> F. Del Giudice, Rome (IT)
A0607	<b>T1 substaging is associated with worse oncological outcomes for patients treated with Bacillus Calmette-Guerin or immediate Radical Cystectomy.</b> R. Contieri, Pieve Emanuele (IT)
<b>15:01 - 15:07</b>	<b>Discussion</b>
A0608	<b>External Validation of the IDENTIFY Risk Calculator</b> S. Khadhour, London (GB)
A0609	<b>The value of urinary based rapid tests during follow-up in bladder cancer: BTA stat®, Alere NMP22® BladderChek®, UBC® rapid test, CancerCheck® UBC® rapid VISUAL, and uromonitor® in comparison to cytology</b> T.H. Ecke, Bad Saarow (DE)
A0610	<b>Bifidobacterium species BB_003 enhances antitumor immunity in patients with NMIBC and improve recurrence-free survival</b> K. Min, Gwangju (KR)
A0611	<b>Implementing the Active surveillance (AS) follow-up schedule for low-grade non-muscle-invasive bladder cancer (NMIBC) tumors.</b> R. Contieri, Pieve Emanuele (IT)
<b>15:15 - 15:23</b>	<b>Discussion</b>
<b>15:23 - 15:30</b>	<b>Closing remarks</b>

---



## Multi modal penile cancer management

Video Session 10

**Sunday 12 March**  
**15:45 - 17:15**

**Location** Pink Area, Coral 7  
**Chairs** O.R. Brouwer, Amsterdam (NL)  
A. Muneer, London (GB)  
L. Barreto, Nitra (SK)

**15:45 - 15:47**

**Introduction**

V071 **Indocyanine green enhanced robot-assisted radical inguinal lymph node dissection for penile cancer: Surgical technique and initial experience**  
J. O'Brien, East Melbourne (AU)

V072 **Real-time detection of lymph leak during inguinal lymph node dissection using ICG lymphography guidance based on lower-limb lymphatic pathway studies**

V073 **Indocyanine Green (ICG ) assisted robotic video endoscopic Inguinal Lymph node (R-VEIL) dissection.**

V074 **Robotic inguinal lymph node dissection by lateral approach**  
T. Jindal, Howrah ()

V075 **Reducing comorbidities and improving the quality of life: 3D minimally invasive inguinal lymph node dissection for penile squamous-cell carcinoma management**  
V.H. Schitcu, Cluj Napoca (RO)

V076 **Robotic video endoscopic inguinal lymph node dissection in post chemotherapy penile cancer**

V077 **Subtotal penectomy and perineostomy configuration in locally advanced penile cancer**  
M. Falcone, Torino (IT)

V078 **A video of penile-scrotal reconstruction due to male genital lymphoedema**

**17:11 - 17:15**

**Closing remarks**

## Most common diseases in paediatric urology

Abstract Session 33

**Sunday 12 March**  
**14:00 - 15:30**

**Location** Pink Area, Coral 1  
**Chairs** To be confirmed  
B. Bañuelos Marco, Berlin (DE)  
K. Park, Seoul (KR)

**14:00 - 14:03**

**Introduction**

- A0612** **Is Dorsal Inlay Graft urethroplasty safe and effective fo revisional hypospadias repair in the pediatric age?**
- A0613** **Primary proximal hypospadias repair in in toilet-trained males is associated with a higher risk of post-operative complications and parental dissatisfaction**
- A0614** **Repair of primary proximal hypospadias with severe chordee: Hayashi modified-Koyanagi vs. double face preputial flap. A prospective randomized comparative study**  
M. Omran , Zagazig (EG)
- A0615** **Dorsal shortening versus ventral lengthening procedure for correction of congenital ventral curvature in patients with and without severe hypospadias: A meta-analysis of comparative studies**  
A. Bobrowski, Toronto (CA)
- A0616** **Flap/graft modified Bracka two stages repair vs. original Bracka for proximal penile hypospadias with moderate and severe chordee repair**  
M. Omran , Zagazig (EG)
- 14:13 - 14:28** **Discussion**
- A0617** **Further experience with fluoxetine for refractory primary monosymptomatic nocturnal enuresis in children: A prospective study**  
M. Hussiny, Mansoura (EG)
- A0618** **Predictive factors of full response to desmopressin treatment in children with primary monosymptomatic enuresis nocturna**
- A0619** **Toilet training in children and adolescent with autism spectrum disorder: A novel and successful protocol**  
M. Gubbiotti, Perugia (IT)
- A0620** **Sacral neuromodulation in pediatric age group: Parents acceptability and therapy effectiveness and safety in our Saudi patients**  
M. Banakhar, Jeddah (SA)
- A0621** **Children with meningomyelocele (mmc) with normal initial renal ultrasound, follow up plan.**  
A. El Helaly, Riyadh (SA)

**14:38 - 14:53**

**Discussion**

## Scientific Programme - EAU23 Milan

---

A0622	<b>The role of circumcision in preventing urinary tract infections in children with antenatal hydronephrosis: Systematic review and meta-analysis</b>
A0623	<b>Acute scrotal pain and COVID-19 in a busy acute hospital in the UK</b> M. Ibrahim, Slough (GB)
A0624	<b>Neoadjuvant hormonal treatment in infants with undescended testis – a prospective case control study</b> V. Fiala, Prague (CZ)
A0625	<b>Gender identity in Klinefelter syndrome: A qualitative review</b> C. Jakes, Bermondsey (GB)
A0626	<b>What if they continued the pregnancy? Using prenatal ultrasound findings to predict postnatal outcomes for fetuses with lower urinary tract obstruction (LUTO) to improve counseling and aid in decision making</b> J. Richter, (DE)
A0627	<b>Prenatal exposure to SSRI antidepressants and time of neonatal first void - A case control study</b> Y. Bar-Yosef, Rehovot (IL)
15:05 - 15:23	<b>Discussion</b>
15:23 - 15:30	<b>Closing remarks</b>

---

## Penile Cancer: data-driven innovation in rare cancer management

Abstract Session 34

**Sunday 12 March**  
**14:00 - 15:30**

**Location** Pink Area, Coral 2  
**Chairs** To be confirmed  
To be confirmed  
A.R. Rodriguez, Winston Salem (US)

**14:00 - 14:03**

**Introduction**

**The tumor micro-environment analyzed**

**A0628** **Expression of PDL-1 and tumour associated macrophages in penile cancer: N0 vs. N+**  
F. Azhar, MAnchester (GB)

**A0629** **Infiltrating pattern and prognostic value of tertiary lymphoid structures, and predicting the efficacy of anti-PD-1 combination therapy in patients with penile cancer**  
T. Xue, ()

**A0630** **B cells and IL-10 producing B cells in the tumor microenvironment of penile cancer**  
T. Rafael, Amsterdam (NL)

**A0631** **Generation of patient-derived primary cell cultures and in-vivo models of penile squamous cell carcinoma**  
J. Linxweiler, Homburg/saar (DE)

**A0632** **Preliminary single-cell transcriptomic analysis reveals the heterogeneity of epithelial cell states involved in carcinogenic pathways in HPV+ and HPV- penile squamous cell carcinoma**  
L. Elst, Leuven (BE)

**14:13 - 14:23**

**Discussion**

**Prognostic biomarkers**

**A0633** **The prognostic value of the 8th AJCC anatomic stage/prognostic groups for penile cancer**  
Z. Li, ShenZhen (CN)

**A0634** **P16 status is an independent predictor of overall survival in metastatic penile cancer in a large contemporary cohort**  
J. Churchill, Manchester (GB)

**A0635** **Sarcopenia as a prognostic indicator for the management of patients with penile cancer: The development of a novel prognostic nomogram**  
M. Christodoulidou, London (GB)

**A0636** **Sec62: A promising biomarker in penile cancer**  
J. Linxweiler, Homburg/saar (DE)

## Scientific Programme - EAU23 Milan

---

A0637	<b>Corporal skip metastases in penile squamous cell carcinoma: An unknown and distinct pattern of spread with poor prognosis</b> L. Elst, Leuven (BE)
A0638	<b>Differentiation of prognosis in penile cancer: An international multicenter study</b> J. Mink, Homburg/Saar (DE)
A0639	<b>Does the detection of human papillomavirus (HPV) DNA in penile carcinoma hold prognostic information regarding patient survival?</b> C.A. Moen, (NO)
<b>14:37 - 14:51</b>	<b>Discussion</b>
	<b>Therapeutic advances</b>
A0640	<b>Multi-center evaluation of morbidity and predictors of response to imiquimod treatment for penile intraepithelial neoplasia (PeIN)</b> O. Avitan, Amsterdam (NL)
A0641	<b>Comparing perioperative outcomes after Robot Assisted Video Endoscopic Inguinal Lymphadenectomy (RAVEIL) with Open Inguinal Lymph Node Dissection (O-ILND) using propensity score match analysis</b>
A0642	<b>Comparison of long term functional and oncological outcomes of robot assisted video endoscopic inguinal lymph node dissection between clinically non-palpable and palpable inguinal lymphadenopathy.</b> A. Singh, Robini / Delhi (IN)
A0643	<b>Evaluation and risk factor analysis of complications of inguinal lymph node dissection in a large multi-disciplinary cohort treated at a high-volume centre.</b> M.T.A. Vreeburg, Amsterdam (NL)
<b>15:01 - 15:11</b>	<b>Discussion</b>
	<b>Quality of care and centralization</b>
A0644	<b>The impact of standardization of penile cancer care on quality of care, outcomes, and academic driven centralization in a single eUROGEN referral center</b> A. Pecoraro, Florence (IT)
A0645	<b>Penile cancer care in the Netherlands over three decades: increased incidence, centralisation of care, and overall survival.</b> M.T.A. Vreeburg, Amsterdam (NL)
A0646	<b>Electronic patient-reported outcome measures (ePROMs) - ready for prime time in penile cancer care?</b> O. Adegboye, Salford (GB)
<b>15:17 - 15:23</b>	<b>Discussion</b>
<b>15:23 - 15:30</b>	<b>Closing remarks</b>

---

## Lymph node management during prostatectomy: Modern staging and outcome

Abstract Session 30

**Sunday 12 March**  
**14:00 - 15:30**

**Location** Yellow Area, Brown 2  
**Chairs** To be confirmed  
M.E. Alvarez-Maestro, Madrid (ES)  
F. Abdollah, Detroit (US)

**14:00 - 14:03**

**Introduction**

**Radio guided surgery**

- A0647** Is there a preferential lymph node metastasis pathway in prostate cancer according to the site of the index lesion at multiparametric mri? A topographic mapping study
- A0648** Defining the optimal target-to-background count rate to identify positive lymph nodes in patients undergoing robot-assisted 99mtc-PSMA-radioguided surgery for prostate cancer: A per-region analysis of a prospective, phase II study
- A0649** Skill-assessment during robot-assisted radioguided surgery - using artificial intelligence to extract kinematic metrics of DROP-IN gamma probe use
- 14:09 - 14:17** **Discussion**
- PSMA decision making**
- A0650** Using the Negative predictive value and SUVmax of PSMA PET/CT for avoiding pelvic lymph node dissection with radical prostatectomy
- A0651** Negative PSMA PET/CT can be used to reduce the number of unnecessary PLND in intermediate risk prostate cancer  
R.B. Incesu, Hamburg (DE)
- A0652** Diagnostic accuracy of PSMA PET/CT in primary lymph node staging prior to radical prostatectomy  
R.B. Incesu, Hamburg (DE)
- A0653** Can we rely on available models to identify candidates for extended Pelvic Lymph Node Dissection (ePLND) in men staged with PSMA-PET? External validation of the Briganti nomograms and development of a novel tool to identify optimal candidates for ePLND
- A0654** Identifying the optimal candidates for a super-extended staging pelvic lymph-node dissection in prostate cancer patients treated in the PET-PSMA era. Results from a multi-institutional series

**14:27 - 14:41**

**Discussion**

**Complications and peritoneal flap**

---

A0655	<b>Super extended pelvic lymph node dissection during robot-assisted radical prostatectomy: Doing more good than harm?</b> B. Israël, Nijmegen (NL)
A0656	<b>A randomised controlled adaptive design phase III trial comparing a peritoneal flap versus no flap for lymphocele prevention after robotic-assisted radical prostatectomy with pelvic lymph node dissection: The PELYCAN study</b> M. Neuberger, Mannheim (DE)
A0657	<b>Impact of peritoneal bladder flap on the risk of lymphoceles after robotic radical prostatectomy: Results of a prospective controlled trial</b> R.M. Pose, Hamburg (DE)
A0658	<b>The effect of peritoneal flap fixation on postoperative lymphocele formation in robot-assisted laparoscopic radical prostatectomy</b> A.S. Gözen, Heilbronn (DE)
<b>14:49 - 14:59</b>	<b>Discussion</b>
	<b>Long term outcome</b>
A0659	<b>Which men with cN1 prostate cancer at PSMA PET/CT represent the ideal candidate for radical prostatectomy? Development of a novel risk stratification tool for individualized approaches based on a large, multi-institutional series</b>
A0660	<b>The impact of pelvic lymph node dissection at the time of radical prostatectomy on long-term prostate cancer outcomes</b>
A0661	<b>Does lymph node dissection improve the prognosis of patients undergoing radical prostatectomy? Results of the MICAN study</b> K. Tada, Matsuyama (JP)
A0662	<b>Nodal tumor burden provides independent predictive value for biochemical recurrence in patients with node-positive prostate cancer after definitive surgery</b> M. Yashi, Tochigi (JP)
A0663	<b>Predictive factors of disease recurrence after radical prostatectomy in pN1 prostate cancer patients</b> Y. Ahallal, Meknes (MA)
<b>15:09 - 15:23</b>	<b>Discussion</b>
<b>15:23 - 15:30</b>	<b>Closing remarks</b>

---

## Retropubic radical prostatectomy: Tips, tricks and pitfalls

ESU Course 35

Sunday 12 March  
14:30 - 17:30

**Location** Pink Area, ESU 1

**Chair** G.N. Thalmann, Bern (CH)

### Learning objectives

In many parts of Europe, open retropubic radical prostatectomy is still the gold standard for treating localised prostate cancer. The competition with radiotherapy and novel techniques like cryosurgery and HIFU, should encourage urologists to optimally perform the surgical resection.

This teaching course is a must for the elder resident and the younger urologist but well trained urologists who do not treat many patients with localised prostate cancer, will benefit.

### Introduction

G.N. Thalmann, Bern (CH)

### Surgical anatomy

I. Varkarakis, Athens (GR)

### Step by step radical retropubic prostatectomy

G.N. Thalmann, Bern (CH)

### Tips, tricks and pitfalls

I. Varkarakis, Athens (GR)

### Treatment of complications

G.N. Thalmann, Bern (CH)

### Discussion and interaction

I. Varkarakis, Athens (GR)



## All about the current BPO surgical therapy

ESU Course 36

**Sunday 12 March**  
**14:30 - 17:30**

**Location** Pink Area, ESU 2  
**Chair** T.R.W. Herrmann, Frauenfeld (CH)

**Surgical treatment of BPO: Current EAU guidelines.**  
S. Gravas, Nicosia (CY)

**What (not) to know about lasers for BPO treatment?**  
T.R.W. Herrmann, Frauenfeld (CH)

**Is there still a role for TUIP and TURP?**  
S. Gravas, Larissa (GR)

**Endoscopic Enucleation of the Prostate: Surgical principles & outcomes**  
T.R.W. Herrmann, Frauenfeld (CH)

**Defining the role of laparoscopic and robotic surgery in BPO surgery**  
N. Barber, Camberley (GB)

**Ejaculation-preserving techniques: TURP & EEP vs. MIST-techniques**  
T.R.W. Herrmann, Frauenfeld (CH)

**Minimally invasive surgical (ablative) techniques (Rezum & Aquablation)**  
N. Barber, Camberley (GB)

**Minimally invasive surgical (non-ablative) techniques (i-Tind, Urolift, PAE)**  
S. Gravas, Nicosia (CY)

**Interactive case discussions**

N. Barber, Camberley (GB)

S. Gravas, Nicosia (CY)

T.R.W. Herrmann, Frauenfeld (CH)

## Lymphadenectomy in urological malignancies

ESU Course 37

Sunday 12 March  
14:30 - 17:30

**Location** Pink Area, ESU 3

**Chair** A. Mattei, Luzern (CH)

### Learning objectives

Mostly, in case of tumour surgery, a loco-regional lymph node (LND) dissection is also indicated.

With the introduction of minimal invasive surgery the LND often seems to have lost the attention of the surgeons and has been practiced in fewer cases and/or less extensively.

Throughout our presentation we will corroborate the indications when a LND has to be performed, the templates, the techniques using different approaches and the oncological as well as functional outcomes.

After attending this course, participants should be able to:

- Know the indication when to perform LND during surgery for urological malignancies.
- Apply the most modern imaging concepts for the preoperative lymph node staging.
- Have solid knowledge about the templates that have to be removed.
- Be informed concerning the oncological and functional results of lymph node dissection as well as complications.

### Welcome and introduction

A. Mattei, Luzern (CH)

### Penile cancer

U. Capitanio, Milan (IT)

### Prostate cancer

A. Mattei, Luzern (CH)

### Urothelial cancer

A. Mattei, Luzern (CH)

### Renal cancer

U. Capitanio, Milan (IT)

### Testicular cancer

To be confirmed

**Renal transplantation: Technical aspects, diagnosis and management of early and late urological complications**

ESU Course 38

**Sunday 12 March  
14:30 - 17:30**

**Location**

Pink Area, ESU 4

**Learning objectives**

## Office management of male sexual dysfunction

ESU Course 39

**Sunday 12 March**  
**14:30 - 17:30**

### **Location**

Pink Area, ESU 5

### **Learning objectives**

The course is aimed at providing practical advice on how to diagnose and treat a patient with premature ejaculation or ED. It will allow:

- An up-to-date understanding of the aetiology of ED and EP.
- An adequate work-up enabling an individually adopted regimen.
- Currently available treatment options as topical and oral drugs, testosterone and devices.
- Post-prostatectomy ED with various approaches.

## Practical management of non-muscle-invasive bladder cancer (NMIBC)

ESU Course 40

**Sunday 12 March**  
**14:30 - 17:30**

**Location**

Pink Area, ESU 6

**Moderator**

J. Palou, Barcelona (ES)

## Advanced course on upper tract laparoscopy: Kidney, ureteropelvic junction (UPJ), ureter and stones

ESU Course 41

Sunday 12 March  
14:30 - 17:30

**Location** Pink Area, ESU 7

**Chair** F. Porpiglia, Turin (IT)

### Learning objectives

Surgery of the kidney by means of laparoscopy is standard of care, and has replaced open surgery to a great extent.

Approach: Transperitoneal, retroperitoneoscopy, posterior, direct through the mesentery of the colon. Each approach has specific advantages also depending on the procedure to be performed.

Procedures: Ablative, reconstruction, stone surgery.

Presentation: Power-point, interactive, videos, tips and tricks, complications.

- For surgery of the kidney, the da Vinci robot is often overkill. Also it is not available everywhere. Therefore standard laparoscopy is still of importance and should be mastered by every endoscopic surgeon.
- Choice of the perfect approach makes the respective surgery easier and safer.
- Standard laparoscopy is greatly facilitated by 3D vision.
- When mastering both laparoscopic surgical skills as well as the surgical concept of the respective procedure complications can either be avoided or managed appropriately.

### Approach: Transperitoneal, retroperitoneoscopy

B. Petrut, Cluj Napoca (RO)

### Kidney: Nephrectomy, management of cysts

M.C. Mir Maresma, Valencia (ES)

### Ureter: Nephroureterectomy, end-to-end anastomosis, replacement

F. Porpiglia, Turin (IT)

### Pyeloplasty: Indication – techniques – problems

F. Porpiglia, Turin (IT)

### Stone surgery

M.C. Mir Maresma, Valencia (ES)

### Complication management

B. Petrut, Cluj Napoca (RO)

### Questions, tips and tricks

M.C. Mir Maresma, Valencia (ES)

F. Porpiglia, Turin (IT)

B. Petrut, Cluj Napoca (RO)

## Joint session of the EAU and the Advanced Prostate Cancer Consensus (APCCC)

Thematic Session

**Sunday 12 March**  
**15:30 - 17:00**

**Location** Yellow Area, eURO Auditorium 1  
**Chairs** S. Gillessen Sommer, Bellinzona (CH)  
B. Tombal, Brussels (BE)

<b>15:30 - 15:32</b>	<b>Introduction and background</b> S. Gillessen Sommer, Bellinzona (CH)
<b>15:32 - 16:31</b>	<b>Metastatic hormone sensitive disease: Change in management by PSMA PET CT?</b>
<b>15:32 - 15:35</b>	<b>Case presentation</b> Patient with high risk localised disease, M0 in conventional imaging but one bone lesion in PSMA PET CT F. Turco, Turin (IT)
<b>15:35 - 15:43</b>	<b>Subtypes of prostate cancer and how they change our management</b> To be confirmed
<b>15:43 - 15:51</b>	<b>Arguments for a surgical approach +/- RT +/- systemic treatment</b> I.M. Van Oort, Nijmegen (NL)
<b>15:51 - 15:59</b>	<b>Arguments for a radiotherapeutic approach +/- systemic treatment</b> T. Zilli, Bellinzona (CH)
<b>15:59 - 16:07</b>	<b>Systemic therapy: What and for how long?</b> To be confirmed
<b>16:07 - 16:15</b>	<b>How to treat a frail and elderly patient in this situation</b> A. Morgans, Boston (US)
<b>16:15 - 16:21</b>	<b>Summary</b> B. Tombal, Brussels (BE)
<b>16:21 - 16:31</b>	<b>Questions and answers</b>
<b>16:31 - 17:00</b>	<b>Important questions for the management of biochemical relapse after RP</b>
<b>16:31 - 16:34</b>	<b>Case presentation</b> Biochemical relapse J. Gómez Rivas, Madrid (ES)
<b>16:34 - 16:42</b>	<b>How early is early salvage or when to start treatment</b> To be confirmed
<b>16:42 - 16:50</b>	<b>Should ADT be added to sRT and what for how long?</b> T. Zilli, Bellinzona (CH)
<b>16:50 - 17:00</b>	<b>Summary, question and answers</b> P. Blanchard, Villejuif (FR)

## Controversies on EAU Guidelines: Prostate, bladder cancer and men's health

Thematic Session

**Sunday 12 March**  
15:30 - 17:00

**Location** Yellow Area, eURO Auditorium 2

**Chairs**  
N. Mottet, Saint-Étienne (FR)  
A. Salonia, Milan (IT)  
J.A. Witjes, Nijmegen (NL)

### Learning objectives

The second debate deals with the best peri-operative treatment for MIBC? The participant will learn what the EAU guidelines recommend for neoadjuvant, adjuvant and combined therapy. Currently neoadjuvant cisplatin based chemotherapy is a strong recommendation, and if that is not given adjuvant chemotherapy in selected patients is recommended, based on the 2022 metanalysis. The role and timing of immunotherapy still has to be determined although adjuvant immunotherapy improves DFS. Also combinations are tested and will become increasingly important in the very near future.

15:30 - 15:59

### Debate Lymph node dissection remains valuable at radical prostatectomy despite PSMA imaging

15:30 - 15:33

#### Introduction

N. Mottet, Saint-Étienne (FR)

15:33 - 15:41

#### Based on nomogram

D. Tilki, Hamburg (DE)

15:41 - 15:49

#### Can be avoided if PSMA is negative

To be confirmed

15:49 - 15:59

#### Discussion: Guideline's perspective

*Discussant*

P. Cornford, Liverpool (GB)

*Panel*

To be confirmed

D. Tilki, Hamburg (DE)

N. Mottet, Saint-Étienne (FR)

15:59 - 16:32

### Debate What's the best peri-operative treatment for MIBC?

15:59 - 16:02

#### Introduction

J.A. Witjes, Nijmegen (NL)

16:02 - 16:07

#### Neo-adjuvant

R. Cathomas, Chur (CH)

16:07 - 16:12

#### Adjuvant

To be confirmed

16:12 - 16:17

#### All-in

A. Lorch, Zürich (CH)

16:17 - 16:32

#### Discussion

*Discussant*

J.A. Witjes, Nijmegen (NL)

*Panel*

R. Cathomas, Chur (CH)

A. Lorch, Zürich (CH)

To be confirmed

16:32 - 16:47

### Debate Does penile size matter?

16:32 - 16:35

#### Introduction

A. Salonia, Milan (IT)



## Scientific Programme - EAU23 Milan

---

16:35 - 16:40

**Yes**

P.S. Kirana, Thessaloniki (GR)

16:40 - 16:45

**No**

D.J. Ralph, London (GB)

16:32 - 16:47

**Discussion**

*Discussant*

A. Salonia, Milan (IT)

*Panel*

P.S. Kirana, Thessaloniki (GR)

D.J. Ralph, London (GB)

## Andrology: Male factor infertility: Novel concepts in conception

Abstract Session 37

**Sunday 12 March**  
**15:45 - 17:15**

**Location** Yellow Area, Brown 3  
**Chairs** To be confirmed  
P. Sangster, London (GB)  
To be confirmed

**15:45 - 15:48**

**Introduction**

**Translational research & risk factors**

A0664

**Klinefelter syndrome testicular organoids: Androgen production and spermatogonia differentiation in vitro**  
G. Galdon, El Ferrol-A Coruña (ES)

A0665

**Human papillomavirus seminal carriage, spermogram abnormalities and male infertility: A french cohort study**  
A. Priam, (FR)

A0667

**The impact of ionising radiation exposure on sperm production: A systematic review and meta analysis**

A0668

**Shorter abstinence period on semen parameters among ejaculated sperm samples: Better or worse? A systematic review and meta-analysis**  
M. Raditya, Jakarta Pusat (ID)

A0669

**Factors associated with progression to azoospermia in infertile men presenting with severe oligozoospermia**  
I-S. Huang, New Taipei (TW)

**16:00 - 16:12**

**Discussion**

**Varicoceles and DNA fragmentation**

A0670

**The definition of idiopathic male infertility should include sperm DNA fragmentation values: findings from a cross-sectional study**  
L. Boeri, Milan (IT)

A0671

**The additional effect of the sperm DNA fragmentation index to predict pregnancy in primary infertile couple undergoing medically assisted reproduction**  
G. Fallara, Milan (IT)

A0672

**Normospermia in primary infertile patients with varicocele: what are we missing?**  
G. Fallara, Milan (IT)

A0673

**Early seminal parameters recovery after varicocelectomy - a study using home-based semen monitoring device LensHooke® X1**  
C-H. Tsai, Taipei (TW)

A0674

**The relationship between varicoceles and iliac vein compression**  
P.T. Chin, Wollongong (AU)

**16:22 - 16:32**

**Discussion**

### Advancing sperm retrieval in NOA

---

A0675	<b>Does Clomiphene citrate administration increase success rate of micro TESE in non-obstructive azoospermic men? A randomized controlled trial</b> S. Abouei, Yazd (IR)
A0676	<b>Does the time from spinal cord injury affect the sperm retrieval rate in testicular sperm extraction?</b> M. Morelli, Milan (IT)
A0677	<b>Available sperm bank laboratory for immediate testicular tissue processing during mTESE. Does it change the course of the operation?</b> A. Hussein, Schaab Village (IL)
A0678	<b>Relevance of sperm origin in Klinefelter patients for ICSI outcome rate: Large single-center experience</b> M.A. Sadighi Gilani, Tehran (IR)
A0679	<b>Does implementing a new protocol for the induction of the spermatogenesis pathway in Klinefelter patients result in improved sperm retrieval?</b> K. Naylor, Welling (GB)
<b>16:42 - 16:52</b>	<b>Discussion</b>
	<b>Male contraception &amp; misc</b>
A0680	<b>Complications of vasectomy: Results from a prospective audit of 94, 000 procedures</b> J. Peacock, Bristol (GB)
A0681	<b>Preliminary results of a first in human clinical trial of ADAM®, a nonhormonal hydrogel-based male contraceptive</b> P. Anderson, Melbourne (AU)
A0682	<b>Fertility preservation and sperm quality in adolescent transgender patients prior to hormonal treatment</b> P. Ralph, Ley Hill (GB)
A0683	<b>Strengths and weaknesses of using Optum Clinformatics Data Mart to study in-vitro fertilization</b>
<b>17:00 - 17:08</b>	<b>Discussion</b>
<b>17:08 - 17:15</b>	<b>Closing remarks</b>

## Storage LUTS/OAB and neurogenic LUTS disorders

Abstract Session 38

**Sunday 12 March**  
**15:45 - 17:15**

**Location** Yellow Area, Amber 3  
**Chairs** J.N. Khastgir, Swansea (GB)  
E. Finazzi Agrò, Rome (IT)  
To be confirmed

**15:45 - 15:48**

**Introduction**

**A0684** **In vivo Crispr-Cas9 targeting matrix metalloproteinase-9 improves bladder voiding in prediabetic female Tally Ho mice**  
P.G. Cammisotto, Montreal (CA)

**A0685** **Inhibition of human detrusor smooth muscle cell growth and modulation of cytoskeletal organization by Immuno-Modulatory Imide Drugs (IMIDs)**

**A0686** **Inhibition of myostatin/Smad pathway signalling in smooth muscle cells**  
D. Eberli, Zürich (CH)

**A0687** **Restoration of bladder function by inhibition of the Ninjurin-1 pathway in rat model of spinal cord injury**

**A0688** **Dihydrotestosterone reduces cholinergic contractions of bladder smooth muscle cells: Novel concepts in the pathogenesis of mixed symptoms in mixed LUTS?**  
M. Hennenberg, Munich (DE)

**15:58 - 16:08**

**Discussion**

**A0689** **Adopting machine vision augmentation to detect detrusor instability in overactive bladder: A frontier of artificial intelligence application in functional urology**

**A0690** **Differences in the urinary microbiome of patients with overactive bladder syndrome with and with-out detrusor overactivity on urodynamics**  
A. Javan Balegh Marand, Maastricht (NL)

**A0691** **Control of neurotrophin secretion by natriuretic peptides in bladder cells in vitro matches urine proteomics from female patients with overactive bladder**  
P.G. Cammisotto, Montreal (CA)

**A0692** **Skin sympathetic nerve activity as a potential biomarker for overactive bladder**  
Y.C. Chen, Kaohsiung (TW)

**16:16 - 16:24**

**Discussion**

**A0693** **Similar artefact susceptibility for water- and air-filled urodynamic systems: Results from a randomized controlled non-inferiority trial**  
M.M.E. Kasten, Schöffland (CH)

**A0694** **Is the pad test reliable for evaluating urinary incontinence ?**  
C. Persu, Bucharest (RO)

**A0695** **Nocturia, does the urologist know best? A survey among general practitioners**  
O.P.J. Vrooman, Emmerich am Rhein (DE)

A0696	<b>Efficacy and safety of low-dose tadalafil compared to tolterodine and placebo in females with overactive bladder symptoms. A prospective double blind controlled study</b> S. Morsy, cairo (EG)
A0697	<b>Mirabegron is more tolerable than solifenacin in Sjogren's syndrome patients with OAB</b> H.X Chen, Taichung (TW)
A0698	<b>The effect of mirabegron on the sexual health of patients with OverActive Bladder (OAB) and sexual dysfunction. A systematic review and meta-analysis</b>
A0699	<b>Impact of diabetes, hypertension, and their combination on basal symptoms and treatment responses in overactive bladder patients</b> M.C. Michel, Mainz (DE)
A0700	<b>Mirabegron in the treatment of neurogenic detrusor overactivity incontinence in patients with Parkinson's disease: Persistence to treatment in a medium-term follow-up</b> A. Giannantoni, Siena (IT)
<b>16:40 - 16:56</b>	<b>Discussion</b>
A0701	<b>Urethral sphincter dysfunction might be an early neurological presentation of central nervous system disorders (minor stroke, Parkinson's disease, early dementia) in aged patients</b> G-R. Ho, Hualien (TW)
A0702	<b>Transcutaneous electrical neurostimulation (TENS) of the tibial nerve for lower urinary tract symptoms secondary to parkinson's syndromes: A multicenter randomized double blind placebo-controlled study</b> X. Gamé, Toulouse (FR)
A0703	<b>Device programming of the rechargeable InterStim Micro sacral neuromodulation device through 12 months in a global post-market study</b> M.A. Perrouin Verbe, Nantes (FR)
<b>17:02 - 17:08</b>	<b>Discussion</b>
<b>17:08 - 17:15</b>	<b>Closing remarks</b>

## Treatment of Non-muscle Invasive Bladder Cancer (NMIBC)

Abstract Session 41

**Sunday 12 March**  
**15:45 - 17:15**

**Location** Pink Area, Coral 4  
**Chairs** To be confirmed  
J. Cresswell, Middlesbrough (GB)  
To be confirmed

**15:45 - 15:48**

**Introduction**

- A0704** **Global variation in early recurrence after TURBT surgery in the RESECT study (NCT05154084): There is significant inter-site variation that is independent of differences in tumour factors**  
K.M. Gallagher, Edinburgh (GB)
- A0705** **En bloc resection versus conventional TURBT for T1HG bladder cancer: A propensity score-matched analysis**  
T. Yanagiswawa, Tokyo (JP)
- A0706** **Clinical impact of detrusor muscle in en bloc resection for T1 bladder cancer**  
T. Yanagiswawa, Tokyo (JP)
- A0707** **Transurethral en bloc resection versus standard resection of bladder tumour: A multi-center randomized trial (EB-StaR Study)**  
Y.C.J. Teoh, Hong Kong (CN)
- 15:56 - 16:04** **Discussion**
- A0708** **Can repeat TURBT in patients presenting with High Grade Ta Urothelial Carcinoma be more nuanced?**  
P. Mariappan, Edinburgh (GB)
- A0709** **Is today still necessary to perform a repeated transurethral resection of the bladder after hexaminolévulinate photodynamic diagnosis-assisted TURB?**
- A0710** **Blue light cystoscopy delays time to recurrence in non-muscle invasive bladder cancer patients treated in a real-world setting**  
S. Daneshmand, Los Angeles (US)
- A0711** **Can experience of blue light cystoscopy improve a surgeon's white light resection? Data from the PHOTO trial**  
P. Gravestock, Newcastle (GB)
- 16:12 - 16:20** **Discussion**
- A0712** **A prospective randomized study comparing short-time with long-time continuous saline bladder irrigation after transurethral resection in non-muscular invasive bladder cancer**  
T. Onishi, Ise (JP)
- A0713** **Prevention of non-muscle-invasive bladder carcinoma recurrence with immediate preoperative instillation of chemotherapy – precave cueto 1802 trial**  
M.B. Alonso Bartolome, Segovia (ES)

---

A0714	<b>Survival analysis of patients with T1LG bladder cancer treated with BCG immunotherapy</b> W. Krajewski, Wrocław (PL)
A0715	<b>Perioperative and oncological outcomes of simultaneous transurethral resection of bladder tumour and prostate: Systematic review and meta-analysis</b> L. Nowak, Wrocław (PL)
<b>16:28 - 16:36</b>	<b>Discussion</b>
A0716	<b>Preliminary Results of First-in-Human Cryotherapy for Non-Muscle Invasive Bladder Cancer</b> A. Hoffman, haifa (IL)
A0717	<b>Prognostic impact of variant histology in bladder cancer: Would early and aggressive treatment shift the paradigm?</b> P. Ramos, Porto (PT)
A0718	<b>Photoactivatable metal organic framework for synergistic ferroptosis and photodynamic therapy using 450 nm laser</b> Y. Chen, Xi'an (CN)
A0719	<b>Outcomes of supervised resident compared to attendings in transurethral resection of bladder cancer: The importance of mentoring</b> P. Diana, Barcelona (ES)
<b>16:44 - 16:52</b>	<b>Discussion</b>
A0720	<b>Clinical validation of the EAU2021 intermediate risk NMIBC definition and implications for adjuvant treatment: A multicenter YAU Urothelial Collaboration</b> M. Rosazza, Torino (IT)
A0721	<b>Adjuvant therapy in intermediate-risk non-muscle-invasive bladder cancer</b> E. Laukhtina, Vienna (AT)
A0722	<b>Bacillus calmette-guerin vs immediate radical cystectomy in eau defined very high-risk non-muscle invasive bladder cancer patients</b> R. Contieri, Pieve Emanuele (IT)
A0723	<b>Sequential intravesical Gemcitabine and Docetaxel as salvage treatment for pretreated high- and very high-risk non-muscle-invasive bladder cancer patients</b> O.M. Pijpers, Rotterdam (NL)
<b>17:00 - 17:08</b>	<b>Discussion</b>
<b>17:08 - 17:15</b>	<b>Closing remarks</b>

---

## Repair of complex fistulae & Award session

Video Session 11

**Sunday 12 March**  
**17:30 - 19:00**

**Location** Pink Area, Coral 4  
**Chairs** J.P.F.A. Heesakkers, Maastricht (NL)  
To be confirmed  
F. Van Der Aa, Leuven (BE)

**17:30 - 17:33**

**Introduction**

V079

**Perineal approach in the management of urorectal fistula**  
A. Marfany Pluchart, Lleida (ES)

V080

**Mid-perineal scrotal flap for the repair of urorectal fistulas: A new technique**  
L. Martínez-Piñeiro , Madrid (ES)

V081

**Urologic complications during hartmann reversal procedure: Robotic-assisted management of two cases of enterovesical fistulae**  
S. Hemal, Los Angeles (US)

V082

**Laparoscopic resection of colovesical fistula secondary to diverticular disease in sigmoid colon. Technical aspects of one-stage surgery**  
O. Vieyra, Nezahualcoyotl (MX)

V016

**Technique and outcomes from prostate capsule-sparing during robotic male cystectomy**  
A. Ta, London (GB)

V083

**Robotic augmentation cystoplasty: 1-year outcome of the anterior and posterior approaches**  
C.H. Yee, Hong Kong (HK)

V040

**Multi-center, prospective, single arm, pivotal study to evaluate the efficacy and safety of robotic-assisted surgery 'easyuretero-100' in patients in need of retrograde intrarenal surgery**

**18:50 - 18:55**

**Closing remarks**



## Basic research and diagnostic tools for urogenital infections

Abstract Session 39

**Sunday 12 March**  
**15:45 - 17:15**

**Location** Pink Area, Coral 1  
**Chairs** T.E. Bjerklund Johansen, Oslo (NO)  
To be confirmed  
To be confirmed

**15:45 - 15:48**

**Introduction**

**A0724** **The challenge for the radical therapy against interstitial cystitis transplanting deciduous dental pulp stem cells.**  
S. Kajioka, Fukuoka (JP)

**A0725** **Etiology of recurrent cystitis based on vaginal microbiome**  
T. Sadahira, Okayama (JP)

**A0726** **Expression of programmed death ligand-1 in the urothelium in nonbacterial chronic cystitis and bladder cancer**  
V. Barsegian, Moscow (RU)

**A0727** **Loss of urothelium in recurrent lower urinary tract infections**

**A0728** **Uropathogen exploits host EPHA2 receptor signaling for bladder epithelial cell infection**

**15:58 - 16:08**

**Discussion**

**A0729** **Animal modeling of prostatitis induced by various bacteria: Assessment of the long-term inflammatory and neoplastic response of prostate tissues**  
M.I. Kogan, Rostov On Don (RU)

**A0730** **Animal modelling of prostatitis induced by various bacteria: Comparative evaluation of microbial load and inflammation severity in the prostate at different infection titers**  
M.I. Kogan, Rostov On Don (RU)

**A0731** **Do serum inflammatory indexes predict prostatic inflammation**  
C. De Nunzio, Rome (IT)

**A0732** **Presence of HPV in prostate tissue from patients submitted to prostate biopsy**  
N.M. Pereira, Goiania (BR)

**A0733** **Fosfomycin for antibiotic prophylaxis in men undergoing a transrectal prostate biopsy: A systematic review and meta-analysis**

**A0734** **Rectal culture-based versus empirical antibiotic prophylaxis to prevent infectious complications in men undergoing transrectal prostate biopsy: a randomized, non-blinded multicenter trial**

**16:20 - 16:32**

**Discussion**

**A0735** **Ciprofloxacin-releasing ROS-sensitive nanoparticles composed of poly (ethylene glycol)/poly(DL-lactide-co-glycolide) for application in urethritis treatment**

A0736	<b>Discovery of antimicrobial peptides from lactobacillus crispatus</b> T. Watanabe, Okayama (JP)
A0737	<b>Enhancing bacteriophage therapeutics through in situ production and release of heterologous antimicrobial effectors</b> L. Leitner, Zürich (CH)
<b>16:38 - 16:44</b>	<b>Discussion</b>
A0738	<b>Impact of untreated positive urine culture on urinary tract infections: A prospective study</b> F Taha, Reims (FR)
A0739	<b>Incidence of infectious complications after nephrostomy tube exchange using different periprocedural antibiotic therapy management: a risk-adapted strategy</b> E. De Lorenzis, Milan (IT)
A0740	<b>Usefulness of stone culture in endoscopic combined intra-renal surgery</b> T. Etani, Nagoya (JP)
A0741	<b>Transition in Antimicrobial Susceptibility and impact of Urease Production on Urinary Stone Formation of P. mirabilis and M. morganii Isolated from Urinary Tract Infections.</b> Y. Maruyama, Okayama (JP)
A0742	<b>Could qSOFA ,NEWS, MEWS and SIRS scores predict sepsis and clinical outcomes in patients with emphysematous pyelonephritis? Comparison of four scoring systems</b> M. Bibi, Tunis (TN)
A0743	<b>Brucellosis epididymo-orchitis; prevalence in an endemic area, diagnosis and management</b>
<b>16:56 - 17:08</b>	<b>Discussion</b>
<b>17:08 - 17:15</b>	<b>Closing remarks</b>

## Testicular Cancer: Biomarkers and the evolving role for retroperitoneal dissection

Abstract Session 40

Sunday 12 March  
15:45 - 17:15

**Location** Pink Area, Coral 2  
**Chairs** C.D. Fankhauser, Lucerne (CH)  
To be confirmed  
To be confirmed

15:45 - 15:48

**Introduction**

**Microlithiasis, primary tumors and prognostic value of teratoma**

A0744

**Clinical significance of testicular microlithiasis**  
E. Durukan, Valby (DK)

A0745

**Predictive factors of testicular cancer in small testicular tumors treated with partial orchiectomy: a retrospective study**  
J. Olivier, Lille (FR)

A0746

**Non-seminomatous testicular germ cell tumours with teratoma-free primaries exhibit a superior early relapse-free survival**  
P. Paffenholz, Cologne (DE)

A0747

**Survival of testicular pure teratoma vs. mixed germ cell tumor patients across all stages**  
C. Cano Garcia, Frankfurt am Main (DE)

15:56 - 16:04

**Discussion**

**Innovative biomarkers and basic research**

A0748

**Radiomics model to predict teratoma in metastatic non-seminomatous testicular germ cell tumors**  
A. Scavuzzo, Mexico City (MX)

A0749

**Validation of AGR2 and KRT19 as specific proteins being significantly and differentially expressed in teratoma compared to necrosis in retroperitoneal lymph node resections after chemotherapy (pcRPLND).**  
T. Nestler, Koblenz (DE)

A0750

**Evaluation of miRNA-371a-3p (miR371a) assay to predict final pathohistology in patients undergoing primary nerve-sparing retroperitoneal lymphadenectomy (nsRPLND) for stage IIA/B seminomas and non-seminomas**

A0751

**Evaluation of the M371 test under real life conditions for the diagnosis and follow up of testicular germ cell tumours**  
C. D'Elia, Bolzano (IT)

A0752

**Identification of resistance mechanisms to evaluate therapeutic options for refractory yolk-sac tumors using multikinase inhibitors or antibody (CLDN6)-/nanobody (CXCR4)-drug-conjugates**  
M.A. Skowron, Dusseldorf (DE)

16:14 - 16:24

Discussion

RPLND for low-volume metastatic seminoma

A0753

**Outcomes of minimally invasive retroperitoneal lymph node dissection (Primary MI-RPLND) followed by adjuvant carboplatin (AUC7) for clinical stage IIa/b seminoma**

W. Cazzaniga, Milan (IT)

A0754

**Surgical and oncologic outcomes of surgery in early metastatic seminoma: Multi-institutional retrospective study**

S.S. Ladi Seyedian, Glendale (US)

A0755

**The early results of the SWENOTECA (Swedish Norwegian Testicular Cancer Group) introduction of primary Retroperitoneal Lymph Node Dissection (RPLND) in seminoma stage IIA-IIb ≤ 3cm**

A. Thor, Stockholm (SE)

A0756

**Interim analysis of the prospective COTRIMS (Cologne Trial of Retroperitoneal Lymphadectomy in Metastatic Seminoma) trial**

A. Heidenreich, Cologne (DE)

16:32 - 16:40

Discussion

pcRPLND, outcomes, complications and centralization

A0757

**A comparative analysis of open vs minimal invasive lymph node dissection for testicular cancer using National Cancer Database**

H. Garg, San Antonio (US)

A0758

**Low rate of teratoma in primary retroperitoneal lymph node dissection for non-seminoma csiiia marker negative patients – a population-based study from the swedish and norwegian testicular cancer group**

A. Gerdtsson, Lund (SE)

A0759

**Need for organ preservation in postchemotherapy retroperitoneal lymph node dissection (PC-RPLND)**

T. Nestler, Koblenz (DE)

A0760

**Analysis of 30-day complications in 225 post-chemotherapy rplnds for testicular germ cell tumors over a decade: A single centre experience**

A0761

**Outcomes of postchemotherapy retroperitoneal lymph node dissection: Comparison of two reference centres to a national data set**

A. Heidenreich, Cologne (DE)

A0762

**Contemporary conditional cancer-specific survival rates in stage III non-seminoma testis cancer patients: A population-based analysis**

R.B. Incesu, Hamburg (DE)

A0763

**Experience of the virtual Canadian testicular cancer second opinion group**

J.J. Cendejas Gomez, Ciudad De Mexico (MX)

16:54 - 17:08

Discussion

17:08 - 17:15

Closing remarks

## Pathophysiological and clinical aspects of chronic pelvic pain and of male stress incontinence

Abstract Session 36

**Sunday 12 March**  
**15:45 - 17:15**

**Location** Yellow Area, Brown 2  
**Chairs** D.A.W. Janssen, Nijmegen (NL)  
To be confirmed  
To be confirmed

**15:45 - 15:48**

**Introduction**

- A0764 **The insula, a key brain area for bladder pain control, is modulated by stress**  
F. Cruz, Porto (PT)
- A0765 **Mechanistic insights from genomic analysis of interstitial cystitis/bladder pain syndrome patient bladder tissue**  
M. Sandberg, Winston Salem (US)
- A0766 **Blood Immunoglobulins G4 measurement and food -related approach in the treatment of chronic pain**  
A. Giannantoni, Siena (IT)
- A0767 **Use of urinary cytokine and chemokine levels for identifying bladder conditions and predicting treatment outcomes in patients with interstitial cystitis/bladder pain syndrome**  
M-C. Liu, Hualien (TW)
- A0768 **Intradetrusor plasmid VEGF165-gene therapy in treatment of cyclophosphamide induced cystitis in rats**  
G.R. Kasyan, Moscow (RU)
- A0769 **Therapeutic effects of AF219 on Interstitial Cystitis/Bladder Pain Syndrome induced by cyclophosphamide and Water Avoidance Stress in rats.**  
I.E. Avci, Dali Kocaeli (TR)
- A0770 **The changes of ultrastructure of the bladder urothelium with IC/BPS before and after the intravesical platelet-rich plasma injection**  
H.C. Kuo, Hualien (TW)
- 16:02 - 16:16** **Discussion**
- A0771 **Pelvic floor myofascial pain might influence treatment outcome of interstitial cystitis/bladder pain syndrome - a prospective study**  
W-R. Yu, Hualien (TW)
- A0772 **Men with chronic prostatitis-like symptoms experienced lower quality of life: From a nationwide survey in Japan**  
Y. Tohi, Kagawa (JP)
- A0773 **Using the systemic immune - inflammatory index in the follow-up of bladder pain syndrome**  
M.F. Sahin, Tekirdag (TR)
- 16:22 - 16:28** **Discussion**

---

A0774	<b>Contemporary trends in the surgical management of stress urinary incontinence after radical prostatectomy in the united states: Insurance claim data on socio-demographic/surgical predictors and differential average costs analysis</b> F. Del Giudice, Rome (IT)
A0775	<b>Patient reported objective and experience measures to assess satisfaction, service evaluation and outcomes following surgery for bothersome stress urinary incontinence in men</b>
A0776	<b>The association between sarcopenia and stress incontinence among older adults in india: A study based on longitudinal aging study in india</b> B. Zeng, Chengdu (CN)
A0777	<b>Which revision strategy is the best in case of non-mechanical failure of male artificial urinary sphincter? A multicenter study</b> B. Peyronnet, Rennes (FR)
A0778	<b>Efficacy, safety and reoperation-free survival of artificial urinary sphincter in non neurological male patients over 75 years of age</b>
A0779	<b>Impact of the previous anastomosis stenosis after radical prostatectomy on the outcome of implantation of artificial urinary sphincter: A prospective study</b> K. Sayed Ahmed, Würselen (DE)
<b>16:40 - 16:52</b>	<b>Discussion</b>
A0780	<b>Impact of irradiation exposure on continence outcome of nonadjustable slings for post-prostatectomy urinary incontinence: A systematic review and meta-analysis</b> C. Gandi, Rome (IT)
A0781	<b>Trends and incidence of reported events associated with male slings: An analysis of the food and drug administration's manufacturer and user facility device experience database</b> A. Nacchia, Prata Sannita (IT)
A0782	<b>Virtue sub-urethral sling for stress urinary incontinence after radical prostatectomy: a single-center experience</b> E. Beatrici, (IT)
A0783	<b>Perineal bladder neck closure as salvage treatment for patients after failed incontinence surgery</b> F. König, Hamburg (DE)
<b>17:00 - 17:08</b>	<b>Discussion</b>
<b>17:08 - 17:15</b>	<b>Closing remarks</b>

---

## Modern treatment in testicular cancer

ESU Course 25

**Saturday 11 March  
16:00 - 18:00**

**Location** Pink Area, ESU 4

**Moderator** P. Albers, Düsseldorf (DE)

### **Learning objectives**

The ESU Course on testicular cancer will cover all important issues in the diagnosis and treatment of patients with germ cell cancer. There will be time for discussion during and after the presentations. Case reports will be discussed to highlight special situations of controversy. In addition, short video clips will be presented to demonstrate surgical techniques in retroperitoneal residual tumour resection.

In brief the following items will be presented and discussed:

- EAU Guideline recommended staging procedures classifications like IGCCCG.
- Stage-by-stage treatment of low-stage disease including TIN.
- Chemotherapy and indication of post- chemotherapy surgery according to EAU Guidelines.
- Recommended follow-up investigations, long-term toxicities, 2nd malignancies.

## How to become an outstanding reviewer

ESU Course 26

**Saturday 11 March**  
**16:00 - 18:00**

**Location**

Pink Area, ESU 5



## Is precision medicine possible in patients with mCRPC?

Thematic Session

**Sunday 12 March**  
17:15 - 18:45

**Location** Yellow Area, eURO Auditorium 1

**Chairs** E. Castro, Madrid (ES)  
J. Walz, Marseille (FR)

### Learning objectives

Today the field of metastatic castrate resistant prostate cancer is changing constantly and rapidly with many new treatment options available. In this context the most important question is about the right treatment for the right patient at the right time. This session provides detailed information about how to tackle the different clinical scenarios and how to select the best treatment for an individual patient with the aim to obtain "precision medicine"

17:15 - 17:25

### State-of-the-art lecture When and how to stage?

B.A. Hadaschik, Essen (DE)

17:25 - 17:35

### State-of-the-art lecture When and how to sequence (molecular testing)?

C.P. Evans, Sacramento (US)

17:35 - 17:40

### Discussion

17:40 - 17:50

### State-of-the-art lecture PARP inhibitors: For which mutations and when?

B. Tombal, Brussels (BE)

17:50 - 18:00

### State-of-the-art lecture What are the best predictive factors for successful treatment with Lu PSMA?

S. Fanti, Bologna (IT)

18:00 - 18:10

### State-of-the-art lecture Optimal treatment sequencing in the area of triplet therapies for hormone sensitive disease

T. Steuber, Hamburg (DE)

18:10 - 18:20

### State-of-the-art lecture Patient related factors that guide treatment decisions

E. Castro, Madrid (ES)

18:20 - 18:25

### Discussion

18:25 - 18:45

### Panel discussion Oligoprogressive disease: Does this entity exist?

18:25 - 18:30

### Case presentation

I. Heidegger, Innsbruck (AT)

18:30 - 18:45

### Discussion

#### Panel

P. Blanchard, Villejuif (FR)  
C.P. Evans, Sacramento (US)  
S. Fanti, Bologna (IT)  
B.A. Hadaschik, Essen (DE)  
I. Heidegger, Innsbruck (AT)  
T. Steuber, Hamburg (DE)  
B. Tombal, Brussels (BE)

## Next steps in immunotherapy for GU malignancies

Thematic Session

**Sunday 12 March**  
**17:15 - 18:45**

**Location** Yellow Area, eURO Auditorium 2

**Chairs** M-O. Grimm, Jena (DE)  
A. Siefker-Radtke, Houston (US)

### Learning objectives

In this presentation we will discuss the toxicity of treatment with immune checkpoint inhibitors, and the evolving strategies that are developing to treat them. We will discuss the current state of knowledge in diagnosing these immune mediated side effects, and the challenges of diagnosing these when patients are receiving multiple agents with overlapping toxicities.

17:15 - 17:18

**Welcome and introduction**

17:18 - 17:42

**Investigational immunotherapy**

17:18 - 17:26

**State-of-the-art lecture** What's next after immune checkpoint inhibitors?  
A. Necchi, Milan (IT)

17:26 - 17:34

**State-of-the-art lecture** Tackling the innate immune system  
A. Alimonti, Bellinzona (CH)

17:34 - 17:42

**State-of-the-art lecture** The role of the microbiome modulating IO therapy  
To be confirmed

17:42 - 17:58

**What to do after reaching complete remission under IO for bladder and kidney cancer**

17:42 - 17:50

**State-of-the-art lecture** De-escalation of systemic treatment  
C. Suárez, Barcelona (ES)

17:50 - 17:58

**State-of-the-art lecture** Surgical strategies  
A. Bex, London (GB)

17:58 - 18:45

**Adjuvant immuno-oncological treatment**

17:58 - 18:06

**State-of-the-art lecture** Toxicity of IO  
A. Siefker-Radtke, Houston (US)

18:06 - 18:08

**Case presentation** RCC  
F. Turco, Bellinzona (CH)

18:08 - 18:13

**Adjuvant treatment: Pro**  
T. Klatter, Berlin (DE)

18:13 - 18:18

**Adjuvant Treatment: Con**  
L. Albiges, Villejuif (FR)

18:18 - 18:26

**State-of-the-art lecture** Novel biomarkers to potentially guide treatment decisions  
L. Dyrskjøl, Aarhus (DK)

18:26 - 18:28

**Case presentation** BCa  
L.S. Mertens, Amsterdam (NL)

18:28 - 18:33

**Adjuvant treatment: Pro**  
S. Shariat, Vienna (AT)

18:33 - 18:38

**Adjuvant treatment: Con**  
T. Powles, London (GB)

18:38 - 18:45

**Discussion**

## Stones: Safety of endourological intervention

Abstract Session 43

**Sunday 12 March**  
**17:30 - 18:45**

**Location** Yellow Area, Brown 3  
**Chairs** I. Saltirov, Sofia (BG)  
A. Pietropaolo, Southampton (GB)  
W. Gamal, Sohag (EG)

**17:30 - 17:33**

**Introduction**

- A0784** **Trends and Incidence of Reported Events Associated With Ureteroscopes: An Analysis of the Food and Drug Administration's Manufacturer and User Facility Device Experience Database**  
A. Nacchia, Prata Sannita (IT)
- A0785** **How does intrarenal pressures affect the nephron? The effect of raised intrarenal pressures on an ex vivo animal model**  
A. Hong, Melbourne (AU)
- A0786** **Human in vivo ureteroscopic intrarenal pressure: A multi-centre analysis of 100 consecutive patients**  
S.M. Croghan, Dublin (IE)
- 17:39 - 17:45** **Discussion**
- A0787** **Intrarenal pressure measurements with a pressure guidewire**  
A. Hong, Melbourne (AU)
- A0788** **First-in-human experience using the LithoVue™ Elite Single Use Ureteroscope to measure intrarenal pressure: the Canadian experience**  
N. Bhojani, Montreal (CA)
- A0789** **In vitro intrarenal pressure comparison of ureteroscopy irrigation systems**
- A0790** **The efficacy and safety of retrograde intrarenal surgery over 250mmHg pressure assisted by automated irrigation pump**  
H.K. Chae, Gangneung-si (KR)
- A0791** **Surgical parameters related to excessive intrarenal pressure during minimally-invasive percutaneous nephrolithotomy in the supine position: A prospective observational clinical study**  
D. Chung, Seoul (KR)
- A0792** **A novel Syphon ureteral access sheath shows clinical potential to reduce renal pressures and improve irrigant flow**  
J. Lazarus, Cape Town (ZA)
- A0793** **Comparison of intrarenal pressure during retrograde intrarenal surgery using various single-use ureteroscopes: An in-vitro study**  
S. Yamashita, Wakayama (JP)

**17:59 - 18:13**

**Discussion**

## Scientific Programme - EAU23 Milan

---

A0794	<b>Trends in radiation protection use and radiation exposure of European endourologists: an ESUT-YAU Endourology Group prospective trial.</b>
A0795	<b>Radiation exposure during different percutaneous renal puncture techniques: a YAU endourology &amp; urolithiasis study</b> T.E. Şener, Istanbul (TR)
A0796	<b>Radiation exposure to the urology surgeon during retrograde intrarenal surgery</b> C.H. Kim, Incheon (KR)
A0797	<b>A novel less traumatic needle for kidney puncture: First clinical experience</b>
<b>18:21 - 18:29</b>	<b>Discussion</b>
A0798	<b>Renal pelvis urine and stone cultures in patients undergoing percutaneous nephrolithotomy and endoscopic combined intrarenal surgery: Are they clinically relevant?</b> S. Mesquita, Porto (PT)
A0799	<b>The efficacy and safety of radiation-free retrograde intrarenal surgery: A prospective multicenter-based randomized controlled study</b> S.H. Lee, Daegu (KR)
A0800	<b>The impact of the use of robotic techniques in the treatment of urolithiasis in children on the reduction of the use of ionising radiation - preliminary report</b> J. Samotyjek, Warsaw (PL)
<b>18:35 - 18:41</b>	<b>Discussion</b>
A0801	<b>Postoperative outcomes in surgical patients at high risk of urosepsis related to persistence of positive preoperative urine culture before and after the adoption of a tailored Multidisciplinary Team protocol: A comparative study</b> C. Labate, Bari (IT)
A0802	<b>High-power laser lithotripsy. Do we treat or harm? Histopathological evaluation: an in vivo experimental study with TFL</b> A. Peteinaris, Patras (GR)
<b>18:45 - 18:49</b>	<b>Discussion</b>
<b>18:49 - 18:56</b>	<b>Closing remarks</b>

---

## E-Health, instruments and disposables in urology and affordable medicine

Abstract Session 44

**Sunday 12 March**  
**17:30 - 19:00**

**Location** Yellow Area, Amber 3  
**Chairs** S. Puliatti, Modena (IT)  
To be confirmed  
To be confirmed

**17:30 - 17:33**

**Introduction**

**A0803** **Utilization of telemedicine in cancer patients: an analysis of the National Health Interview Survey Data in the Covid-19 era**  
K. Alkhatib, Boston (US)

**A0804** **Improving shared decision making in elective urological surgery using a digital consent process: a prospective study**  
M.J. Connor, London (GB)

**A0805** **The role of e-health literacy on short-term quality of life in localized prostate cancer patients following radical prostatectomy: Preliminary results of a prospective single-center study**  
A. Keles, Istanbul ()

**A0806** **The impact of misinformation on patient perceptions prior to their urological consultation/procedure**

**A0807** **Did the Covid-19 pandemic accelerate the shift to outpatient surgery in urologic oncology? –Results from a state administrative database**  
Z. Qian, Boston (US)

**A0808** **An online prostate cancer patient decision aid structurally improves patient care: Results from the EvEnt-PCA randomized controlled trial**  
J. Huber, Marburg (DE)

**17:45 - 17:54**

**Discussion**

**A0809** **Incidence of incisional hernia´s after robot-assisted, radical prostatectomy: supra-umbilical versus „off midline“ extraction site**  
J. Vollemaere, Ostend (BE)

**A0810** **Randomized cross over study to evaluate patient preference for quality of life (EPIC-26) follow-up: mobile application versus standard paper questionnaire**  
A.S. Rannikko, Espoo (FI)

**A0811** **How to distinguish a gem from a lemon: the TULIP-tool**  
N. Hendriks, Den Haag (NL)

**A0812** **Uroflow measurements on festival toilets of adult volunteers**  
L. Bladt, Antwerp (BE)

**A0813** **Evaluation of the “home continence stress test” as a research tool for female stress urinary incontinence objective outcome in trials**  
C. Young, Aberdeen (GB)

## Scientific Programme - EAU23 Milan

---

A0814	<b>Patients' perceptions for urodynamic study</b> M. Samarinas, Larisa (GR)
<b>18:06 - 18:15</b>	<b>Discussion</b>
A0815	<b>Trends and Incidence of Reported Events Associated with Staplers: An Analysis of the Food and Drug Administration's Manufacturer and User Facility Device Experience Database</b> J. Stira, Rome (IT)
A0816	<b>Allium Ureteral Stent for the treatment of ureteral stricture and fistula after abdominal surgery</b>
A0817	<b>Comparison of stent-related symptoms between conventional double-J stents and two novel metallic stents: A validated-questionnaire-based study</b> A. Kantartzi, London (GB)
A0818	<b>Novel anti-reflux ureteral skirt: Proof of concept in a porcine model</b> Y. Lu, Singapore (SG)
<b>18:23 - 18:31</b>	<b>Discussion</b>
-	<b>Affordable medicine and new technology</b>
A0819	<b>A novel, cost-effective and useful simulation for transperineal prostate biopsy training</b> H.P.N. Wong, Singapore (SG)
A0820	<b>Cost-efficacy analysis of urological lubricants</b> C. Munoz Calahorro, Sevilla (ES)
A0821	<b>First results of human testing of a noninvasive wireless bladder volume-monitoring device using bio-impedance</b> N. Assayed Leonardi, Lausanne (CH)
A0822	<b>Cystoscopy: Can we reduce waste while working safe?</b>
A0823	<b>Environmental and human health impact of flexible ureterorenoscopy – analysis of intra-clinical aspects for life cycle assessment</b> S. Rausch, Tübingen (DE)
A0824	<b>Fluorescence as a tool for intraoperative differentiation of lymphatic drainage patterns in prostate cancer - a multi-color approach</b> A.C. Berrens, Amsterdam (NL)
<b>18:43 - 18:53</b>	<b>Discussion</b>
<b>18:53 - 19:00</b>	<b>Closing remarks</b>

---

## Modifications in partial nephrectomy

Video Session 08

**Sunday 12 March**  
**10:45 - 12:15**

**Location** Pink Area, Coral 7  
**Chairs** U. Capitano, Milan (IT)  
S. Dabestani, Malmö (SE)  
To be confirmed

**10:45 - 10:47**

**Introduction**

V056	<b>The role of three-dimensional virtual models to plan a “minimal surgical impact” robot assisted partial nephrectomy for the treatment of small renal masses</b> D. Amparore, Turin (IT)
V057	<b>Use of a 3d printed model of renal tumor as a single hemostatic device in renal laparoscopic surgery</b> D. Subirá-Rios, Madrid (ES)
V058	<b>Hemostatic renal surgical device (RSD).</b> D. Subirá-Rios, Madrid (ES)
V059	<b>Z-shaped running suture for outer layer renorrhaphy during robot-assisted partial nephrectomy: step-by-step technique and preliminary results of a large single-surgeon series</b> F. Ambrosini, Veduggio (IT)
V060	<b>Non-absorbable clip migration after robot-assisted partial nephrectomy: a rare but challenging complication</b> G. Basile, Milan (IT)
V061	<b>Learning and teaching partial nephrectomy with a nephron sparing bovine model</b> M. Lezrek, Meknes (MA)
V062	<b>Retroperitoneal access for renal masses: our series and feasibility in high volume renal tumors</b> S. Lopez Garcia, Vigo (ES)
V063	<b>TALA: The transabdominal lumbar approach for robotic renal surgery. Instructional video and presentation of surgical outcome</b> L. Hefermehl, Baden (CH)
<b>12:11 - 12:15</b>	<b>Closing remarks</b>

## Robotic (r)evolution

Video Session 12

**Sunday 12 March**  
**17:30 - 19:00**

**Location** Pink Area, Coral 7  
**Chairs** To be confirmed  
P. Sooriakumaran, London (GB)  
To be confirmed

**17:30 - 17:31**

**Introduction**

- |      |  |
|------|--|
| V084 | <b>Single-port robot-assisted retroperitoneal surgery. Feasibility using a multi-arm system</b><br>D. Vazquez-Martul , A Coruña (ES)   |
| V085 | <b>Robotic assisted ureteral reconstruction for lower ureteral injury: Tapping the Columbus' egg on table!</b><br>T. Mistry, New Delhi (IN)  |
| V086 | <b>Initial experience of robot-assisted partial nephrectomy with Hugo RAS™ system: Implications for surgical setting</b><br>A. Uleri, Milan (IT)   |
| V087 | <b>Step-by-step description of robot-assisted radical prostatectomy with the novel HUGO RAS robotic system using the “Aalst technique”</b><br>M. Paciotti, Rozzano, Milan (IT)                   |
| V088 | <b>A synoptic journey in robotic assisted radical prostatectomy with three different platforms: Clinical cases by a single surgeon with the Da Vinci, HugoTMRAS and Versius surgical systems</b> |
| V089 | <b>Extraperitoneal daVinci SP-based radical prostatectomy: A step-by-step procedure and early comparative outcomes</b><br>Y.H. Ko, Daegu (KR)  |
| V090 | <b>Improving the safety of robotic surgery with a new artificial intelligence-based system</b><br>E. Checcucci, Venaria Reale (IT)   |
| V091 | <b>The integration of computer and human assistance for 3D augmented reality robotic surgery</b><br>E. Checcucci, Venaria Reale (IT)   |



## Urogenital reconstruction apart from the urethra

Abstract Session 45

**Sunday 12 March**  
**17:30 - 19:00**

**Location** Pink Area, Coral 1  
**Chairs** To be confirmed  
To be confirmed  
S. Mourad, New Cairo (EG)

**17:30 - 17:33**

**Introduction**

A0825

**Appendicular flap transposition in case of the left ureters defects.**

A0826

**Ureteric reconstruction during posterior or lateral pelvic exenteration for locally advanced and recurrent malignancy**  
A. Combes, Sydney (AU)

A0827

**Time for Double-J (DJ) indwelling ureteral stent removal following primary or salvage pyeloplasty in US adult patients is affected by demographic and perioperative factors: results from a large population-based cohort analysis**  
V. Asero, Rome (IT)

A0828

**Self-expanding large caliber ureteral stents for treatment of idiopathic ureteral stricture**  
S.B. Jo, seoul (KR)

A0829

**Extra-Anatomical Ureteral Bypass (EAUB) for the treatment of complex ureteral stenosis: Long-term follow up and analysis of risk factors for complications**  
I. Kartalas Goumas, Vigevano (IT)

**17:43 - 17:52**

**Discussion**

A0830

**Functional outcomes and quality of life of patients undergoing partial cystectomy as part of pelvic exenteration**  
C. Palma, Sydney (AU)

A0831

**Robot-assisted versus open ureteroenteric reimplantation in patients with ureteroenteric stricture after radical cystectomy; a multicenter study of eight referral institutions**  
A. Carrion, Barcelona (ES)

A0832

**Functional evaluation of a spiral neobladder with an angled Chimney; a prospective randomized comparative study**  
A.M. Moeen, Assiut (EG)

A0833

**Predictors of success of rectourethral fistula repair**  
S. Herschorn, Toronto (CA)

**18:00 - 18:06**

**Discussion**

A0834

**Progress (patient reported outcomes in genital reconstructive surgeries) a validated patient reported outcome measure questionnaire to assess post operative functional improvement following feminising genital reconstructive surgery**

## Scientific Programme - EAU23 Milan

---

A0835	<b>Insertion of novel penile prosthesis after latissimus dorsi phalloplasty: Initial experience</b>
A0836	<b>Associations in prostate size in transgender women on hormone therapy</b>
A0837	<b>Outcomes of primary surgical treatment in advanced peyronie's disease: A multi-institutional study</b> L. Tryfonyuk, Rivne (UA)
A0838	<b>Searching for an explanation for the high complication rate after hypospadias surgery: A comparative histology study between the urethral plate in hypospadias patients and the healthy urethra.</b> G. Tsachouridis, Utrecht (NL)
<b>18:16 - 18:25</b>	<b>Discussion</b>
A0839	<b>Long-term follow-up and comprehensive patient-reported outcomes after female urogenital fistula repair</b> J. Klemm, Hamburg (DE)
A0840	<b>Catheterizable channel creation for neurogenic bladder : comparison of the robotic and open approaches</b>
A0841	<b>Stress urinary incontinence following urethral diverticulum excision: Incidence and management</b> J. O'Riordan, . (AU)
A0842	<b>In-vitro evaluation of macrophage response to polypropylene mesh before and after application of mechano-oxidative stress</b> S. Saad, London (GB)
A0843	<b>Development of urine biomarker-based decision tree to predict female lower urinary tract dysfunctions</b> C.H. Chiang, Hualien (TW)
A0844	<b>Urothelial remodeling after spinal cord injury</b>
A0845	<b>Molecular characterization of neurogenic intrinsic sphincter deficiency of spina bifida patients</b> B. Peyronnet, Rennes (FR)
A0846	<b>Study on the mechanism of underactive bladder based on transcriptome sequencing</b>
<b>18:41 - 18:55</b>	<b>Discussion</b>
<b>18:55 - 19:00</b>	<b>Closing remarks</b>

---

## Localised kidney cancer: Preoperative surgical planning, surgical & functional outcome predictors

Abstract Session 46

**Sunday 12 March**  
**17:30 - 19:00**

**Location** Pink Area, Coral 2  
**Chairs** To be confirmed  
M. Rossanese, Noventa di Piave (IT)  
To be confirmed

**17:30 - 17:33**

**Introduction**

**Complexity predictors prior to partial nephrectomy**

**A0847** **Pre-operative risk calculator for the probability of completing surgery for kidney cancer: the key role of tumour complexity and surgical experience**

**A0848** **3D virtual models improve the accuracy of nephrometric scores in predicting surgical complexity during robotic partial nephrectomy: results of a collaborative ERUS validation study**  
D. Amparore, Turin (IT)

**A0849** **Evaluation of factors predicting adherent perinephric fat in laparoscopic retroperitoneal partial nephrectomy**  
S. Senel, Ankara (TR)

**A0850** **Two-dimensional shear wave elastography: A promising tool in predicting adherent perinephric fat in robot-assisted partial nephrectomy**  
F. Ambrosini, Veduggio (IT)

**A0851** **Partial or radical nephrectomy for complex renal mass: A comparative analysis of oncological outcomes and complications from the rosula (robotic surgery for large renal mass) collaborative group**

**17:43 - 17:53**

**Discussion**

**Predictors of complications/trifecta/pentafecta**

**A0852** **Frailty Index in predicting surgical outcomes after partial nephrectomy in patients with renal cell carcinoma**

**A0853** **Impact of renal sinus protrusion morphology of tumors on achieving trifecta in robot-assisted partial nephrectomy**  
Y. Hattori, Kobe (JP)

**A0854** **3D-derived volumetric and morphologic parameters to predict complications after robotic partial nephrectomy in patients with renal cancer.**

**A0855** **A new machine learning model to predict Novel Trifecta achievement and validation of its prognostic significance in a large single centre series of minimally invasive partial nephrectomy**  
A. Uleri, Milan (IT)

---

A0856	<b>Prospective evaluation of interobserver variability of the SPARE and comparison with traditional nephrometry scores in patients undergoing Robotic assisted partial Nephrectomy</b> G. Garofano, Pieve Emanuele (IT)
A0857	<b>Lawton instrumental activities of daily living scale identifies patients at high-risk of adverse outcomes after kidney surgery for renal cancer: A prospective clinical study</b>
A0858	<b>Are we improving rates of pentafecta achievement after robot-assisted partial nephrectomy? a single high-volume institution experience over more than a decade</b> L. Nocera, Milan (IT)
A0859	<b>Impact of benign histology on perioperative complication and functional outcomes of robot assisted partial nephrectomy</b> R.S. Flammia, Rome (IT)
A0860	<b>Percutaneous glue ablation of persistent urinary fistula after Robot-assisted nephron sparing surgery: Case-series and experiences at a tertiary care center</b> S. Tyagi, Hapur (IN)
<b>18:11 - 18:23</b>	<b>Discussion</b>
	<b>Renal function assessment with partial nephrectomy</b>
A0861	<b>Surgery or Frailty: who is the master in eGFR decline after renal surgery in living donor and renal cancer patients?</b> F. Trevisani, Milan (IT)
A0862	<b>Urine analysis: A convenient and strong indicator for renal function assessment in surgery for renal cancer</b> H. Garg, San Antonio (US)
A0863	<b>Association of preoperative proteinuria and postoperative renal function after partial nephrectomy</b>
A0864	<b>Does Simplified PADUA Renal (SPARE) Nephrometry scoring system can help predicting renal function outcomes after Robot-Assisted Partial Nephrectomy (RAPN) (UroCCR study 93)?</b> C. Klein, Merignac (FR)
A0865	<b>Functional outcomes prediction after robotic partial nephrectomy using PADUA score assessed with 3D virtual models: Preliminary results of a collaborative ERUS study</b> D. Amparore, Turin (IT)
A0866	<b>Analysis of CKD progression for purely Off-Clamp and On-Clamp robotic partial nephrectomy for high nephrometry renal masses: Results of a multicentric series</b> F. Prata, Rome (IT)
A0867	<b>Development and internal validation of a nomogram to predict five-years significant CKD upstaging after robot-assisted partial nephrectomy</b> R.S. Flammia, Rome (IT)

---

## Scientific Programme - EAU23 Milan

---

A0868	Transition from Acute Kidney Injury (AKI) to Acute Kidney Disease (AKD) After Robot Assisted Partial Nephrectomy (RAPN): results from a single tertiary referral centre.
18:39 - 18:53	Discussion
18:53 - 19:00	Closing remarks

## Female stress urinary incontinence: More than slings

Abstract Session 42

**Sunday 12 March**  
**17:30 - 19:00**

**Location** Yellow Area, Brown 2  
**Chairs** To be confirmed  
E. Costantini, Perugia (IT)  
To be confirmed

**17:30 - 17:32**

**Introduction**

A0869

**Hysterectomy for uterine fibroids and stress urinary incontinence surgery: A nationwide cohort study**

J-H. Lee, Seoul (KR)

**17:34 - 17:36**

**Discussion**

A0870

**Stress urinary incontinence even after weight loss: Are there risk scores?**

A.F. Rodrigues, São Paulo (BR)

**17:38 - 17:40**

**Discussion**

A0871

**Arnold® magnetic stimulation for stress urinary incontinence: A quasi-experimental study**

S. Maruccia, Monza (IT)

**17:42 - 17:44**

**Discussion**

A0872

**Effectiveness of transperineal pelvic floor electrical stimulation system in improving female stress urinary incontinence: A pilot study**

H.W. Kim, Busan (KR)

**17:46 - 17:48**

**Discussion**

To be confirmed

A0873

**Current trends on surgery for female stress urinary incontinence and pelvic organ prolapse: An international survey**

**17:50 - 17:52**

**Discussion**

A0874

**Detrusor Hyperactivity with Impaired Contractility: prevalence and impact on middle urethral sling results**

F. Ditunno, Verona (IT)

**17:54 - 17:56**

**Discussion**

A0875

**Impact of pre-operative detrusor under activity in women undergone middle urethral sling for complicated and uncomplicated stress urinary incontinence**

I. Gentile, trebisacce (IT)

**17:58 - 18:00**

**Discussion**

---

<b>A0876</b>	<b>Transurethral injection of autologous muscle precursor cells for the treatment of female stress urinary incontinence – a prospective and randomized phase I clinical trial</b> F.A. Schmid, Zurich (CH)
<b>18:02 - 18:04</b>	<b>Discussion</b>
<b>A0877</b>	<b>Novel autologous tissue coated midurethral sling versus synthetic sling in treatment of female stress urinary incontinence; prospective randomized controlled trial</b> I. Samaha, Zagazig (EG)
<b>18:06 - 18:08</b>	<b>Discussion</b>
<b>A0878</b>	<b>European prospective observational study evaluating patient reported outcomes of altis single incision sling in women operated for stress urinary incontinence: Observational results after 3 years</b>
<b>18:10 - 18:12</b>	<b>Discussion</b>
<b>A0879</b>	<b>Altis™ single incision sling for female stress urinary incontinence: a multicenter, prospective post-market clinical study</b> J-N.L. Cornu, Rouen (FR)
<b>18:14 - 18:16</b>	<b>Discussion</b>
<b>A0880</b>	<b>Single-incision mini-slings versus standard mid-urethral slings in the surgical management of female stress urinary incontinence: An updated systematic review and meta-analysis</b>
<b>18:18 - 18:20</b>	<b>Discussion</b>
<b>A0881</b>	<b>Sexual function in women following tension-free vaginal tape-obturator procedure: a prospective study</b> A. Sakly, Monastir (TN)
<b>18:22 - 18:24</b>	<b>Discussion</b>
<b>A0882</b>	<b>Risk factors for stress urinary incontinence recurrence after midurethral sling revision</b> B. Peyronnet, Rennes (FR)
<b>18:26 - 18:28</b>	<b>Discussion</b>
<b>A0883</b>	<b>Long-term results of women suffering from severe stress urinary incontinence treated with rectus fascial sling: a high-volume single-center experience</b> F. Ditunno, Verona (IT)
<b>18:30 - 18:32</b>	<b>Discussion</b>
<b>A0884</b>	<b>Outcomes of colposuspension and paravaginal repair for the treatment of stress urinary incontinence after continence mesh removal</b>
<b>18:34 - 18:36</b>	<b>Discussion</b>

---

## Scientific Programme - EAU23 Milan

---

A0885	<b>Robotic colposuspension for female stress urinary incontinence: a prospective series</b> N.J.Q. Tan, London (GB)
18:38 - 18:40	<b>Discussion</b>
A0886	<b>Bulkamid® injection as a salvage treatment option in patients with recurrent stress urinary incontinence: medium term outcomes from a tertiary unit</b> I. Loufopoulos, London (GB)
18:42 - 18:44	<b>Discussion</b>
A0887	<b>Two years' experience with Bulkamid®, a peri-urethral bulking agent (PUBA) as first surgical option offered to treat uncomplicated or complicated stress urinary incontinence (USUI or CSUI).</b> F. Michel, Marseille (FR)
18:46 - 18:48	<b>Discussion</b>
A0888	<b>Single centre experience and long-term outcomes of implantable devices ACT and Pro-ACT (Uromedica, Irvin, CA, USA) - adjustable continence therapy for treatment of stress urinary incontinence</b> U. Pinar, Paris (FR)
18:50 - 18:52	<b>Discussion</b>
A0889	<b>Robot-assisted laparoscopic artificial urinary sphincter implantation in women with posterior approach and intraoperative cystoscopic monitoring</b> L. Broudeur, Nantes (FR)
18:54 - 18:56	<b>Discussion</b>
18:56 - 19:00	<b>Closing remarks</b>

---



## Prostate cancer - prime time for smart screening

Abstract Session 48

**Sunday 12 March**  
**17:30 - 19:00**

**Location** Pink Area, Coral 6  
**Chairs** H. Van Poppel, Leuven (BE)  
To be confirmed  
R.J. Bryant, Oxford (GB)

**17:30 - 17:33**

**Introduction**

[A0890](#)

**The Stockholm3 prostate cancer screening trial (STHLM3): An interim analysis of mortality results after 6.5 years of follow-up**

C. Micoli, Solna (SE)

**17:35 - 17:37**

**Discussion**

[A0891](#)

**Repeat prostate cancer screening using prostate-specific antigen, a multiplex blood-test and magnetic resonance imaging: 2nd screening round outcomes of STHLM3-MRI**

T. Nordström, Stockholm (SE)

**17:39 - 17:41**

**Discussion**

[A0892](#)

**Prostate cancers detected in the PSA interval 1.8-3 ng/mL - results from the Göteborg 2 prostate cancer screening trial**

F. Möller Billig, Skövde (SE)

**17:43 - 17:45**

**Discussion**

[A0893](#)

**Causal modeling to unravel the screening effect in ERSPC: Structural equation analysis of the Dutch, Finnish and Swedish data**

S. Remmers, Rotterdam (NL)

**17:47 - 17:49**

**Discussion**

[A0894](#)

**Population-based organised prostate cancer testing: Outcomes of the first 999 men – a pilot project**

M. Alterbeck, ()

**17:51 - 17:53**

**Discussion**

[A0895](#)

**Prostate cancer incidence and mortality after stop age in the Göteborg branch of ERSPC.**

**17:55 - 17:57**

**Discussion**

[A0896](#)

**How to screen elderly men for prostate cancer: A risk-based approach using data from ERSPC rotterdam**

S. Remmers, Rotterdam (NL)

**17:59 - 18:01**

**Discussion**

## Scientific Programme - EAU23 Milan

---

A0897	<b>Effect of shared decision making on racial and ethnic disparity in prostate cancer screening: results from a National Behavioral Survey</b> N. Frego, Rozzano (IT)
18:03 - 18:05	Discussion
A0898	<b>Evaluation of a solely MRI-based prostate cancer screening programme - visioning Stage II</b> M.O. Matthias, Basel (CH)
18:07 - 18:09	Discussion
A0899	<b>Digital rectal examination (DRE) is not useful as a solitary screening tool for prostate cancer in young men – Results from the PROBACE trial</b> A. Krilaviciute, Heidelberg (DE)
18:11 - 18:13	Discussion
A0900	<b>Negative predictive value of prostate MRI in real world practice: Results from a statewide surgical collaborative in the United States</b>
18:15 - 18:17	Discussion
A0901	<b>A dedicated screening for early detection of prostate cancer in men with germline mutations in DNA-repair genes</b> G. Chiarelli, Milan (IT)
18:19 - 18:21	Discussion
A0902	<b>Prospective multicenter validation of the Stockholm-3 (STHLM3) test in a Middle European population</b> A. Elyan, Basel (CH)
18:23 - 18:25	Discussion
A0903	<b>The effect of limited English proficiency on PSA screening rates in American men</b>
18:27 - 18:29	Discussion
A0904	<b>Does obesity-related traits affect prostate cancer risk through serum testosterone? A Mendelian randomization study</b> Y. Chi, Chengdu (CN)
18:31 - 18:33	Discussion
A0905	<b>Decision regret after prostate biopsy for diagnosis of prostate cancer: Multicenter study in Korea</b> H. Kim, Anyang-Si (KR)
18:35 - 18:37	Discussion
A0906	<b>External validation of the Rotterdam Prostate Cancer Risk Calculator (RPCRC) and comparison to Stockholm3 for prostate cancer diagnosis in a Swedish population-based screening cohort</b>
18:37 - 18:39	Discussion

---

## Scientific Programme - EAU23 Milan

---

18:39 - 18:49

**State-of-the-art lecture Prime time for organised, risk-adapted prostate cancer screening - Impact of the EU recommendations**  
H. Van Poppel, Leuven (BE)

---

18:49 - 18:51

**Questions and answers**

---

18:51 - 18:58

**Closing remarks**

## Sequelae of surgically treated upper tract urothelial carcinoma

Abstract Session 47

**Sunday 12 March**  
**17:30 - 19:00**

**Location** Pink Area, Coral 3  
**Chairs** B. Foerster, Zurich (CH)  
M.R. Hassler, Vienna (AT)  
J.L. Domínguez Escrig, Castellón de la Plana (ES)  
To be confirmed

**17:30 - 17:33**

**Introduction**

**Postoperative complications**

- A0913** **The geriatric nutritional risk index predicts prognosis and postoperative complications in upper urinary tract urothelial carcinoma patients after radical nephroureterectomy**  
L. Jianyong, Beijing (CN)
- A0914** **Assessing post-operative morbidity after retrograde/antegrade ureteroscopy for upper tract urinary cancer management using the EAU quality criteria for standardized reporting**  
P. Verri, Torino (IT)
- A0915** **Predictive factors of complications in patients undergoing minimally invasive radical nephroureterectomy**  
S.D. Pandolfo, Napels (IT)
- A0916** **The prediction of renal function change after unilateral nephroureterectomy in upper tract urothelial carcinoma patients by using tc-99m mag3 renal scan**  
K-S. Su, Taipei City (TW)
- 17:41 - 17:49** **Discussion**
- Prognosis**
- A0917** **Prognostic models for upper urinary tract urothelial carcinoma patients after radical nephroureterectomy based on a novel systemic immune-inflammation score with machine learning**  
L. Jianyong, Beijing (CN)
- A0918** **Prognostic significance of multifocal upper tumors with presence of high inflammation status in upper tract urothelial carcinoma following radical nephroureterectomy**  
L-C. Yu, Tainan (TW)
- A0919** **The impact of histological subtypes on stage at presentation and overall survival of patients with upper tract urothelial carcinoma: A nationwide cohort analysis**  
F. Abdollah, Detroit (US)
- A0920** **Evaluating the role of lymphovascular invasion as an indicator for adverse outcomes for patients with upper tract urothelial carcinoma and its histological subtypes**  
F. Abdollah, Detroit (US)

## Scientific Programme - EAU23 Milan

---

A0921	<b>Predictive factors of Intravesical recurrence after radical nephroureterectomy for upper tract urothelial carcinoma</b> C-Y. Chen, Kaohsiung City (TW)
<b>17:59 - 18:07</b>	<b>Discussion</b>
	<b>Surgery</b>
A0922	<b>Outcomes of lymph node dissection in upper tract urothelial cell carcinoma in clinical N0 disease: Analysis of the national cancer database</b>
A0923	<b>Oncological outcomes of distal ureterectomy for high risk urothelial carcinoma: A multicenter study</b> V. Vaillant, Paris (FR)
A0924	<b>Management of the distal ureter in Nephroureterectomy</b>
<b>18:13 - 18:23</b>	<b>Discussion</b>
	<b>Follow-up</b>
A0925	<b>Detection of individualized mutations and monitoring of postoperative recurrence using circulating tumor DNA in patients with upper tract urothelial carcinoma</b> D. Tamura, Morioka (JP)
A0926	<b>Follow-up intensity scheme for upper tract urothelial carcinoma after nephron-sparing surgery</b> G. Basile, Milan (IT)
A0927	<b>Development and validation of the artificial intelligence-based disease-free status prediction model for upper-urinary tract urothelial carcinoma patient with radical nephroureterectomy</b> Y. Jung, Seoul (KR)
<b>18:29 - 18:35</b>	<b>Discussion</b>
A0928	<b>Radical therapy for low-risk upper tract urothelial carcinoma (ROBUUST collaborative group)</b> N. Corsi, Detroit (US)
A0929	<b>Role of perioperative chemotherapy in Upper Tract Urothelial Carcinoma patients undergoing Nephroureterectomy: Analysis from the ROBUUST 2.0 Registry</b> G. Tuderti, Roma (IT)
<b>18:39 - 18:53</b>	<b>Discussion</b>
<b>18:53 - 19:00</b>	<b>Closing remarks</b>

---

## Stones 2023: Progress and challenges

Plenary Session

**Monday 13 March**  
08:00 - 10:00

**Location** Yellow Area, eURO Auditorium 1

**Chairs** S. Ferretti, Modena (IT)  
T. Knoll, Sindelfingen (DE)

### Learning objectives

Management of urinary stones may turn from simple to complex quickly. This session discusses the current developments and concepts in treatment and prevention of urolithiasis in routine and difficult situations.

The multidisciplinary approach to stone disease and pediatric care are also considered.

08:00 - 08:01

**Welcome and introduction**

08:01 - 08:09

**State-of-the-art lecture** How urologists and nephrologists can cooperate in metabolic stone management

J.P. Haymann, Paris (FR)

08:09 - 08:17

**State-of-the-art lecture** Role of endourology in the management of paediatric stones: Do the guidelines need to be revised?

B. Bañuelos Marco, Berlin (DE)

08:17 - 08:38

**Panel discussion** Temperature rise by laser application: Fact of myth?

08:17 - 08:18

**Introduction**

C.C. Seitz, Vienna (AT)

08:18 - 08:23

**Fact: We may cook the kidney**

P. Kallidonis, Patras (GR)

08:23 - 08:28

**Myth: Bench is not bedside**

T. Tailly, Ghent (BE)

08:28 - 08:38

**Discussion**

*Moderator*

C.C. Seitz, Vienna (AT)

*Panel*

P. Kallidonis, Patras (GR)

T. Tailly, Ghent (BE)

08:38 - 08:48

**State-of-the-art lecture** Beyond Holmium Laser: A new laser technology every year?

O. Traxer, Paris (FR)

08:48 - 09:14

**Panel discussion** Access for PCNL shall be done ...

08:48 - 08:49

**Introduction**

G.M. Kamphuis, Amsterdam (NL)

08:49 - 08:54

**... by fluoroscopy**

F. Darcy, Galway (IE)

08:54 - 08:59

**... by ultrasound**

G.H. Zeng, Guangzhou (CN)

08:59 - 09:04

**... by combined ultrasound and fluoroscopy**

M. Desai, Nadiad (IN)

09:04 - 09:14

**Discussion**

## Scientific Programme - EAU23 Milan

---

*Moderator* G.M. Kamphuis, Amsterdam (NL)  
*Panel* F. Darcy, Galway (IE)  
M. Desai, Nadiad (IN)  
G.H. Zeng, Guangzhou (CN)

---

**09:14 - 09:24** **American Urological Association (AUA) lecture What is new in stents?**  
J. Denstedt, London (CA)

---

**09:24 - 09:32** **State-of-the-art lecture Did the new follow-up algorithms for stone patients change practice?**  
A. Skolarikos, Athens (GR)

---

**09:32 - 09:49** **Case discussion Stone in Horseshoe Kidney**

**09:32 - 09:34** **Case presentation**  
O.R. Durutovic, Belgrade (RS)

**09:34 - 09:39** **Flexible URS**  
E.K. Bres-Niewada, Pruszkow (PL)

**09:39 - 09:44** **PCNL**  
G. Giusti, Milan (IT)

**09:44 - 09:49** **Robotic**  
A. Hemal, Winston Salem (US)

---

**09:49 - 09:59** **Discussion**  
*Moderator* O.R. Durutovic, Belgrade (RS)  
*Panel* E.K. Bres-Niewada, Pruszkow (PL)  
G. Giusti, Milan (IT)  
A. Hemal, Winston Salem (US)

---

**09:59 - 10:00** **Closing remarks**  
S. Ferretti, Modena (IT)

## Men's health as catchphrase: Evidence vs. marketing in the aging male

Plenary Session

**Monday 13 March**  
**08:00 - 10:00**

**Location** Yellow Area, eURO Auditorium 2

**Chairs** M. Albersen, Leuven (BE)  
C. Gratzke, Freiburg (DE)

<b>08:00 - 08:30</b>	<b>Case discussion</b> Minimising ejaculatory dysfunction in BPH surgery: Is the game not worth the candle?
<b>08:00 - 08:03</b>	<b>Case presentation</b> F. Cancrini, Rome (IT)
<b>08:03 - 08:13</b>	<b>The case for minimally invasive techniques</b> D. Elterman, Toronto (CA)
<b>08:13 - 08:23</b>	<b>The case for ejaculation-sparing enucleation/resection</b> F. Gomez Sancha, Madrid (ES)
<b>08:23 - 08:30</b>	<b>Rebuttals and conclusion</b>
<b>08:30 - 08:40</b>	<b>State-of-the-art lecture</b> Do patients have to choose between ejaculation and micturition? T.R.W. Herrmann, Frauenfeld (CH)
<b>08:40 - 08:50</b>	<b>State-of-the-art lecture</b> Medical treatment of BPH: Nothing new on the horizon? M.C. Michel, Mainz (DE)
<b>08:50 - 09:00</b>	<b>State-of-the-art lecture</b> Telemedicine in urology: Here to stay? To be confirmed
<b>09:00 - 09:10</b>	<b>State-of-the-art lecture</b> Wearables for erectile quality: Catchy gadget or valuable clinical instrument? F. Yafi, Orange (US)
<b>09:10 - 09:40</b>	<b>Case discussion</b> Regenerative injectables for erectile dysfunction: Hype or hope?
<b>09:10 - 09:13</b>	<b>Case presentation</b> M. Skrodzka, London (GB)
<b>09:13 - 09:23</b>	<b>Give him the shot! If it does not help, it does not hurt either</b> D. Hatzichristou, Thessaloniki (GR)
<b>09:23 - 09:33</b>	<b>Not quite yet, the evidence is lacking</b> M.M. Fode, Herlev (DK)
<b>09:33 - 09:40</b>	<b>Rebuttals and conclusion</b>
<b>09:40 - 09:50</b>	<b>State-of-the-art lecture</b> What is the ideal timing for an erectile implant after ischemic priapism: A state of the evidence D.J. Ralph, London (GB)
<b>09:50 - 10:00</b>	<b>State-of-the-art lecture</b> Should (all) prediabetic men receive exercise, metformin or testosterone? An update for the urologist G. Rastrelli, Florence (IT)



## Flexible ureterorenoscopy and retrograde intrarenal surgery: Instrumentation, technique, tips, tricks and indications

ESU Course 42

Monday 13 March  
08:00 - 11:00

**Location** Pink Area, ESU 1

**Chair** O. Traxer, Paris (FR)

### Learning objectives

The aims and objectives of this course is to provide a complete overview of instruments, endoscopes, indications, technique and special tips and tricks concerning Retrograde IntraRenal Surgery (RIRS) using flexible ureterorenoscopes and Holmium YAG lasers. At the end the participants will know the equipment and the technique to perform flexible ureterorenoscopy in the best conditions.

- To learn about equipment.
- To learn about technique and indications.
- To learn how to use an Holmium Laser.
- To learn tips and tricks for special circumstances.

### Welcome and introduction

O. Traxer, Paris (FR)

### Instrumentation: Endoscopes

O. Traxer, Paris (FR)

### Instrumentation: Laser and lithotripsy devices

B. Somani, Southampton (GB)

### Instrumentation: Disposable (wires, retrieving devices, ureteral access sheath (UAS), irrigation devices and others)

P.J.S. Osther, Fredericia (DK)

### Technique: Stones

O. Traxer, Paris (FR)

### Technique: Urothelial tumours and strictures

B. Somani, Southampton (GB)

### Tips and tricks and special circumstances

O. Traxer, Paris (FR)

### Indications (guidelines) and clinical cases

P.J.S. Osther, Fredericia (DK)

### Conclusions

O. Traxer, Paris (FR)

## Advanced course on laparoscopic renal surgery

ESU Course 43

**Monday 13 March**  
**08:00 - 11:00**

**Location** Pink Area, ESU 2

**Chair** A. Breda, Barcelona (ES)

### **Learning objectives**

Minimally-invasive surgery has steadily improved over the last years. Today one can approach with confidence new, difficult and challenging situations. The course is structured to evaluate and explore the increasing indications and possible complications of laparoscopic and robotic kidney surgery. This course will focus upon common and uncommon complications and how to manage and prevent them. In addition, special situations such as single port inguinal approach, zero ischaemia time, cava thrombus, accidental splenectomy and living donor nephrectomy will be presented.

### **Introduction**

A. Breda, Barcelona (ES)

### **Transperitoneal renal surgery: Step by step**

A. Breda, Barcelona (ES)

### **Retroperitoneal renal surgery: Step by step**

A. Breda, Barcelona (ES)

P.J. Zondervan, Amsterdam (NL)

### **Complex kidney cases**

A. Breda, Barcelona (ES)

P.J. Zondervan, Amsterdam (NL)

### **Intraoperative complications: Incidence and management**

P.J. Zondervan, Amsterdam (NL)

### **Postoperative complications: Incidence and management**

A. Breda, Barcelona (ES)

### **Special cases**

A. Breda, Barcelona (ES)

P.J. Zondervan, Amsterdam (NL)

## Prolapse management and female pelvic floor problems

ESU Course 44

**Monday 13 March**  
**08:00 - 11:00**

**Location**

Pink Area, ESU 3

**Chair**

V. Phé, Paris (FR)

## Prostate cancer imaging: When and how to use it

ESU Course 45

**Monday 13 March**  
**08:00 - 11:00**

**Location** Pink Area, ESU 4

**Chair** J. Walz, Marseille (FR)

### Learning objectives

Recently new imaging technologies have been developed to improve the diagnosis and management of prostate cancer. These are multiparametric MRI, choline PET and new ultrasound-based technologies.

The course's aim is to provide:

- An overview on the currently available imaging tools for prostate cancer.
- Practical information about their use.
- A critical assessment of their clinical performance and their limitations.

### Introduction and objective of course

J. Walz, Marseille (FR)

### Diagnosis of prostate cancer

#### Standardisation, acquisition and reporting of multiparametric MRI

I.G. Schoots, Rotterdam (NL)

#### Reading of a prostate MRI and use of MRI for diagnosis of prostate cancer

I.G. Schoots, Rotterdam (NL)

#### MRI-guided biopsy and image fusion (mp MRI and Ultrasound)

J. Walz, Marseille (FR)

#### What are possible alternatives to multiparametric MRI?

J. Walz, Marseille (FR)

### Staging of prostate cancer

#### Staging with CT, MRI and bone scintigraphy

G. Villeirs, Ghent (BE)

#### MRI in local staging of prostate cancer

G. Villeirs, Ghent (BE)

### Recurrent disease

#### Use of PET in the management of prostate cancer (initial staging and recurrence)

J. Walz, Marseille (FR)

#### MRI in detection of locally recurrent prostate cancer

G. Villeirs, Ghent (BE)

#### When to do imaging of the prostate? Case discussion and current practical questions

I.G. Schoots, Rotterdam (NL)

G. Villeirs, Ghent (BE)

J. Walz, Marseille (FR)

**Closure and evaluation**  
J. Walz, Marseille (FR)

**Surgical complications during laparoscopic/robotic urological procedures:  
Prevention, diagnosis, management, complications**

ESU Course 46

**Monday 13 March  
08:00 - 11:00**

**Location**

Pink Area, ESU 5

**Chair**

B.M.C. Rocco, Milan (IT)

## Advanced course on urethral stricture surgery

ESU Course 47

Monday 13 March  
08:00 - 11:00

**Location** Pink Area, ESU 6

**Chair** L. Martínez-Piñeiro , Madrid (ES)

### Learning objectives

The advanced urethral stricture course will cover the assessment and surgical treatment of strictures of the penile, bulbar and posterior urethra. General principles of assessment and follow-up, oral mucosa harvest and complications will be reviewed with evidence. Techniques of penile, bulbar and full length urethroplasty will be discussed and compared and cases reviewed with audience participation encouraged.

Pelvic fracture urethral injuries will also be discussed together with management techniques. Female urethroplasty will also be discussed and assessed.

Prior knowledge of relevant anatomy and basic endoscopic techniques will be helpful to those attending the course.

### General principles in urethral stricture surgery. Preoperative workup and follow-up. Indications of endourological treatments.

P. Nyirády, Budapest (HU)

### Penile urethroplasty. Lichen sclerosus.

P. Nyirády, Budapest (HU)

### Bulbar urethroplasty. Grafts, anastomotic and combined techniques, Perineal urethrostomy.

F. Campos Juanatey, Santander (ES)

### Posterior urethroplasty (pelvic fracture distraction injuries, bladder neck contractures).

L. Martínez-Piñeiro , Madrid (ES)


### Female urethroplasty

F. Campos Juanatey, Santander (ES)

### Discussion / Cases

L. Martínez-Piñeiro , Madrid (ES)

P. Nyirády, Budapest (HU)


 Game changing session

**Monday 13 March**  
**10:00 - 10:30**

**Location**

Yellow Area, eURO Auditorium 1



 Game changing session

**Monday 13 March**  
**10:00 - 10:30**

**Location**

Yellow Area, eURO Auditorium 2

## Latest scientific developments in male post prostatectomy incontinence (PPI)

Thematic Session

**Monday 13 March**  
**10:45 - 12:15**

**Location** Yellow Area, eURO Auditorium 2

**Chairs** J.P.F.A. Heesakkers, Maastricht (NL)  
L.M. Renström Koskela, Stockholm (SE)

### Learning objectives

Post Prostatectomy Incontinence (PPI) is a part of our daily urological activities. We still are trying to discover the reasons, risk factors and preventive measures for developing PPI. This will hopefully lead to avoiding PPI. However we are not that far yet. This implies that we will still have to treat PPI in the coming years. For proper consultation we need to know which treatment works best for which patient. This session will try to elucidate some aspects of the above mentioned issues

**10:45 - 10:48**

### Welcome and introduction

J.P.F.A. Heesakkers, Maastricht (NL)

**10:48 - 10:58**

### What causes PPI? Anatomy, patient characteristics or the surgeon?

L. De Kort, Utrecht (NL)

**10:58 - 11:08**

### The value of urodynamics for PPI

E. Finazzi Agrò, Rome (IT)

**11:08 - 11:18**

### The value of imaging for PPI

L. Moris, Leuven (BE)

**11:18 - 11:33**

### Saturn registry: Set-up, patient accrual, case mix and first results

R. Hamid, London (GB)

**11:33 - 11:43**

### Master trial: The classic RCT

M. Drake, Bristol (GB)

**11:43 - 11:53**

### Reflection on RCT vs. registries: Benefits and flaws

F. Van Der Aa, Leuven (BE)

**11:53 - 12:03**

### What's new on slings for PPI?

J. Angulo Cuesta, Getafe (ES)

**12:03 - 12:13**

### What are the new artificial urinary sphincters for PPI?

T.S. Pottek, Berlin (DE)

**12:13 - 12:15**

### Closing remarks

L.M. Renström Koskela, Stockholm (SE)

## Stones: Percutaneous nephrolithotomy

Abstract Session 50

**Monday 13 March**  
**10:45 - 12:15**

**Location** Yellow Area, Brown 3  
**Chairs** M. Sofer, Tel-Aviv (IL)  
S.Y. Cho, Seoul (KR)  
To be confirmed

**10:45 - 10:48**

**Introduction**

- A0930** **Which stone-treatment approach is the most urologist-friendly?**  
M. Henderickx, Wilrijk (BE)
- A0931** **Which is easier for beginners: Supine or prone position percutaneous nephrolithotomy? Assessment of the learning curve in novice urologists**
- A0932** **Is supine a preferred position for percutaneous nephrolithotomy in the pediatric age group? A randomized controlled study**  
A. Higazy, Cairo (EG)
- A0933** **Comparison between different stone complexity scoring systems in prediction of Percutaneous Nephrolithotomy outcomes: A Prospective cohort study**  
A. Shahin, Zagazig (EG)
- 10:56 - 11:05** **Discussion**
- A0934** **Super-mini PCNL (SMP) vs. Standard PCNL for the management of renal calculi > 1.5 cm size : a randomized controlled study**  
A.K. Chawla, Manipal (IN)
- A0935** **MiniPerc for treatment of renal stones between 10 and 20 mm: A comparison between high-power Holmium:YAG laser (Cyber Ho) versus Thulium Fiber Laser (Fiber Dust) generators**  
D. Perri, Robecco sul naviglio (IT)
- A0936** **A prospective randomised controlled study between miniPCNL and RIRS using thulium fiber laser for lower pole stones 10-20mm**  
G. Soundarya, Hyderabad (IN)
- A0937** **A proposed mathematical model to help preoperative planning between RIRS and MiniPerc for renal stones between 10 and 20 mm using Holmium:YAG laser (Cyber Ho): The Stone Management According to Size-Hardness (SMASH) score**  
D. Perri, Robecco sul naviglio (IT)
- A0938** **Percutaenous nephrolithotripsy versus upfront endoscopic combined intrarenal surgery - a cost-effectiveness analysis using real-world outcomes**  
J.Y.M. Tung, Singapore (SG)
- A0939** **Comparing operative outcomes using suction percutaneous nephrolithotomy (SPCNL) with direct in scope suction (DISS) during retrograde intra-renal surgery: A multi-centre study of 350 patients**  
D. Castellani, Ancona (IT)

A0940	<b>A multicenter propensity score matched pair study in 313 patients comparing percutaneous nephrolithotomy versus retrograde intra renal surgery for management of urolithiasis in calyceal diverticulum</b> E.J. Lim, Singapore (SG)
<b>11:19 - 11:33</b>	<b>Discussion</b>
A0941	<b>Vacuum-assisted access sheet in minimally invasive percutaneous nephrolithotomy in the supine position</b> J.J. Szczesniewski, Milagros (ES)
A0942	<b>Preliminary results of the implementation of an ambulatory mini percutaneous nephrolithotomy program</b> A. Abella Serra, Barcelona (ES)
A0943	<b>Tubeless percutaneous nephrolithotomy with backup through and through re-entry safety guide wire: A novel exit strategy</b> E.A.E. Desoky, Zagazig (EG)
A0944	<b>Evaluating learning curve for renal access during mini-ECIRS: robotic-assisted fluoroscopic-guidance vs ultrasound-guidance</b> K. Taguchi, Nagoya (JP)
<b>11:41 - 11:50</b>	<b>Discussion</b>
A0945	<b>Miniaturized accesses in endoscopic combined intrarenal surgery (ECIRS): Which advantages?</b> C. Di Gaetano, Catania (IT)
A0946	<b>Erector spinae plane blocks for analgesia after percutaneous nephrolithotomy: A pathway to reduce opiates</b> S. Bechis, San Diego (US)
A0947	<b>Supine percutaneous nephrolithotomy under segmental epidural block in high risk compromised cardiovascular patients: A prospective analysis</b> J.A. Kalathia, Botad (IN)
A0948	<b>Application of virtual reality in optimizing surgical outcomes and resident training in percutaneous nephrolithotomy: A randomized control trial</b>
<b>11:58 - 12:08</b>	<b>Discussion</b>
<b>12:08 - 12:15</b>	<b>Closing remarks</b>

## ERN eUROGEN: Update on rare & complex urology

Thematic Session

**Monday 13 March**  
**10:45 - 12:15**

**Location** Yellow Area, Amber 3

**Chairs** M. Battye, Nijmegen (NL)  
W.F.J. Feitz, Nijmegen (NL)

### Learning objectives

This session brings an update on eUROGEN in general and the three workstreams in particular. It also features a lecture from the ERN Patient Advocacy Group (EPAG). ERN eUROGEN welcomes collaboration with all groups and sections within the EAU. See our website to learn more about ERN eUROGEN: <https://eurogen-ern.eu>

**10:45 - 10:55**

### Update on ERN eUROGEN developments

M. Battye, Nijmegen (NL)

**10:55 - 11:15**

### ERN Patient Advocacy Group (ePAG) Lecture The importance of communication in rare diseases & complex conditions: The patient perspective

To be confirmed

R. Cornes, London (GB)

To be confirmed

J. Osborne, Nottingham (GB)

**11:15 - 11:35**

### Workstream 1: Rare congenital uro-recto-genital anomalies Urogenital problems in rare and complex forms of anorectal malformation: Paediatric surgical, urological, & gynaecological perspectives

To be confirmed

To be confirmed

J. Dekker, Amsterdam (NL)

To be confirmed

To be confirmed

**11:35 - 11:55**

### Workstream 2: Functional urogenital conditions requiring highly specialised surgery Interstitial cystitis: Current evidence, personal perspectives, ideas for the future

To be confirmed

**11:55 - 12:15**

### Workstream 3: Rare urogenital tumours Testicular Cancer: Collaborative projects

A. Alberts, Rotterdam (NL)

Y. Che, Düsseldorf (DE)

P.M. Willemse, Utrecht (NL)

T. Zuiverloon, Rotterdam (NL)

## Is artificial intelligence (AI) in urology ready for prime time?

Thematic Session

**Monday 13 March**  
**10:45 - 12:15**

**Location** Pink Area, Coral 4  
**Chairs** M.J. Ribal Caparros, Barcelona (ES)  
K.A.O. Tikkinen, Helsinki (FI)

<b>10:45 - 10:50</b>	<b>Welcome and introduction</b>
<b>10:50 - 11:00</b>	<b>Application of AI to overcome clinical data overload in urology</b> J. Ghith, New York (US)
<b>11:00 - 11:10</b>	<b>AI and virtual cystoscopy</b> M.C. Kriegmair, Planegg (DE)
<b>11:10 - 11:20</b>	<b>AI and augmented reality in urological surgery</b> A. Mottrie, Melle (BE)
<b>11:20 - 11:30</b>	<b>AI for diagnosis and Gleason grading of prostate cancer</b> M Eklund, Stockholm (SE)
<b>11:30 - 11:40</b>	<b>Digital biomarkers in oncology</b> To be confirmed
<b>11:40 - 11:45</b>	<b>Discussion</b>
<b>11:45 - 11:55</b>	<b>Common pitfalls and challenges in AI in urology</b> To be confirmed
<b>11:55 - 12:05</b>	<b>Ongoing initiative using AI in urology</b> To be confirmed
<b>12:05 - 12:15</b>	<b>Discussion</b>

## Extending the boundaries in high risk prostate cancer

Video Session 13

**Monday 13 March**  
**10:45 - 12:15**

**Location** Pink Area, Coral 7  
**Chairs** To be confirmed  
C. Stranne, Göteborg (SE)  
I.M. Van Oort, Nijmegen (NL)

**10:45 - 10:48**

**Introduction**

V092 **Intraoperative use of PET/CT specimen imager to guide robotic radical prostatectomy and pelvic lymph node dissection**  
M. Oderda, Turin (IT)

V093 **Finals results in the safety and performance evaluation of a drop-in gamma probe for sentinel lymph node dissection in prostate cancer**  
L. Polaina Barroso, ()

V094 **En-bloc extended pelvic lymph node dissection during robot-assisted radical prostatectomy: A step-by-step description of the aalst technique**  
A. Mottaran, Bologna (IT)

V095 **Surgery in advanced prostate cancer scenarios: Do benefits outweigh the risks?**  
M. Oderda, Turin (IT)

V096 **Salvage vesiculectomy for local prostate cancer recurrence: surgical technique, complications and early postoperative outcomes**  
A. Giesen, Alken (BE)

V097 **Near-infrared fluorescence imaging with indocyanine green: a novel intra-operative tool for the management of massive lymphorrhea after robot-assisted radical prostatectomy**  
M. Martiriggiano, Aradeo (IT)

V098 **Salvage radical prostatectomy following 177Lu-PSMA-617 radioligand therapy in men with high-risk localized prostate cancer: surgical aspects of the LuTectomy study**  
J. O'Brien, East Melbourne (AU)

**12:03 - 12:08**

**Closing remarks**

## Active surveillance and focal therapy: Standard of care?

Abstract Session 51

**Monday 13 March**  
**10:45 - 12:15**

**Location** Pink Area, Coral 1  
**Chairs** G. Lughezzani, Milano (IT)  
M. Valerio, Lausanne (CH)  
O.U. Ukimura, Kyoto (JP)

**10:45 - 10:48**

**Introduction**

**Long-term outcome**

- |       |  |
|-------|--|
| A0949 | <b>Evaluation after 15 years of the PRIAS study: Over 10000 men on active surveillance in daily clinical practice</b><br>I.I. de Vos, Rotterdam (NL)                           |
| A0950 | <b>Has active surveillance of prostate cancer become safer? Lessons learned from a global clinical registry: Movember GAP3 consortium</b><br>P.N. Doan, Darlinghurst (AU)      |
| A0951 | <b>Thirty-year outcomes for men with prostate cancer on watchful waiting. Nationwide population-based study</b><br>E. Ventimiglia, Milan (IT)                                  |
| A0952 | <b>The effect of prostate cancer active surveillance on erectile and urinary function: results of the Finnish arm of the prospective trial (PRIAS)</b><br>O. Kerro, Espoo (FI) |

**10:56 - 11:04**

**Discussion**

**Selection**

- |       |   |
|-------|---|
| A0953 | <b>Does prostate cancer family history have an impact on active surveillance adherence in men with low- or favourable intermediate risk disease?</b>  |
| A0954 | <b>A patient tailored follow-up protocol for men with prostate cancer managed with active surveillance with the use of multiparametric magnetic resonance imaging: Identifying predictors of early and late reclassification in a large single institution cohort</b> |
| A0955 | <b><sup>68</sup>Ga-PSMA-PET/CT in patients starting on Active Surveillance for Prostate cancer - Trial (PASPoRT)</b>  |
| A0956 | <b>Is there an impact of the center performing baseline multiparametric MRI on active surveillance outcomes in prostate cancer patients?</b>  |
| A0957 | <b>Machine learning algorithm to define optimal candidates for active surveillance in intermediate-risk prostate cancer</b><br>M. Baboudjian, Marseille (FR)  |

**11:14 - 11:23**

**Discussion**

**Biopsy and MRI**



## Scientific Programme - EAU23 Milan

---

A0958	<b>Prognostic impact of prostate cancer grade inflation in targeted biopsies</b> A.O. Batouche, Helsinki (FI)
A0959	<b>Natural history of prostate cancer during active surveillance on MRI using the PRECISE criteria: A multicentre study</b> F. Giganti, London (GB)
A0960	<b>MRI-guided Active Surveillance without annual re-biopsy in patients with ISUP 1 and 2 prostate cancer – The prospective PROMM-AS Study</b> J.P. Radtke, Düsseldorf (DE)
A0961	<b>Clinical application of the PRECISE score for reporting magnetic resonance imaging in men on active surveillance for prostate cancer</b> J. Aerts, Gent (BE)
A0962	<b>The mpMRI PRECISE score predicts disease progression in patients undergoing active surveillance for prostate cancer</b> Y. Trachsel, Winterthur (CH)
<b>11:33 - 11:42</b>	<b>Discussion</b>
	<b>Focal therapy</b>
A0963	<b>Initial clinical trial of focal laser ablation utilising ProFocal-Rx™ for localised prostate cancer</b> J. Kam, (AU)
A0964	<b>Four-year follow-up of MRI-guided transurethral ultrasound ablation (TULSA) in men with localized prostate cancer</b> J. Chin, London-Ontario (CA)
A0965	<b>Salvage transurethral ultrasound ablation (TULSA) for localized radio-recurrent prostate cancer: 12-month safety and oncological outcomes</b>
A0966	<b>12-month clinical outcomes of MRI-guided transurethral ultrasound ablation for localized prostate cancer</b>
A0967	<b>Focal high-intensity focused ultrasound therapy for localized prostate cancer: results of the FASST registry</b> A. Ebner, Gockhausen (CH)
A0968	<b>Targeted Microwave Ablation (TMA) of localized prostate cancer guided by MRI-Ultrasound fusion and organ-based tracking: experience from the first study on clinical efficacy</b> P.K-F. Chiu, Hong Kong (HK)
A0969	<b>Transperineal targeted microwave ablation for low to intermediate-risk prostate cancer: results of a phase I-II study (NCT04627896)</b> M. Oderda, Turin (IT)
<b>11:56 - 12:08</b>	<b>Discussion</b>
<b>12:08 - 12:15</b>	<b>Closing remarks</b>

---

## Prostate cancer diagnosis by imaging: which role for MRI, PET and Micro-US

Abstract Session 52

**Monday 13 March**  
**10:45 - 12:15**

**Location** Pink Area, Coral 2  
**Chairs** V. Kasivisvanathan, London (GB)  
To be confirmed  
To be confirmed

**10:45 - 10:47**

**Introduction**

**MRI reporting issues, AI and CAD use**

**A0970** **Global variation in the quality of multiparametric Magnetic Resonance Imaging of the prostate from the PRIMETrial (the glimpse study)**  
A. Ng, London (GB)

**A0971** **Inter-center variability in positive predictive values of PIRADS score in patients undergoing prostate biopsy: Results from the PROMOD study group**  
M. Finati, Gavirate (IT)

**A0972** **Impact of Prostate Imaging Quality (PI-QUAL) score on the detection of clinically significant prostate cancer in men undergoing MRI-targeted biopsy**

**10:53 - 10:58**

**Discussion**

**MRI PET and micro-US imaging for AI and CAD use**

**A0973** **Prospective comparison of PSMA PET/CT vs. mpMRI in patients with a high suspicion of prostate cancer and previously negative biopsy: preliminary data from PROSPET-BX trial**

**A0974** **Comparison of the diagnostic performance between multiparametric MRI and microUS in the detection of clinically significance prostate cancer among patients with previous negative biopsy**  
N. Frego, Rozzano (IT)

**A0975** **Is micro-ultrasound a reliable tool for prostate cancer diagnosis? results from a single-institution cohort of over 1,000 men**  
N. Frego, Rozzano (IT)

**A0976** **A preliminary assessment of microultrasound performance in detecting clinically significant prostate cancer in the anterior prostate: An inter-reader evaluation**  
Ss Schaer, Montmollin (CH)

**A0977** **Assessment of a novel bpMRI-based machine learning framework to automate the detection of clinically significant prostate cancer using the PI-CAI (Prostate Imaging: Cancer AI) challenge dataset**  
G. Cacciamani, Los Angeles (US)

**A0978** **Assessing the potential of artificial intelligence for prostate MRI in a diverse multi-centre diagnostic population**  
N. Vasdev, Letchworth Garden City (GB)

## Scientific Programme - EAU23 Milan

---

A0979	<b>A new and highly-accurate AI-based algorithm for the automatic identification of prostate cancer on mpMRI</b> T. Telecan, Cluj-Napoca (RO)
A0980	<b>PROSTAITE one – AI-based prostate volumetry and zonal development</b> M.O. Matthias, Basel (CH)
A0981	<b>Beyond multiparametric MRI and towards radiomics to detect prostate cancer: A machine learning model to predict clinically significant lesions</b>
<b>11:16 - 11:32</b>	<b>Discussion</b>
	<b>Imaging grade/aggressiveness prediction</b>
A0982	<b>The role of diagnostic PSMA-PET and PSMA scores in prostate cancer preoperative assessment: Results from a single center study</b>
A0983	<b>Impact of radiologist expertise on PI-RADS distribution and detection of clinically significant prostate cancer: Results from a single, high volume center</b>
A0984	<b>68Ga-PSMA PET radiomics for the prediction of post-surgical ISUP grade in primary prostate cancer patients</b> S. Ghezzi, Milan (IT)
A0985	<b>Providing quality benchmarks for the management of PIRADS / LIKERT 3 lesions identified on multiparametric magnetic resonance imaging – the South West Prostate Dashboard regionwide multicentre experience</b> J. Aning, Bristol (GB)
A0986	<b>Significance of atypical nodules upgraded to category 3 in PI-RADS version 2.1 for the prostate cancer diagnosis</b> S. Asai, Tokyo (JP)
A0987	<b>Clinical, radiological, pathological and genomic evaluation of MRI-invisible prostate cancers</b> M. Oderda, Turin (IT)
A0988	<b>PSMA-driven changing of clinical trends and internal guidelines, and their impact on oncological outcomes of prostate cancer</b>
A0989	<b>Diagnostic performance of 18F-rhPSMA-7.3 PET in men with newly diagnosed unfavourable intermediate to very high-risk prostate cancer: Results from the phase 3 LIGHTHOUSE study</b> T. Maurer, Hamburg (DE)
A0990	<b>SUVmax of the primary prostate lesion on the PSMA PET CT – an indicator of aggressive pathology</b>
A0991	<b>Mri and psma in the primary staging of ductal variant prostate cancer</b> N. Patel, Brisbane (AU)
<b>11:52 - 12:10</b>	<b>Discussion</b>
<b>12:10 - 12:15</b>	<b>Closing remarks</b>

---

## Partial nephrectomy: Surgical advancements & technique comparison

Abstract Session 54

**Monday 13 March**  
**10:45 - 12:15**

**Location** Pink Area, Coral 6  
**Chairs** To be confirmed  
D. Amparore, Turin (IT)  
M. Eto, Fukuoka (JP)

**10:45 - 10:48**

**Introduction**

**Technical comparisons of techniques**

- A1012** **Comparison of perioperative outcomes of open vs robotic-assisted partial nephrectomy for renal cell carcinoma: A propensity matched analysis relying on 20 years of tertiary care experience**  
B. Hoeh, Frankfurt am Main (DE)
- A1013** **Quality of life outcomes after robotic-assisted versus open partial nephrectomy: Results from the randomized ROBOCOP II trial**  
K-F. Kowalewski, Mannheim (DE)
- A1014** **Comparing continuous wound infiltration with thoracic epidural analgesia for postoperative pain management in open nephrectomy**  
N. Assayed Leonardi, Lausanne (CH)
- A1015** **Laparoscopic versus robot-assisted partial nephrectomy for cT1 renal tumors in obese patients: Analysis of perioperative and follow-up functional outcomes (the RECORd2 project)**  
A. Mari, Firenze (IT)
- A1016** **Transperitoneal vs. retroperitoneal robot assisted partial nephrectomy – propensity matched analysis between two multinational high volume subspecialist centres**  
M. Aldiwani, Ruislip (GB)
- A1017** **Partial versus Radical Nephrectomy for Complex Renal Mass: multicenter comparative analysis of Functional Outcomes (ROSULA Collaborative Group)**
- A1018** **NEphron Sparing Treatment (NEST) for small renal masses: A feasibility cohort-embedded randomised controlled trial**  
H. Warren, London (GB)
- 11:02 - 11:14**
- Discussion**
- On vs Off clamp partial nephrectomy**
- A1019** **Assessing the trade-off between safety and effectiveness of off-clamp robotic partial nephrectomy in patients with high RENAL score: A propensity score-matched comparison of perioperative and functional outcomes in a multicenter analysis**  
G. Tuderti, Roma (IT)
- A1020** **Off-clamp versus on-clamp robot-assisted partial nephrectomy: a propensity-matched analysis.**  
G. Sharma, Delhi (IN)

A1021	<b>Outcomes of on-clamp vs. off-clamp robot-assisted partial nephrectomy for large highly complex renal tumors: A multicenter study</b> A. Brassetti, Rome (IT)
11:20 - 11:27	<b>Discussion</b>
	<b>Applications of 3D modelling for partial nephrectomy</b>
A1022	<b>Image-guided minimally invasive treatment of cT1b renal cell carcinoma: A comparative matched-pair analysis of percutaneous tumor ablation and 3D image-guided robotic-assisted partial nephrectomy (UroCCR 80)</b> C. Klein, Merignac (FR)
A1023	<b>Usefulness of three-dimensional reconstruction during nephron sparing surgery: A retrospective single institution analysis</b>
A1024	<b>New 3D virtual models with renal perfusion volumes: optimizing the clamping strategy during robot-assisted partial nephrectomy to minimize the postoperative renal injury</b> D. Amparore, Turin (IT)
11:33 - 11:40	<b>Discussion</b>
	<b>New surgical robotic platforms</b>
A1025	<b>Feasibility study of novel avatera system for transperitoneal partial nephrectomy: An in vivo experimental animal study</b> V. Tatanis, Athens (GR)
A1026	<b>Perioperative outcomes of single-port robotic assisted partial nephrectomy compared to multi-port robotic-assisted partial nephrectomy</b> R. Mehrazin, Philadelphia (US)
A1027	<b>Cryotherapy assisted robotic partial nephrectomy: Short term outcomes</b>
11:46 - 11:54	<b>Discussion</b>
	<b>Warm ischemia relevance during partial nephrectomy</b>
A1028	<b>The role of warm ischemia time on functional outcomes after robotic partial nephrectomy: Data from the clock randomized trial</b>
A1029	<b>Renal function trajectories after enucleative robot-assisted partial nephrectomy for non-metastatic renal masses in patients with two kidneys and preserved baseline renal function: Does warm ischemia still have a role?</b> R. Campi, Florence (IT)
A1030	<b>Unveil the interplay between baseline renal function, warm ischemia time and tumor complexity when assessing renal functional outcomes of on- vs off-clamp robot-assisted partial nephrectomy</b> R.S. Flammia, Rome (IT)
12:00 - 12:08	<b>Discussion</b>
12:08 - 12:15	<b>Closing remarks</b>

## Cell biology and novel biomarkers in kidney cancer

Abstract Session 55

**Monday 13 March**  
**10:45 - 12:15**

**Location** Blue Area, Room 1  
**Chairs** G. Lucarelli, Bari (IT)  
K. Junker, Homburg (DE)  
W. Nakata, Ikeda ()

**10:45 - 10:48**

**Introduction**

**IO and immune contexture**

**A1031** **Early kinetics of C-reactive protein predicts oncological outcome of patients with metastatic renal cell carcinoma under first-line therapy with immune checkpoint inhibitors**  
K. Erdmann, Dresden (DE)

**A1032** **Preclinical evaluation of targeted radionuclide therapy combined with immune checkpoint inhibition**  
E. Oosterwijk, Nijmegen (NL)

**A1033** **Evaluation of PBRM1, PD-L1, CD31 and CD4/CD8 ratio as predictive biomarkers of response to VEGFR-TKI-based therapy in metastatic renal cell carcinoma (mRCC) patients with IMDC intermediate prognosis: Results from the APACHe-I study**

**A1034** **Immunophenotype analysis of tumor-infiltrating immune cells to elucidate the mechanism of antitumor effect of IL-7 and CCL19 producing CAR-T cells against solid cancer**  
S. Goto, Fukuoka-shi (JP)

**A1035** **The role of cytoreductive nephrectomy in perspectives of tumor immune microenvironment**

**A1036** **Prognostic impact of CD73/adenosine receptor 2 (A2aR) in renal cell carcinoma and immune microenvironmental status with sarcomatoid changes and rhabdoid features**

**11:00 - 11:12**

**Discussion**

**Biomarkers and biology investigations**

**A1037** **Single-cell landscape analysis reveals macrophage infiltration and glycolytic metabolism in kidney renal cell carcinoma**  
C-Y. Wen, Kaohsiung (TW)

**A1038** **Renal tumor heterogeneity analysis in Von Hippel-Lindau disease using single-cell RNA sequencing**

**A1039** **SCG2 might be a new molecule in sunitinib-resistant renal cells**  
W. Fukumoto, Kagoshima (JP)

**A1040** **Therapeutic target for HIF-2 $\alpha$  antagonist-resistant clear cell renal cell carcinoma**  
D.H. Son, Seoul (KR)

## Scientific Programme - EAU23 Milan

---

A1041	<b>Comprehensive analysis of copy number variation and sensitivity to targeted therapy in renal cell carcinoma using in-house cancer gene panel testing</b> A. Takeuchi, Aichi (JP)
A1042	<b>Genomic features of renal cell carcinoma developed during end-stage renal disease and dialysis</b> S. Maekawa, Iwate (JP)
A1043	<b>Targeting glutamine addiction with potent drug combination therapy for renal cell carcinoma</b> Y. Muto, Aichi (JP)
A1044	<b>Low Gamma-butyrobetaine dioxygenase (BBOX1) expression associated with low CD8+ T cells decreases the survival rate in patients with Renal cell Carcinoma: Machine learning approach</b> K. Kim, Seoul (KR)
A1045	<b>Gene Expression-Based Signature for predicting tumor progression in Clear-Cell Renal Cell Carcinoma</b> F.L. Roldan Chavez, Barcelona (ES)
<b>11:30 - 11:48</b>	<b>Discussion</b>
	<b>Liquid biomarkers</b>
A1046	<b>Detection of hypermethylated SHOX2 in circulating cell-free DNA post nephrectomy identifies patients with renal cell carcinoma at highest risk for disease recurrence independent of TNM</b> T. Büttner, Bonn (DE)
A1047	<b>Exosomal lncRNA BCYRN1 as a target for diagnosis and therapy in renal cell carcinoma</b> H. Yoshino, Kagoshima (JP)
A1048	<b>IFN<math>\gamma</math>-mediated stimulation of PD-L1 expression on exosomes in urological malignancies and their effect on CD8+ T cells</b> G. Jaschkowitz, Homburg (DE)
A1049	<b>PD-L1 as urine biomarker in urological malignancies</b> P. Reimold, Heidelberg (DE)
A1050	<b>Volatilome analysis in renal cancer by electronic nose: A pilot monocentric study</b> M. Costantini, Rome (IT)
<b>11:58 - 12:08</b>	<b>Discussion</b>
<b>12:08 - 12:15</b>	<b>Closing remarks</b>

---

## How can we improve staging and outcomes of muscle-invasive bladder cancer patients?

Abstract Session 53

**Monday 13 March**  
**10:45 - 12:15**

**Location** Pink Area, Coral 3  
**Chairs** M. Burger, Regensburg (DE)  
To be confirmed  
To be confirmed

**10:45 - 10:48**

**Introduction**

**Nuclear imaging**

**A1051** **Diagnostic performance of PET-CT compared to conventional CT for lymph node staging in bladder cancer patients undergoing radical cystectomy and bilateral pelvic lymph node dissection**

**A1052** **The influence of FDG-PET/CT on the nodal stage and treatment in muscle-invasive bladder cancer: A nationwide cohort study**  
L.S. Mertens, Amsterdam (NL)

**10:52 - 10:56**

**Discussion**

**Endoscopy**

**A1053** **Near-infrared spectroscopy as a novel method of bladder cancer identification and characterisation: A feasibility study**  
A. Yim, CAMBERWELL (AU)

**A1054** **International experts consensus on performance metrics for a transurethral resection of bladder (TURB)**  
M. Paciotti, Rozzano, Milan (IT)

**A1055** **The accuracy of cystoscopy in predicting detrusor invasion in newly diagnosed bladder cancer patients**  
A.G. Van Der Heijden, Nijmegen (NL)

**A1056** **Cancer Reporting Protocols in TURBT – standardized reporting of bladder cancer and improvement of communication between pathologists and urologists**  
L. Gallardo Zamora, Wuppertal (DE)

**A1057** **Assessing the impact of TURBT specimens review by a dedicated uropathologist on clinical decision making process: Results from a single tertiary referral center**  
D. Robesti, Milan (IT)

**11:06 - 11:16**

**Discussion**

**Biomarkers**

**A1058** **A composite biomarker approach to spare neoadjuvant chemotherapy in select muscle-invasive bladder cancer patients**



## Scientific Programme - EAU23 Milan

---

A1059	<b>M7G-related-lncRNA signature predicts the prognosis correlating with immunotherapy and chemotherapy responses in bladder cancer patients</b> D. Li, Chengdu (CN)
<b>11:20 - 11:26</b>	<b>Discussion</b>
	<b>MRI imaging</b>
A1060	<b>A novel pathway to detect Muscle-Invasive Bladder Cancer (MIBC) combining clinical features and preoperative VI-RADS scoring criteria: Results from a prospective multicenter validation analysis</b> F. Del Giudice, Rome (IT)
A1061	<b>Multiparametric MRI in differentiation between muscle invasive and non-muscle invasive urinary bladder cancer with vesical imaging reporting and data system (VI-RADS) application: Our initial experience</b> A. Giordano, Torino (IT)
A1062	<b>Comparison between biparametric and multiparametric MRI in predicting muscle invasion by bladder cancer based on the VI-RADS</b> T.I. Noh, Seoul (KR)
A1063	<b>Accuracy of actual stage prediction using Vesical Imaging-Reporting and Data System (VI-RADS) before radical cystectomy for urothelial carcinoma</b>
<b>11:34 - 11:44</b>	<b>Discussion</b>
	<b>Radical surgery</b>
A1064	<b>Diagnostic performance of Node-RADS by preoperative CT or MRI scans for prediction of pathological nodal (pN) status from Muscle-Invasive Bladder Cancers (MIBCs) undergoing Radical Cystectomy (RC) with extended Pelvic Lymph-node Dissection (ePLND)</b> F. Del Giudice, Rome (IT)
A1065	<b>Predicting the MIBC in stalked tumor of VI-RADS 2 using nomogram of MRI characteristics</b> Q. Lu, Nanjing (CN)
<b>11:48 - 11:54</b>	<b>Discussion</b>
A1066	<b>Age represents the main driver of surgical decision making in patients candidate to radical cystectomy</b> P. Dell'Oglio, Milan (IT)
A1067	<b>Impact of functional impairment and cognitive status on peri-operative outcomes and costs after radical cystectomy: the role of Barthel Index</b> A. Panunzio, (IT)
A1068	<b>Risk factors for benign ureteroenteric anastomosis strictures in patients undergoing Bricker urinary diversion for bladder cancer</b> F. Gavi, Rome (IT)
<b>12:00 - 12:08</b>	<b>Discussion</b>
<b>12:08 - 12:15</b>	<b>Closing remarks</b>

---

## Controversies on EAU Guidelines: Testicular and renal cancer and stones

Thematic Session

**Monday 13 March**  
**12:30 - 14:00**

**Location** Yellow Area, eURO Auditorium 1

**Chairs**  
B. Ljungberg, Umeå (SE)  
D. Nicol, London (GB)  
A. Skolarikos, Athens (GR)

### Learning objectives

This session explores some of the less clearly-defined topics in the EAU Guidelines, where debate and controversy exist. The session will cover, in 30-minute debates, testicular cancer, renal cancer and stones. We are expecting your interactive participation!

The EAU Guidelines recommend retroperitoneal lymph node dissection (RPLND) for patients presenting with stage II marker negative disease. The issue is less clear for stage I patients undergoing surveillance who subsequently relapse with stage II disease. The case for initial surgery in this clinical scenario will be debated in this EAU Guidelines Controversy session. Opposing views will be presented by clinicians. A patient's perspective will also be presented as an additional consideration in considering the initial options of surgery or chemotherapy. A panel will then discuss.

The second debate considers the question of optimal treatment for patients with primary metastatic RCC cytoreductive nephrectomy after response to immune check point inhibitors. Experts will argue, followed by a panel discussion.

The EAU Guidelines algorithms for urinary stone treatment are mainly based on stone composition and stone size. This is largely due to the best evidence existing in the literature. Currently, the patient-reported outcomes on their quality of life during and after the applied "stone treatments" are not well documented. In the third debate, experts will discuss whether stone-free rates are more important than the quality of life.

**12:30 - 13:03**

### Debate Surgery is the preferred option for stage IIA relapse of NSGCT

**12:30 - 12:33**

#### Introduction

D. Nicol, London (GB)

**12:33 - 12:38**

#### Yes

A. Heidenreich, Cologne (DE)

**12:38 - 12:43**

#### No

To be confirmed

**12:43 - 12:48**

#### Patient's view

R. Cornes, London (GB)

**12:48 - 13:03**

#### Discussion

*Discussant*

R. Leão, Coimbra (PT)

*Panel*

R. Cornes, London (GB)

To be confirmed

A. Heidenreich, Cologne (DE)

**13:03 - 13:31**

### Debate Should deferred cytoreductive nephrectomy be performed in primary metastatic RCC after response to immune check point inhibitors?

**13:03 - 13:06**

#### Introduction

B. Ljungberg, Umeå (SE)

13:06 - 13:11

**Yes**

T. Kuusk, London (GB)

13:11 - 13:16

**No**

P.J. Zondervan, Amsterdam (NL)

13:16 - 13:31

**Discussion**

*Discussant*

J. Bedke, Tübingen (DE)

*Panel*

T. Kuusk, London (GB)

P.J. Zondervan, Amsterdam (NL)

---

13:31 - 13:59

**Debate Are stone free rates more important than Quality of Life?**

13:31 - 13:34

**Introduction**

A. Skolarikos, Athens (GR)

13:34 - 13:39

**Yes**

N.D. Davis, Dublin (IE)

13:39 - 13:44

**No**

R. Geraghty, Newcastle upon Tyne (GB)

13:44 - 13:59

**Discussion**

*Discussant*

A. Petřík, Ceske Budejovice (CZ)

*Panel*

N.D. Davis, Dublin (IE)

R. Geraghty, Newcastle upon Tyne (GB)

---

13:59 - 14:00

**Closing remarks**

## How to assess men with familial prostate cancer

Thematic Session

**Monday 13 March**  
**12:30 - 14:00**

**Location** Yellow Area, eURO Auditorium 2

**Chairs** C.H. Bangma, Rotterdam (NL)  
P. Albers, Düsseldorf (DE)

### Learning objectives

Genetic testing is proposed to be offered to men with familial prostate cancer. However, the details of counseling and testing are still in discussion. The first part of this session will give insights in the practical assessment of men with potential germline mutations of prostate cancer. In the second part, genetic classifiers will be discussed based on a special case scenario. In addition, the provocative issue of treatment of especially young men with prostate cancer BRCA mutations will be in the focus of a panel discussion. This session aims to let urologist become more familiar with the newest tools in genetic testing and other cutting-edge diagnostic tools.

**12:30 - 12:34**

**Welcome and introduction**

**12:34 - 12:44**

**Molecular screening for germline mutations in practice: When and how?**  
To be confirmed

**12:44 - 12:47**

**Case presentation**  
E. Linares Espinós, Madrid (ES)

**12:47 - 12:57**

**Genetic counselling in practice**  
To be confirmed

**12:57 - 13:07**

**Role of MRI in the work-up of young men with familial prostate cancer**  
H.P.S. Schlemmer, Heidelberg (DE)

**13:07 - 13:12**

**Recommendations for clinical practice**  
A. Morgans, Boston (US)

**13:12 - 14:00**

**Case discussion Treatment of GG1 Cancer in young men with BRCA 2**

**13:12 - 13:15**

**Case Presentation**  
To be confirmed

**13:15 - 13:25**

**The role of molecular classifiers**  
To be confirmed

**13:25 - 13:35**

**Radical prostatectomy**  
To be confirmed

**13:35 - 13:45**

**MRI-guided active surveillance**  
L. Boesen, Herlev (DK)

**13:45 - 14:00**

**Discussion Optimal treatment of GG1 PCa in young men**

*Panel*

L. Boesen, Herlev (DK)

To be confirmed

To be confirmed

To be confirmed

E. Linares Espinós, Madrid (ES)

To be confirmed

A. Morgans, Boston (US)

H.P.S. Schlemmer, Tübingen (DE)

To be confirmed

## Stones: New technology and shock wave lithotripsy

Abstract Session 57

**Monday 13 March**  
**12:30 - 14:00**

**Location** Yellow Area, Brown 3  
**Chairs** N. Bernardo, Buenos Aires (AR)  
To be confirmed  
H.U. Jung, Odense C (DK)

**12:30 - 12:33**

**Introduction**

A1069 **On the way to residue-free stone fragment removal after ureteroscopic laser lithotripsy - Significance of the hydrogel method**  
T. Amiel, Munich (DE)

A1070 **Novel single-use 7.5fr flexible ureteroscope can control intrarenal pressure and improve irrigation flow: An in vitro study**  
L. Linhu, Chengdu (CN)

A1071 **First Clinical audit of the utility, effectiveness and limitations of the flexible and navigable suction ureteric access sheath (FANS)**  
D. Castellani, Ancona (IT)

A1072 **Peri operative outcomes and efficacy of Direct In Scope Suction technique (DISS) versus non suction Retrograde Intrarenal Surgery (RIRS): Is there a clear winner?**  
E.J. Lim, Singapore (SG)

**12:41 - 12:49**

**Discussion**

A1073 **Better targeting strategies during lithotripsy by in vitro and in vivo study considering respiratory regularity**  
D. Chung, Seoul (KR)

A1074 **Comparative study on stone retropulsion using pulse modulation mode in virtual ureter model**  
Y. Maruyama, wakayama (JP)

A1075 **A comprehensive in vitro assessment of thulium fiber laser in soft tissues and stones**

**12:55 - 13:01**

**Discussion**

A1076 **Feasibility of cone-beam CT-guided percutaneous needle positioning with an optical navigation system percutaneous nephrolithotomy: A pilot study**  
I. Spengelink, Nijmegen (NL)

A1077 **Cone-beam computed tomography assisted percutaneous nephrolithotomy in a hybrid operating room: evaluation of experience and optimization of patient selection**

A1078 **The newly reported (0-90°) versus (0-30°) bi-planar fluoroscopic puncture technique for percutaneous nephrolithotomy: Prospective randomized pilot study**  
M. El-Shazly, Shebin elkom (EG)

## Scientific Programme - EAU23 Milan

---

A1079	<b>Tubed versus tubeless with track coagulation: A revolutionary step for the death of tubed percutaneous nephrolithotomy</b> M.K.M. Omar, Shibin El Kom (EG)
<b>13:09 - 13:17</b>	<b>Discussion</b>
A1080	<b>ESWL: Prematurely falling out of favour? A 10 year audit from a high volume stone centre</b> N. Patel, Brisbane (AU)
A1081	<b>Extracorporeal shock wave lithotripsy: effectiveness and factors related to stone fragmentation and hematoma</b> A.C. Tagalos Munoz, Madrid (ES)
A1082	<b>Predictive model for one-session success rate of shock wave lithotripsy using linear calculus density</b>
A1083	<b>A new nomogram for prediction of shock wave treatment success in ureteral stones</b>
A1084	<b>Does gender influence extracorporeal shock wave lithotripsy practice (ESWL)? Results from a global survey</b> E.J. Lim, Singapore (SG)
A1085	<b>Can Machine Learning Improve Success Rate of Extracorporeal Shock Wave Lithotripsy?</b> J. Svihra jr., Martin (SK)
<b>13:29 - 13:41</b>	<b>Discussion</b>
A1086	<b>What is the ideal interval between repeated shockwaves lithotripsy sessions for renal stones? A randomized controlled trial</b> A.R. El-Nahas, Mansoura (EG)
A1087	<b>A randomized, double-blind, placebo-controlled clinical trial of the use of hydroxycitric acid adjuvant to shock wave lithotripsy therapy in patients with calcium stones. Stone fragmentation results</b> Y.M. Yanez Castillo, Granada (ES)
A1088	<b>Management of large renal stones during covid 19 pandemic- shockwave lithotripsy as the rescue strategy – a single-center experience</b> A. Kumar Pal, Kolkata (IN)
<b>13:47 - 13:53</b>	<b>Discussion</b>
<b>13:53 - 14:00</b>	<b>Closing remarks</b>

---

## Immediate and delayed management of priapism

Thematic Session

**Monday 13 March**  
**12:30 - 14:00**

**Location** Yellow Area, Amber 3

**Chairs** To be confirmed  
K. Van Renterghem, Hasselt (BE)

### Learning objectives

What are the pathophysiological mechanisms in priapism.

How to make an adequate diagnosis and how to decide on a treatment strategy in priapism patients.

What options do we have to decompress.

If an implant is indicated, when, which patient, which device?

**12:30 - 13:17**

### Recurrent and high-flow priapism management

**12:30 - 12:40**

#### State-of-the-art lecture Sleep-related painful erections

M. Johnson, Leeds (GB)

**12:40 - 12:50**

#### State-of-the-art lecture Stuttering priapism

M. Falcone, Torino (IT)

**12:50 - 13:00**

#### State-of-the-art lecture Priapism in sickle cell patients

To be confirmed

**13:00 - 13:10**

#### State-of-the-art lecture Current management of non-ischemic priapism

E. Akkus, Istanbul (TR)

**13:10 - 13:17**

### Questions and discussion

**13:17 - 13:27**

#### Guideline snapshot Management of ischemic priapism: To shunt or to implant?

S. Minhas, London (GB)

**13:27 - 14:00**

### How I do it: Surgical priapism management illustrated

**13:27 - 13:32**

#### Case presentation

E.C. Şerefoğlu, Istanbul (TR)

**13:32 - 13:39**

#### Video-based presentation Distal shunt

S.C. Morgenstern, Frankfurt am Main (DE)

**13:39 - 13:46**

#### Video-based presentation Penoscrotal decompression

J. Romero-Otero, Madrid (ES)

**13:46 - 13:53**

#### Video-based presentation Immediate erectile prosthesis

P. Sangster, London (GB)

**13:53 - 14:00**

### Questions and discussion



## EAU Data initiatives

Thematic Session

**Monday 13 March**  
**12:30 - 14:00**

**Location** Pink Area, Coral 4

**Chairs** P. Cornford, Liverpool (GB)  
To be confirmed

### **Learning objectives**

Greater understanding of the application of Artificial Intelligence in urology and the Data Initiatives active in the EAU. With a focus on how these developments will affect clinical practice in the future.

**12:30 - 12:35**

### **EAU Data initiatives - PIONEER, OPTIMA, IMAGINE...**

M.J. Ribal Caparros, Barcelona (ES)

**12:35 - 12:50**

### **How real world data and real world evidence can complement traditional evidence synthesis & guideline development**

A. Golozar, New York (US)

**12:50 - 13:00**

### **Artificial intelligence in healthcare - a guide for beginners**

M. Bussmann, Dresden (DE)

**13:00 - 13:10**

### **Artificial intelligence in urology - what it means for urologists**

P. Lambin, Maastricht (NL)

**13:10 - 13:20**

### **Which patients benefit most from the different treatment options for mHSPC - results of the 2nd PIONEER Studyathon**

J. Gómez Rivas, Madrid (ES)

**13:20 - 13:30**

### **Measuring Guidelines adherence for improved patient outcomes - IMAGINE and OPTIMA**

S. MacLennan, Aberdeen (GB)

**13:30 - 13:40**

### **Developing computer interpretable guidelines - why and how**

A. Hijazy, Vourles (FR)

**13:40 - 13:50**

### **Patient engagement in data initiatives - why it is essential**

To be confirmed

**13:50 - 14:00**

### **Sustainability of data initiatives - building a platform for future RWE research**

To be confirmed

## Advancing robotic reconstructive surgery

Video Session 14

**Monday 13 March**  
**12:30 - 14:00**

**Location** Pink Area, Coral 7

**Chairs** B.Y. Padilla Fernandez, San Cristóbal De La Laguna (ES)  
To be confirmed  
To be confirmed

**12:30 - 12:33**

**Introduction**

V083

**Robotic augmentation cystoplasty: 1-year outcome of the anterior and posterior approaches**

C.H. Yee, Hong Kong (HK)

V099

**Robot-assisted intracorporeal Monti catheterizable channel**

V100

**Robotic assisted vaginoplasty using peritoneal flap and penile skin inversion: Initial experience**

V. Lozano, L'Hospitalet de Llobregat (ES)

V101

**Robotical release of pudendal neuro-vascular pedicle for entrapment nevralgia**

O. Celhay, bordeaux (FR)

V102

**Robot-assisted ureterectomy with Boari flap reconstruction for distal ureteral stenosis**

A. Bonutto, (IT)

V103

**Robotic extraperitoneal artificial urinary sphincter implantation in female patients**

V104

**Robot-assisted female artificial urinary sphincter (AUS) implantation by posterior approach with endoscopy monitoring**

C. Ochoa Vargas, Bristol (GB)

V105

**Robot-assisted bladder neck artificial urinary sphincter implantation in male patient with spinal cord traumatism incontinence**

H-A. Bourgeno , Uccle (BE)

**13:56 - 14:00**

**Closing remarks**

## Rare and complex urology

Abstract Session 58

**Monday 13 March**  
**12:30 - 14:00**

**Location** Pink Area, Coral 1  
**Chairs** W.F.J. Feitz, Nijmegen (NL)  
To be confirmed  
To be confirmed

**12:30 - 12:33**

**Introduction**

A1089	<b>TNM-stage matched comparative analysis of urachal cancer to urothelial carcinoma : Results from a large cohort</b> S.H. Song, Seongnam (KR)
A1090	<b>Urachal cancer: Experience of a high-volume bladder cancer centre</b> A.K.A.A. Uthman, Pontyln (GB)
A1091	<b>Tertiary lymphoid structures correlate with better prognosis in retroperitoneal sarcoma</b> T. Kijima, Tochigi (JP)
A1092	<b>Demographics and clinical characteristics of solitary fibrous tumours: A contemporary population-based analysis</b>
<b>12:41 - 12:53</b>	
<b>Discussion</b>	
A1093	<b>CXCR4-directed Ga-68-PentixaFor PET/CT as a novel diagnostic modality in primary aldosteronism</b> A.H. Chaman Baz, Nijmegen (NL)
A1094	<b>Multicenter experience in Minimally invasive adrenalectomy for the treatment of adreno cortical carcinoma (ACC): A Junior ERUS/YAU robotic study</b>
A1095	<b>Minimally invasive adrenalectomy for the treatment of malignant adrenal metastasis: results from two high volume centers</b>
A1096	<b>Transcriptomic analysis of the lncRNA-miRNA-mRNA axis network in aldosterone-producing adenoma</b> C-S. Tseng, Taipei (TW)
A1097	<b>Perirenal fat thickness is a powerful predictor for surgical outcomes of laparoscopic adrenalectomy: A retrospective study of laparoscopic adrenalectomy with 215 Japanese cases</b> M.H. Hayashida, Tokyo (JP)
<b>13:03 - 13:17</b>	
<b>Discussion</b>	
A1098	<b>Abdominopelvic paragangliomas: a cohort review of 15-year experience</b> K. Agarwal, New Delhi (IN)
A1099	<b>Adrenalectomy procedure: Is there any difference between general surgeons and urologists?</b> A. Gudeloglu, Ankara (TR)

## Scientific Programme - EAU23 Milan

---

A1100	<b>Regional differences in stage distribution and rates of treatment for adrenocortical carcinoma across United States SEER registries</b> A. Panunzio, (IT)
A1101	<b>Predictors of successful outcome after adrenalectomy for primary aldosteronism</b> A. Saadi, Tunis (TN)
13:27 - 13:41	<b>Discussion</b>
13:41 - 13:51	<b>Update of ERN</b> W.F.J. Feitz, Nijmegen (NL)
13:51 - 13:53	<b>Questions and answers</b>
13:53 - 14:00	<b>Closing remarks</b>

## Improving local treatment of prostate cancer

Abstract Session 59

**Monday 13 March**  
**12:30 - 14:00**

**Location** Pink Area, Coral 2  
**Chairs** To be confirmed  
To be confirmed  
To be confirmed

**12:30 - 12:33**

**Introduction**

**Surgery**

**A1103** **Analysis of predictors of early trifecta achievement after robot-assisted radical prostatectomy for high-risk prostate cancer for trainees and expert surgeons: Introducing a novel, advanced proficiency score**  
U. Anceschi, Rome (IT)

**A1104** **Is it safe to change from a standard anterior approach to a Retzius-sparing approach in robot-assisted radical prostatectomy?**  
E. Lambert, Erpe-Mere (BE)

**A1105** **Changing nationwide trend away from overtreatment among patients undergoing radical prostatectomy over the past 25 years in Germany**  
V.H. Meissner, Munich (DE)

**A1106** **Robot-assisted radical prostatectomy for prostate cancer: 18-year oncological outcomes from a Belgian high-volume center**  
L. Nocera, Milan (IT)

**A1107** **The surgical learning curve for positive surgical margins after robot-assisted radical prostatectomy: Results from a multi-institutional collaboration**  
C.A. Bravi, Milan (IT)

**12:43 - 12:53**

**Discussion**

**New approaches**

**A1108** **Prostate Specific Antigen response to neoadjuvant Lutetium-177-PSMA treatment in high-risk localized prostate cancer patients**  
M. Frumer, Givat Shmuel (IL)

**A1109** **Robot assisted radical prostatectomy performed with the novel surgical robotic platform Hugo™ RAS: Initial experience and perioperative outcomes at a tertiary referral robotic center**  
M. Campetella, Rome (IT)

**A1110** **Surgical outcomes of robot-assisted radical prostatectomy with the novel HUGO™ robotic system: Initial 100 cases performed at a tertiary referral robotic center**  
M. Paciotti, Rozzano, Milan (IT)

**A1111** **Senhance robotic radical prostatectomy: Long-term results**  
T. Kuliš, Zagreb (HR)

---

A1112	<b>Trends and safety profile of same-day discharge for robot-assisted laparoscopic prostatectomy: a retrospective analysis of two tertiary centers in the northeastern United States</b> M. Labban, Riad El Solh - Beirut (LB)
13:03 - 13:13	<b>Discussion</b>
13:13 - 13:13	<b>Radiotherapy and ADT</b>
A1113	<b>Integrating high-precision diagnostics in external-beam radiotherapy for personalized dose escalation of intraprostatic lesions</b>
A1114	<b>Prediction of prostate cancer specific mortality in men undergoing radiotherapy with or without hormonal treatment, risk stratification based on clinical characteristics and PSA treatment response.</b> U.G. Falagario, Bari (IT)
A1115	<b>Tailoring the optimal use of androgen-deprivation therapy concomitant to post-operative radiotherapy among men with pN1 prostate cancer. Long-term results of a large, single Institution series</b>
A1116	<b>Adjuvant therapy with antiandrogens vs. gonadotropin releasing hormone agonists combined with radiotherapy and risk of prostate cancer death in men with high-risk prostate cancer</b> T. Bonde Miranda, Malmö (SE)
A1117	<b>The difference in serum testosterone recovery between Gn-RH antagonist and LH-RH agonist among prostate cancer patients treated radiation therapy</b> S. Sakamoto, Chiba (JP)
13:23 - 13:33	<b>Discussion</b>
	<b>Salvage treatments</b>
A1118	<b>Nadir prostate-specific antigen after salvage cryotherapy as a potential prognostic factor for oncologic outcomes</b> E. Carbonell, Barcelona (ES)
A1119	<b>EAU patient selection criteria are predictors of metastasis-free survival in a large contemporary salvage radical prostatectomy patients cohort</b> G. Callaris, Turin (IT)
A1120	<b>Identifying the optimal candidates for concomitant androgen-deprivation therapy among patients receiving metastasis-directed therapy for positive 68Ga-PSMA PET/CT for biochemical recurrent prostate cancer after radical prostatectomy</b>
A1121	<b>The prognostic role of 68Ga-PSMA PET/CT and the impact of Metastasis-Directed Therapy on cancer progression in men with biochemical recurrence from prostate cancer. Results from a large, single Institution series.</b>
A1122	<b>Complete biochemical response below 0.1 ng/ml predicts long-term therapy-free survival of patients treated with salvage lymph node dissection via PSMA-radioguided surgery</b> S. Knipper, Hamburg (DE)
13:43 - 13:53	<b>Discussion</b>

---

---

13:53 - 14:00

Closing remarks

## Ablative therapy for BPO relief: EEP vs robotics vs aquablation

Abstract Session 56

**Monday 13 March**  
**12:30 - 14:00**

**Location** Yellow Area, Brown 2  
**Chairs** C. De Nunzio, Rome (IT)  
G.Y. Robert, Bordeaux (FR)  
R. Katz, Zefat (IL)

**12:30 - 12:33**

**Introduction**

- A1123** Trends in surgical treatment for benign hyperplasia of prostate: a multi-center 12-year retrospective study from Israel
- A1124** Experience with 3,000 cases of holmium laser enucleation of prostate in a single institution  
H.M. Lee, seoul (KR)
- A1125** Can we predict HoLEP surgery operating times for a given prostate volume to enhance theatre utilization?  
A. Kooplikattil Pushkaran, Luton (GB)
- A1126** Short hospitalization after Holmium Laser Prostatectomy (HoLEP) for prostates volume over 150 CC  
G. Verhovsky, Rehovot (IL)
- 12:41 - 12:49** **Discussion**
- A1127** Comparing the use of AquaBeam® and HoLEP for the treatment of patients with benign prostatic hyperplasia  
C. Toribio-Vazquez, Madrid (ES)
- A1128** A prospective multicenter comparison between holmium laser enucleation of the prostate (HoLEP) and aquabeam robotic system for the treatment of benign prostatic hyperplasia  
J. Justo Quintas, Las rozas de Madrid (ES)
- A1129** Functional and endoscopic results up to two years after Aquablation for BPH-related LUTS: A single centre first clinical experience  
S.T. De Cillis, Turin (IT)
- A1130** Aquablation for benign prostatic hyperplasia in large prostates (80-150ml): Final 5-year results  
N. Bhojani, Montreal (CA)
- A1131** Aquablation Therapy® vs transurethral resection of the prostate: 5-year outcomes of the WATER randomized clinical trial for medium-sized prostates  
K. Oumedjbeur, Beaconsfield (CA)
- A1132** Waterjet ablation therapy (aquabeam) vs. urethral-sparing robot-assisted simple prostatectomy for large prostate volumes (>80mL): Results of a multicentric series according to the standardized BPH6 achievement  
U. Anceschi, Rome (IT)

**13:01 - 13:13**

**Discussion**  
To be confirmed



A1133	<b>Initial experience with superpulsed thulium laser in prostate enucleation: Prospective randomized multicenter comparative study between HoLEP and ThuLEP in terms of efficacy and safety</b> J. Romero-Otero, Madrid (ES)
A1134	<b>Endoscopic enucleation of the prostate for large prostate glands more than 80 cc; ThuLEP Vs BipoLEP</b> A.S. Elsayed, Buffalo (US)
A1135	<b>Greenlight laser 180-W vaporessection versus thulium laser 200-W enucleation of the prostate: A randomised controlled trial</b> F-S. Hsu, New Taipei City (TW)
A1136	<b>Perioperative and Functional Outcomes of Greenlight 180-W Photovaporization in Large (&gt;80 cc) Prostates: an Analysis from 7 Centers in the International Global Greenlight Group</b> N. Corsi, Detroit (US)
<b>13:21 - 13:29</b>	<b>Discussion</b>
A1137	<b>Robot-assisted simple prostatectomy versus Holmium Laser Enucleation for the treatment of benign prostatic hyperplasia in large (&gt;100 ml) prostates: Updated comparative analysis from a high-volume center</b> A. Mottaran, Bologna (IT)
A1138	<b>Peri-operative and short-term functional outcomes comparison between HoLEP and robotic simple prostatectomy for large prostate</b> G. Cochetti, Perugia (IT)
A1139	<b>Novel composite BPH3 trifecta performance for robotic assisted simple prostatectomy (RASP) vs. BPH6: A multicenter outcomes comparison</b> A.M. Bove, Roma (IT)
A1140	<b>Laparoscopic vs. open transcapsular adenomectomy (Millin): A comparative study of perioperative outcomes and complications</b> G. Mendes, Porto (PT)
A1141	<b>Identifying candidates for one-night stay robot assisted simple prostatectomy: single center analysis</b> A.M. Bove, Roma (IT)
A1142	<b>Robot-assisted simple prostatectomy for the treatment of large benign prostatic hyperplasia: A systematic review and meta-analysis of comparative studies</b> L. Jinze, Chengdu (CN)
<b>13:41 - 13:53</b>	<b>Discussion</b>
<b>13:53 - 14:00</b>	<b>Closing remarks</b>

## Cell biology and novel therapies in prostate cancer

Abstract Session 61

**Monday 13 March**  
**12:30 - 14:00**

**Location** Pink Area, Coral 6  
**Chairs** To be confirmed  
To be confirmed  
To be confirmed

**12:30 - 12:33**

**Introduction**

**Cell biology**

- |       |   |
|-------|---|
| A1143 | <b>Dissecting prostate cancer stem cell-associated phenotypic heterogeneity at single-cell resolution</b><br>C. Le Magnen, Basel (CH)   |
| A1144 | <b>Identification of tumor heterogeneity and drug sensitivity in primary prostate cancer</b>  |
| A1145 | <b>Role of tumor-associated fibroblasts and their exosomes in the development and progression of prostate cancer</b><br>A. Tagat, Homburg (DE)  |
| A1146 | <b>Cribriform pattern in prostate tissues will be predictor for intraductal carcinoma of the prostate based on biopsy and radical prostatectomy pathology</b><br>E. Shiomi, Morioka (JP)                |
| A1147 | <b>Bone metastasis enrichment factor SHMT2 promotes prostate cancer metastasis and affects immune infiltration through Akt/<math>\beta</math>-catenin signaling pathway</b><br>H. Huang, Guangzhou (CN) |
| A1148 | <b>Mechanism of SERPINH1 in promoting bone metastasis of prostate cancer by inhibiting P62 ubiquitination degradation</b><br>H. Huang, Guangzhou (CN)   |
| A1149 | <b>Patient-derived organoids represent intra- and interindividual heterogeneity in castration-resistant prostate cancer</b><br>A. Van Hemelryk, Rotterdam (NL)  |
| A1150 | <b>ADP-dependent glucokinase controls metabolic fitness in prostate cancer progression</b>  |
| A1151 | <b>Investigating the effects of homologous recombination deficiency on radiotherapy response in pre-clinical prostate cancer.</b><br>R.J. Bryant, Oxford (GB)   |
| A1152 | <b>Cancer-associated fibroblasts augment prostate cancer resistance to enzalutamide through CCI5-CCR5 paracrine signaling</b><br>Z. Xiong, GuangZhou (CN)   |
| A1153 | <b>SHCBP1 promote prostate cancer metastasis and progression by regulating PLK1 activation</b><br>H. Huang, Guangzhou (CN)  |

## Scientific Programme - EAU23 Milan

---

A1154	<b>Cripto as a key factor in aggressive lethal prostate cancer: generation of a new transgenic mouse model</b>
12:57 - 13:21	<b>Discussion</b>
	<b>Novel therapies</b>
A1155	<b>Distinct genomic features and evolutionary relationships between concurrent intraductal carcinoma and adenocarcinoma of the prostate</b>
A1156	<b>Specific gut microbial environment and intratumoral lipid metabolism change in lard diet-induced prostate cancer progression</b>
A1157	<b>A novel epigenetic driver and actionable target in castration-resistant prostate cancer</b> A. Cacciatore, Bellinzona (CH)
A1158	<b>Towards a new horizon in prostate cancer: PSMA-targeted Docetaxel-conjugated nanomedicines for intratumoral treatment in xenograft model</b> A. Bernal Gomez, Valencia (ES)
A1159	<b>Octreotide as a possible solution to decrease the post-operative lymphorrea after radical prostatectomy</b> P. Mannone, Castelvetro (IT)
A1160	<b>PROpel: Efficacy of abiraterone + olaparib vs. abiraterone + placebo in the first-line treatment of patients with asymptomatic/mildly symptomatic metastatic castration-resistant prostate cancer (mCRPC) at baseline</b> N.W. Clarke, Manchester (GB)
A1161	<b>Application of the CRISPR/Cas9 system to identify the role of N-terminal region of PIP5K1<math>\alpha</math> in castration resistant prostate cancer</b> J. Persson, Umeå (SE)
A1162	<b>A novel protein-encoding circular RNA ccdc719-15 inhibits the progression of prostate cancer by up-regulating flrt3</b> Q. Wang, Guangzhou (CN)
13:37 - 13:53	<b>Discussion</b>
13:53 - 14:00	<b>Closing remarks</b>

---

## Expanding horizons in endourology

Video Session 16

**Monday 13 March**  
**14:15 - 15:45**

**Location** Pink Area, Coral 7  
**Chairs** E.X. Keller, Zurich (CH)  
To be confirmed  
I. Rivero Belenchón, Seville (ES)

**14:15 - 14:18**

**Introduction**

- V114** **First-in-human experience with the LithoVue™ elite single use ureteroscope: Can intrarenal pressure be manipulated?**  
N. Bhojani, Montreal (CA)
- V115** **MOSES technology HoYAG vs Thulium fiber laser for ureteroscopy: When to choose and how to use**  
S.Y. Cho, Seoul (KR)
- V116** **Ex vivo confocal microscopy to diagnose upper tract urothelial carcinoma during URS**  
A. Territo, Barcelona (ES)
- V117** **Management of atypical recurrence after treatment of localized renal cell carcinoma: Retrograde intrarenal surgery as an option**  
L. Villa, Milan (IT)
- V118** **Endoscopic stapler entrapment during laparoscopic nephrectomy: Nightmare scenario for urologist**  
H-C. Yang, Taichung (TW)
- V119** **Enucleation with 3 types of laser : HoLEP vs. ThuLEP TFL and GreenLep**  
J. Romero-Otero, Madrid (ES)
- V120** **First human NOTES for bladder leiomyoma enucleation and cystorraphy**  
A. Cardoso, Braga (PT)
- 15:34 - 15:39** **Closing remarks**

## Cell biology and novel biomarkers in muscle invasive- and upper tract urothelial cancer

Abstract Session 60

Monday 13 March  
12:30 - 14:00

**Location** Pink Area, Coral 3  
**Chairs** To be confirmed  
A. Vlahou, Athens (GR)  
To be confirmed

12:30 - 12:33

**Introduction**

**Subtypes**

- |       |  |
|-------|--|
| A1163 | <b>Proteomic profiling of muscle invasive bladder cancer treated with neoadjuvant chemotherapy</b><br>M.J. Reike, Münster (DE)   |
| A1164 | <b>Molecular analysis of urothelial carcinoma to predict the efficacy of immune checkpoint inhibitor therapy</b><br>T. Szarvas, Budapest (HU)                                      |
| A1165 | <b>Distinct gene expression patterns identify patients who relapse after neoadjuvant pembrolizumab and radical cystectomy in the PURE-01 study</b><br>M.J. Reike, Münster (DE)     |
| A1166 | <b>Integrated multi-omics analysis identified cisplatin resistant cancer cells rely on methionine metabolism in bladder cancer microenvironment</b><br>C. Yang, Shanghai (CN)      |
| A1167 | <b>Patient-Derived Organoids as a Promising Preclinical Model for Assessing therapy Response in Bladder Cancer</b>   |
| A1168 | <b>Spatial immunophenotypes of distant metastases but not matched primary urothelial carcinomas predict response to immune checkpoint inhibition</b><br>M. Eckstein, Erlangen (DE) |
| A1169 | <b>Intratumoral heterogeneity of molecular subtypes in muscle-invasive bladder cancer – An extensive multi-regional immunohistochemical analysis</b><br>G.B. Schulz, Munich (DE)   |
| A1170 | <b>Associations between bladder cancer molecular subtypes and metastatic sites</b><br>G. Sjö Dahl, Malmö (SE)  |
| A1171 | <b>Intrinsic molecular urothelial cancer subtypes remain stable during metastatic evolution</b><br>A. Cox, Bonn (DE)   |
| A1172 | <b>Bladder cancer master regulators; a multi-modal precision oncology framework</b>  |
| A1173 | <b>Protein-based molecular subtypes associate with clinical-pathological characteristics in a multi-institutional cohort of upper tract urothelial carcinomas</b>                  |

---

A1174	<b>Trans-ethnic comprehensive genomic cluster stratification of upper tract urothelial carcinoma</b> T-C. Wei, Taipei (TW)
<b>12:57 - 13:21</b>	<b>Discussion</b>
	<b>Tumor biology</b>
A1175	<b>Targeting NPEPPS overcomes cisplatin resistance in patient-derived muscle-invasive bladder cancer tumoroids</b> M.P. Scholtes , Rotterdam (NL)
A1176	<b>Exosomal circSOX6 promotes lymph node metastasis of bladder cancer via SUMOylation-dependent manner</b>
A1177	<b>Tumor antigen vaccine enhances anti-tumor effects of Immune checkpoint inhibitors against refractory cancers.</b>
A1178	<b>Prognostic impact of the Interleukin-1-Beta / Interleukin-1-Receptor-Antagonist axis in bladder cancer</b> M. Vukovic, Podgorica (ME)
A1179	<b>Evaluation of tumor-specific targets in urothelial carcinoma using patient-based tissue microarrays</b> C.M. Grunewald, Düsseldorf (DE)
A1180	<b>Patients with bladder cancer have an increased NETosis and impaired DNaseI-mediated NET degradation, which can be therapeutically restored in vitro</b> J. Perez Ardavin, Valencia (ES)
A1181	<b>Pre-adipocyte-driven NRG1 promotes resistance to FGFR3 inhibition in urothelial carcinoma</b> A. Alajati, Bonn (DE)
A1182	<b>HIF-1 activator Mint3 promotes tumor progression in urothelial carcinoma</b> J. Ikeda, Hirakata (JP)
<b>13:37 - 13:53</b>	<b>Discussion</b>
	<b>Closing remarks</b>

---

Special Session: Best of EAU

**Monday 13 March**  
**14:15 - 16:15**

**Location**

Yellow Area, eURO Auditorium 1

## Novel prognostic factors and optimal treatment for patients with metastatic prostate cancer

Abstract Session 62

Monday 13 March  
14:15 - 15:45

**Location** Yellow Area, eURO Auditorium 2  
**Chairs** R. Cathomas, Chur (CH)  
To be confirmed  
G. Palapattu, Ann Arbor (US)

14:15 - 14:18

**Introduction**

**Metastatic hormone sensitive disease**

- A1183** **Efficacy and safety of darolutamide (DARO) in combination with androgen-deprivation therapy (ADT) and docetaxel (DOC) in patients (pts) with metastatic hormone sensitive prostate cancer (mHSPC) by metastatic burden: subgroup analyses of ARASENS**  
B. Tombal, Brussels (BE)
- A1184** **Tolerability and pharmacokinetic analyses of combination therapy with darolutamide (DARO), androgen-deprivation therapy (ADT), and docetaxel (DOC) in patients with metastatic hormone sensitive prostate cancer (mHSPC) from ARASENS**  
B. Tombal, Brussels (BE)
- A1185** **Survival outcomes in octogenarian patients with de novo metastatic prostate cancer: Propensity score matching and net overall survival analyses**  
N. Narita, Aktia (JP)
- A1186** **Docetaxel versus abiraterone for metastatic hormone-sensitive prostate cancer with focus on efficacy of sequential therapy**  
T. Yanagiswawa, Tokyo (JP)
- A1187** **Survival in men with newly diagnosed hormone sensitive metastatic prostate cancer**  
H.V. Stroomborg, Birkerød (DK)
- 14:28 - 14:38
- Discussion**
- Metastatic castration resistant prostate cancer**  
To be confirmed
- A1188** **Early outcomes from a phase II randomized trial testing stereotactic body radiation therapy in patients undergoing I line treatment with abiraterone acetate for oligometastatic castration resistant prostate cancer (ARTO trial-NCT03449719)**  
G. Francolini, Florence (IT)
- A1189** **Patient characteristic, treatment and outcomes in metastatic castration resistant prostate cancer (mCRPC) in Finland**  
A.S. Rannikko, Espoo (FI)
- A1190** **Comparison of oncologic outcome between with versus without confirmatory bone scan in men with metastatic castration-resistant prostate cancer treated with enzalutamide**  
J.H. Han, Seoul (KR)



14:44 - 14:49

Discussion

Novel prognostic factors

- A1191 **Prognostic value of pretreatment lung immune prognostic index in patients with metastatic hormone-sensitive and castration-resistant prostate cancer**  
Z. Wang, CHENGDU (CN)
- A1192 **Leukocyte ImmunoTest scores: a novel point-of-care test for evaluating radiorecurrent prostate cancer. An analysis from the FOcal RECurrent Assessment and Salvage Treatment (FORECAST) trial**  
A. Light, Cambridge (GB)
- A1193 **Safety, tolerability, and duration of continued darolutamide treatment in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC): ARAMIS Rollover Study (ROS)**  
K. Fizazi, Villejuif (FR)
- A1194 **Circulating tumor DNA analysis on metastatic prostate cancer with disease progression**  
S. Bang, Seoul (KR)
- A1195 **The value of prostate-specific antigen density in long-term prostate cancer-mortality risk prediction**  
S. Yousef Yacoub, Stockholm (SE)
- A1196 **Efficacy of systemic treatment in prostate cancer patients with visceral metastasis: A systematic review, meta-analysis, and network meta-analysis**  
T. Yanagiswawa, Tokyo (JP)
- A1197 **Survival Patterns based on Site-Specific Visceral Metastasis in Metastatic Prostate Cancer Patients: Are Outcomes of Visceral Metastases the Same?**  
M. Ahmed, Rochester (US)
- A1198 **Racial disparities in future development of lethal prostate cancer based on PSA levels in midlife**  
F. Abdollah, Detroit (US)
- 15:05 - 15:15
- Discussion
- Complications of treatment and how to mitigate them
- A1199 **Clinical fracture incidence in metastatic hormone-sensitive prostate cancer and risk-reduction following addition of zoledronic acid to androgen deprivation therapy with or without docetaxel: Long-term results from the STAMPEDE trial**  
C. Jones, Manchester (GB)
- A1200 **Auto-recruit path for bone health screening of outpatient management system for patient with prostate cancer initiating androgen deprivation therapy**  
H-C. Yang, Taichung (TW)
- A1201 **Major adverse cardiovascular events of enzalutamide versus abiraterone in prostate cancer: a prospective cohort study**  
C.F.A. Ng, Hong Kong (HK)

## Scientific Programme - EAU23 Milan

---

A1202	<b>Incidence of cardiovascular events in men with BCR following a radical prostatectomy: ADT versus no ADT</b> T. Ahlering, Orange (US)
A1203	<b>Changes in quality of life and sexual function after LHRH agonists vs. orchiectomy in men with metastatic prostate cancer: Results from a randomized trial</b>
A1204	<b>Risk of cardiovascular events in prostate cancer patients on androgen deprivation therapy increases with age across all age groups</b>
15:27 - 15:36	<b>Discussion</b>
15:29 - 15:36	<b>Closing remarks</b>

---

## Stones: Ureteroscopy and stents

Abstract Session 64

**Monday 13 March**  
**14:15 - 15:45**

**Location** Yellow Area, Brown 3

**Chairs** M. Brehmer, Stockholm (SE)  
M. Fernández, Santiago (CL)  
K. Taguchi, Nagoya (JP)

**14:15 - 14:18**

**Introduction**

**A1205** **Decision Regret Analysis of patients opting for early Ureteroscopy versus trial of Medical Expulsive Therapy after shared decision making for management of ureteric calculi  $\leq 10\text{mm}$ : Interim results from the DRAUMET study**  
A. Singh, Udupi (IN)

**A1206** **Ureteroscopic stone extraction is not always needed after urgent drainage for obstructive uropathy due to ureteric stones**  
A. Nogara, Perugia (IT)

**A1207** **Effect of renal parenchyma volume on stone clearance and stone-free rate after retrograde intrarenal surgery**  
M. Gül, Konya (TR)

**A1208** **Hounsfield unit in predicting intra and postoperative outcomes in retrograde intrarenal surgery using holmium and thulium fiber laser? Results from multicentre FLEXible ureteroscopy outcomes registry (FLEXOR)**  
D. Ragoori, Hyderabad (IN)

**A1209** **Does gender have any influence on RIRS outcomes? Data from the FLEXible ureteroscopy Outcomes Registry (FLEXOR)**

**14:28 - 14:36**

**Discussion**

**A1210** **Ureteroscopic assessment of renal papillae anatomy identifies racial differences in papillary morphology**  
L. Reynolds, Chicago, Illinois (US)

**A1211** **A multi-center study utilising FLEXOR (FLEXible ureteroscopy Outcomes Registry) for comparing sitting versus standing surgeon posture for performing flexible ureteroscopy for renal stone disease: A retrospective analysis**  
M.M. Sinha, Cheltenham (GB)

**A1212** **The controlling nutritional status (CONUT) score may predict the development of febrile urinary tract infection after ureterorenoscopic lithotripsy**  
K. Tanabe, Saitama (JP)

**A1213** **Single use versus disposable scopes in retrograde intrarenal surgery, is there a winner? A global multicentre real world experience**  
D. Ragoori, Hyderabad (IN)

**A1214** **Evaluation of PneumoRIRS for the treatment of kidney stones associated to kidney anomalies or in case of difficult percutaneous access**  
A. Pacchetti, Genova (IT)

**14:46 - 14:54**

**Discussion**

A1215	<b>What are the optimal laser settings for Stone dusting using the popcorn technique</b> O. Chepeliuk, Ramat Gan (IL)
A1216	<b>Who is the winner? - holmium (hol) versus thulium fiber laser (tfl) for retrograde intra renal surgery (rirs) – a prospective randomized study</b> G. Tak, Hyderabad (IN)
A1217	<b>Thulium fibre versus Moses laser lithotripsy for retrograde intrarenal surgery: Is there a clear winner? Outcomes from the FLEXOR study</b> D. Ragoori, Hyderabad (IN)
A1218	<b>Cumulative thulium fiber laser energy and stone-free rates: Outcomes from the team of worldwide endourological researchers' (TOWER) thulium fiber laser registry</b>
<b>15:02 - 15:10</b>	<b>Discussion</b>
A1219	<b>Ultralim pneumatic lithoclast probe through single channel with dormia trapping the stone versus laser uerterolithotripsy in the treatment of ureteric stones; multicenter study</b> I. Samaha, Zagazig (EG)
A1220	<b>Comparing Retrograde Intrarenal Surgery (RIRS) outcomes between pre-stented vs non-stented patients Inferences from 6679 patients of the global FLEXible ureteroscopy Outcomes Registry (FLEXOR)</b> D. Ragoori, Hyderabad (IN)
A1221	<b>Retrograde intrarenal surgery learning curve of urology residents supervised by an experienced endourologist: A rirsearch study</b> M.F. Sahin, Tekirdag (TR)
<b>15:16 - 15:22</b>	<b>Discussion</b>
A1222	<b>Safety and effectiveness of magnetic ureteral stent removal under ultrasound control: A randomized single center trial</b>
A1223	<b>The use of Pigtail Suture Stents at the end of ureteroscopy: the first large case series</b> A. Bosio, Torino (IT)
A1224	<b>Probiotics together with potassium citrate and magnesium reduce crystalluria in patients undergoing endourological surgery for stone disease: Report from a pilot study</b> M. Vittori, Rome (IT)
A1225	<b>Risk factors for failure of tandem ureteral stents drainage for malignant ureteral obstruction</b> O. Carmona, Tel Aviv (IL)
<b>15:28 - 15:36</b>	<b>Discussion</b>
<b>15:30 - 15:37</b>	<b>Closing remarks</b>

## Guidelines and evidence-based medicine

Abstract Session 49

**Monday 13 March**  
**10:45 - 12:15**

**Location** Yellow Area, Brown 2

**Chairs** To be confirmed  
M.I. Omar, Aberdeen (GB)  
S. Canfield, Houston (US)

**10:45 - 10:48**

**Introduction**

A0992	<p><b>OPTIMA: New research project aims to improve treatment for patients with prostate, breast and lung cancer through artificial intelligence</b> J. N'Dow, Aberdeen (GB)</p>
A0993	<p><b>Clinical decision making in prostate cancer care - Evaluation of EAU-guidelines use and novel decision support software</b> C. Engesser, Basel (CH)</p>
A0994	<p><b>Impact of Performance Status on Survival Outcomes in Prostate Cancer Patients Treated with Systemic Therapy: A Systematic Review and Meta-analysis of Randomized Controlled Trials</b> T. Yanagiswawa, Tokyo (JP)</p>
A0995	<p><b>Epidemiological outcomes in immunocompromised vs. immunocompetent prostate cancer patients: A systematic review, meta-analysis and meta-regression</b> A. Tedde, Sassari (IT)</p>
<p><b>10:56 - 11:04</b></p>	<p><b>Discussion</b></p>
A0996	<p><b>Fracture and fall risk in men with advanced or metastatic prostate cancer treated with novel androgen receptor signalling inhibitors: A systematic review and meta-analysis of randomised controlled trials</b> C. Jones, Manchester (GB)</p>
A0997	<p><b>Surgical versus medical castration in the treatment of metastatic prostate cancer; a systematic review and meta-analysis</b></p>
A0998	<p><b>A systematic review to evaluate Patient-Reported Outcomes Measures (PROMs) for metastatic prostate cancer according to the COSMIN methodology – a PIONEER wp2 project</b></p>
A0999	<p><b>Patient reported outcomes(PRO) in clinical trials leading to gu cancer drug approvals: A focus on the quality of data reporting and analysis</b></p>
<p><b>11:12 - 11:20</b></p>	<p><b>Discussion</b></p>
A1000	<p><b>Comparing treatment outcomes for fluoroscopic and fluoroscopy-free endourological procedures: A systematic review on behalf of the EAU urolithiasis guidelines panel</b> N.D. Davis, Dublin (IE)</p>
A1001	<p><b>In pediatric patients with an upper tract urinary stone of less than 2cm in diameter does ureteroscopy compared to shock wave lithotripsy improves the stone-free rate? A systematic review and meta-analysis from the EAU Urolithiasis Panel</b></p>

A1002	<b>Outcomes of medical and surgical paediatric cystine stones management: Results of a systematic review over 22 years</b> F. Ripa, Southampton (GB)
11:26 - 11:32	<b>Discussion</b>
A1003	<b>Do current definitions of BCG Failure/ BCG Unresponsive NMIBCs correlate with disease progression? Results of an Individual Patient Data Validation international multi-center retrospective study.</b> P. Gontero, Turin (IT)
A1004	<b>International opinions on grading of urothelial carcinoma: A survey among European Association of Urology and International Society of Urological Pathology members</b> I.J. Beijert, Amsterdam (NL)
A1005	<b>Functional outcomes in female patients after traditional, organ- and nerve-sparing radical cystectomy and urinary diversion for bladder cancer: A systematic review and pooled analyses</b> M. von Deimling, Hamburg (DE)
11:38 - 11:44	<b>Discussion</b>
A1006	<b>Estimating postoperative renal function after surgery for nonmetastatic renal masses: A systematic review of available prediction models</b> A. Pecoraro, Florence (IT)
A1007	<b>Minimally invasive pyeloplasty in adults: A systematic review on stent vs. stentless technique</b> M. Alberto, Frankston (AU)
A1008	<b>Defining minimal volume standard in urological robotic assisted surgery. A systematic review</b> E. Day, Bishopton (GB)
A1009	<b>Timing of symptomatic venous thromboembolism after surgery: A systematic review and meta-analysis</b> K.A.O. Tikkinen, Helsinki (FI)
A1010	<b>Conservative and surgical treatments for overactive bladder: A systematic review of the literature</b> M. Beverini, Genova (IT)
A1011	<b>Is a course of intermittent self-dilatation (ISD) with topical corticosteroids superior at stabilising urethral stricture disease in men and improving functional outcomes over a course of ISD alone? A systematic review and meta-analysis</b> W. Verla, Ghent (BE)
11:56 - 12:08	<b>Discussion</b>
12:08 - 12:15	<b>Closing remarks</b>

---

## To the upper tract and beyond

Video Session 15

**Monday 13 March**  
**12:30 - 14:00**

**Location** Blue Area, Room 1  
**Chairs** To be confirmed  
To be confirmed  
P. Wiklund, Stockholm (SE)

**12:30 - 12:31**

**Introduction**

- V106 **Robotic management of complex ureteric strictures: Buccal mucosal graft ureteroplasty with the use of da Vinci fluorescence imaging and multi-image display technologies**
- V107 **99 Robot-assisted buccal mucosa graft ureteroplasty: Case series and lessons learnt at a tertiary care center**  
S. Tyagi, Hapur (IN)
- V108 **Robot-assisted jejunal replacement of the left ureter for long, left ischemic stricture**  
B. Foerster, Zurich (CH)
- V109 **Totally intracorporeal robot-assisted ileal ureteric replacement following an ureteral intussusception**  
R. Mastroianni, Rome (IT)
- V110 **3D augmented reality robotic-assisted segmental ureterectomy with buccal mucosa graft for the repair of upper complex ureteral strictures**  
A. Piana, Turin (IT)
- V111 **Left robot-assisted upper pole heminephrectomy for upper urinary tract urothelial cancer in lynch syndrom**  
A. Khaddad, Bordeaux (FR)
- V112 **A novel “closed transfixion” technique for managing the distal ureter during robotic nephro-ureterectomy - technique demonstration and long term outcomes**  
M. Aldiwani, Ruislip (GB)
- V113 **Feasibility and safety of full retroperitoneoscopic radical nephroureterectomy: A single-center experience**

**Prostate cancer imaging and biopsy prediction: Stage, pathology results, outcomes, local recurrence post RT**

Abstract Session 65

**Monday 13 March  
14:15 - 15:45**

**Location** Pink Area, Coral 2  
**Chairs** F.K-H. Chun, (DE)  
To be confirmed  
S.T. Pang, Taipei (TW)

**14:15 - 14:17**

**Introduction**

**Imaging prediction of stage**

A1226

**Improving prediction of local stage by PSMA-PET: Development of a novel integrated tool for extracapsular extension and seminal vesicle invasion combining clinical and imaging features in localized prostate cancer**

A1227

**Development of a microultrasound-based nomogram to predict extracapsular extension in patients with prostate cancer undergoing robot-assisted radical prostatectomy**  
N. Frego, Rozzano (IT)

A1228

**Comparison of the diagnostic accuracy of PSMA PET/CT scan and Briganti nomogram to predict lymph node invasion in candidates to robot-assisted radical prostatectomy: A single institutional analysis**  
V. Fasulo, Milano (IT)

**14:23 - 14:29**

**Discussion**

**Biopsy prediction of pathology results**

A1229

**Head-to-head comparison between microUS, the partin tables and memorial sloan kettering cancer center nomogram in predicting extraprostatic disease in patients undergoing robot-assisted radical prostatectomy**  
N. Frego, Rozzano (IT)

A1230

**Detection of intraductal carcinoma of the prostate (IDCP) cases focusing on high-grade prostatic intraepithelial neoplasia (PIN) findings regarding invasive carcinoma of the prostate**  
R. Watanabe, Toon City (JP)

A1231

**photoscanning and 3D remodeling for next generation pathology reporting in radical prostatectomy**  
J. Hohage, Wuppertal (DE)

A1232

**Clinicopathological correlate of urine 8-hydroxydeoxyguanosine levels in patients with prostate biopsy**

A1233

**Has the introduction of multiparametric magnetic resonance imaging of the prostate and targeted biopsies led to a risk of overgrading of high risk prostate cancer? Results from a contemporary, large multi-institutional series**



---

A1234	<b>Adverse pathology of prostate cancer after radical prostatectomy. Summary after 7 years and 1500 patients since introduction of mpMRI-guided biopsy in a real world setting</b> B. Ebner, München (DE)
A1235	<b>Spatial transcriptomic analysis of virtual prostate biopsy reveals confounding effect of heterogeneity on genomic signature scoring</b> S. Figiel, Tours (FR)
A1236	<b>Is immunohistochemistry relevant for the diagnosis of prostate cancer? A 2-year retrospective analysis in a single tertiary centre in the UK</b> M. Bertonecchi Tanaka, London (GB)
<b>14:45 - 15:00</b>	<b>Discussion</b>
	<b>Biopsy prediction of outcomes</b>
A1237	<b>Baseline PSMA PET-CT is prognostic for treatment failure in men with intermediate-to-high risk prostate cancer: 54 months follow-up of the proPSMA randomised trial</b> V. Kasivisvanathan, London (GB)
A1238	<b>Added value of MRI radiomics to predict pathological status of prostate cancer patients</b>
A1239	<b>Profiling PCa patients with BCR in the era of early imaging detection: An AIRO-URO group study</b>
A1240	<b>MRI-based t-staging to predict biochemical recurrence after radical prostatectomy: A step towards the iTNM classification</b> M. Baboudjian, Marseille (FR)
A1241	<b>Development and internal validation of nomograms incorporating SUVmax of 68Ga-PSMA PET/CT to predict GG2 and GG3 prostate cancer in biopsy</b>
A1242	<b>The location of tumor volume over 2.8cc predict the prognosis among Japanese localized prostate cancer</b> S. Sakamoto, Chiba (JP)
A1243	<b>When is central histological review of prostate biopsy really needed to reduce the risk of misclassification of prostate cancer? The importance of patient risk stratification</b>
A1244	<b>Development and validation of a novel radiomic model for predicting post-treatment prostate cancer recurrence</b> L. Huynh, Orange (US)
<b>15:16 - 15:29</b>	<b>Discussion</b>
	<b>Biopsy prediction of local recurrence post RT</b>
A1245	<b>Tumor characteristics of multiparametric MRI-detected and -undetected lesions in patients with suspected radiorecurrent prostate cancer: An analysis from the Focal RECurrent Assessment and Salvage Treatment (FORECAST) trial</b> A. Light, Cambridge (GB)

---

A1246	<b>Characteristics of 68Ga-PSMA PET/CT-detected versus -undetected intra-prostatic radiorecurrent prostate cancer</b> A. Light, Cambridge (GB)
<b>15:33 - 15:39</b>	<b>Discussion</b>
<b>15:39 - 15:45</b>	<b>Closing remarks</b>

## Andrology: Medical and surgical therapy of male sexual dysfunction

Abstract Session 63

**Monday 13 March**  
**14:15 - 15:45**

**Location** Yellow Area, Brown 2  
**Chairs** To be confirmed  
To be confirmed  
To be confirmed

**14:15 - 14:18**

**Introduction**

**PDE5 inhibitors**

**A1247** **Reviewing the evidence for the benefits and risks of making tadalafil available as a non-prescription medicine; using the Group Delphi technique to achieve a consensus opinion amongst clinical experts**  
K. Miller, Berlin (DE)

**A1248** **Pharmacovigilance analysis of melanoma adverse events in men treated with sildenafil for erectile dysfunction**  
M. Labban, Riad El Solh - Beirut (LB)

**A1249** **Major adverse cardiovascular events (MACE) related to phosphodiesterase 5 inhibitors (PDE5i): Analysis of real-life data from Eudra-Vigilance (EV) database**  
A. Nacchia, Prata Sannita (IT)

**14:24 - 14:30**

**Discussion**

**Regenerative therapies**

**A1250** **Expectations of partners of our patients undergoing penile rehabilitation programs after nerve-sparing prostatectomy – What do they expect about sexual outcome?**  
A. Bannowsky, Fockbek (DE)

**A1251** **Low-Intensity Extracorporeal Shock Wave Treatment (LI-ESWT) efficacy treating a cohort of real-life patients with erectile dysfunction**  
A.P. Fernandes Carvalho, Braga (PT)

**14:34 - 14:38**

**Discussion**

**Surgical management of penile conditions**

**A1252** **Is intracavernosal PRP a placebo? – A quantitative study to estimate the VEGF-A levels in sexually active and dysfunction men and quantitative estimation of VEGF-A levels needed in endothelial dysfunction**  
S.P. Jayaprakash, CHENNAI (IN)

**A1253** **Prospective randomised treatment of erectile dysfunction after radical prostatectomy with autologous adipose-derived regenerative cells.**  
S. Toft Hansen, . (DK)

**A1254** **Penoscrotal decompression should be considered for prolonged ischemic priapism**  
W.G. Lee, London (GB)

---

A1255	<b>Penile fracture surgery – does it impacts sexual function?</b> A. Costa Silva, Porto (PT)
A1256	<b>Efficacy and safety of two disposable circumcision suture devices for circumcision in adults: A prospective comparative multicenter study</b>
A1257	<b>Outcomes of penile reconstruction for salvage of penile gangrene</b> W.G. Lee, London (GB)
A1258	<b>Clinical characteristics at presentation of Peyronie's disease patients have changed over the last 20 years</b> E. Pozzi, Milan (IT)
A1259	<b>Systematic review of Peyronie's plication surgery: Is it time to confine grafting to the graveyard?</b> R. Gilani, Manchester (GB)
<b>14:54 - 15:10</b>	<b>Discussion</b>
	<b>Penile implants</b>
A1260	<b>Trends and incidence of reported events associated with penile prosthesis: An analysis of the food and drug administration's manufacturer and user facility device experience database</b> G. Tema, Rome (IT)
A1261	<b>Drained versus non-drained inflatable penile prosthesis implantation: A multicenter prospective pilot study</b> A. Ragheb, Giza (EG)
A1262	<b>Surgical and functional outcomes of penile prosthesis implantation in men with neurological conditions</b> M. Falcone, Torino (IT)
A1263	<b>Penile prosthesis implantation as first line surgery for Peyronie's Disease in patients with or without ED</b> I. Moncada Iribarren, Madrid (ES)
A1264	<b>Midline submuscular penile prosthesis reservoir placement for patients with bilateral inaccessible inguinal rings: Technique and outcomes</b> A. Zisman, Haifa (IL)
A1265	<b>Very long-term outcomes and couples' satisfaction after penile prosthesis for patients with erectile dysfunction: A retrospective study in a single center.</b>
A1266	<b>Patient and partner-reported outcomes after penile prosthesis implantation in men with/without Peyronie disease</b> E. Lledó García, Madrid (ES)
<b>15:24 - 15:38</b>	<b>Discussion</b>
<b>15:38 - 15:45</b>	<b>Closing remarks</b>

---

## Localised renal cell carcinoma: Not only surgery!

Abstract Session 67

**Monday 13 March**  
**14:15 - 15:45**

**Location** Pink Area, Coral 6  
**Chairs** To be confirmed  
To be confirmed  
S. Psutka, Seattle (US)

**14:15 - 14:18**

**Introduction**

**Novel staging categories and risk factors**

A1267

**An analysis of national data on the risk of kidney cancer using metformin cumulative use**

A1268

**New size cut-off proposed by EAU Renal Cancer Working group better identifies patients who can benefit from local tumor ablation**

A1269

**Potential impact of the renewed TNM Staging System proposed by the EAU guidelines on renal cell carcinoma on decision-making for patients with localized renal masses: Insights from a referral kidney cancer centre**  
R. Campi, Florence (IT)

A1270

**Proposal for reclassification of T1 and T2A renal cell carcinoma: Analysis of the National Cancer Database**

A1271

**Is it really safe to omit staging chest computed tomography in patients with incidentally diagnosed cT1a renal masses who are candidates for surgery? An audit from a high-volume referral academic centre**  
R. Campi, Florence (IT)

**14:28 - 14:38**

**Discussion**

**Pathology predictors in localized RCC**

A1272

**Development of a nomogram to predict benign pathology in a large series of minimally invasive partial nephrectomy**  
A. Uleri, Milan (IT)

A1273

**The potential of fibrinogens to differentiate between complex renal cysts and cystic renal cell carcinomas in small renal masses**

A1274

**Radiomics in the differentiation between upper tract urothelial carcinoma and renal cell carcinoma – can we overcome the performance of conventional diagnostics by machine learning?**  
S. Rodler, Munich (DE)

A1275

**Development and Validation of a Machine learning-based CT Radiomics Model for Differentiation of Benign and Malignant Solid Renal Tumors**

**14:46 - 14:55**

**Discussion**

**Renal mass biopsy status**

## Scientific Programme - EAU23 Milan

---

A1276	<b>Clinical benefit and cost-effectiveness of a biopsy-all strategy in patients diagnosed with renal mass: Simulation of a randomized controlled trial</b>
A1277	<b>The current role of renal tumor biopsy in the management of small renal masses: Long-term results from a prospective, single-institutional database</b>
A1278	<b>Diagnostic performance of tumor biopsy for the diagnosis of renal tumors in the UroCCR network</b> P. Proye, (FR)
A1279	<b>Practice and impact of tumor biopsy on the management of kidney tumors in the UroCCR registry (Ancillary Study n°118)</b> P. Proye, (FR)
<b>15:03 - 15:12</b>	<b>Discussion</b>
	<b>Active surveillance for SRM</b>
A1280	<b>Active surveillance of small renal masses: Growth rate and oncological outcomes in a prospective series with standardized follow-up protocol</b>
A1281	<b>Active surveillance for very small renal masses: analysis from an observational prospective trial (NCT03804320)</b> G. Musso, Milan (IT)
A1282	<b>Active surveillance as a therapeutic option in elderly patients with renal tumor. A single center experience</b> A. Francés Comalat, Barcelona (ES)
A1283	<b>Surveillance interruption and need for active treatment in Von Hippel-Lindau disease: a prospective study from a multidisciplinary program</b>
<b>15:20 - 15:28</b>	<b>Discussion</b>
	<b>Focal therapy</b>
A1284	<b>Oncological and peri-operative outcomes of percutaneous cryoablation of renal cell carcinoma for patients with hereditary RCC diseases - An analysis of European multi-centre prospective EuRECA registry</b>
A1285	<b>Stereotactic body radiotherapy for frail-patients with primary renal cell carcinoma: local control, toxicity and impact on renal function</b> R. Delonca, Marseille (FR)
<b>15:32 - 15:38</b>	<b>Discussion</b>
<b>15:38 - 15:45</b>	<b>Closing remarks</b>

---

## Better safe than sorry preventing and treating bladder neck issues

Video Session 17

**Monday 13 March**  
**14:15 - 15:45**

**Location** Blue Area, Room 1  
**Chairs** To be confirmed  
To be confirmed  
M.W. Vetterlein, Hamburg (DE)

**14:15 - 14:18**

**Introduction**

V121	<b>Beyond bladder neck sparing: Complete Urethral Preservation (CUP) during RARP. Video description of surgical technique and reported continence outcomes</b> T. Al-Hammouri, Harrow (GB)
V122	<b>Robot-assisted radical prostatectomy in large (<math>\geq 100</math> gr) prostate glands: Results and different techniques for bladder neck dissection</b> C.A. Bravi, Milan (IT)
V123	<b>Hybrid thulium laser incision in bladder neck contracture: Surgical technique and early outcomes</b>
V124	<b>Revision of vesico-urethral anastomosis for post-prostatectomy bladder neck contracture</b> A. Marfany Pluchart, Lleida (ES)
V125	<b>YV plasty for vesico-urethral anastomosis stenosis by combined robotic and perineal approach and concomitant artificial urinary sphincter implantation</b> L. Freton, Rennes (FR)
V126	<b>Sphincter sparing vesicourethral anastomosis suture</b> L. Antonelli, bovezzo (IT)
V127	<b>The adjustable Artificial Urinary Sphincter (VICTO): early prospective results and surgical technique in a high-risk cohort</b> G. Ameli, Vienna (AT)
<b>15:35 - 15:40</b>	<b>Closing remarks</b>

## Interventions to improve outcomes of local treatment of muscle-invasive bladder cancer

Abstract Session 66

Monday 13 March  
14:15 - 15:45

**Location** Pink Area, Coral 3  
**Chairs** To be confirmed  
To be confirmed  
To be confirmed

14:15 - 14:18

**Introduction**

**Perioperative interventions**

A1286 **Effect of tranexamic acid in radical cystoprostatectomy: A randomized controlled study**  
M. Bibi, Tunis (TN)

A1287 **High perioperative opioid doses are associated with worse cancer-specific survival in patients undergoing radical cystectomy for urothelial carcinoma of the bladder**  
J. Marcon, Munich (DE)

A1288 **Oncological outcomes for patients harboring positive surgical margins following radical cystectomy for muscle-invasive bladder cancer: A retrospective multicentric study of the EAU Young Academic Urologists (YAU) urothelial carcinoma working group**  
G. Marcq, Marcq-en-Baroeul (FR)

A1289 **Urethrectomy at the time of radical cystectomy for non-metastatic urothelial carcinoma of the bladder**  
E. Laukhtina, Vienna (AT)

A1290 **Does early introduction of self intermittent catheterization improve functional outcomes and urinary infection in orthotopic ileal neobladder? Results from a prospective multicentre study**

A1291 **Perioperative and survival outcomes of patients with a history of pelvic radiation undergoing salvage robot-assisted radical cystectomy. An rrc-icud collaborative study**  
G. Cacciamani, Los Angeles (US)

14:30 - 14:42

**Discussion**

**Neoadjuvant therapy**

A1292 **Chemotherapy vs. immunotherapy as neoadjuvant therapies in cisplatin-eligible patients undergoing radical cystectomy for muscle invasive bladder cancer**  
L. Nocera, Milan (IT)

A1293 **Impact of neoadjuvant immune-checkpoint inhibitor on intra and post operative outcomes in patients with muscle-invasive bladder cancer treated with radical cystectomy**



---

A1294	<b>Neoadjuvant chemoradiotherapy followed by radical cystectomy for muscle-invasive bladder cancer: Efficacy and feasibility in 119 patients</b> M. Fujiwara, Toride (JP)
<b>14:48 - 14:55</b>	<b>Discussion</b>
	<b>Non-surgical treatment</b>
A1295	<b>Inverse probability treatment weighting comparison of radical cystectomy to trimodality therapy for cT2-cT4 muscle invasive bladder cancer</b> A.R. Zlotta, Toronto (CA)
A1296	<b>Benefit from BCON? The unmet need of bladder cancer patients unsuitable for chemoradiation treated with radical radiotherapy alone: a single institution retrospective case note review</b> H. Egan, Manchester (GB)
A1297	<b>Benefit of whole-pelvis radiation for patients with muscle-invasive bladder cancer: An inverse probability treatment weighted analysis</b> G. Marcq, Marcq-en-Baroeul (FR)
<b>15:01 - 15:08</b>	<b>Discussion</b>
	<b>Variant histology</b>
A1298	<b>Adenocarcinoma of the bladder: Assessment of survival benefit associated with radical cystectomy and comparison with urothelial bladder cancer</b> S. Tappero, Genova (IT)
A1299	<b>Effect of chemotherapy in sarcomatoid bladder cancer patients treated with radical cystectomy</b> F. Chierigo, Schio (IT)
A1300	<b>Sarcomatoid vs urothelial bladder cancer: Impact of radical cystectomy on cancer control outcomes</b> F. Chierigo, Schio (IT)
A1301	<b>The role of extended versus standard lymphadenectomy lymph node dissection in clinically lymph node-positive bladder cancer</b> M. von Deimling, Hamburg (DE)
<b>15:16 - 15:25</b>	<b>Discussion</b>
	<b>Outcomes</b>
A1302	<b>Comparison of contemporary treatment strategies for locally advanced (stage IIIB) urothelial bladder cancer using National Cancer Database</b> H. Garg, San Antonio (US)
A1303	<b>Gender specific differences in health-related quality of life for bladder cancer patients following radical cystectomy – Results from a large prospective propensity score-matched cohort</b>
A1304	<b>Prognostic value of angiogenesis related marker vascular endothelial growth factor and vascular cell adhesion molecule-1 in bladder carcinoma treated with radical cystectomy</b> K. Mori, Vienna (AT)

---

**15:31 - 15:38**

**Discussion**

---

**15:38 - 15:45**

**Closing remarks**

